U.S. patent application number 12/116651 was filed with the patent office on 2008-12-18 for cold-adapted equine influenza viruses.
Invention is credited to Patricia W. Dowling, Julius S. Youngner.
Application Number | 20080311154 12/116651 |
Document ID | / |
Family ID | 24013960 |
Filed Date | 2008-12-18 |
United States Patent
Application |
20080311154 |
Kind Code |
A1 |
Dowling; Patricia W. ; et
al. |
December 18, 2008 |
COLD-ADAPTED EQUINE INFLUENZA VIRUSES
Abstract
The present invention provides experimentally-generated
cold-adapted equine influenza viruses, and reassortant influenza A
viruses comprising at least one genome segment of such an equine
influenza virus, wherein the equine influenza virus genome segment
confers at least one identifying phenotype of the cold-adapted
equine influenza virus, such as cold-adaptation, temperature
sensitivity, dominant interference, or attenuation. Such viruses
are formulated into therapeutic compositions to protect animals
from diseases caused by influenza A viruses, and in particular, to
protect horses from disease caused by equine influenza virus. The
present invention also includes methods to protect animals from
diseases caused by influenza A virus utilizing the claimed
therapeutic compositions. Such methods include using a therapeutic
composition as a vaccine to generate a protective immune response
in an animal prior to exposure to a virulent virus, and using a
therapeutic composition as a treatment for an animal that has been
recently infected with a virulent virus, or is likely to be
subsequently exposed to virulent virus in a few days whereby the
therapeutic composition interferes with the growth of the virulent
virus, even in the absence of immunity. The present invention also
provides methods to produce cold-adapted equine influenza viruses,
and reassortant influenza A viruses having at least one genome
segment of an equine influenza virus generated by
cold-adaptation.
Inventors: |
Dowling; Patricia W.;
(Pittsburgh, PA) ; Youngner; Julius S.;
(Pittsburgh, PA) |
Correspondence
Address: |
HESKA CORPORATION;LEGAL DEPARTMENT
3760 ROCKY MOUNTAIN AVE
LOVELAND
CO
80538
US
|
Family ID: |
24013960 |
Appl. No.: |
12/116651 |
Filed: |
May 7, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11625941 |
Jan 23, 2007 |
7399477 |
|
|
12116651 |
|
|
|
|
10734373 |
Dec 12, 2003 |
7169397 |
|
|
11625941 |
|
|
|
|
10065133 |
Sep 19, 2002 |
6685946 |
|
|
10734373 |
|
|
|
|
09506286 |
Feb 16, 2000 |
6482414 |
|
|
10065133 |
|
|
|
|
09133921 |
Aug 13, 1998 |
6177082 |
|
|
09506286 |
|
|
|
|
PCT/US99/18583 |
Aug 12, 1999 |
|
|
|
09133921 |
|
|
|
|
Current U.S.
Class: |
424/206.1 ;
424/93.2; 435/236; 435/239; 530/350; 536/23.72 |
Current CPC
Class: |
A61K 2039/5254 20130101;
C07K 14/005 20130101; A61K 39/12 20130101; C12N 2760/16134
20130101; A61K 39/00 20130101; C12N 2760/16164 20130101; A61P 31/16
20180101; C12N 7/00 20130101; C12N 2760/16122 20130101; A61K 39/145
20130101 |
Class at
Publication: |
424/206.1 ;
435/236; 424/93.2; 536/23.72; 530/350; 435/239 |
International
Class: |
A61K 39/12 20060101
A61K039/12; C12N 7/04 20060101 C12N007/04; C07H 21/00 20060101
C07H021/00; C07K 2/00 20060101 C07K002/00; C12N 7/02 20060101
C12N007/02; A61P 31/16 20060101 A61P031/16 |
Claims
1. A cold-adapted equine influenza virus.
2. The virus of claim 1, wherein said virus replicates in
embryonated chicken eggs at a temperature ranging from about
26.degree. C. to about 30.degree. C.
3. The virus of claim 1, wherein said virus is attenuated.
4. The virus of claim 1, wherein said virus is temperature
sensitive.
5. The virus of claim 1, wherein said virus replicates in
embryonated chicken eggs at a temperature ranging from about
26.degree. C. to about 30.degree. C., but does not form plaques in
tissue culture cells at a temperature of about 39.degree. C.
6. The virus of claim 1, wherein said virus replicates in
embryonated chicken eggs at a temperature ranging from about
26.degree. C. to about 30.degree. C., but does not form plaques in
tissue culture cells at a temperature of about 37.degree. C.
7. The virus of claim 1, wherein a phenotype comprising a
non-permissive temperature of about 39.degree. C. is conferred on
said virus by at least two mutations in the genome of said virus,
comprising a first mutation and a second mutation.
8. The virus of claim 7, wherein said first mutation confers a
phenotype on said virus comprising inhibition of plaque formation
at a temperature of about 39.degree. C., and wherein said first
mutation co-segregates with the segment of said genome comprising
the nucleoprotein gene of said virus.
9. The virus of claim 7, wherein said second mutation confers a
phenotype on said virus comprising inhibition of protein synthesis
of said virus at a temperature of about 39.degree. C.
10. The virus of claim 7, further comprising at least one
additional mutation, wherein said additional mutation confers a
phenotype comprising a non-permissive temperature of about
37.degree. C. on said virus, and wherein said phenotype is selected
from the group consisting of inhibition of plaque formation at a
temperature of about 37.degree. C. and inhibition of the expression
of the late genes of said virus at a temperature of about
37.degree. C.
11. The virus of claim 1, wherein said virus is produced by a
method comprising the steps of: a. passaging a wild-type equine
influenza virus; and b. selecting viruses that grow at a reduced
temperature.
12. The virus of claim 11, wherein said virus is produced by a
method further comprising repetition of said passaging and
selection steps one or more times, wherein said reduced temperature
is made progressively lower.
13. The virus of claim 11, wherein said passaging step is carried
out in embryonated chicken eggs.
14. The virus of claim 11, wherein said virus comprises a dominant
interference phenotype.
15. The virus of claim 1, wherein said virus is derived from strain
A/equine/Kentucky/1/91 (H3N8).
16. The virus of claim 1, wherein said virus comprises the
identifying phenotypes of a virus selected from the group
consisting of: EIV-P821, identified by accession No. ATCC VR-2625
EIV-P824, identified by accession No. ATCC VR-2624 and MSV+5,
identified by accession No. ATCC VR-2627.
17. The virus of claim 1, wherein said virus is selected from the
group consisting of: EIV-P821, identified by accession No. ATCC
VR-2625; EIV-P824, identified by accession No. ATCC VR-2624; MSV+5,
identified by accession No. ATCC VR-2627; and progeny of any of
said viruses having any of said accession numbers.
18. A reassortant influenza A virus comprising at least one genome
segment of an equine influenza virus generated by cold-adaptation,
said equine influenza virus having an identifying phenotype
selected from the group consisting of cold-adaptation, temperature
sensitivity, dominant interference, and attenuation, wherein said
equine influenza virus genome segment confers at least one of said
identifying phenotypes to said reassortant virus.
19. The reassortant influenza A virus of claim 18, wherein said
virus is produced by a method comprising the steps of: a. mixing
the genome segments of a donor cold-adapted equine influenza virus
with the genome segments of a recipient influenza A virus; and b.
selecting a reassortant virus comprising at least one phenotype of
said donor equine influenza virus, wherein said phenotype is
selected from the group consisting of cold-adaptation, temperature
sensitivity, dominant interference, and attenuation.
20. The reassortant influenza A virus of claim 18, wherein said
recipient influenza A virus comprises hemagglutinin and
neuraminidase phenotypes different than those of said donor equine
influenza virus, and wherein said reassortant virus comprises the
hemagglutinin and neuraminidase phenotypes of said recipient
virus.
21. A therapeutic composition to protect an animal against disease
caused by an influenza A virus, comprising a virus selected from
the group consisting of: (a) a cold-adapted equine influenza virus;
and (b) a reassortant influenza A virus comprising at least one
genome segment of an equine influenza virus generated by
cold-adaptation, said equine influenza virus having an identifying
phenotype selected from the group consisting of cold-adaptation,
temperature sensitivity, dominant interference, and attenuation,
wherein said equine influenza virus genome segment confers at least
one of said identifying phenotypes to said reassortant virus.
22. The therapeutic composition of claim 21, wherein said
therapeutic composition comprises a cold-adapted equine influenza
virus, wherein said disease is caused by equine influenza virus,
and wherein said therapeutic composition is administered
prophylactically to an equid, thereby eliciting an immune response
against equine influenza virus in said equid.
23. The therapeutic composition of claim 21, wherein said
therapeutic composition comprises from about 10.sup.5 TCID.sub.50
units to about 10.sup.8 TCID.sub.50 units of said virus.
24. The therapeutic composition of claim 21, further comprising an
excipient.
25. A method to protect an animal against disease caused by an
influenza A virus comprising administering to said animal a
therapeutic composition comprising a virus selected from the group
consisting of: (a) a cold-adapted equine influenza virus; and (b) a
reassortant influenza A virus comprising at least one genome
segment of an equine influenza virus generated by cold-adaptation,
said equine influenza virus having an identifying phenotype
selected from the group consisting of cold-adaptation, temperature
sensitivity, dominant interference, and attenuation, wherein said
equine influenza virus genome segment confers at least one of said
identifying phenotypes to said reassortant virus.
26. The method of claim 25, wherein said animal is an equid.
27. The method of claim 25, wherein said therapeutic composition
comprises a cold-adapted equine influenza virus, wherein said
disease is caused by equine influenza virus, and wherein said
therapeutic composition is administered prophylactically to an
equid, thereby eliciting an immune response against equine
influenza virus in said equid.
28. The method of claim 25, wherein said therapeutic composition is
administered to said animal by a route that will allow virus entry
into mucosal cells of the upper respiratory tract.
29. A method to produce a cold-adapted equine influenza virus
comprising the steps of: a. passaging a wild-type equine influenza
virus; and b. selecting viruses that grow at a reduced
temperature.
30. The method of claim 29, wherein said cold-adapted equine
influenza virus is produced by a method further comprising
repetition of said passaging and selection steps one or more times,
wherein said reduced temperature is made progressively lower.
31. A method to produce a reassortant influenza A virus having at
least one genome segment of an equine influenza virus generated by
cold-adaptation, said equine influenza virus having an identifying
phenotype selected from the group consisting of cold-adaptation,
temperature sensitivity, dominant interference, and attenuation,
comprising the steps of: a. mixing the genome segments of a donor
cold-adapted equine influenza virus with the genome segments of a
recipient influenza A virus; and b. selecting reassortant a virus
comprising at least one phenotype of said donor equine influenza
virus, wherein said phenotype is selected from the group consisting
of cold-adaptation, temperature sensitivity, dominant interference,
and attenuation.
32. The method of claim 31, wherein said recipient influenza A
virus comprises hemagglutinin and neuraminidase phenotypes
different than those of said donor equine influenza virus, and
wherein said reassortant virus comprises the hemagglutinin and
neuraminidase phenotypes of said recipient virus.
33. A method to propagate a cold-adapted equine influenza virus
comprising a method selected from the group consisting of
propagating said virus in eggs and propagating said virus in tissue
culture cells.
34. An isolated equine influenza nucleic acid molecule selected
from the group consisting of: a. an isolated nucleic acid molecule
that encodes a protein comprising an amino acid sequence selected
from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8,
SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID
NO:24, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:55, SEQ
ID NO:58, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:77,
SEQ ID NO:81, SEQ ID NO:86, SEQ ID NO:89, SEQ ID NO:92, SEQ ID
NO:95, SEQ ID NO:104 and SEQ ID NO:107; and b. an isolated nucleic
acid molecule fully complementary to a nucleic acid molecule of
(a).
35. The nucleic acid molecule of claim 34, wherein said nucleic
acid molecule comprises a nucleic acid sequence selected from the
group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID
NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID
NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25 SEQ ID NO:44,
SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID
NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:57, SEQ
ID NO:59, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67,
SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:76, SEQ ID
NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:85, SEQ
ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:93,
SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:103, SEQ ID NO:105, SEQ ID
NO:106 and SEQ ID NO:108 and a nucleic acid molecule comprising a
nucleic acid sequence which is fully complementary to any of said
nucleic acid sequences.
36. A nucleic acid molecule of claim 34, wherein said nucleic acid
molecule encodes a protein.
37. A nucleic acid molecule of claim 34, wherein said nucleic acid
molecule is selected from the group consisting of
Pei.sub.ca1M.sub.252, Pei.sub.ca1HA.sub.565,
Pei.sub.ca1PB2-N.sub.404, Pei.sub.ca1PB2-C.sub.398,
Pei.sub.ca1PB2.sub.759, Pei.sub.ca1NS.sub.230,
Pei.sub.ca1PB1-N.sub.395, Pei.sub.ca1PA-C.sub.390
Pei.sub.ca1PB1-C.sub.396, Pei.sub.ca2PB1-C.sub.396 and
Pei.sub.ca1PB1.sub.757.
38. An isolated equine influenza protein that comprises an amino
acid sequence selected from the group consisting of SEQ ID NO:2,
SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17,
SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:45, SEQ ID NO:48, SEQ ID
NO:51, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:63, SEQ ID NO:66, SEQ
ID NO:69, SEQ ID NO:77, SEQ ID NO:81, SEQ ID NO:86, SEQ ID NO:89,
SEQ ID NO:92, SEQ ID NO:95, SEQ ID NO:104 and SEQ ID NO:107.
39. The protein of claim 38, wherein said protein is encoded by a
nucleic acid molecule selected from the group consisting of SEQ ID
NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID
NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ
ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:22,
SEQ ID NO:23, SEQ ID NO:25 SEQ ID NO:44, SEQ ID NO:46, SEQ ID
NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ
ID NO:54, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:62,
SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:68, SEQ ID
NO:70, SEQ ID NO:71, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:79, SEQ
ID NO:80, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88,
SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:94, SEQ ID
NO:96, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:106 and SEQ ID
NO:108.
40. An isolated virus comprising a nucleic acid molecule that
encodes a protein selected from the group consisting SEQ ID NO:2,
SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17,
SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:45, SEQ ID NO:48, SEQ ID
NO:51, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:63, SEQ ID NO:66, SEQ
ID NO:69, SEQ ID NO:77, SEQ ID NO:81, SEQ ID NO:86, SEQ ID NO:89,
SEQ ID NO:92, SEQ ID NO:95, SEQ ID NO:104 and SEQ ID NO:107.
41. The virus of claim 40, wherein said virus comprises a nucleic
acid sequence selected from the group consisting of SEQ ID NO:1,
SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9,
SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID
NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:22, SEQ
ID NO:23, SEQ ID NO:25 SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:47,
SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID
NO:54, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:62, SEQ
ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:70,
SEQ ID NO:71, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:79, SEQ ID
NO:80, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ
ID NO:90, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:96,
SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:106 and SEQ ID NO:108.
42. The virus of claim 40, wherein said virus is selected from the
group consisting of equine influenza virus and a reassortant
influenza virus.
43. The virus of claim 1, wherein said virus comprises a nucleic
acid molecule having a nucleic acid sequence selected from the
group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:10, SEQ ID
NO:12, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:25, SEQ
ID NO:47, SEQ ID NO:49, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:68,
SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:80, SEQ ID NO:82, SEQ ID
NO:91, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:106 and
SEQ ID NO:108.
44. The virus of claim 1, wherein said virus encodes a protein
selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11,
SEQ ID NO:17, SEQ ID NO:24, SEQ ID NO:48, SEQ ID NO:58, SEQ ID
NO:69, SEQ ID NO:81, SEQ ID NO:92, SEQ ID NO:95 and SEQ ID
NO:107.
45. The virus of claim 18, wherein said virus comprises a nucleic
acid molecule having a nucleic acid sequence selected from the
group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:10, SEQ ID
NO:12, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:25, SEQ
ID NO:47, SEQ ID NO:49, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:68,
SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:80, SEQ ID NO:82, SEQ ID
NO:91, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:106 and
SEQ ID NO:108.
46. The virus of claim 18, wherein said virus encodes a protein
selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11,
SEQ ID NO:17, SEQ ID NO:24, SEQ ID NO:48, SEQ ID NO:58, SEQ ID
NO:69, SEQ ID NO:81, SEQ ID NO:92, SEQ ID NO:95 and SEQ ID NO:107.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. patent application
Ser. No. 09/133,921, filed Aug. 13, 1998; and PCT/US99/18583, filed
Aug. 12, 1999; each entitled COLD-ADAPTED EQUINE INFLUENZA VIRUSES.
The patent applications referred to in this section are
incorporated by reference herein in their entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to experimentally-generated
cold-adapted equine influenza viruses, and particularly to
cold-adapted equine influenza viruses having additional phenotypes,
such as attenuation, dominant interference, or temperature
sensitivity. The invention also includes reassortant influenza A
viruses which contain at least one genome segment from such an
equine influenza virus, such that the reassortant virus includes
certain phenotypes of the donor equine influenza virus. The
invention further includes genetically-engineered equine influenza
viruses, produced through reverse genetics, which comprise certain
identifying phenotypes of a cold-adapted equine influenza virus of
the present invention. The present invention also relates to the
use of these viruses in therapeutic compositions to protect animals
from diseases caused by influenza viruses.
BACKGROUND OF THE INVENTION
[0003] Equine influenza virus has been recognized as a major
respiratory pathogen in horses since about 1956. Disease symptoms
caused by equine influenza virus can be severe, and are often
followed by secondary bacterial infections. Two subtypes of equine
influenza virus are recognized, namely subtype-1, the prototype
being A/Equine/Prague/1/56 (H7N7), and subtype-2, the prototype
being A/Equine/Miami/1/63 (H3N8). Presently, the predominant virus
subtype is subtype-2, which has further diverged among Eurasian and
North American isolates in recent years.
[0004] The currently licensed vaccine for equine influenza is an
inactivated (killed) virus vaccine. This vaccine provides minimal,
if any, protection for horses, and can produce undesirable side
effects, for example, inflammatory reactions at the site of
injection. See, e.g., Mumford, 1987, Equine Infectious Disease IV,
207-217, and Mumford, et al., 1993, Vaccine 11, 1172-1174.
Furthermore, current modalities cannot be used in young foals,
because they cannot overcome maternal immunity, and can induce
tolerance in a younger animal. Based on the severity of disease,
there remains a need for safe, effective therapeutic compositions
to protect horses against equine influenza disease.
[0005] Production of therapeutic compositions comprising
cold-adapted human influenza viruses is described, for example, in
Maassab, et al., 1960, Nature 7, 612-614, and Maassab, et al.,
1969, J. Immunol. 102, 728-732. Furthermore, these researchers
noted that cold-adapted human influenza viruses, i.e., viruses that
have been adapted to grow at lower than normal temperatures, tend
to have a phenotype wherein the virus is temperature sensitive;
that is, the virus does not grow well at certain higher,
non-permissive temperatures at which the wild-type virus will grow
and replicate. Various cold-adapted human influenza A viruses,
produced by reassortment with existing cold-adapted human influenza
A viruses, have been shown to elicit good immune responses in
vaccinated individuals, and certain live attenuated cold-adapted
reassortant human influenza A viruses have proven to protect humans
against challenge with wild-type virus. See, e.g., Clements, et
al., 1986, J. Clin. Microbiol. 23, 73-76. In U.S. Pat. No.
5,149,531, by Youngner, et al., issued Sep. 22, 1992, the inventors
of the present invention further demonstrated that certain
reassortant cold-adapted human influenza A viruses also possess a
dominant interference phenotype, i.e., they inhibit the growth of
their corresponding parental wild-type strain, as well as
heterologous influenza A viruses.
[0006] U.S. Pat. No. 4,683,137, by Coggins et al., issued Jul. 28,
1987, and U.S. Pat. No. 4,693,893, by Campbell, issued Sep. 15,
1987, disclose attenuated therapeutic compositions produced by
reassortment of wild-type equine influenza viruses with attenuated,
cold-adapted human influenza A viruses. Although these therapeutic
compositions appear to be generally safe and effective in horses,
they pose a significant danger of introducing into the environment
a virus containing both human and equine influenza genes.
SUMMARY OF THE INVENTION
[0007] The present invention provides experimentally-generated
cold-adapted equine influenza viruses, reassortant influenza A
viruses that comprise at least one genome segment of an equine
influenza virus generated by cold-adaptation such that the equine
influenza virus genome segment confers at least one identifying
phenotype of a cold-adapted equine influenza virus on the
reassortant virus, and genetically-engineered equine influenza
viruses, produced through reverse genetics, which comprise at least
one identifying phenotype of a cold-adapted equine influenza virus.
Identifying phenotypes include cold-adaptation, temperature
sensitivity, dominant interference, and attenuation. The invention
further provides a therapeutic composition to protect an animal
against disease caused by an influenza A virus, where the
therapeutic composition includes a cold-adapted equine influenza
virus a reassortant influenza A virus, or a genetically-engineered
equine influenza virus of the present invention. Also provided is a
method to protect an animal from diseases caused by an influenza A
virus which includes the administration of such a therapeutic
composition. Also provided are methods to produce a cold-adapted
equine influenza virus, and methods to produce a reassortant
influenza A virus which comprises at least one genome segment of a
cold-adapted equine influenza virus, where the equine influenza
genome segment confers on the reassortant virus at least one
identifying phenotype of the cold-adapted equine influenza
virus.
[0008] A cold-adapted equine influenza virus is one that replicates
in embryonated chicken eggs at a temperature ranging from about
26.degree. C. to about 30.degree. C. Preferably, a cold-adapted
equine influenza virus, reassortant influenza A virus, or
genetically-engineered equine influenza virus of the present
invention is attenuated, such that it will not cause disease in a
healthy animal.
[0009] In one embodiment, a cold-adapted equine influenza virus,
reassortant influenza A virus, or genetically-engineered equine
influenza virus of the present invention is also temperature
sensitive, such that the virus replicates in embryonated chicken
eggs at a temperature ranging from about 26.degree. C. to about
30.degree. C., forms plaques in tissue culture cells at a
permissive temperature of about 34.degree. C., but does not form
plaques in tissue culture cells at a non-permissive temperature of
about 39.degree. C.
[0010] In one embodiment, such a temperature sensitive virus
comprises two mutations: a first mutation that inhibits plaque
formation at a temperature of about 39.degree. C., that mutation
co-segregating with the genome segment that encodes the viral
nucleoprotein gene; and a second mutation that inhibits all viral
protein synthesis at a temperature of about 39.degree. C.
[0011] In another embodiment, a cold-adapted, temperature sensitive
equine influenza virus of the present invention replicates in
embryonated chicken eggs at a temperature ranging from about
26.degree. C. to about 30.degree. C., forms plaques in tissue
culture cells at a permissive temperature of about 34.degree. C.,
but does not form plaques in tissue culture cells or express late
viral proteins at a non-permissive temperature of about 37.degree.
C.
[0012] Typically, a cold-adapted equine influenza virus of the
present invention is produced by passaging a wild-type equine
influenza virus one or more times, and then selecting viruses that
stably grow and replicate at a reduced temperature. A cold-adapted
equine influenza virus produced thereby includes, in certain
embodiments, a dominant interference phenotype, that is, the virus,
when co-infected with a parental equine influenza virus or
heterologous wild-type influenza A virus, will inhibit the growth
of that virus.
[0013] Examples of cold-adapted equine influenza viruses of the
present invention include EIV-P821, identified by accession No.
ATCC VR-2625; EIV-P824, identified by accession No. ATCC VR-2624;
EIV-MSV+5, identified by accession No. ATCC VR-627; and progeny of
such viruses.
[0014] Therapeutic compositions of the present invention include
from about 10.sup.5 TCID.sub.50 units to about 10.sup.8 TCID.sub.50
units, and preferably about 2.times.10.sup.6 TCID.sub.50 units, of
a cold-adapted equine influenza virus, reassortant influenza A
virus, or genetically-engineered equine influenza virus of the
present invention.
[0015] The present invention also includes a method to protect an
animal from disease caused by an influenza A virus, which includes
the step of administering to the animal a therapeutic composition
including a cold-adapted equine influenza virus, a reassortant
influenza A virus, or a genetically-engineered equine influenza
virus of the present invention. Preferred animals to protect
include equids, with horses and ponies being particularly
preferred.
[0016] Yet another embodiment of the present invention is a method
to generate a cold-adapted equine influenza virus. The method
includes the steps of passaging a wild-type equine influenza virus;
and selecting viruses that grow at a reduced temperature. In one
embodiment, the method includes repeating the passaging and
selection steps one or more times, while progressively reducing the
temperature. Passaging of equine influenza virus preferably takes
place in embryonated chicken eggs.
[0017] Another embodiment is an method to produce a reassortant
influenza A virus through genetic reassortment of the genome
segments of a donor cold-adapted equine influenza virus of the
present invention with the genome segments of a recipient influenza
A virus. Reassortant influenza A viruses of the present invention
are produced by a method that includes the steps of: (a) mixing the
genome segments of a donor cold-adapted equine influenza virus with
the genome segments of a recipient influenza A virus, and (b)
selecting viruses which include at least one identifying phenotype
of the donor equine influenza virus. Identifying phenotypes include
cold-adaptation, temperature sensitivity, dominant interference,
and attenuation. Preferably, such reassortant viruses at least
include the attenuation phenotype of the donor virus. A typical
reassortant virus will have the antigenicity of the recipient
virus, that is, it will retain the hemagglutinin (HA) and
neuraminidase (NA) phenotypes of the recipient virus.
[0018] The present invention further provides methods to propagate
cold-adapted equine influenza viruses or reassortant influenza A
viruses of the present invention. These methods include propagation
in embryonated chicken eggs or in tissue culture cells.
[0019] The present invention also describes nucleic acid molecules
encoding wild-type and cold-adapted equine influenza proteins M,
HA, NS, PB2, PB2-N, PB2-C, PB1, PB1-N, PB 1-C, and PA-C. One
embodiment of the present invention is an isolated equine nucleic
acid molecule having a nucleic acid sequence selected from a group
consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6,
SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13,
SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID
NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25 SEQ ID NO:44, SEQ
ID NO:46, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52,
SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:57, SEQ ID
NO:59, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ
ID NO:68, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:76, SEQ ID NO:78,
SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:85, SEQ ID
NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:93, SEQ
ID NO:94, SEQ ID NO:96, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:106
and SEQ ID NO:108 and a nucleic acid molecule comprising a nucleic
acid sequence which is fully complementary to any of such nucleic
acid sequences. Another embodiment of the present invention is an
isolated equine nucleic acid molecule that encodes a protein
comprising an amino acid sequence selected from the group
consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11,
SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:24, SEQ ID
NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:55, SEQ ID NO:58, SEQ
ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:77, SEQ ID NO:81,
SEQ ID NO:86, SEQ ID NO:89, SEQ ID NO:92, SEQ ID NO:95, SEQ ID
NO:104 and SEQ ID NO:107. Another embodiment is an isolated equine
influenza protein that comprises an amino acid sequence selected
from a group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8,
SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID
NO:24, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:55, SEQ
ID NO:58, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:77,
SEQ ID NO:81, SEQ ID NO:86, SEQ ID NO:89, SEQ ID NO:92, SEQ ID
NO:95, SEQ ID NO:104 and SEQ ID NO:107. Also included in the
present invention is a virus that include any of these nucleic acid
molecules or proteins. In one embodiment, such a virus is equine
influenza virus or a reassortant virus.
DETAILED DESCRIPTION OF THE INVENTION
[0020] The present invention provides experimentally-generated
cold-adapted equine influenza viruses comprising certain defined
phenotypes, which are disclosed herein. It is to be noted that the
term "a" or "an" entity, refers to one or more of that entity; for
example, "a cold-adapted equine influenza virus" can include one or
more cold-adapted equine influenza viruses. As such, the terms "a"
(or "an"), "one or more," and "at least one" can be used
interchangeably herein. It is also to be noted that the terms
"comprising," "including," and "having" can be used
interchangeably. Furthermore, an item "selected from the group
consisting of" refers to one or more of the items in that group,
including combinations thereof.
[0021] A cold-adapted equine influenza virus of the present
invention is a virus that has been generated in the laboratory, and
as such, is not a virus as occurs in nature. Since the present
invention also includes those viruses having the identifying
phenotypes of such a cold-adapted equine influenza virus, an equine
influenza virus isolated from a mixture of naturally-occurring
viruses, i.e., removed from its natural milieu, but having the
claimed phenotypes, is included in the present invention. A
cold-adapted equine influenza virus of the present invention does
not require any specific level of purity. For example, a
cold-adapted equine influenza virus grown in embryonated chicken
eggs may be in a mixture with the allantoic fluid (AF), and a
cold-adapted equine influenza virus grown in tissue culture cells
may be in a mixture with disrupted cells and tissue culture
medium.
[0022] As used herein, an "equine influenza virus" is an influenza
virus that infects and grows in equids, e.g., horses or ponies. As
used herein, "growth" of a virus denotes the ability of the virus
to reproduce or "replicate" itself in a permissive host cell. As
such, the terms, "growth of a virus" and "replication of a virus"
are used interchangeably herein. Growth or replication of a virus
in a particular host cell can be demonstrated and measured by
standard methods well-known to those skilled in the art of
virology. For example, samples containing infectious virus, e.g.,
as contained in nasopharyngeal secretions from an infected horse,
are tested for their ability to cause cytopathic effect (CPE),
e.g., virus plaques, in tissue culture cells. Infectious virus may
also be detected by inoculation of a sample into the allantoic
cavity of embryonated chicken eggs, and then testing the AF of eggs
thus inoculated for its ability to agglutinate red blood cells,
i.e., cause hemagglutination, due to the presence of the influenza
virus hemaglutinin (HA) protein in the AF.
[0023] Naturally-occurring, i.e., wild-type, equine influenza
viruses replicate well at a temperature from about 34.degree. C. to
about 39.degree. C. For example, wild-type equine influenza virus
replicates in embryonated chicken eggs at a temperature of about
34.degree. C., and replicates in tissue culture cells at a
temperature from about 34.degree. C. to about 39.degree. C. As used
herein, a "cold-adapted" equine influenza virus is an equine
influenza virus that has been adapted to grow at a temperature
lower than the optimal growth temperature for equine influenza
virus. One example of a cold-adapted equine influenza virus of the
present invention is a virus that replicates in embryonated chicken
eggs at a temperature of about 30.degree. C. A preferred
cold-adapted equine influenza virus of the present invention
replicates in embryonated chicken eggs at a temperature of about
28.degree. C. Another preferred cold-adapted equine influenza virus
of the present invention replicates in embryonated chicken eggs at
a temperature of about 26.degree. C. In general, preferred
cold-adapted equine influenza viruses of the present invention
replicate in embryonated chicken eggs at a temperature ranging from
about 26.degree. C. to about 30.degree. C., i.e., at a range of
temperatures at which a wild-type virus will grow poorly or not at
all. It should be noted that the ability of such viruses to
replicate within that temperature range does not preclude their
ability to also replicate at higher or lower temperatures. For
example, one embodiment is a cold-adapted equine influenza virus
that replicates in embryonated chicken eggs at a temperature of
about 26.degree. C., but also replicates in tissue culture cells at
a temperature of about 34.degree. C. As with wild-type equine
influenza viruses, cold-adapted equine influenza viruses of the
present invention generally form plaques in tissue culture cells,
for example Madin Darby Canine Kidney Cells (MDCK) at a temperature
of about 34.degree. C. Examples of suitable and preferred
cold-adapted equine influenza viruses of the present invention are
disclosed herein.
[0024] One embodiment of the present invention is a cold-adapted
equine influenza virus that is produced by a method which includes
passaging a wild-type equine influenza virus, and then selecting
viruses that grow at a reduced temperature. Cold-adapted equine
influenza viruses of the present invention can be produced, for
example, by sequentially passaging a wild-type equine influenza
virus in embryonated chicken eggs at progressively lower
temperatures, thereby selecting for certain members of the virus
mixture which stably replicate at the reduced temperature. An
example of a passaging procedure is disclosed in detail in the
Examples section. During the passaging procedure, one or more
mutations appear in certain of the single-stranded RNA segments
comprising the influenza virus genome, which alter the genotype,
i.e., the primary nucleotide sequence of those RNA segments. As
used herein, a "mutation" is an alteration of the primary
nucleotide sequence of any given RNA segment making up an influenza
virus genome. Examples of mutations include substitution of one or
more nucleotides, deletion of one or more nucleotides, insertion of
one or more nucleotides, or inversion of a stretch of two or more
nucleotides. By selecting for those members of the virus mixture
that stably replicate at a reduced temperature, a virus with a
cold-adaptation phenotype is selected. As used herein, a
"phenotype" is an observable or measurable characteristic of a
biological entity such as a cell or a virus, where the observed
characteristic is attributable to a specific genetic configuration
of that biological entity, i.e., a certain genotype. As such, a
cold-adaptation phenotype is the result of one or more mutations in
the virus genome. As used herein, the terms "a mutation," "a
genome," "a genotype," or "a phenotype" refer to one or more, or at
least one mutation, genome, genotype, or phenotype,
respectively.
[0025] Additional, observable phenotypes in a cold-adapted equine
influenza virus may occur, and will generally be the result of one
or more additional mutations in the genome of such a virus. For
example, a cold-adapted equine influenza virus of the present
invention may, in addition, be attenuated, exhibit dominant
interference, and/or be temperature sensitive.
[0026] In one embodiment, a cold-adapted equine influenza virus of
the present invention has a phenotype characterized by attenuation.
A cold-adapted equine influenza virus is "attenuated," when
administration of the virus to an equine influenza
virus-susceptible animal results in reduced or absent clinical
signs in that animal, compared to clinical signs observed in
animals that are infected with wild-type equine influenza virus.
For example, an animal infected with wild-type equine influenza
virus will display fever, sneezing, coughing, depression, and nasal
discharges. In contrast, an animal administered an attenuated,
cold-adapted equine influenza virus of the present invention will
display minimal or no, i.e., undetectable, clinical disease
signs.
[0027] In another embodiment, a cold-adapted equine influenza virus
of the present invention comprises a temperature sensitive
phenotype. As used herein, a temperature sensitive cold-adapted
equine influenza virus replicates at reduced temperatures, but no
longer replicates or forms plaques in tissue culture cells at
certain higher growth temperatures at which the wild-type virus
will replicate and form plaques. While not being bound by theory,
it is believed that replication of equine influenza viruses with a
temperature sensitive phenotype is largely restricted to the cool
passages of the upper respiratory tract, and does not replicate
efficiently in the lower respiratory tract, where the virus is more
prone to cause disease symptoms. A temperature at which a
temperature sensitive virus will grow is referred to herein as a
"permissive" temperature for that temperature sensitive virus, and
a higher temperature at which the temperature sensitive virus will
not grow, but at which a corresponding wild-type virus will grow,
is referred to herein as a "non-permissive" temperature for that
temperature sensitive virus. For example, certain temperature
sensitive cold-adapted equine influenza viruses of the present
invention replicate in embryonated chicken eggs at a temperature at
or below about 30.degree. C., preferably at about 28.degree. C. or
about 26.degree. C., and will form plaques in tissue culture cells
at a permissive temperature of about 34.degree. C., but will not
form plaques in tissue culture cells at a non-permissive
temperature of about 39.degree. C. Other temperature sensitive
cold-adapted equine influenza viruses of the present invention
replicate in embryonated chicken eggs at a temperature at or below
about 30.degree. C., preferably at about 28.degree. C. or about
26.degree. C., and will form plaques in tissue culture cells at a
permissive temperature of about 34.degree. C., but will not form
plaques in tissue culture cells at a non-permissive temperature of
about 37.degree. C.
[0028] Certain cold-adapted equine influenza viruses of the present
invention have a dominant interference phenotype; that is, they
dominate an infection when co-infected into cells with another
influenza A virus, thereby impairing the growth of that other
virus. For example, when a cold-adapted equine influenza virus of
the present invention, having a dominant interference phenotype, is
co-infected into MDCK cells with the wild-type parental equine
influenza virus, A/equine/Kentucky/1/91 (H3N8), growth of the
parental virus is impaired. Thus, in an animal that has recently
been exposed to, or may be soon exposed to, a virulent influenza
virus, i.e., an influenza virus that causes disease symptoms,
administration of a therapeutic composition comprising a
cold-adapted equine influenza virus having a dominant interference
phenotype into the upper respiratory tract of that animal will
impair the growth of the virulent virus, thereby ameliorating or
reducing disease in that animal, even in the absence of an immune
response to the virulent virus.
[0029] Dominant interference of a cold-adapted equine influenza
virus having a temperature sensitive phenotype can be measured by
standard virological methods. For example, separate monolayers of
MDCK cells can be infected with (a) a virulent wild-type influenza
A virus, (b) a temperature sensitive, cold-adapted equine influenza
virus, and (c) both viruses in a co-infection, with all infections
done at multiplicities of infection (MOI) of about 2 plaque forming
units (pfu) per cell. After infection, the virus yields from the
various infected cells are measured by duplicate plaque assays
performed at the permissive temperature for the cold-adapted equine
influenza virus and at the non-permissive temperature of that
virus. A cold adapted equine influenza virus having a temperature
sensitive phenotype is unable to form plaques at its non-permissive
temperature, while the wild-type virus is able to form plaques at
both the permissive and non-permissive temperatures. Thus it is
possible to measure the growth of the wild-type virus in the
presence of the cold adapted virus by comparing the virus yield at
the non-permissive temperature of the cells singly infected with
wild-type virus to the yield at the non-permissive temperature of
the wild-type virus in doubly infected cells.
[0030] Cold-adapted equine influenza viruses of the present
invention are characterized primarily by one or more of the
following identifying phenotypes: cold-adaptation, temperature
sensitivity, dominant interference, and/or attenuation. As used
herein, the phrase "an equine influenza virus comprises the
identifying phenotype(s) of cold-adaptation, temperature
sensitivity, dominant interference, and/or attenuation" refers to a
virus having such a phenotype(s). Examples of such viruses include,
but are not limited to, EIV-P821, identified by accession No. ATCC
VR-2625, EIV-P824, identified by accession No. ATCC VR-2624, and
EIV-MSV+5, identified by accession No. ATCC VR-2627, as well as
EIV-MSV0, EIV, MSV+1, EIV-MSV+2, EIV-MSV+3, and EIV-MSV+4.
Production of such viruses is described in the examples. For
example, cold-adapted equine influenza virus EIV-P821 is
characterized by, i.e., has the identifying phenotypes of, (a)
cold-adaptation, e.g., its ability to replicate in embryonated
chicken eggs at a temperature of about 26.degree. C.; (b)
temperature sensitivity, e.g., its inability to form plaques in
tissue culture cells and to express late gene products at a
non-permissive temperature of about 37.degree. C., and its
inability to form plaques in tissue culture cells and to synthesize
any viral proteins at a non-permissive temperature of about
39.degree. C.; (c) its attenuation upon administration to an equine
influenza virus-susceptible animal; and (d) dominant interference,
e.g., its ability, when co-infected into a cell with a wild-type
influenza A virus, to interfere with the growth of that wild-type
virus. Similarly, cold-adapted equine influenza virus EIV-P824 is
characterized by (a) cold adaptation, e.g., its ability to
replicate in embryonated chicken eggs at a temperature of about
28.degree. C.; (b) temperature sensitivity, e.g., its inability to
form plaques in tissue culture cells at a non-permissive
temperature of about 39.degree. C.; and (c) dominant interference,
e.g., its ability, when co-infected into a cell with a wild-type
influenza A virus, to interfere with the growth of that wild-type
virus. In another example, cold-adapted equine influenza virus
EIV-MSV+5 is characterized by (a) cold-adaptation, e.g., its
ability to replicate in embryonated chicken eggs at a temperature
of about 26.degree. C.; (b) temperature sensitivity, e.g., its
inability to form plaques in tissue culture cells at a
non-permissive temperature of about 39.degree. C.; and (c) its
attenuation upon administration to an equine influenza
virus-susceptible animal.
[0031] In certain cases, the RNA segment upon which one or more
mutations associated with a certain phenotype occur may be
determined through reassortment analysis by standard methods, as
disclosed herein. In one embodiment, a cold-adapted equine
influenza virus of the present invention comprises a temperature
sensitive phenotype that correlates with at least two mutations in
the genome of that virus. In this embodiment, one of the two
mutations, localized by reassortment analysis as disclosed herein,
inhibits, i.e., blocks or prevents, the ability of the virus to
form plaques in tissue culture cells at a non-permissive
temperature of about 39.degree. C. This mutation co-segregates with
the segment of the equine influenza virus genome that encodes the
nucleoprotein (NP) gene of the virus, i.e., the mutation is located
on the same RNA segment as the NP gene. In this embodiment, the
second mutation inhibits all protein synthesis at a non-permissive
temperature of about 39.degree. C. As such, at the non-permissive
temperature, the virus genome is incapable of expressing any viral
proteins. Examples of cold-adapted equine influenza viruses
possessing these characteristics are EIV-P821 and EIV MSV+5.
EIV-P821 was generated by serial passaging of a wild-type equine
influenza virus in embryonated chicken eggs by methods described in
Example 1A. EIV-MSV+5 was derived by further serial passaging of
EIV-P821, as described in Example 1E.
[0032] Furthermore, a cold-adapted, temperature sensitive equine
influenza virus comprising the two mutations which inhibit plaque
formation and viral protein synthesis at a non-permissive
temperature of about 39.degree. C. can comprise one or more
additional mutations, which inhibit the virus' ability to
synthesize late gene products and to form plaques in tissue culture
cells at a non-permissive temperature of about 37.degree. C. An
example of a cold-adapted equine influenza virus possessing these
characteristics is EIV-P821. This virus isolate replicates in
embryonated chicken eggs at a temperature of about 26.degree. C.,
and does not form plaques or express any viral proteins at a
temperature of about 39.degree. C. Furthermore, EIV-P821 does not
form plaques on MDCK cells at a non-permissive temperature of about
37.degree. C., and at this temperature, late gene expression is
inhibited in such a way that late proteins are not produced, i.e.,
normal levels of NP protein are synthesized, reduced or
undetectable levels of M1 or HA proteins are synthesized, and
enhanced levels of the polymerase proteins are synthesized. Since
this phenotype is typified by differential viral protein synthesis,
it is distinct from the protein synthesis phenotype seen at a
non-permissive temperature of about 39.degree. C., which is
typified by the inhibition of synthesis of all viral proteins.
[0033] Pursuant to 37 CFR .sctn. 1.802 (a-c), cold-adapted equine
influenza viruses, designated herein as EIV-P821, an EIV-P824 were
deposited with the American Type Culture Collection (ATCC, 10801
University Boulevard, Manassas, Va. 20110-2209) under the Budapest
Treaty as ATCC Accession Nos. ATCC VR-2625, and ATCC VR-2624,
respectively, on Jul. 11, 1998. Cold-adapted equine influenza virus
EIV-MSV+5 was deposited with the ATCC as ATCC Accession No. ATCC
VR-2627 on Aug. 3, 1998. Pursuant to 37 CFR.sctn. 1.806, the
deposits are made for a term of at least thirty (30) years and at
least five (5) years after the most recent request for the
furnishing of a sample of the deposit was received by the
depository. Pursuant to 37 CFR .sctn. 1.808 (a)(2), all
restrictions imposed by the depositor on the availability to the
public will be irrevocably removed upon the granting of the
patent.
[0034] Preferred cold-adapted equine influenza viruses of the
present invention have the identifying phenotypes of EIV-P821,
EIV-P824, and EIV-MSV+5. Particularly preferred cold-adapted equine
influenza viruses include EIV-P821, EIV-P824, EIV-MSV+5, and
progeny of these viruses. As used herein, "progeny" are
"offspring," and as such can slightly altered phenotypes compared
to the parent virus, but retain identifying phenotypes of the
parent virus, for example, cold-adaptation, temperature
sensitivity, dominant interference, or attenuation. For example,
cold-adapted equine influenza virus EIV-MSV+5 is a "progeny" of
cold-adapted equine influenza virus EIV-P821. "Progeny" also
include reassortant influenza A viruses that comprise one or more
identifying phenotypes of the donor parent virus.
[0035] Reassortant influenza A viruses of the present invention are
produced by genetic reassortment of the genome segments of a donor
cold-adapted equine influenza virus of the present invention with
the genome segments of a recipient influenza A virus, and then
selecting a reassortant virus that derives at least one of its
eight RNA genome segments from the donor virus, such that the
reassortant virus acquires at least one identifying phenotype of
the donor cold-adapted equine influenza virus. Identifying
phenotypes include cold-adaptation, temperature sensitivity,
attenuation, and dominant interference. Preferably, reassortant
influenza A viruses of the present invention derive at least the
attenuation phenotype of the donor virus. Methods to isolate
reassortant influenza viruses are well known to those skilled in
the art of virology and are disclosed, for example, in Fields, et
al., 1996, Fields Virology, 3d ed., Lippincott-Raven; and Palese,
et al., 1976, J. Virol., 17, 876-884. Fields, et al., ibid. and
Palese, et al., ibid.
[0036] A suitable donor equine influenza virus is a cold-adapted
equine influenza virus of the present invention, for example,
EIV-P821, identified by accession No. ATCC VR-2625, EIV-P824,
identified by accession No. ATCC VR-2624, or EIV-MSV+5, identified
by accession No. ATCC VR-2627. A suitable recipient influenza A
virus can be another equine influenza virus, for example a Eurasian
subtype 2 equine influenza virus such as A/equine/Suffolk/89 (H3N8)
or a subtype 1 equine influenza virus such as A/Prague/1/56 (H7N7).
A recipient influenza A virus can also be any influenza A virus
capable of forming a reassortant virus with a donor cold-adapted
equine influenza virus. Examples of such influenza A viruses
include, but are not limited to, human influenza viruses such as
A/Puerto Rico/8/34 (H1N1), A/Hong Kong/156/97 (H5N1),
A/Singapore/1/57 (H2N2), and A/Hong Kong/1/68 (H3N2); swine viruses
such as A/Swine/Iowa/15/30 (H1N1); and avian viruses such as
A/mallard/New York/6750/78 (H2N2) and A/chicken/Hong Kong/258/97
(H5N1). A reassortant virus of the present invention can include
any combination of donor and recipient gene segments, as long as
the resulting reassortant virus possesses at least one identifying
phenotype of the donor virus.
[0037] One example of a reassortant virus of the present invention
is a "6+2" reassortant virus, in which the six "internal gene
segments," i.e., those comprising the NP, PB2, PB1, PA, M, and NS
genes, are derived from the donor cold-adapted equine influenza
virus genome, and the two "external gene segments," i.e., those
comprising the HA and NA genes, are derived from the recipient
influenza A virus. A resultant virus thus produced has the
attenuated, cold-adapted, temperature sensitive, and/or dominant
interference phenotypes of the donor cold-adapted equine influenza
virus, but the antigenicity of the recipient strain.
[0038] In yet another embodiment, a cold-adapted equine influenza
virus of the present invention can be produced through recombinant
means. In this approach, one or more specific mutations, associated
with identified cold-adaptation, attenuation, temperature
sensitivity, or dominant interference phenotypes, are identified
and are introduced back into a wild-type equine influenza virus
strain using a reverse genetics approach. Reverse genetics entails
using RNA polymerase complexes isolated from influenza
virus-infected cells to transcribe artificial influenza virus
genome segments containing the mutation(s), incorporating the
synthesized RNA segment(s) into virus particles using a helper
virus, and then selecting for viruses containing the desired
changes. Reverse genetics methods for influenza viruses are
described, for example, in Enami, et al., 1990, Proc. Natl. Acad.
Sci. 87, 3802-3805; and in U.S. Pat. No. 5,578,473, by Palese, et
al., issued Nov. 26, 1996. This approach allows one skilled in the
art to produce additional cold-adapted equine influenza viruses of
the present invention without the need to go through the lengthy
cold-adaptation process, and the process of selecting mutants both
in vitro and in vivo with the desired virus phenotype.
[0039] A cold-adapted equine influenza virus of the present
invention may be propagated by standard virological methods
well-known to those skilled in the art, examples of which are
disclosed herein. For example, a cold-adapted equine influenza
virus can be grown in embryonated chicken eggs or in eukaryotic
tissue culture cells. Suitable continuous eukaryotic cell lines
upon which to grow a cold-adapted equine influenza virus of the
present invention include those that support growth of influenza
viruses, for example, MDCK cells. Other suitable cells upon which
to grow a cold-adapted equine influenza virus of the present
invention include, but are not limited to, primary kidney cell
cultures of monkey, calf, hamster or chicken.
[0040] In one embodiment, the present invention provides a
therapeutic composition to protect an animal against disease caused
by an influenza A virus, where the therapeutic composition includes
either a cold-adapted equine influenza virus or a reassortant
influenza A virus comprising at least one genome segment of an
equine influenza virus generated by cold-adaptation, wherein the
equine influenza virus genome segment confers at least one
identifying phenotype of the cold-adapted equine influenza virus.
In addition, a therapeutic composition of the present invention can
include an equine influenza virus that has been genetically
engineered to comprise one or more mutations, where those mutations
have been identified to confer a certain identifying phenotype on a
cold-adapted equine influenza virus of the present invention. As
used herein, the phrase "disease caused by an influenza A virus"
refers to the clinical manifestations observed in an animal which
has been infected with a virulent influenza A virus. Examples of
such clinical manifestations include, but are not limited to,
fever, sneezing, coughing, nasal discharge, rates, anorexia and
depression. In addition, the phrase "disease caused by an influenza
A virus" is defined herein to include shedding of virulent virus by
the infected animal. Verification that clinical manifestations
observed in an animal correlate with infection by virulent equine
influenza virus may be made by several methods, including the
detection of a specific antibody and/or T-cell responses to equine
influenza virus in the animal. Preferably, verification that
clinical manifestations observed in an animal correlate with
infection by a virulent influenza A virus is made by the isolation
of the virus from the afflicted animal, for example, by swabbing
the nasopharyngeal cavity of that animal for virus-containing
secretions. Verification of virus isolation may be made by the
detection of CPE in tissue culture cells inoculated with the
isolated secretions, by inoculation of the isolated secretions into
embryonated chicken eggs, where virus replication is detected by
the ability of AF from the inoculated eggs to agglutinate
erythrocytes, suggesting the presence of the influenza virus
hemagglutinin protein, or by use of a commercially available
diagnostic test, for example, the Directigen.RTM. FLU A test.
[0041] As used herein, the term "to protect" includes, for example,
to prevent or to treat influenza A virus infection in the subject
animal. As such, a therapeutic composition of the present invention
can be used, for example, as a prophylactic vaccine to protect a
subject animal from influenza disease by administering the
therapeutic composition to that animal at some time prior to that
animal's exposure to the virulent virus.
[0042] A therapeutic composition of the present invention,
comprising a cold-adapted equine influenza virus having a dominant
interference phenotype, can also be used to treat an animal that
has been recently infected with virulent influenza A virus or is
likely to be subsequently exposed in a few days, such that the
therapeutic composition immediately interferes with the growth of
the virulent virus, prior to the animal's production of antibodies
to the virulent virus. A therapeutic composition comprising a
cold-adapted equine influenza virus having a dominant interference
phenotype may be effectively administered prior to subsequent
exposure for a length of time corresponding to the approximate
length of time that a cold-adapted equine influenza virus of the
present invention will replicate in the upper respiratory tract of
a treated animal, for example, up to about seven days. A
therapeutic composition comprising a cold-adapted equine influenza
virus having a dominant interference phenotype may be effectively
administered following exposure to virulent equine influenza virus
for a length of time corresponding to the time required for an
infected animal to show disease symptoms, for example, up to about
two days.
[0043] Therapeutic compositions of the present invention can be
administered to any animal susceptible to influenza virus disease,
for example, humans, swine, horses and other equids, aquatic birds,
domestic and game fowl, seals, mink, and whales. Preferably, a
therapeutic composition of the present invention is administered
equids. Even more preferably, a therapeutic composition of the
present invention is administered to a horse, to protect against
equine influenza disease.
[0044] Current vaccines available to protect horses against equine
influenza virus disease are not effective in protecting young
foals, most likely because they cannot overcome the maternal
antibody present in these young animals, and often, vaccination at
an early age, for example 3 months of age, can lead to tolerance
rather than immunity. In one embodiment, and in contrast to
existing equine influenza virus vaccines, a therapeutic composition
comprising a cold-adapted equine influenza virus of the present
invention apparently can produce immunity in young animals. As
such, a therapeutic composition of the present invention can be
safely and effectively administered to young foals, as young as
about 3 months of age, to protect against equine influenza disease
without the induction of tolerance.
[0045] In one embodiment, a therapeutic composition of the present
invention can be multivalent. For example, it can protect an animal
from more than one strain of influenza A virus by providing a
combination of one or more cold-adapted equine influenza viruses of
the present invention, one or more reassortant influenza A viruses,
and/or one or more genetically-engineered equine influenza viruses
of the present invention. Multivalent therapeutic compositions can
include at least two cold-adapted equine influenza viruses, e.g.,
against North American subtype-2 virus isolates such as
A/equine/Kentucky/1/91 (H1N8), and Eurasian subtype-2 virus
isolates such as A/equine/Suffolk/89 (H3N8); or one or more
subtype-2 virus isolates and a subtype-1 virus isolate such as
A/equine/Prague/1/56 (H7N7). Similarly, a multivalent therapeutic
composition of the present invention can include a cold-adapted
equine influenza virus and a reassortant influenza A virus of the
present invention, or two reassortant influenza A viruses of the
present invention. A multivalent therapeutic composition of the
present invention can also contain one or more formulations to
protect against one or more other infectious agents in addition to
influenza A virus. Such other infectious agents include, but not
limited to: viruses; bacteria; fungi and fungal-related
microorganisms; and parasites. Preferable multivalent therapeutic
compositions include, but are not limited to, a cold-adapted equine
influenza virus, reassortant influenza A virus, or
genetically-engineered equine influenza virus of the present
invention plus one or more compositions protective against one or
more other infectious agents that afflict horses. Suitable
infectious agents to protect against include, but are not limited
to, equine infectious anemia virus, equine herpes virus, eastern,
western, or Venezuelan equine encephalitis virus, tetanus,
Streptococcus equi, and Ehrlichia resticii.
[0046] A therapeutic composition of the present invention can be
formulated in an excipient that the animal to be treated can
tolerate. Examples of such excipients include water, saline,
Ringer's solution, dextrose solution, Hank's solution, and other
aqueous physiologically balanced salt solutions. Excipients can
also contain minor amounts of additives, such as substances that
enhance isotonicity and chemical or biological stability. Examples
of buffers include phosphate buffer, bicarbonate buffer, and Tris
buffer, while examples of stabilizers include A1/A2 stabilizer,
available from Diamond Animal Health, Des Moines, Iowa. Standard
formulations can either be liquids or solids which can be taken up
in a suitable liquid as a suspension or solution for administration
to an animal. In one embodiment, a non-liquid formulation may
comprise the excipient salts, buffers, stabilizers, etc., to which
sterile water or saline can be added prior to administration.
[0047] A therapeutic composition of the present invention may also
include one or more adjuvants or carriers. Adjuvants are typically
substances that enhance the immune response of an animal to a
specific antigen, and carriers include those compounds that
increase the half-life of a therapeutic composition in the treated
animal. One advantage of a therapeutic composition comprising a
cold-adapted equine influenza virus or a reassortant influenza A
virus of the present invention is that adjuvants and carriers are
not required to produce an efficacious vaccine. Furthermore, in
many cases known to those skilled in the art, the advantages of a
therapeutic composition of the present invention would be hindered
by the use of some adjuvants or carriers. However, it should be
noted that use of adjuvants or carriers is not precluded by the
present invention.
[0048] Therapeutic compositions of the present invention include an
amount of a cold-adapted equine influenza virus that is sufficient
to protect an animal from challenge with virulent equine influenza
virus. In one embodiment, a therapeutic composition of the present
invention can include an amount of a cold-adapted equine influenza
virus ranging from about 10.sup.5 tissue culture infectious dose-50
(TCID.sub.50) units of virus to about 10.sup.8 TCID.sub.50 units of
virus. As used herein, a "TCID.sub.50 unit" is amount of a virus
which results in cytopathic effect in 50% of those cell cultures
infected. Methods to measure and calculate TCID.sub.50 are known to
those skilled in the art and are available, for example, in Reed
and Muench, 1938, Am. J. of Hyg. 27, 493-497. A preferred
therapeutic composition of the present invention comprises from
about 10.sup.6 TCID.sub.50 units to about 10.sup.7 TCID.sub.50
units of a cold-adapted equine influenza virus or reassortant
influenza A virus of the present invention. Even more preferred is
a therapeutic composition comprising about 2.times.10.sup.6
TCID.sub.50 units of a cold-adapted equine influenza virus or
reassortant influenza A virus of the present invention.
[0049] The present invention also includes methods to protect an
animal against disease caused by an influenza A virus comprising
administering to the animal a therapeutic composition of the
present invention. Preferred are those methods which protect an
equid against disease caused by equine influenza virus, where those
methods comprise administering to the equid a cold-adapted equine
influenza virus. Acceptable protocols to administer therapeutic
compositions in an effective manner include individual dose size,
number of doses, frequency of dose administration, and mode of
administration. Determination of such protocols can be accomplished
by those skilled in the art, and examples are disclosed herein.
[0050] A preferable method to protect an animal against disease
caused by an influenza A virus includes administering to that
animal a single dose of a therapeutic composition comprising a
cold-adapted equine influenza virus, a reassortant influenza A
virus, or genetically-engineered equine influenza virus of the
present invention. A suitable single dose is a dose that is capable
of protecting an animal from disease when administered one or more
times over a suitable time period. The method of the present
invention may also include administering subsequent, or booster
doses of a therapeutic composition. Booster administrations can be
given from about 2 weeks to several years after the original
administration. Booster administrations preferably are administered
when the immune response of the animal becomes insufficient to
protect the animal from disease. Examples of suitable and preferred
dosage schedules are disclosed in the Examples section.
[0051] A therapeutic composition of the present invention can be
administered to an animal by a variety of means, such that the
virus will enter and replicate in the mucosal cells in the upper
respiratory tract of the treated animal. Such means include, but
are not limited to, intranasal administration, oral administration,
and intraocular administration. Since influenza viruses naturally
infect the mucosa of the upper respiratory tract, a preferred
method to administer a therapeutic composition of the present
invention is by intranasal administration. Such administration may
be accomplished by use of a syringe fitted with cannula, or by use
of a nebulizer fitted over the nose and mouth of the animal to be
vaccinated.
[0052] The efficacy of a therapeutic composition of the present
invention to protect an animal against disease caused by influenza
A virus can be tested in a variety of ways including, but not
limited to, detection of antibodies by, for example,
hemagglutination inhibition (HAI) tests, detection of cellular
immunity within the treated animal, or challenge of the treated
animal with virulent equine influenza virus to determine whether
the treated animal is resistant to the development of disease. In
addition, efficacy of a therapeutic composition of the present
invention comprising a cold-adapted equine influenza virus having a
dominant interference phenotype to ameliorate or reduce disease
symptoms in an animal previously inoculated or susceptible to
inoculation with a virulent, wild-type equine influenza virus can
be tested by screening for the reduction or absence of disease
symptoms in the treated animal.
[0053] The present invention also includes methods to produce a
therapeutic composition of the present invention. Suitable and
preferred methods for making a therapeutic composition of the
present invention are disclosed herein. Pertinent steps involved in
producing one type of therapeutic composition of the present
invention, i.e., a cold-adapted equine influenza virus, include (a)
passaging a wild-type equine influenza virus in vitro, for example,
in embryonated chicken eggs; (b) selecting viruses that grow at a
reduced temperature; (c) repeating the passaging and selection
steps one or more times, at progressively lower temperatures, until
virus populations are selected which stably grow at the desired
lower temperature; and (d) mixing the resulting virus preparation
with suitable excipients.
[0054] The pertinent steps involved in producing another type of
therapeutic composition of the present invention, i.e., a
reassortant influenza A virus having at least one genome segment of
an equine influenza virus generated by adaptation, includes the
steps of (a) mixing the genome segments of a donor cold-adapted
equine influenza virus, which preferably also has the phenotypes of
attenuation, temperature sensitivity, or dominant interference,
with the genome segments of a recipient influenza A virus, and (b)
selecting reassortant viruses that have at least one identifying
phenotype of the donor equine influenza virus. Identifying
phenotypes to select for include attenuation, cold-adaptation,
temperature sensitivity, and dominant interference. Methods to
screen for these phenotypes are well known to those skilled in the
art, and are disclosed herein. It is preferable to screen for
viruses that at least have the phenotype of attenuation.
[0055] Using this method to generate a reassortant influenza A
virus having at least one genome segment of a equine influenza
virus generated by cold-adaptation, one type of reassortant virus
to select for is a "6+2" reassortant, where the six "internal gene
segments," i.e., those coding for the NP, PB2, PB1, PA, M, and NS
genes, are derived from the donor cold-adapted equine influenza
virus genome, and the two "external gene segments," i.e., those
coding for the HA and NA genes, are derived from the recipient
influenza A virus. A resultant virus thus produced can have the
cold-adapted, attenuated, temperature sensitive, and/or
interference phenotypes of the donor cold-adapted equine influenza
virus, but the antigenicity of the recipient strain.
[0056] The present invention includes nucleic acid molecules
isolated from equine influenza virus wild type strain
A/equine/Kentucky/1/91 (H3N8), and cold-adapted equine influenza
virus EIV-P821.
[0057] In accordance with the present invention, an isolated
nucleic acid molecule is a nucleic acid molecule that has been
removed from its natural milieu (i.e., that has been subject to
human manipulation) and can include DNA, RNA, or derivatives of
either DNA or RNA. As such, "isolated" does not reflect the extent
to which the nucleic acid molecule has been purified.
[0058] The present invention includes nucleic acid molecules
encoding wild-type and cold-adapted equine influenza virus
proteins. Nucleic acid molecules of the present invention can be
prepared by methods known to one skilled in the art. Proteins of
the present invention can be prepared by methods known to one
skilled in the art, i.e., recombinant DNA technology. Preferred
nucleic acid molecules have coding strands comprising nucleic acid
sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ
ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ
ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:21,
SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:44, SEQ ID
NO:46, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO: 50, SEQ ID NO: 52,
SEQ ID NO: 53, SEQ ID NO:54, SEQ ID NO: 56, SEQ ID NO:57, SEQ ID
NO:59, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67,
SEQ ID NO: 68, SEQ ID NO:70, SEQ ID NO: 71, SEQ ID NO: 76, SEQ ID
NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO:82, SEQ ID NO: 85,
SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID
NO: 93, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO:103, SEQ ID NO:105,
SEQ ID NO:106 and SEQ ID NO:108 and/or a complement thereof.
Complements are defined as two single strands of nucleic acid in
which the nucleotide sequence is such that they will hybridize as a
result of base pairing throughout their full length. Given a
nucleotide sequence, one of ordinary skill in the art can deduce
the complement.
[0059] Preferred nucleic acid molecules encoding equine influenza M
proteins are nei.sub.wtM.sub.1023, nei.sub.wt1M.sub.1023,
nei.sub.wt2M.sub.1023, nei.sub.wtM.sub.756, nei.sub.wt1M.sub.756,
nei.sub.wt2M.sub.756, nei.sub.ca1M.sub.1023, nei.sub.ca2M.sub.1023,
nei.sub.ca1M.sub.756, and/or nei.sub.ca2M.sub.756, the coding
strands of which are represented by SEQ ID NO:1, SEQ ID NO:3, SEQ
ID NO:4, and/or SEQ ID NO:6.
[0060] Preferred nucleic acid molecules encoding equine influenza
HA proteins are nei.sub.wtHA.sub.1762, nei.sub.wtHA.sub.1695,
nei.sub.ca1HA.sub.1762, nei.sub.ca2HA.sub.1762,
nei.sub.ca1HA.sub.1695, and/or nei.sub.ca2HA.sub.1695, the coding
strands of which are represented by SEQ ID NO:7, SEQ ID NO:9, SEQ
ID NO:10, and/or SEQ ID NO:12.
[0061] Preferred nucleic acid molecules encoding equine influenza
PB2-N proteins are nei.sub.wtPB2-N.sub.1241,
nei.sub.wtPB2-N.sub.1214, nei.sub.ca1PB2-N.sub.1241,
nei.sub.ca2PB2-N.sub.1241, nei.sub.ca1PB2-N.sub.1214 nei.sub.ca2,
and/or PB2-N.sub.1214, the coding strands of which are represented
by SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, and/or SEQ ID
NO:18.
[0062] Preferred nucleic acid molecules encoding equine influenza
PB2-C proteins are nei.sub.wt1PB2-C.sub.1233,
nei.sub.wt2PB2-C.sub.1232, nei.sub.wtPB2-C.sub.1194,
nei.sub.ca1PB2-C.sub.1232, nei.sub.ca2PB2-C.sub.1231, and/or
nei.sub.ca1PB2-C.sub.1194, the coding strands of which are
represented by SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:21, SEQ ID
NO:23, and/or SEQ ID NO:25.
[0063] Preferred nucleic acid molecules encoding equine influenza
PB2 proteins are nei.sub.wtPB2.sub.2341, nei.sub.wtPB2.sub.2277,
nei.sub.ca1PB2.sub.2341, and/or nei.sub.ca1PB2.sub.2277, the coding
strands of which are represented by SEQ ID NO:44, SEQ ID NO:46, SEQ
ID NO:47, and/or SEQ ID NO:49.
[0064] Preferred nucleic acid molecules encoding equine influenza
NS proteins are nei.sub.wt1NS.sub.891, nei.sub.wt2NS.sub.891,
nei.sub.wt1NS.sub.690, nei.sub.wt2NS.sub.690,
nei.sub.wt3NS.sub.888, nei.sub.wt3NS.sub.690,
nei.sub.wt4NS.sub.468, nei.sub.wt4NS.sub.293,
nei.sub.ca1NS.sub.888, nei.sub.ca2NS.sub.888,
nei.sub.ca1NS.sub.690, and/or nei.sub.ca2NS.sub.690 other coding
strands of which are represented by SEQ ID NO:50, SEQ ID NO:52, SEQ
ID NO:53, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:57 and/or SEQ ID
NO:59.
[0065] Preferred nucleic acid molecules encoding equine influenza
PB1-N proteins are nei.sub.wt1PB1-N.sub.1229,
nei.sub.wt1PB1N.sub.1194, nei.sub.wt2PB1-N.sub.673,
nei.sub.wt2PB1-N.sub.636, nei.sub.ca1PB1-N.sub.1225,
nei.sub.ca1PB1-N.sub.1185, nei.sub.ca2PB1-N.sub.1221, and/or
nei.sub.ca2PB1-N.sub.1185 the coding strands of which are
represented by SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID
NO:67, SEQ ID NO:68, SEQ ID NO:70, and/or SEQ ID NO:71.
[0066] Preferred nucleic acid molecules encoding equine influenza
PA-C proteins are nei.sub.wt1PA-C.sub.1228,
nei.sub.wt1PA-C.sub.1164, nei.sub.wt2PA-C.sub.1223,
nei.sub.wt2PA-C.sub.1164, nei.sub.ca1PA-C.sub.1233,
nei.sub.ca2PA-C.sub.1233, nei.sub.ca1PA-C.sub.1170, and/or
nei.sub.ca2PA-C.sub.1170 the coding strands of which are
represented by SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:79, SEQ ID
NO:80, and/or SEQ ID NO:82.
[0067] Preferred nucleic acid molecules encoding equine influenza
PB1-C proteins are nei.sub.wt1PB1-C.sub.1234,
nei.sub.wt1PB1-C.sub.1188, nei.sub.wt2PB1-C.sub.1240,
nei.sub.wt2PB1-C.sub.1188, nei.sub.ca1PB1-C.sub.1241,
nei.sub.ca1PB1-C.sub.1188, nei.sub.ca2PB1-C.sub.1241 and/or
nei.sub.ca2PB1-C.sub.1188, the coding strands of which are
represented by SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID
NO:90, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:94 and/or SEQ ID
NO:96.
[0068] Preferred nucleic acid molecules encoding equine influenza
PB1 proteins are nei.sub.wtPB1.sub.2341, nei.sub.wtPB1.sub.2271,
nei.sub.ca1PB1.sub.2341, nei.sub.ca1PB1.sub.2271, the coding
strands of which are represented by SEQ ID NO:103, SEQ ID NO:105,
SEQ ID NO:106, and/or SEQ ID NO:108.
[0069] The present invention includes proteins comprising SEQ ID
NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID
NO:17, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:45, SEQ ID NO:48, SEQ
ID NO:51, SEQ ID NO: 55, SEQ ID NO:58, SEQ ID NO: 63, SEQ ID NO:66,
SEQ ID NO: 69, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO:86, SEQ ID
NO: 89, SEQ ID NO: 92, SEQ ID NO:95, SEQ ID NO:104 and SEQ ID NO:
107 as well as nucleic acid molecules encoding such proteins.
[0070] Preferred equine influenza M proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wtM.sub.1023, nei.sub.wt1M.sub.1023,
nei.sub.wt2M.sub.1023, nei.sub.wtM.sub.756, nei.sub.wt1M.sub.756,
nei.sub.wt2M.sub.756, nei.sub.ca1M.sub.1023, nei.sub.ca2M.sub.1023,
nei.sub.ca1M.sub.756, and/or nei.sub.ca2M.sub.756. Preferred equine
influenza M proteins are Pei.sub.wtM.sub.252, Pei.sub.ca1M.sub.252,
and/or Pei.sub.ca2M.sub.252. In one embodiment, a preferred equine
influenza M protein of the present invention is encoded by SEQ ID
NO:1, SEQ ID NO:3, SEQ ID NO:4, and/or SEQ ID NO:6, and, as such,
has an amino acid sequence that includes SEQ ID NO:2 and/or SEQ ID
NO:5.
[0071] Preferred equine influenza HA proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wtHA.sub.1762, nei.sub.wtHA.sub.1695,
nei.sub.ca1HA.sub.1762, nei.sub.ca2HA.sub.1762,
nei.sub.ca1HA.sub.1695, and/or nei.sub.ca2HA.sub.1695. Preferred
equine influenza HA proteins are P Pei.sub.wtHA.sub.565,
Pei.sub.ca1HA.sub.565, and/or Pei.sub.ca2HA.sub.565. In one
embodiment, a preferred equine influenza HA protein of the present
invention is encoded by SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10,
and/or SEQ ID NO:12, and, as such, has an amino acid sequence that
includes SEQ ID NO:8 and/or SEQ ID NO:11.
[0072] Preferred equine influenza PB2-N proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wtPB2-N.sub.1241, nei.sub.wtPB2-N.sub.1214,
nei.sub.ca1PB2-N.sub.1241 nei.sub.ca2PB2-N.sub.1241,
nei.sub.ca1PB2-N.sub.1214 nei.sub.ca2, and/or PB2-N.sub.1214.
Preferred equine influenza PB2-N proteins are
P.sub.wtPB2-N.sub.404, P.sub.ca1PB2-N.sub.404, and/or
P.sub.ca2PB2-N.sub.404. In one embodiment, a preferred equine
influenza PB2-N protein of the present invention is encoded by SEQ
ID NO:13, SEQ ID NO:15, SEQ ID NO:16, and/or SEQ ID NO:18, and, as
such, has an amino acid sequence that includes SEQ ID NO:14 and/or
SEQ ID NO:17.
[0073] Preferred equine influenza PB2-C proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wt1PB2-C.sub.1233, nei.sub.wt2PB2-C.sub.1232,
nei.sub.wtPB2-C.sub.1194, nei.sub.ca1PB2-C.sub.1232,
nei.sub.ca2PB2-C.sub.1231, and/or nei.sub.ca1PB2-C.sub.1194.
Preferred equine influenza PB2-N proteins are
P.sub.wtPB2-C.sub.398, P.sub.ca1PB2-C.sub.398, and/or
P.sub.ca2PB2-C.sub.398. In one embodiment, a preferred equine
influenza PB2-C protein of the present invention is encoded by SEQ
ID NO:19, SEQ ID NO:22, SEQ ID NO:21, SEQ ID NO:23, and/or SEQ ID
NO:25, and, as such, has an amino acid sequence that includes SEQ
ID NO:20 and/or SEQ ID NO:24.
[0074] Preferred equine influenza PB2 proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wtPB2.sub.2341, nei.sub.wtPB2.sub.2277,
nei.sub.ca1PB2.sub.2341, and or nei.sub.ca1PB2.sub.2277. Preferred
equine influenza PB2 proteins are Pei.sub.wtPB2.sub.759, and/or
Pei.sub.ca1PB2.sub.759. In one embodiment, a preferred equine
influenza PB2 protein of the present invention is encoded by SEQ ID
NO:44, SEQ ID NO:46, SEQ ID NO:47, and/or SEQ ID NO:49, and, as
such, has an amino acid sequence that includes SEQ ID NO:45 and/or
SEQ ID NO:48.
[0075] Preferred equine influenza NS proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wt1NS.sub.891, nei.sub.wt2NS.sub.891,
nei.sub.wt1NS.sub.690, nei.sub.wt3NS.sub.888,
nei.sub.wt4NS.sub.468, nei.sub.wt4NS.sub.293,
nei.sub.ca1NS.sub.888, nei.sub.ca2NS.sub.888, and/or
nei.sub.ca1NS.sub.690. Preferred equine influenza NS proteins are
Pei.sub.wtNS.sub.230, Pei.sub.wt4NS.sub.97, and/or
Pei.sub.ca1NS.sub.230. In one embodiment, a preferred equine
influenza NS protein of the present invention is encoded by SEQ ID
NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:56, SEQ
ID NO:57 and/or SEQ ID NO:59, and, as such, has an amino acid
sequence that includes SEQ ID NO:51, SEQ ID NO:55 and/or SEQ ID
NO:58.
[0076] Preferred equine influenza PB1-N proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wt1PB1-N.sub.1229, nei.sub.wt1PB1N.sub.1194,
nei.sub.wt2PB1-N.sub.673, nei.sub.wt2PB1-N.sub.636,
nei.sub.ca1PB21-N.sub.1225, nei.sub.ca1PB1-N.sub.1185, and/or
nei.sub.ca2PB1-N.sub.1221. Preferred equine influenza PB1-N
proteins are Pei.sub.wt1PB1-N.sub.398, P.sub.wt2PB1-N.sub.212,
and/or P.sub.ca1PB1-N.sub.395. In one embodiment, a preferred
equine influenza PB1-N protein of the present invention is encoded
by SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID
NO:68, SEQ ID NO:70, and/or SEQ ID NO:71, and, as such, has an
amino acid sequence that includes SEQ ID NO:63, SEQ ID NO:66 and/or
SEQ ID NO:69.
[0077] Preferred equine influenza PB1-C proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wt1PB1-C.sub.1234, nei.sub.wt1PB1-C.sub.1188,
nei.sub.wt2PB1-C.sub.1240, nei.sub.wt2PB1-C.sub.1188,
nei.sub.ca1PB1-C.sub.1241, nei.sub.ca1PB1-C.sub.1188,
nei.sub.ca2PB1-C.sub.1241 and/or nei.sub.ca2PB1-C.sub.1188.
Preferred equine influenza PB1-C proteins are
Pei.sub.wt1PB1-C.sub.396, Pei.sub.wt2PB1-C.sub.396
Pei.sub.ca1PB1-C.sub.396, and/or Pei.sub.ca2PB1-C.sub.396. In one
embodiment, a preferred equine influenza PB1-C protein of the
present invention is encoded by SEQ ID NO:85, SEQ ID NO:87, SEQ ID
NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:94,
and/or SEQ ID NO:96, and, as such, has an amino acid sequence that
includes SEQ ID NO:86, SEQ ID NO:89, SEQ ID NO:92, and/or SEQ ID
NO:95.
[0078] Preferred equine influenza PB1 proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wtPB1.sub.2341, nei.sub.wtPB1.sub.2271,
nei.sub.ca1PB1.sub.2341, nei.sub.ca1PB1.sub.2271. Preferred equine
influenza PB1 proteins are Pei.sub.wtPB1.sub.757, and/or
Pei.sub.ca1PB1.sub.757. In one embodiment, a preferred equine
influenza PB1 protein of the present invention is encoded by SEQ ID
NO:103, SEQ ID NO:105, SEQ ID NO:106, and/or SEQ ID NO:108, and, as
such, has an amino acid sequence that includes SEQ ID NO:104 and/or
SEQ ID NO:107.
[0079] Preferred equine influenza PA-C proteins of the present
invention include proteins encoded by a nucleic acid molecule
comprising nei.sub.wt1PA-C.sub.1228, nei.sub.wt1PA-C.sub.1164,
nei.sub.wt2PA-C.sub.1223, nei.sub.ca1PA-C.sub.1233,
nei.sub.ca2PA-C.sub.1233, and/or nei.sub.ca1PA-C.sub.1170.
Preferred equine influenza PA-C proteins are
Pei.sub.wt1PA-C.sub.388, and/or Pei.sub.ca1PA-C.sub.390. In one
embodiment, a preferred equine influenza PA-C protein of the
present invention is encoded by SEQ ID NO:76, SEQ ID NO:78, SEQ ID
NO:79, SEQ ID NO:80, and/or SEQ ID NO:82, and, as such, has an
amino acid sequence that includes SEQ ID NO:77 and/or SEQ ID
NO:81.
[0080] Nucleic acid sequence SEQ ID NO:1 represents the consensus
sequence deduced from the coding strand of PCR amplified nucleic
acid molecules denoted herein as nei.sub.wt1M.sub.1023 and
nei.sub.wt2M.sub.1023, the production of which is disclosed in the
Examples. Nucleic acid sequence SEQ ID NO:4 represents the deduced
sequence of the coding strand of PCR amplified nucleic acid
molecules denoted herein as nei.sub.ca1M.sub.1023 and
nei.sub.ca2M.sub.1023, the production of which is disclosed in the
Examples. Nucleic acid sequence SEQ ID NO:7 represents the deduced
sequence of the coding strand of a PCR amplified nucleic acid
molecule denoted herein as nei.sub.wtHA.sub.1762, the production of
which is disclosed in the Examples. Nucleic acid sequence SEQ ID
NO:10 represents the deduced sequence of the coding strand of PCR
amplified nucleic acid molecules denoted herein as
nei.sub.ca1HA.sub.1762 and nei.sub.ca2HA.sub.1762, the production
of which is disclosed in the Examples. Nucleic acid sequence SEQ ID
NO:13 represents the deduced sequence of the coding strand of a PCR
amplified nucleic acid molecule denoted herein as
nei.sub.wtPB2-N.sub.1241, the production of which is disclosed in
the Examples. Nucleic acid sequence SEQ ID NO:16 represents the
deduced sequence of the coding strand of PCR amplified nucleic acid
molecules denoted herein as nei.sub.ca1PB2-N.sub.1241 and
nei.sub.ca2PB2-N.sub.1241, the production of which is disclosed in
the Examples. Nucleic acid sequence SEQ ID NO:19 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.wt1PB2-C.sub.1233, the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:22 represents the deduced sequence of the coding
strand of a PCR amplified nucleic acid molecule denoted herein as
nei.sub.wt2PB2-C.sub.1232, the production of which is disclosed in
the examples. Nucleic acid sequence SEQ ID NO:23 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.ca1PB2-C.sub.1232, the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:44 represents the deduced sequence of the coding
strand of a PCR amplified nucleic acid molecule denoted herein as
nei.sub.wtPB2.sub.2341 the production of which is disclosed in the
Examples. Nucleic acid sequence SEQ ID NO:47 represents the deduced
sequence of the coding strand of PCR amplified nucleic acid
molecules denoted herein as nei.sub.ca1PB2.sub.2341 the production
of which is disclosed in the Examples. Nucleic acid sequence SEQ ID
NO:50 represents the deduced sequence of the coding strand of a PCR
amplified nucleic acid molecule denoted herein as
nei.sub.wt1NS.sub.891 and nei.sub.wt2NS.sub.891 the production of
which is disclosed in the examples. Nucleic acid sequence SEQ ID
NO:53 represents the deduced sequence of the coding strand of a PCR
amplified nucleic acid molecule denoted herein as
nei.sub.wt3NS.sub.888, the production of which is disclosed in the
examples. Nucleic acid sequence SEQ ID NO:54 represents the deduced
sequence of the coding strand of a PCR amplified nucleic acid
molecule denoted herein as nei.sub.wt4NS.sub.468, the production of
which is disclosed in the examples. Nucleic acid sequence SEQ ID
NO:57 represents the deduced sequence of the coding strand of a PCR
amplified nucleic acid molecule denoted herein as
nei.sub.ca1NS.sub.888 and nei.sub.ca1NS.sub.887 the production of
which is disclosed in the Examples. Nucleic acid sequence SEQ ID
NO:62 represents the deduced sequence of the coding strand of PCR
amplified nucleic acid molecules denoted herein as
nei.sub.wt1PB1-N.sub.1229, the production of which is disclosed in
the Examples. Nucleic acid sequence SEQ ID NO:65 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.wt2PB2-N.sub.673, the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:68 represents the deduced sequence of the coding
strand of a PCR amplified nucleic acid molecule denoted herein as
nei.sub.ca1PB1-N.sub.1225, the production of which is disclosed in
the examples. Nucleic acid sequence SEQ ID NO:71 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.ca2PB1-N.sub.1221, the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:76 represents the deduced sequence of the coding
strand of a PCR amplified nucleic acid molecule denoted herein as
nei.sub.wt1PA-C.sub.1228, the production of which is disclosed in
the examples. Nucleic acid sequence SEQ ID NO:79 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.wt2PA-C.sub.1223, the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:80 represents the deduced sequence of the coding
strand of a PCR amplified nucleic acid molecule denoted herein as
nei.sub.ca1PA-C.sub.1233 and nei.sub.ca2PA-C.sub.1233 the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:85 represents the deduced sequence of the coding
strand of a PCR amplified nucleic acid molecule denoted herein as
nei.sub.ca1PB1-C.sub.1234 the production of which is disclosed in
the examples. Nucleic acid sequence SEQ ID NO:88 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.wt2PB1-C.sub.1240 the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:91 represents the deduced sequence of the coding
strand of a PCR amplified nucleic acid molecule denoted herein as
nei.sub.ca1PB1-C.sub.1241 the production of which is disclosed in
the examples. Nucleic acid sequence SEQ ID NO:94 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.ca2PB1-C.sub.1241 the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:103 represents the deduced sequence of the
coding strand of a PCR amplified nucleic acid molecule denoted
herein as nei.sub.wtPB1.sub.2341 the production of which is
disclosed in the examples. Nucleic acid sequence SEQ ID NO:105
represents the deduced sequence of the coding strand of a PCR
amplified nucleic acid molecule denoted herein as
nei.sub.wtPB1.sub.2271 the production of which is disclosed in the
examples. Nucleic acid sequence SEQ ID NO:106 represents the
deduced sequence of the coding strand of a PCR amplified nucleic
acid molecule denoted herein as nei.sub.caPB1.sub.2341 the
production of which is disclosed in the examples. Nucleic acid
sequence SEQ ID NO:108 represents the deduced sequence of the
coding strand of a PCR amplified nucleic acid molecule denoted
herein as nei.sub.caPB1.sub.2271 the production of which is
disclosed in the examples. Additional nucleic acid molecules,
nucleic acid sequences, proteins and amino acid sequences are
described in the Examples.
[0081] The present invention includes nucleic acid molecule
comprising a cold-adapted equine influenza virus encoding an M
protein having an amino acid sequence comprising SEQ ID NO:5.
Another embodiment of the present invention includes a nucleic acid
molecule comprising a cold-adapted equine influenza virus encoding
an HA protein having an amino acid sequence comprising SEQ ID
NO:11. Another embodiment of the present invention includes a
nucleic acid molecule comprising a cold-adapted equine influenza
virus encoding a PB2-N protein having an amino acid sequence
comprising SEQ ID NO:17. Another embodiment of the present
invention includes a nucleic acid molecule comprising a
cold-adapted equine influenza virus encoding a PB2-C protein having
an amino acid sequence comprising SEQ ID NO:24. Another embodiment
of the present invention includes a nucleic acid molecule
comprising a cold-adapted equine influenza virus encoding a PB
protein having an amino acid sequence comprising SEQ ID NO:48.
Another embodiment of the present invention includes a nucleic acid
molecule comprising a cold-adapted equine influenza virus encoding
a NS protein having an amino acid sequence comprising SEQ ID NO:58.
Another embodiment of the present invention includes a nucleic acid
molecule comprising a cold-adapted equine influenza virus encoding
a PB1-N protein having an amino acid sequence comprising SEQ ID
NO:69. Another embodiment of the present invention includes a
nucleic acid molecule comprising a cold-adapted equine influenza
virus encoding a PA-C protein having an amino acid sequence
comprising SEQ ID NO:81. Another embodiment of the present
invention includes a nucleic acid molecule comprising a
cold-adapted equine influenza virus encoding a PB1-C protein having
an amino acid sequence comprising SEQ ID NO:92. Another embodiment
of the present invention includes a nucleic acid molecule
comprising a cold-adapted equine influenza virus encoding a PB1
protein having an amino acid sequence comprising SEQ ID NO:107.
[0082] It should be noted that since nucleic acid sequencing
technology is not entirely error-free, the nucleic acid sequences
and amino acid sequences presented herein represent, respectively,
apparent nucleic acid sequences of nucleic acid molecules of the
present invention and apparent amino acid sequences of M, HA,
PB2-N, PB2-C, PB2, NS, PB1-N, PA-C, PB1-C and PB1 proteins of the
present invention.
[0083] Another embodiment of the present invention is an antibody
that selectively binds to an wild-type virus M, HA, PB2-N, PB2-C,
PB2, NS, PB1-N, PA-C, PB1-C and PB1 protein of the present
invention. Another embodiment of the present invention is an
antibody that selectively binds to a cold-adapted virus M, HA,
PB2-N, PB2-C, PB2, NS, PB1-N, PA-C, PB1-C and PB1 protein of the
present invention. Preferred antibodies selectively bind to SEQ ID
NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID
NO:17, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:45, SEQ ID NO:48, SEQ
ID NO:51, SEQ ID NO: 55, SEQ ID NO:58, SEQ ID NO: 63, SEQ ID NO:66,
SEQ ID NO: 69, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO:86, SEQ ID
NO: 89, SEQ ID NO: 92, SEQ ID NO:95, SEQ ID NO:104 and SEQ ID NO:
107.
[0084] The following examples are provided for the purposes of
illustration and are not intended to limit the scope of the present
invention.
EXAMPLE 1
[0085] This example discloses the production and phenotypic
characterization of several cold-adapted equine influenza viruses
of the present invention.
[0086] A. Parental equine influenza virus, A/equine/Kentucky/1/91
(H3N8) (obtained from Tom Chambers, the University of Kentucky,
Lexington, Ky.) was subjected to cold-adaptation in a foreign host
species, i.e., embryonated chicken eggs, in the following manner.
Embryonated, 10 or 11-day old chicken eggs, available, for example,
from Truslow Farms, Chestertown, Md. or from HyVac, AdeI, IA, were
inoculated with the parental equine influenza virus by injecting
about 0.1 milliliter (ml) undiluted AF containing approximately
10.sup.6 plaque forming units (pfu) of virus into the allantoic
cavity through a small hole punched in the shell of the egg. The
holes in the eggs were sealed with nail polish and the eggs were
incubated in a humidified incubator set at the appropriate
temperature for three days. Following incubation, the eggs were
candled and any non-viable eggs were discarded. AF was harvested
from viable embryos by aseptically removing a portion of the egg
shell, pulling aside the chorioallantoic membrane (CAM) with
sterile forceps and removing the AF with a sterile pipette. The
harvested AF was frozen between passages. The AF was then used,
either undiluted or diluted 1:1000 in phosphate-buffered saline
(PBS) as noted in Table 1, to inoculate a new set of eggs for a
second passage, and so on. A total of 69 passages were completed.
Earlier passages were done at either about 34.degree. C. (passages
1-2) or about 30.degree. C. and on subsequent passages, the
incubation temperature was shifted down either to about 28.degree.
C., or to about 26.degree. C. In order to increase the possibility
of the selection of the desired phenotype of a stable, attenuated
virus, the initial serial passage was expanded to included five
different limbs of the serial passage tree, A through E, as shown
in Table 1.
TABLE-US-00001 TABLE 1 Passage history of the limbs A through E.
Passage # Temperature Limb A Limb B Limb C Limb D Limb E 34.degree.
C. 1-2 1-2 1-2 1-2 1-2 30.degree. C. 3-8 3-29 3-29 3-29 3-29
28.degree. C. 30-33* 30-68* 30-33 30-69 26.degree. C. 9-65 34-69*
34-65 *= the infectious allantoic fluid was diluted 1:1000 in these
passages
[0087] B. Virus isolates carried through the cold-adaptation
procedure described in section A were tested for temperature
sensitivity, i.e., a phenotype in which the cold-adapted virus
grows at the lower, or permissive temperature (e.g., about
34.degree. C.), but no longer forms plaques at a higher, or
non-permissive temperature (e.g., about 37.degree. C. or about
39.degree. C.), as follows. At each cold-adaptation passage, the AF
was titered by plaque assay at about 34.degree. C. Periodically,
individual plaques from the assay were clonally isolated by
excision of the plaque area and placement of the excised agar plug
in a 96-well tray containing a monolayer of MDCK cells. The 96-well
trays were incubated overnight and the yield assayed for
temperature sensitivity by CPE assay in duplicate 96-well trays
incubated at about 34.degree. C. and at about 39.degree. C. The
percent of the clones that scored as temperature sensitive mutants
by this assay, i.e., the number of viral plaques that grew at
34.degree. C. but did not grow at 39.degree. C., divided by the
total number of plaques, was calculated, and is shown in Table 2.
Temperature sensitive isolates were then evaluated for protein
synthesis at the non-permissive temperature by visualization of
radiolabeled virus-synthesized proteins by SDS polyacrylamide gel
electrophoresis (SDS-PAGE).
TABLE-US-00002 TABLE 2 Percent of isolated Clones that were
temperature sensitive. Percent Temperature Sensitive Passage# Limb
A Limb B Limb C Limb D Limb E p36 56% 66% 0% 66% 54% p46 80% 60%
75% p47 80% p48 100% p49 100% 100% 50% p50 90% p51 100% p52 57% p62
100% 100% p65 100% p66 100% 88%
[0088] From the clonal isolates tested for temperature sensitivity,
two were selected for further study. Clone EIV-P821 was selected
from the 49th passage of limb B and clone EIV-P824 was selected
from the 48th passage of limb C, as defined in Table 1. Both of
these virus isolates were temperature sensitive, with plaque
formation of both isolates inhibited at a temperature of about
39.degree. C. At this temperature, protein synthesis was completely
inhibited by EIV-P821, but EIV-P824 exhibited normal levels of
protein synthesis. In addition, plaque formation by EIV-P821 was
inhibited at a temperature of about 37.degree. C., and at this
temperature, late gene expression was inhibited, i.e., normal
levels of NP protein were synthesized, reduced or no M1 or HA
proteins were synthesized, and enhanced levels of the polymerase
proteins were synthesized. The phenotype observed at 37.degree. C.,
being typified by differential viral protein synthesis, was
distinct from the protein synthesis phenotype seen at about
39.degree. C., which was typified by the inhibition of synthesis of
all viral proteins. Virus EIV-P821 has been deposited with the
American Type Culture Collection (ATCC) under Accession No. ATCC
VR-2625, and virus EIV-P824 has been deposited with the ATCC under
Accession No. ATCC VR-2624.
[0089] C. Further characterization of the mutations in isolate
EIV-P821 were carried out by reassortment analysis, as follows.
Reassortment analysis in influenza viruses allows one skilled in
the art, under certain circumstances, to correlate phenotypes of a
given virus with putative mutations occurring on certain of the
eight RNA segments that comprise an influenza A virus genome. This
technique is described, for example, in Palese, et al., ibid. A
mixed infection of EIV-P821 and an avian influenza virus,
A/mallard/New York/6750/78 was performed as follows. MDCK cells
were co-infected with EIV-P821 at a multiplicity of infection (MOI)
of 2 pfu/cell and A/mallard/New York/6750/78 at an MOI of either 2,
5, or 10 pfu/cell. The infected cells were incubated at a
temperature of about 34.degree. C. The yields of the various
co-infections were titered and individual plaques were isolated at
about 34.degree. C., and the resultant clonal isolates were
characterized as to whether they were able to grow at about
39.degree. C. and about 37.degree. C., and express their genes,
i.e., synthesize viral proteins, at about 39.degree. C., about
37.degree. C., and about 34.degree. C. Protein synthesis was
evaluated by SDS-PAGE analysis of radiolabeled infected-cell
lysates. The HA, NP and NS-1 proteins of the two parent viruses,
each of which is encoded by a separate genome segment, were
distinguishable by SDS-PAGE analysis, since these particular viral
proteins, as derived from either the equine or the avian influenza
virus, migrate at different apparent molecular weights. In this way
it was possible, at least for the HA, NP, and NS-1 genes, to
evaluate whether certain phenotypes of the parent virus, e.g., the
temperature sensitive and the protein synthesis phenotypes,
co-segregate with the genome segments carrying these genes. The
results of the reassortment analyses investigating co-segregation
of a) the mutation inhibiting plaque formation, i.e., the induction
of CPE, at a non-permissive temperature of about 39.degree. C. or
b) the mutation inhibiting protein synthesis at a non-permissive
temperature of about 39.degree. C. with each of the EIV-P821 HA, NP
and NS-1 proteins are shown in Tables 3 and 4, respectively.
TABLE-US-00003 TABLE 3 Reassortment analysis of the EIV-P821
39.degree. C. plaque formation phenotype with avian influenza
virus, A/mallard/New York/6750/78 Gene Virus ts+.sup.1 ts-.sup.2 HA
avian 26 13 equine 11 44 NP avian 37 8 equine 0 49 NS-1 avian 9 8
equine 12 20 .sup.1number of clonal isolates able to induce CPE in
tissue culture cells at a temperature of about 39.degree. C.
.sup.2number of clonal isolates inhibited in the ability to induce
CPE in tissue culture cells at a temperature of about 39.degree.
C.
TABLE-US-00004 TABLE 4 Reassortment analysis of the EIV-P821
39.degree. C. protein synthesis phenotype with avian influenza
virus, A/mallard/New York/6750/78 Gene Virus ts+.sup.1 ts-.sup.2 HA
avian 18 1 equine 11 7 NP avian 34 5 equine 7 8 NS-1 avian 10 4
equine 14 5 .sup.1number of clonal isolates which synthesize all
viral proteins at a temperature of about 39.degree. C. .sup.2number
of clonal isolates inhibited in the ability to synthesize all viral
proteins at a temperature of about 39.degree. C.
[0090] The results demonstrated an association of the equine NP
gene with a mutation causing the inability of EIV-P821 to form
plaques at a non-permissive temperature of about 39.degree. C., but
the results did not suggest an association of any of the HA, NP, or
NS-1 genes with a mutation causing the inability of EIV-P821 to
express viral proteins at a non-permissive temperature of about
39.degree. C. Thus, these data also demonstrated that the plaque
formation phenotype and the protein synthesis phenotype observed in
virus EIV-P821 were the result of separate mutations.
[0091] D. Studies were also conducted to determine if cold-adapted
equine influenza viruses of the present invention have a dominant
interference phenotype, that is, whether they dominate in mixed
infection with the wild type parental virus A/Kentucky/1/91 (H3N8).
The dominant interference phenotype of viruses EIV-P821 and
EIV-P824 were evaluated in the following manner. Separate
monolayers of MDCK cells were singly infected with the parental
virus A/Kentucky/1/91 (H3N8) at an MOI of 2, singly infected with
either cold-adapted virus EIV-P821 or EIV-P824 at an MOI of 2, or
simultaneously doubly infected with both the parental virus and one
of the cold adapted viruses at an MOI of 2+2, all at a temperature
of about 34.degree. C. At 24 hours after infection, the media from
the cultures were harvested and the virus yields from the various
infected cells were measured by duplicate plaque assays performed
at temperatures of about 34.degree. C. and about 39.degree. C. This
assay took advantage of the fact that cold adapted equine influenza
viruses EIV-P821 or EIV-P824 are temperature sensitive and are thus
unable to form plaques at a non-permissive temperature of about
39.degree. C., while the parental virus is able to form plaques at
both temperatures, thus making it possible to measure the growth of
the parental virus in the presence of the cold adapted virus.
Specifically, the dominant interference effect of the cold adapted
virus on the growth of the parental virus was quantitated by
comparing the virus yield at about 39.degree. C. of the cells
singly infected with parental virus to the yield of the parental
virus in doubly infected cells. EIV-P821, in mixed infection, was
able to reduce the yield of the parental virus by approximately 200
fold, while EIV-P824, in mixed infection, reduced the yield of the
parental virus by approximately 3200 fold. This assay therefore
showed that cold-adapted equine influenza viruses EIV-P821 and
EIV-P824 both exhibit the dominant interference phenotype.
[0092] E. Virus isolate EIV-MSV+5 was derived from EIV-P821, as
follows. EIV-P821 was passaged once in eggs, as described above, to
produce a Master Seed Virus isolate, denoted herein as EIV-MSV0.
EIV-MSV0 was then subjected to passage three additional times in
eggs, the virus isolates at the end of each passage being
designated EIV-MSV+1, EIV-MSV+2, and EIV-MSV+3, respectively.
EIV-MSV+3 was then subjected to two additional passages in MDCK
cells, as follows. MDCK cells were grown in 150 cm.sup.2 tissue
culture flasks in MEM tissue culture medium with Hanks Salts,
containing 10% calf serum. The cells were then washed with sterile
PBS and the growth medium was replaced with about 8 ml per flask of
infection medium (tissue culture medium comprising MEM with Hanks
Salts, 1 .mu.g/ml TPCK trypsin solution, 0.125% bovine serum
albumin (BSA), and 10 mM HEPES buffer). MDCK cells were inoculated
with AF containing virus EIV-MSV+3 (for the first passage in MDCK
cells) or virus stock harvested from EIV-MSV+4 (for the second
passage in MDCK cells), and the viruses were allowed to adsorb for
1 hour at about 34.degree. C. The inoculum was removed from the
cell monolayers, the cells were washed again with PBS, and about
100 ml of infection medium was added per flask. The infected cells
were incubated at about 34.degree. C. for 24 hours. The
virus-infected MDCK cells were harvested by shaking the flasks
vigorously to disrupt the cell monolayer, resulting in virus
isolates EIV-MSV+4 (the first passage in MDCK cells), and EIV-MSV+5
(the second passage in MDCK cells).
[0093] Viruses EIV-MSV0 and EIV-MSV+5 were subjected to phenotypic
analysis, as described in section B above, to determine their
ability to form plaques and synthesize viral proteins at
temperatures of about 34.degree. C., about 37.degree. C., and about
39.degree. C. Both EIV-MSV0 and EIV-MSV+5 formed plaques in tissue
culture cells at a temperature of about 34.degree. C., and neither
virus isolate formed plaques or exhibited detectable viral protein
synthesis at a temperature of about 39.degree. C. Virus EIV-MSV0
had a similar temperature sensitive phenotype as EIV-P821 at a
temperature of about 37.degree. C., i.e., it was inhibited in
plaque formation, and late gene expression was inhibited. However,
EIV-MSV+5, unlike its parent virus, EIV-P821, did form plaques in
tissue culture at a temperature of about 37.degree. C., and at this
temperature, the virus synthesized normal amounts of all proteins.
Virus EIV-MSV+5 has been deposited with the ATCC under Accession
No. ATCC VR-2627.
EXAMPLE 2
[0094] Therapeutic compositions of the present invention were
produced as follows.
[0095] A. A large stock of EIV-P821 was propagated in eggs as
follows, About 60 specific pathogen-free embryonated chicken eggs
were candled and non-viable eggs were discarded. Stock virus was
diluted to about 1.0.times.10.sup.5 pfu/ml in sterile PBS. Virus
was inoculated into the allantoic cavity of the eggs as described
in Example 1A. After a 3-day incubation in a humidified chamber at
a temperature of about 34.degree. C., AF was harvested from the
eggs according to the method described in Example 1A. The harvested
AF was mixed with a stabilizer solution, for example A1/A2
stabilizer, available from Diamond Animal Health, Des Moines, Iowa,
at 25% V/V (stabilizer/AF). The harvested AF was batched in a
centrifuge tube and was clarified by centrifugation for 10 minutes
at 1000 rpm in an IEC Centra-7R refrigerated table top centrifuge
fitted with a swinging bucket rotor. The clarified fluid was
distributed into 1-ml cryovials and was frozen at about -70.degree.
C. Virus stocks were titrated on MDCK cells by CPE and plaque assay
at about 34.degree. C.
[0096] B. A large stock of EIV-P821 was propagated in MDCK cells as
follows. MDCK cells were grown in 150 cm.sup.2 tissue culture
flasks in MEM tissue culture medium with Hanks Salts, containing
10% calf serum. The cells were then washed with sterile PBS and the
growth medium was replaced with about 8 ml per flask of infection
medium. The MDCK cells were inoculated with virus stock at an MOI
ranging from about 0.5 pfu per cell to about 0.005 pfu per cell,
and the viruses were allowed to adsorb for 1 hour at about
34.degree. C. The inoculum was removed from the cell monolayers,
the cells were washed again with PBS, and about 100 ml of infection
medium was added per flask. The infected cells were incubated at
about 34.degree. C. for 24 hours. The virus-infected MDCK cells
were harvested by shaking the flasks vigorously to disrupt the cell
monolayer and stabilizer solution was added to the flasks at 25%
V/V (stabilizer/virus solution). The supernatants were distributed
aseptically into cryovials and frozen at -70.degree. C.
[0097] C. Therapeutic compositions comprising certain cold-adapted
temperature sensitive equine influenza viruses of the present
invention were formulated as follows. Just prior to vaccination
procedures, such as those described in Examples 3-7 below, stock
vials of EIV-P821 or EIV-MSV+5 were thawed and were diluted in an
excipient comprising either water, PBS, or in MEM tissue culture
medium with Hanks Salts, containing 0.125% bovine serum albumin
(BSA-MEM solution) to the desired dilution for administration to
animals. The vaccine compositions were held on ice prior to
vaccinations. All therapeutic compositions were titered on MDCK
cells by standard methods just prior to vaccinations and wherever
possible, an amount of the composition, treated identically to
those administered to the animals, was titered after the
vaccinations to ensure that the virus remained viable during the
procedures.
EXAMPLE 3
[0098] A therapeutic composition comprising cold-adapted equine
influenza virus EIV-P821 was tested for safety and its ability to
replicate in three horses showing detectable prior immunity to
equine influenza virus as follows. EIV-P821, produced as described
in Example 1A, was grown in eggs as described in Example 2A and was
formulated into a therapeutic composition comprising 10.sup.7 pfu
EIV-P821/2 ml BSA-MEM solution as described in Example 2C.
[0099] Three ponies having prior detectable hemagglutination
inhibition (HAT) titers to equine influenza virus were inoculated
with a therapeutic composition comprising EIV-P821 by the following
method. Each pony was given a 2-ml dose of EIV-P821, administered
intranasally using a syringe fitted with a blunt cannula long
enough to reach past the false nostril, 1 ml per nostril.
[0100] The ponies were observed for approximately 30 minutes
immediately following and at approximately four hours after
vaccination for immediate type allergic reactions such as sneezing,
salivation, labored or irregular breathing, shaking, anaphylaxis,
or fever. The animals were further monitored on days 1-11
post-vaccination for delayed type allergic reactions, such as
lethargy or anorexia. None of the three ponies in this study
exhibited any allergic reactions from the vaccination.
[0101] The ponies were observed daily, at approximately the same
time each day, starting two days before vaccination and continuing
through day 11 following vaccination for clinical signs consistent
with equine influenza. The ponies were observed for nasal
discharge, ocular discharge, anorexia, disposition, heart rate,
capillary refill time, respiratory rate, dyspnea, coughing, lung
sounds, presence of toxic line on upper gum, and body temperature.
In addition submandibular and parietal lymph nodes were palpated
and any abnormalities were described. None of the three ponies in
this study exhibited any abnormal reactions or overt clinical signs
during the observation period.
[0102] To test for viral shedding in the animals, on days 0 through
111 following vaccination, nasopharyngeal swabs were collected from
the ponies as described in Chambers, et al., 1995, Equine Practice,
17, 19-23. Chambers, et al., ibid. Briefly, two sterile Dacron
polyester tipped applicators (available, e.g., from Hardwood
Products Co., Guilford, Me.) were inserted, together, into each
nostril of the ponies. The swabs (four total, two for each nostril)
were broken off into a 15-ml conical centrifuge tube containing 2.5
ml of chilled transport medium comprising 5% glycerol, penicillin,
streptomycin, neomycin, and gentamycin in PBS at physiological pH.
Keeping the samples on wet ice, the swabs were aseptically wrung
out into the medium and the nasopharyngeal samples were divided
into two aliquots. One aliquot was used to attempt isolation of EIV
by inoculation of embryonated eggs, using the method described in
Example 1. The AF of the inoculated eggs was then tested for its
ability to cause hemagglutination, by standard methods, indicating
the presence of equine influenza virus in the AF. On days 2 and 3
post-vaccination, the other aliquots were tested for virus by the
Directigen.RTM.V Flu A test, available from Becton-Dickinson
(Cockeysville, Md.).
[0103] Attempts to isolate EIV from the nasopharyngeal secretions
of the three animals by egg inoculation were unsuccessful. However
on days 2 and 3, all animals tested positive for the presence of
virus shedding using the Directigen Flu A test, consistent with the
hypothesis that EIV-P821 was replicating in the seropositive
ponies.
[0104] To test the antibody titers to EIV in the inoculated animals
described in this example, as well as in the animals described in
Examples 4-7, blood was collected from the animals prior to
vaccination and on designated days post-vaccination. Serum was
isolated and was treated either with trypsin/periodate or kaolin to
block the nonspecific inhibitors of hemagglutination present in
normal sera. Serum samples were tested for hemagglutination
inhibition (HAI) titers against a recent EIV isolate by standard
methods, described, for example in the "Supplemental assay method
for conducting the hemagglutination inhibition assay for equine
influenza virus antibody" (SAM 124), provided by the U.S.D.A.
National Veterinary Services Laboratory under 9 CFR 113.2.
[0105] The HAI titers of the three ponies are shown in Table 5. As
can be seen, regardless of the initial titer, the serum HAI titers
increased at least four-fold in all three animals after vaccination
with EIV-P821.
[0106] These data demonstrate that cold-adapted equine influenza
virus EIV-P821 is safe and non-reactogenic in sero-positive ponies,
and that these animals exhibited an increase in antibody titer to
equine influenza virus, even though they had prior demonstrable
titers.
TABLE-US-00005 TABLE 5 HAI titers of vaccinated animals* HAI Titer
Animal (days after vaccination) ID 0 7 14 21 18 40 80 160 160 19 10
20 40 80 25 20 40 320 80 *HAI titers are expressed as the
reciprocal of the highest dilution of serum which inhibited
hemagglutination of erythrocytes by a recent isolate of equine
influenza virus.
EXAMPLE 4
[0107] This Example discloses an animal study to evaluate the
safety and efficacy of a therapeutic composition comprising
cold-adapted equine influenza virus EIV-P821.
[0108] A therapeutic composition comprising cold-adapted equine
influenza virus EIV-P821 was tested for attenuation, as well as its
ability to protect horses from challenge with virulent equine
influenza virus, as follows. EIV-P821, produced as described in
Example 1, was grown in eggs as described in Example 2A and was
formulated into a therapeutic composition comprising 10.sup.7 pfu
of virus/2 ml water, as described in Example 2C. Eight
EIV-seronegative ponies were used in this study. Three of the eight
ponies were vaccinated with a 2-ml dose comprising 10.sup.7 pfu of
the EIV-P821 therapeutic composition, administered intranasally,
using methods similar to those described in Example 3. One pony was
given 10.sup.7 pfu of the EIV-P821 therapeutic composition,
administered orally, by injecting 6 ml of virus into the pharynx,
using a 10-ml syringe which was adapted to create a fine spray by
the following method. The protruding "seat" for the attachment of
needles was sealed off using modeling clay and its cap was left in
place. About 10 holes were punched through the bottom of the
syringe, i.e., surrounding the "seat," using a 25-gauge needle. The
syringe was placed into the interdental space and the virus was
forcefully injected into the back of the mouth. The remaining four
ponies were held as non-vaccinated controls.
[0109] The vaccinated ponies were observed for approximately 30
minutes immediately following and at approximately four hours after
vaccination for immediate type allergic reactions, and the animals
were farther monitored on days 1-11 post-vaccination for delayed
type allergic reactions, both as described in Example 3. None of
the four vaccinated ponies in this study exhibited any abnormal
reactions from the vaccination.
[0110] The ponies were observed daily, at approximately the same
time each day, starting two days before virus vaccination and
continuing through day 11 following vaccination for clinical signs,
such as those described in Example 3. None of the four vaccinated
ponies in this study exhibited any clinical signs during the
observation period. This result demonstrated that cold-adapted
equine influenza virus EIV-P821 exhibits the phenotype of
attenuation.
[0111] To test for viral shedding in the vaccinated animals, on
days 0 through 11 following vaccination, nasopharyngeal swabs were
collected from the ponies as described in Example 3. The
nasopharyngeal samples were tested for virus in embryonated chicken
eggs according to the method described in Example 3.
[0112] As shown in Table 6, virus was isolated from only one
vaccinated animal using the egg method. However, as noted in
Example 3, the lack of isolation by this method does not preclude
the fact that virus replication is taking place, since replication
may be detected by more sensitive methods, e.g., the Directigen Flu
A test.
TABLE-US-00006 TABLE 6 Virus isolation in eggs after vaccination.
Animal Virus Isolation (days after vaccination) ID Route 0 1 2 3 4
5 6 7 8 9 10 11 91 IN - - + + + + + + + + + - 666 IN - - - - - - -
- - - - - 673 IN - - - - - - - - - - - - 674 Oral - - - - - - - - -
- - -
[0113] To test the antibody titers to equine influenza virus in the
vaccinated animals, blood was collected from the animals prior to
vaccination and on days 7, 14, 21, and 28 post-vaccination. Serum
samples were isolated and were tested for hemagglutination
inhibition (HAI) titers against a recent EIV isolate according to
the methods described in Example 3.
[0114] The HAI titers of the four vaccinated ponies are shown in
Table 7.
TABLE-US-00007 TABLE 7 HAI titers after vaccination. Animal HAI
Titer (days after vaccination) ID Route 0 7 14 21 28 91 IN <10
<10 <10 <10 <10 666 IN 10 10 10 20 20 673 IN 10 10 10
20 20 674 Oral 20 40 40 40 40
[0115] Unlike the increase in HAI titer observed with the three
animals described in the study in Example 3, the animals in this
study did not exhibit a significant increase, i.e., greater than
four-fold, in HAI titer following vaccination with EIV-P821.
[0116] Approximately four and one-half months after vaccine virus
administration, all 8 ponies, i.e., the four that were vaccinated
and the four non-vaccinated controls, were challenged by the
following method. For each animal, 10.sup.7 pfu of the virulent
equine influenza virus strain A/equine/Kentucky/1/91 (H3N8) was
suspended in 5 ml of water. A mask was connected to a nebulizer,
and the mask was placed over the animal's muzzle, including the
nostrils. Five (5) ml was nebulized for each animal, using settings
such that it took 5-10 minutes to deliver the full 5 ml. Clinical
observations, as described in Example 3, were performed on all
animals three days before challenge and daily for 11 days after
challenge.
[0117] Despite the fact that the vaccinated animals did not exhibit
marked increases in their HAI titers to equine influenza virus, all
four vaccinated animals were protected against equine influenza
virus challenge. None of the vaccinated animals showed overt
clinical signs or fever, although one of the animals had a minor
wheeze for two days. On the other hand, all four non-vaccinated
ponies shed virus and developed clinical signs and fever typical of
equine influenza virus infection. Thus, this example demonstrates
that a therapeutic composition of the present invention can protect
horses from equine influenza disease.
EXAMPLE 5
[0118] This Example discloses an additional animal study to
evaluate attenuation of a therapeutic composition comprising
cold-adapted equine influenza virus EIV-P821, and its ability to
protect vaccinated horses from subsequent challenge with virulent
equine influenza virus. Furthermore, this study evaluated the
effect of exercise stress on the safety and efficacy of the
therapeutic composition.
[0119] A therapeutic composition comprising cold-adapted equine
influenza virus EIV-P821 was tested for safety and efficacy in
horses, as follows. EIV-P821, produced as described in Example 1,
was grown in eggs as described in Example 2A and was formulated
into a therapeutic composition comprising 10.sup.7 pfu virus/5 ml
water, as described in Example 2C. Fifteen ponies were used in this
study. The ponies were randomly assigned to three groups of five
animals each, as shown in Table 8, there being two vaccinated
groups and one unvaccinated control group. The ponies in group 2
were exercise stressed before vaccination, while the ponies in
vaccinate group 1 were held in a stall.
TABLE-US-00008 TABLE 8 Vaccination/challenge protocol. Group No.
Ponies Exercise Vaccine Challenge 1 5 -- Day 0 Day 90 2 5 Days -4
to 0 Day 0 Day 90 3 5 -- -- Day 90
[0120] The ponies in group 2 were subjected to exercise stress on a
treadmill prior to vaccination, as follows. The ponies were
acclimated to the use of the treadmill by 6 hours of treadmill use
at a walk only. The actual exercise stress involved a daily
exercise regimen starting 4 days before and ending on the day of
vaccination (immediately prior to vaccination). The treadmill
exercise regimen is shown in Table 9.
TABLE-US-00009 TABLE 9 Exercise regimen for the ponies in Group 2.
Speed (m/sec) Time (min.) Incline (.degree.) 1.5 2 0 3.5 2 0 3.5 2
7 4.5.dagger. 2 7 5.5.dagger. 2 7 6.5.dagger. 2 7 7.5.dagger. 2 7
8.5.dagger. 2 7 3.5 2 7 1.5 10 0.dagger. .dagger.Speed, in meters
per second (m/sec) was increased for each animal every 2 minutes
until the heart rate reached and maintained .gtoreq.200 beats per
minute
[0121] Groups 1 and 2 were given a therapeutic composition
comprising 10.sup.7 pfu of EIV-P821, by the nebulization method
described for the challenge described in Example 4. None of the
vaccinated ponies in this study exhibited any immediate or delayed
allergic reactions from the vaccination.
[0122] The ponies were observed daily, at approximately the same
time each day, starting two days before vaccination and continuing
through day 11 following vaccination for clinical signs, such as
those described in Example 3. None of the vaccinated ponies in this
study exhibited any overt clinical signs during the observation
period.
[0123] To test for viral shedding in the vaccinated animals, before
vaccination and on days 1 through 11 following vaccination,
nasopharyngeal swabs were collected from the ponies as described in
Example 3. The nasopharyngeal samples were tested for virus in
embryonated chicken eggs according to the method described in
Example 3. Virus was isolated from the vaccinated animals, i.e.,
Groups 1 and 2, as shown in Table 10.
TABLE-US-00010 TABLE 10 Virus isolation after vaccination. Animal
Virus Isolation (days after vaccination) Group ID Exercise 0 1 2 3
4 5 6 7 8 9 10 11 1 12 No - - + + + + + - + + - - 16 - - + + + + +
- - - - - 17 - - + + + + + + + - + - 165 - - - - - - - - - - - -
688 - - - - - + - + - - - - 2 7 Yes - - - + + + + - - - - - 44 - -
- - - - - - - - - - 435 - - + + + + - - - - - - 907 - - - + - + + -
- - - - 968 - - - - - + - + - - - -
[0124] To test the antibody titers to equine influenza virus in the
vaccinated animals, blood was collected prior to vaccination and on
days 7, 14, 21, and 28 post-vaccination. Serum samples were
isolated and were tested for HAI titers against a recent EIV
isolate according to the methods described in Example 3. These
titers are shown in Table 11.
TABLE-US-00011 TABLE 11 HAI titers after vaccination and after
challenge on day 90. Animal Day Post-vaccination Group ID -1 7 14
21 28 91 105 112 119 126 1 12 <10 <10 <10 <10 <10
<10 80 320 320 640 1 16 <10 <10 20 20 <10 <10 20 160
320 320 1 17 <10 <10 10 10 10 10 80 160 160 160 1 165 <10
<10 10 10 10 10 80 80 80 80 1 688 <10 <10 20 20 20 20 20
20 20 40 2 7 <10 <10 10 10 <10 <10 20 80 80 40 2 44
<10 <10 20 20 20 10 80 320 320 320 2 435 <10 <10 20 20
10 <10 20 80 80 80 2 907 <10 <10 10 10 20 10 10 40 80 80 2
968 <10 <10 <10 <10 <10 <10 40 160 160 160 3 2
<10 80 640 640 320 3 56 <10 80 320 320 320 3 196 <10 20
160 80 80 3 198 10 40 160 320 320 3 200 <10 20 80 80 40 Group
Description 1 Vaccination only 2 Vaccination and Exercise 3
Control
[0125] On day 90 post vaccination, all 15 ponies were challenged
with 10.sup.7 pfu of equine influenza virus strain
A/equine/Kentucky/1/91 (H3N8) by the nebulizer method as described
in Example 4. Clinical observations, as described in Example 3,
were performed on all animals three days before challenge and daily
for 11 days after challenge. There were no overt clinical signs
observed in any of the vaccinated ponies. Four of the five
non-vaccinated ponies developed fever and clinical signs typical of
equine influenza virus infection.
[0126] Thus, this example demonstrates that a therapeutic
composition of the present invention protects horses against equine
influenza disease, even if the animals are stressed prior to
vaccination.
EXAMPLE 6
[0127] This Example compared the infectivities of therapeutic
compositions of the present invention grown in eggs and grown in
tissue culture cells. From a production standpoint, there is an
advantage to growing therapeutic compositions of the present
invention in tissue culture rather than in embryonated chicken
eggs. Equine influenza virus, however, does not grow to as high a
titer in cells as in eggs. In addition, the hemagglutinin of the
virus requires an extracellular proteolytic cleavage by
trypsin-like proteases for infectivity. Since serum contains
trypsin inhibitors, virus grown in cell culture must be propagated
in serum-free medium that contains trypsin in order to be
infectious. It is well known by those skilled in the art that such
conditions are less than optimal for the viability of tissue
culture cells. In addition, these growth conditions may select for
virus with altered binding affinity for equine cells, which may
affect viral infectivity since the virus needs to bind efficiently
to the animal's nasal mucosa to replicate and to stimulate
immunity. Thus, the objective of the study disclosed in this
example was to evaluate whether the infectivity of therapeutic
compositions of the present invention was adversely affected by
growth for multiple passages in vitro tissue culture.
[0128] EIV-P821, produced as described in Example 1, was grown in
eggs as described in Example 2A or in MDCK cells as described in
Example 2B. In each instance, the virus was passaged five times.
EIV-P821 was tested for its cold-adaptation and temperature
sensitive phenotypes after each passage. The egg and cell-passaged
virus preparations were formulated into therapeutic compositions
comprising 10.sup.7 pfu virus/2 ml BSA-MEM solution, as described
in Example 2C, resulting in an egg-grown EIV-P821 therapeutic
composition and an MDCK cell-grown EIV-P821 therapeutic
composition, respectively.
[0129] Eight ponies were used in this study. Serum from each of the
animals was tested for HAI titers to equine influenza virus prior
to the study. The animals were randomly assigned into one of two
groups of four ponies each. Group A received the egg-grown EIV-P821
therapeutic composition, and Group B received the MDCK-grown
EIV-P821 therapeutic composition, prepared as described in Example
2B. The therapeutic compositions were administered intranasally by
the method described in Example 3.
[0130] The ponies were observed daily, at approximately the same
time each day, starting two days before vaccination and continuing
through day 11 following vaccination for allergic reactions or
clinical signs as described in Example 3. No allergic reactions or
overt clinical signs were observed in any of the animals.
[0131] Nasopharyngeal swabs were collected before vaccination and
daily for 11 days after vaccination. The presence of virus material
in the nasal swabs was determined by the detection of CPE on MDCK
cells infected as described in Example 1, or by inoculation into
eggs and examination of the ability of the infected AF to cause
hemagglutination, as described in Example 3. The material was
tested for the presence of virus only, and not for titer of virus
in the sample. Virus isolation results are listed in Table 12.
Blood was collected and serum samples from days 0, 7, 14, 21 and 28
after vaccination were tested for hemagglutination inhibition
antibody titer against a recent isolate. HAI titers are also listed
in Table 12.
TABLE-US-00012 TABLE 12 HAI titers and virus isolation after
vaccination. HAI Titer (DPV.sup.3) Virus Isolation.sup.1
(DPV.sup.3) Group.sup.2 ID 0 7 14 21 28 0 1 2 3 4 5 6 7 8 9 10 11 1
31 <10 20 160 160 160 -- EC -- C EC EC C C EC -- -- -- 37 <10
40 160 160 160 -- EC C C EC C C C -- -- -- -- 40 <10 20 80 160
80 -- EC EC C -- C EC C -- EC EC -- 41 <10 40 160 160 80 -- EC
EC C EC C EC EC -- -- -- -- 2 32 <10 <10 80 80 40 -- EC -- C
-- C -- C -- EC -- -- 34 <10 20 160 160 160 -- EC -- C EC C EC C
-- -- -- -- 35 <10 <10 80 80 40 -- EC -- C -- C -- C -- EC --
-- 42 <10 <10 80 80 40 -- -- -- C -- C EC EC -- -- -- --
.sup.1E = Egg isolation positive; C = CPE isolation positive; -- =
virus not detected by either of the methods .sup.2Group 1: Virus
passaged 5X in MDCK cells; Group 2: Virus passaged 5X in Eggs
.sup.3Days Post-vaccination
[0132] The results in Table 12 show that there were no significant
differences in infectivity or immunogenicity between the egg-grown
and MDCK-grown EIV-P821 therapeutic compositions.
EXAMPLE 7
[0133] This example evaluated the minimum dose of a therapeutic
composition comprising a cold-adapted equine influenza virus
required to protect a horse from equine influenza virus
infection.
[0134] The animal studies disclosed in Examples 3-6 indicated that
a therapeutic composition of the present invention was efficacious
and safe. In those studies, a dose of 10.sup.7 pfu, which
correlates to approximately 10.sup.8 TCID.sub.50 units, was used.
However, from the standpoints of cost and safety, it is
advantageous to use the minimum virus titer that will protect a
horse from disease caused by equine influenza virus. In this study,
ponies were vaccinated with four different doses of a therapeutic
composition comprising a cold-adapted equine influenza virus to
determine the minimum dose which protects a horse against virulent
equine influenza virus challenge.
[0135] EIV-P821, produced as described in Example 1A, was passaged
and grown in MDCK cells as described in Example 2B and was
formulated into a therapeutic composition comprising either
2.times.10.sup.4, 2.times.10.sup.5, 2.times.10.sup.6, or
2.times.10.sup.7 TCID.sub.50 units/1 ml BSA-MEM solution as
described in Example 2C. Nineteen horses of various ages and breeds
were used for this study. The horses were assigned to four vaccine
groups, one group of three horses and three groups of four horses,
and one control group of four horses (see Table 13). Each of the
ponies in the vaccine groups were given a 1-ml dose of the
indicated therapeutic composition, administered intranasally by
methods similar to those described in Example 3.
TABLE-US-00013 TABLE 13 Vaccination protocol. Vaccine Dose, Group
No. No. Animals TCID.sub.50 Units 1 3 2 .times. 10.sup.7 2 4 2
.times. 10.sup.6 3 4 2 .times. 10.sup.5 4 4 2 .times. 10.sup.4 5 4
control
[0136] The ponies were observed for approximately 30 minutes
immediately following and at approximately four hours after
vaccination for immediate type reactions, and the animals were
further monitored on days 1-11 post-vaccination for delayed type
reactions, both as described in Example 3. None of the vaccinated
ponies in this study exhibited any abnormal reactions or overt
clinical signs from the vaccination.
[0137] Blood for serum analysis was collected 3 days before
vaccination, on days 7, 14, 21, and 28 after vaccination, and after
challenge on Days 35 and 42. Serum samples were tested for HAI
titers against a recent EIV isolate according to the methods
described in Example 3. These titers are shown in Table 14. Prior
to challenge on day 29, 2 of the 3 animals in group 1, 4 of the 4
animals in group 2, 3 of the 4 animals in group 3, and 2 of the 4
animals in group 4 showed at least 4-fold increases in HAI titers
after vaccination. In addition, 2 of the 4 control horses also
exhibited increases in HAI titers. One interpretation for this
result is that the control horses were exposed to vaccine virus
transmitted from the vaccinated horses, since all the horses in
this study were housed in the same barn.
TABLE-US-00014 TABLE 14 HAI titers post-vaccination and
post-challenge, and challenge results. Dose Chall. in TCID.sub.50
Animal Vaccination on Day 0, Challenge on Day 29 Sick No. units ID
-1 7 14 21 28 35 42 +/- 1 2 .times. 10.sup.7 41 <10 <10 10 40
10 20 80 - 42 40 40 40 40 40 <10 80 - 200 <10 <10 80 40
160 40 40 - 2 2 .times. 10.sup.6 679 <10 10 40 40 40 20 20 - 682
<10 <10 40 40 40 40 40 - 795 20 80 160 160 320 320 640 - R
<10 10 40 20 160 40 40 - 3 2 .times. 10.sup.5 73 <10 <10
160 40 80 160 160 - 712 <10 <10 20 20 40 40 20 - 720 <10
20 80 40 80 80 160 - 796 <10 <10 <10 <10 <10 10 80 +
4 2 .times. 10.sup.4 75 <10 <10 <10 <10 <10 <10
160 + 724 <10 >10 <10 <10 <10 20 320 + 789 <10 10
320 160 320 320 320 - 790 <10 <10 80 40 160 80 40 5 Control
12 <10 <10 <10 20 20 40 40 - 22 10 20 40 10 160 40 640 -
71 <10 <10 <10 <10 10 20 160 + 74 <10 <10 <10
<10 <10 <10 20 +
[0138] On day 29 post vaccination, all 19 ponies were challenged
with equine influenza virus strain A/equine/Kentucky/1/91 (H3N8) by
the nebulizer method as described in Example 4. The challenge dose
was prospectively calculated to contain about 10.sup.8 TCID.sub.50
units of challenge virus in a volume of 5 ml for each animal.
Clinical observations, as described in Example 3, were monitored
beginning two days before challenge, the day of challenge, and for
11 days following challenge. As shown in Table 14, no animals in
groups 1 or 2 exhibited clinical signs indicative of equine
influenza disease, and only one out of four animals in group 3
became sick. Two out of four animals in group 4 became sick, and
only two of the four control animals became sick. The results in
Table 14 suggest a correlation between seroconversion and
protection from disease, since, for example, the two control
animals showing increased HAI titers during the vaccination period
did not show clinical signs of equine influenza disease following
challenge. Another interpretation, however, was that the actual
titer of the challenge virus may have been less than the calculated
amount of 10.sup.8 TCID.sub.50 units, since, based on prior
results, this level of challenge should have caused disease in all
the control animals.
[0139] Nonetheless, the levels of seroconversion and the lack of
clinical signs in the groups that received a therapeutic
composition comprising at least 2.times.10.sup.6 TCID.sub.50 units
of a cold-adapted equine influenza virus suggests that this amount
was sufficient to protect a horse against equine influenza disease.
Furthermore, a dose of 2.times.10.sup.5 TCID.sub.50 units induced
seroconversion and gave clinical protection from challenge in 3 out
of 4 horses, and thus even this amount may be sufficient to confer
significant protection in horses against equine influenza
disease.
EXAMPLE 8
[0140] This example discloses an animal study to evaluate the
duration of immunity of a therapeutic composition comprising
cold-adapted equine influenza virus EIV-P821.
[0141] A therapeutic composition comprising cold-adapted equine
influenza virus EIV-P821, produced as described in Example 1, was
grown in eggs similarly to the procedure described in Example 2A,
was expanded by passage in MDCK cells similarly to the procedure
described in Example 2B, and was formulated into a therapeutic
composition as described in Example 2C. Thirty horses approximately
11 to 12 months of age were used for this study. Nineteen of the
horses were each vaccinated intranasally into one nostril using a
syringe with a delivery device tip attached to the end, with a 1.0
ml dose comprising 6 logs of TCID.sub.50 units of the EIV-P821
therapeutic composition. Vaccinations were performed on Day 0.
[0142] The horses were observed on Day 0 (before vaccination and up
to 4 hours post-vaccination) and on Study Days 1, 2, 3, 7, 15, and
169 post-vaccination. On these days, a distant examination for a
period of at least 15 minutes was performed. This distant
examination included observation for demeanor, behavior, coughing,
sneezing, and nasal discharge. The examination on Day 169 also
served to confirm that the horses were in a condition of health
suitable for transport to the challenge site which was located
approximately 360 miles from the vaccination site.
[0143] The animals were acclimated to the challenge site and were
observed approximately daily by a veterinarian or animal technician
for evidence of disease. A general physical examination was
performed on Day 171 post-vaccination to monitor the following:
demeanor, behavior, coughing, sneezing, and nasal discharge. From
Days 172 to 177, similar observations as well as rectal temperature
were recorded, according to the judgment of the attending
veterinarian for any individual horse with abnormal clinical
presentation.
[0144] No vaccinated horses showed any adverse reactions
post-vaccination. One vaccinate was found dead about two months
after vaccination. This horse showed no evidence of adverse
reaction when observed for at least one month after vaccination.
Although no cause of death could be firmly established, the death
was not instantaneous and was considered to be consistent with
possible contributing factors such as colic, bone fracture, or
severe worm burden. Since there was no other evidence for any
adverse reactions post-vaccination in any other vaccinates, it is
highly unlikely that the vaccine contributed to any adverse
reaction in this case.
[0145] Challenges were performed on Day 181 post-vaccination. The
following wild-type isolate of equine influenza virus previously
shown to cause disease in horses was used as the challenge virus:
A/equine/2/Kentucky/91. Prior to infection of each challenge group,
the challenge material was rapidly thawed at approximately
37.degree. C. The virus was diluted with phosphate-buffered saline
to a total volume of approximately 21 ml. The diluted material was
stored chilled on ice until immediately before inoculation. Before
inoculation and at the end of nebulization for each challenge
group, a sample of diluted challenge virus was collected for pre-
and post-inoculation virus titer confirmation. Vaccinates and
controls were randomly assigned to 4 challenge groups of 6 horses
each and one challenge group of 5 horses so that each challenge
group contained a mixture of 4 vaccinates and 2 controls or 3
vaccinates and 2 controls.
[0146] Challenge virus in aerosol form was delivered through a tube
inserted through a small opening centrally in the plastic ceiling
with an ultrasonic nebulizer (e.g., DeVilbiss Model 099HD,
DeVilbiss Healthcare Inc., Somerset, Pa.) for a period of
approximately 10 minutes. The horses remained in the chamber for a
further period of approximately 30 minutes after the nebulization
had been completed (total exposure time, approximately 40 minutes).
At that time, the plastic was removed to vent the chamber, and the
horses were released and returned to their pen. The challenge
procedure was repeated for each group.
[0147] All statistical methods in this study were performed using
SAS (SAS Institute, Cary, N.C.), and P<0.05 was considered to be
statistically significant. Beginning on Day 178 post-vaccination
(three days prior to challenge) through Day 191 (day 10
post-challenge), the horses were observed daily by both distant and
individual examinations. Rectal temperatures were measured at these
times. Data from day 0 (challenge day) to day 10 were included in
the analysis; see Table 15.
TABLE-US-00015 TABLE 15 Effect of challenge on daily temperatures
(.degree. C.) in vaccinated and control horses (least squares
means). Day post Vaccinated non-vaccinated challenge (n = 19) (n =
10) P-value 0 100.7 100.8 0.8434 1 100.5 100.4 0.7934 2 103.4 104.9
0.0024 3 101.8 103.9 0.0001 4 101.5 103.2 0.0002 5 101.7 103.8
0.0001 6 101.3 103.6 0.0001 7 100.7 102.3 0.0007 8 100.5 101.4
0.0379 9 100.1 100.3 0.7416 10 100.3 100.5 0.7416 pooled SEM* 0.27
0.38 *Standard error of the mean
[0148] Table 15 shows that on days 2 through 8, vaccinated horses
had lower temperatures (P<0.05) than the non-vaccinated control
horses.
[0149] The distant examination consisted of a period of 20 minutes
where the following observations were made: coughing, nasal
discharge, respiration, and depression. Scoring criteria are shown
in Table 16.
TABLE-US-00016 TABLE 16 Clinical signs and scoring index. Clinical
Sign Description Score Coughing normal during observation period of
15 min 0 coughing once during observation 1 coughing twice or more
during observation 2 Nasal discharge normal 0 abnormal, serous 1
abnormal, mucopurulent 2 abnormal, profuse 3 Respiration normal 0
abnormal (dyspnea, tachypnea) 1 Depression normal 0 depression
present.sup..dagger. 1 .sup..dagger.Depression was assessed by
subjective evaluation of individual animal behavior that included
the following: failure to approach food rapidly, general lethargy,
inappetence, and anorexia.
[0150] Each horse was scored for each of these categories.
Additionally, submandibular lymph nodes were palpated to monitor
for possible bacterial infection. In any case where there was a
different value recorded for a subjective clinical sign score from
an observation on the same day at the distant versus the individual
examination, the greater score was used in the compilation and
analysis of results. For purposes of assessing the health of the
horses prior to final disposition, distant examinations were
performed at 14, 18, and 21 days post-challenge. Data from days 1
through 10 post-challenge were included in the analysis. These
scores were summed on each day for each horse, and the vaccinates
and controls were compared using the Wilcoxon rank sums test. In
addition, these scores were summed across all days for each horse,
and compared in the same manner. The mean ranks and mean clinical
scores are shown in Tables 17 and 18, respectively. Five days
post-challenge, the mean rank of scores in the vaccinated horses
was lower (P<0.05) than in the non-vaccinated control horses;
and this effect continued on days 6, 7, 8, 9, and 10 (P<0.05).
The cumulative rank over the entire test period was also lower
(P<0.05) in the vaccinated horses than the non-vaccinated
controls.
TABLE-US-00017 TABLE 17 Effect of challenge on clinical sign scores
in vaccinated and control horses (mean rank). Vaccinated
Non-vaccinated Day post (n = 19), (n = 10), challenge mean rank*
mean rank P-value 0 13.6 17.6 0.1853 1 16.4 12.4 0.2015 2 15.1 14.9
0.9812 3 13.3 18.3 0.1331 4 13.5 17.9 0.1721 5 12.4 19.9 0.0237 6
12.7 19.4 0.0425 7 12.1 20.6 0.0074 8 12.6 19.6 0.0312 9 13.1 18.7
0.0729 10 12.3 20.1 0.0135 total over 11.8 21.2 0.0051 11 days *By
Wilcoxon rank sum test.
TABLE-US-00018 TABLE 18 Effect of challenge on clinical sign scores
in vaccinated and control horses (mean scores). Day post Vaccinated
Non-vaccinated challenge (n = 19) (n = 10) 0 1.2 1.6 1 1.5 0.9 2
2.4 2.5 3 3.2 4.1 4 3.4 4.3 5 3.2 4.7 6 3.4 4.8 7 3.3 4.7 8 3.2 4.5
9 3.2 3.9 10 2.4 3.4
[0151] Nasopharyngeal swabs were obtained on the day prior to
challenge and on days 1 to 8 post-challenge, as described in
Example 3, and tested for shed virus by cell culture assay. The
percent of horses shedding challenge virus in each group is shown
in Table 19. The percent of horses shedding the challenge virus in
the vaccinated group was lower (P<0.05) on days 5 and 6
post-challenge than in the non-vaccinated controls. The mean number
of days the challenge virus was shed was also lower (P<0.05) in
the vaccinated group as compared to the non-vaccinated
controls.
TABLE-US-00019 TABLE 19 Percent of horses shedding virus per day
post-challenge and mean number of days of shedding per group. Day
post Vaccinated Non-vaccinated challenge (n = 19) (n = 10) -1 0 0 1
63.2 90 2 100 100 3 84.2 100 4 100 100 5 47.4 88.9* 6 10.5 77.8* 7
5.3 20 8 0 0 average number of 4.1 5.6* days shedding *Within a
time point, vaccinates different from non-vaccinates (P < 0.05)
by either Fisher's exact test (percent data) or Wilcoxon rank sums
test (days shedding).
[0152] The scores from clinical signs relevant to influenza and the
objective temperature measurements both demonstrated a
statistically significant reduction in the group of vaccinates when
compared to those from the control group; this is consistent with
an interpretation that the vaccine conferred significant protection
from disease.
[0153] The ability of horses to shed influenza virus post-challenge
was also significantly reduced in vaccinates as compared to
controls in both the incidence of horses positive for shedding on
certain days post-challenge and the mean number of days of shedding
per horse. This decreased shedding by vaccinates is important in
that it should serve to reduce the potential for exposure of
susceptible animals to the wild-type virus in an outbreak of
influenza.
[0154] The results of this study are consistent with the
interpretation that the vaccine safely conferred protection for 6
months from clinical disease caused by equine influenza and reduced
the potential for the spread of naturally occurring virulent equine
influenza virus. While the degree of protection from disease was
not complete (13 out of 19 vaccinates were protected, while 10/10
controls were sick), there was a clear reduction in the severity
and duration of clinical illness and a noticeable effect on the
potential for viral shedding after exposure to a virulent strain of
equine influenza. The finding that both vaccinates and controls
were seronegative immediately prior to challenge at 6 months
post-immunization suggests that immunity mediated by something
other than serum antibody may be of primary importance in the
ability of this vaccine to confer measurable and durable
protection.
EXAMPLE 9
[0155] This Example discloses an animal study to evaluate the
ability of a therapeutic composition comprising cold-adapted equine
influenza virus EIV-P821 to aid in the prevention of disease
following exposure to a heterologous strain of equine influenza
virus.
[0156] The heterologous strain tested was A/equine/2/Saskatoon/90,
described genetically as a Eurasian strain (obtained from Hugh
Townsend, University of Saskatchewan). Twenty female Percheron
horses approximately 15 months of age (at the time of vaccination)
were used for the efficacy study. The horses were assigned to two
groups, one group of 10 to be vaccinated and another group of 10 to
serve as non-vaccinated controls. On day 0, the vaccinate group was
vaccinated in the manner described in Example 8.
[0157] The challenge material, i.e. equine flu strain
A/equine/2/Saskatoon/90 [H3N8] was prepared similarly to the
preparation in Example 8. Vaccinates and controls were randomly
assigned to 4 challenge groups of 5 horses each such that each
challenge group contained a mixture of 2 vaccinates and three
controls or vice versa. The challenge procedure was similar to that
described in Example 8. Challenges were performed on Day 28
post-vaccination.
[0158] Clinical observations were performed for the vaccinates and
controls on Day -4 and on Study Days 0 (before vaccination and up
to 4 hours post-vaccination), 1 to 7, 12, 15 to 17, 19 to 23, 25 to
38, and 42. For days on which clinical observations were performed
during Days -4 to 42, clinical observations including rectal
temperature were recorded according to the judgment of the
attending veterinarian for any individual horse with abnormal
clinical presentation. Horses were scored using the same criteria
as in Example 8 (Table 15). Distant examinations were performed on
these days as described in Example 8. On Day 20 and from Days 25 to
38, the horses were also observed by both distant and individual
examinations (also performed as described in Example 8).
[0159] Rectal temperatures were measured daily beginning 3 days
prior to challenge, and continuing until 10 days post-challenge.
Day 0 is the day relative to challenge. Data from days 0 through 10
were included in the analysis. Statistical methods and criteria
were identical to those used in Example 8. On days 2, 5 and 7,
vaccinated horses had statistically significant lower body
temperatures than the non-vaccinated control horses (Table 20).
TABLE-US-00020 TABLE 20 Effect of challenge on daily temperatures
(.degree. C.) in vaccinated and control horses (least squares
means). Day post Vaccinated Non-vaccinated challenge (n = 10) (n =
10) P-value 0 99.9 99.8 0.9098 1 100.5 100.3 0.4282 2 101.0 102.8
0.0001 3 100.7 100.6 0.7554 4 101.0 101.3 0.4119 5 100.8 102.1
0.0004 6 100.4 100.4 0.9774 7 100.3 101.1 0.0325 8 100.6 100.7
0.8651 9 100.5 100.6 0.8874 10 100.5 100.1 0.2465 Standard error of
the mean = 0.249.
[0160] Data from days 1 through 10 post-challenge were included in
the analysis. These scores were summed on each day for each horse,
and the vaccinates and controls were compared using the Wilcoxon
rank sums test. All statistical methods were performed as described
in Example 9. In addition, these scores were summed across all days
for each horse, and compared in the same manner. Mean ranks are
shown in Table 21.
TABLE-US-00021 TABLE 21 Effect of challenge on clinical sign scores
in vaccinated and control horses (mean rank). Day post Vaccinated
Non-vaccinated challenge (n = 10) (n = 10) P-value* 1 8.85 12.15
0.1741 2 8.80 12.20 0.1932 3 8.90 12.10 0.2027 4 7.60 13.40 0.0225
5 6.90 14.10 0.0053 6 7.00 14.00 0.0059 7 6.90 14.10 0.0053 8 7.60
13.40 0.0251 9 6.90 14.10 0.0048 10 6.10 14.90 0.0006 total over
5.70 15.30 0.0003 10 days *By Wilcoxon 2 sample test.
[0161] On day 4 post-challenge, the mean rank of scores in the
vaccinated horses was lower (P<0.05) than the non-vaccinated
control horses, and this effect continued throughout the remainder
of the study (P<0.05). The cumulative rank over the entire test
period was also lower in the vaccinated horses than the
non-vaccinated controls (P<0.05).
[0162] Nasopharyngeal swabs were collected on days 1 and 8
post-challenge, as described in Example 3. The nasal samples were
analyzed for the presence of virus by cell inoculation with virus
detection by cytopathogenic effect (CPE) or by egg inoculation with
virus detection by hemagglutination (HA). The cell-culture assay
was performed as generally described by Youngner et al., 1994, J.
Clin. Microbiol. 32, 750-754. Serially diluted nasal samples were
added to wells containing monolayers of Madin Darby Canine Kidney
(MDCK) cells. After incubation, wells were examined for the
presence and degree of cytopathogenic effect. The quantity of virus
in TCID.sub.50 units was calculated by the Reed-Muench technique.
The egg infectivity assay was performed as described in Example 1.
The percent of horses shedding challenge virus for each assay in
each group is shown in Tables 22 and 23. The percent of horses
shedding the challenge virus in the vaccinated group was lower
(P<0.05) on days 2 through 7 post-challenge by either method. No
differences were seen on days 1 or 8 post-challenge. The number of
days the challenge virus was shed was also lower (P<0.05) in the
vaccinated group as compared to the non-vaccinated controls; see
Tables 22 and 23.
TABLE-US-00022 TABLE 22 Percent of horses shedding virus following
challenge - cell culture assay. Day post Vaccinated Non-vaccinated
challenge (n = 10) (n = 10) 1 0 0 2 0 70* 3 0 70* 4 20 100* 5 10
100* 6 20 100* 7 0 80* 8 0 30 average 0.5 5.5* number of days
shedding *Within a time point, vaccinates different from
non-vaccinates, P < 0.05 by either Fisher's exact test (percent
data) or Wilcoxon 2 sample test (days shedding)
TABLE-US-00023 TABLE 23 Percent of horses shedding virus following
challenge - egg infectivity assay. Day post Vaccinated
Non-vaccinated challenge (n = 10) (n = 10) 1 0 0 2 0 70* 3 10 70* 4
0 90* 5 10 70* 6 20 90* 7 0 50* 8 0 0 average 0.4 4.4* number of
days shedding *Within a time point, vaccinates different from
non-vaccinates, P < 0.05 by either Fisher's exact test (percent
data) or Wilcoxon 2 sample test (days shedding).
[0163] The extent (severity and duration) of clinical signs of
influenza among vaccinates was substantially reduced relative to
the controls. The scores from clinical signs relevant to influenza
and the objective temperature measurements both demonstrated a
statistically significant reduction in the group of vaccinates when
compared to those from the control group; indicating that the
vaccine conferred significant protection from disease by the
heterologous strain.
[0164] The ability of horses to shed influenza virus post-challenge
was also significantly reduced in vaccinates as opposed to controls
in both the incidence of horses positive for shedding on certain
days post-challenge and the mean number of days of shedding per
horse. This decreased shedding by vaccinates is important in that
it should serve to reduce the potential for exposure of susceptible
animals to the wild-type virus in an outbreak of influenza.
[0165] Overall, the results of this study show that the vaccine
conferred protection against a heterologous challenge by a member
of the Eurasian lineage of equine influenza virus strains.
EXAMPLE 10
[0166] This Example discloses an animal study to evaluate the
ability of a therapeutic composition comprising cold-adapted equine
influenza virus EIV-P821 to aid in the prevention of disease
following exposure to a heterologous strain of equine influenza
virus.
[0167] The heterologous strain tested was A/equine/2/Kentucky/98
[H3N8] (obtained from Tom Chambers, University of Kentucky). Eight
ponies aged 5 to 7 months were used for this efficacy study. The
horses were assigned to two groups, one group of 4 to be vaccinated
and another group of 4 to serve as non-vaccinated controls. Ponies
were vaccinated as described in Example 8, on Day 0.
[0168] Clinical observations were performed for the vaccinates on
Study Day 0 (before vaccination and at 4 hours post-vaccination),
as well as on Days 1 to 8, 23, 30 to 50, and 57 post-vaccination.
Controls were observed clinically on Days 29 to 50 and 57. The
observations were performed and scored as described in Example
8.
[0169] The challenge material i.e. equine flu strain from
Kentucky/98, was prepared by passing the isolated virus two times
in eggs. The inoculum for each horse was prepared by thawing 0.5 ml
of the virus, then diluting in 4.5 ml of sterile phosphate-buffered
saline. The inoculum was administered by nebulization using a mask
for each individual horse on Day 36 post-vaccination.
[0170] The clinical observation scores were summed on each day for
each horse, and horses were ranked according to the cumulative
total score from days 1 to 9 post-challenge. Theses results are
shown in Table 24.
TABLE-US-00024 TABLE 24 Clinical sign observations: total scores,
ranked by total score. Total Score.sup.# Halter Days 1 to 9 Group
Identity post-challenge 1-Vaccinate 50 0 1-Vaccinate 52 0
1-Vaccinate 55 1 1-Vaccinate 15 2 2-Control 61 21 2-Control 20 25
2-Control 7 26 2-Control 13 26 .sup.#Total scores represent the sum
of daily scores (where daily scores equal the sum of scores for
coughing, nasal discharge, respiration, and depression) and are
ranked from the lowest (least severe) to highest (most severe)
scores.
[0171] The results of Table 24 show that the scores for vaccinates
were between 0 and 2, which was significantly lower than the score
for controls, which were between 21 and 26.
[0172] Rectal temperatures were measured daily beginning 6 days
prior to challenge, and continuing until 9 days post-challenge. Day
0 is the day relative to challenge. Data from days 0 through 9 were
included in the analysis. These results are shown in Table 25.
TABLE-US-00025 TABLE 25 Effect of Challenge on daily mean
temperatures (.degree. C.) in vaccinated and control horses. Day
post challenge control vaccinate difference 0 99.7 99.5 0.2 1 100.0
99.6 0.4 2 103.9 100.2 3.7 3 99.8 99.2 0.6 4 99.6 99.1 0.5 5 99.8
99.3 0.5 6 99.6 99.3 0.3 7 99.3 99.0 0.3 8 99.7 99.6 0.1 9 99.5
99.1 0.4
[0173] The temperatures of the control horses were higher than the
temperatures of the vaccinated horses on all days. The temperature
in control horses was significantly higher on day 2.
[0174] Nasopharyngeal swabs were collected on days 1 and 8,
post-challenge, as described in Example 3. These samples were
tested for shed virus by an egg infectivity assay as described in
Example 1. The results of the assay are shown in Table 26.
TABLE-US-00026 TABLE 26 Virus shedding post-challenge detected by
egg infectivity. Study day No. 35 37 38 39 40 41 42 43 44 days Days
post-challenge positive Identity -1 1 2 3 4 5 6 7 8 per Group No.
Detection of virus* horse Vaccinates 15 0 2 0 3 3 0 2 1 0 5 50 0 0
0 0 0 1 0 0 0 1 52 0 0 3 3 2 2 0 0 0 4 55 0 2 3 1 3 0 0 0 0 4 No.
horses positive 0 2 2 3 3 2 1 1 0 per day Controls 07 0 3 3 3 3 3 3
1 0 7 13 0 3 3 3 3 3 3 1 0 7 20 0 2 3 3 3 3 3 1 0 7 61 0 3 3 3 3 3
3 2 0 7 No. horses positive 0 4 4 4 4 4 4 4 0 per day *Values refer
to the number of eggs testing positive of 3 eggs tested per sample.
For statistical analysis, a sample was considered positive for
virus if at least 1 egg was positive per sample.
[0175] The results of Table 26 show that the number of horses
positive per day was higher for the controls than for the
vaccinates. Additionally, control horses were positive for more
days than vaccinates.
[0176] The scores from clinical signs relevant to influenza and the
objective temperature measurements both demonstrated significant
differences in the group of vaccinates when compared to the control
group; this shows that the vaccine conferred significant protection
from disease caused by the heterologous strain Kentucky/98.
[0177] The ability of horses to shed influenza virus post-challenge
was also significantly reduced in vaccinates as opposed to controls
in the mean number of days of shedding per horse. This decreased
shedding by vaccinates is important in that it should serve to
reduce the potential for exposure of susceptible animals to the
wild-type virus in an outbreak of influenza.
[0178] Overall, the results of this study show that the vaccine
safely conferred protection to a heterologous challenge by a recent
and clinically relevant isolate. When the results of this study are
viewed in the light of the protection previously demonstrated
against heterologous challenge with a Eurasian strain (Example 9),
there is clear evidence to support the assertion that this modified
live vaccine can confer protection against heterologous as well as
homologous equine influenza infection.
EXAMPLE 11
[0179] This example describes the cloning and sequencing of equine
influenza M (matrix) protein nucleic acid molecules for wild type
and cold-adapted equine influenza viruses.
[0180] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus M protein, were produced as follows. A PCR
product containing an equine M gene was produced by PCR
amplification from equine influenza virus DNA, and primers w584 and
w585, designated SEQ ID NO:26, and SEQ ID NO:27, respectively. A
nucleic acid molecule of 1023 nucleotides, denoted
nei.sub.wtM.sub.1023, with a coding strand having a nucleic acid
sequence designated SEQ ID NO:1 was produced by further PCR
amplification using the above described PCR product as a template
and cloned into pCR 2.1.RTM.TA cloning vector, available from
Invitrogen, Carlsbad, Calif., using standard procedures recommended
by the manufacturer. The primers used were the T7 primer,
designated by SEQ ID NO:29 and the REV primer, designated by SEQ ID
NO:28. Plasmid DNA was purified using a mini-prep method available
from Qiagen, Valencia, Calif. PCR products were prepared for
sequencing using a PRISM.TM. Dye Terminator Cycle Sequencing Ready
Reaction kit, a PRISM.TM. dRhodamine Terminator Cycle Sequencing
Ready Reaction kit, or a PRISM.TM. BigDye.TM. Terminator Cycle
Sequencing Ready Reaction kit, all available from PE Applied
Biosystems, Foster City, Calif., following the manufacturer's
protocol. Specific PCR conditions used with the kit were a rapid
ramp to 95.degree. C., hold for 10 seconds followed by a rapid ramp
to 50.degree. C. with a 5 second hold then a rapid ramp to
60.degree. C. with a 4 minute hold, repeating for 25 cycles.
Different sets of primers were used in different reactions: T7 and
REV were used in one reaction; w584 and w585 were used in a second
reaction; and efM-a1, designated SEQ ID NO:31 and efM-s1,
designated SEQ ID NO:30 were used in a third reaction. PCR products
were purified by ethanol/magnesium chloride precipitation.
Automated sequencing of DNA samples was performed using an ABI
PRISM.TM. Model 377 with XL upgrade DNA Sequencer, available from
PE Applied Biosystems.
[0181] Translation of SEQ ID NO:1 indicates that nucleic acid
molecule nei.sub.wtM.sub.1023 encodes a full-length equine
influenza M protein of about 252 amino acids, referred to herein as
Pei.sub.wtM.sub.252, having amino acid sequence SEQ ID NO:2,
assuming an open reading frame in which the initiation codon spans
from nucleotide 25 through nucleotide 28 of SEQ ID NO:1 and the
termination codon spans from nucleotide 781 through nucleotide 783
of SEQ ID NO:1. The region encoding Pei.sub.wtM.sub.252, designated
nei.sub.wtM.sub.756, and having a coding strand comprising
nucleotides 25 to 780 of SEQ ID NO:1, is represented by SEQ ID
NO:3.
[0182] SEQ ID NO:1 and SEQ ID NO:3 represent the consensus sequence
obtained from two wild type nucleic acid molecules, which differ in
one nucleotide. Nucleotide 663 of nei.sub.wt1M.sub.1023, i.e.,
nucleotide 649 of nei.sub.wt1M.sub.756, was adenine, while
nucleotide 663 of nei.sub.wt2M.sub.1023, i.e., nucleotide 649 of
nei.sub.wt2M.sub.756, was guanine. Translation of these sequences
does not result in an amino acid change at the corresponding amino
acid; both translate to valine at residue 221 in
Pei.sub.wtM.sub.252.
[0183] B. A nucleic acid molecule of 1023 nucleotides encoding a
cold-adapted equine influenza virus M, denoted
nei.sub.ca1M.sub.1023, with a coding strand having a sequence
designated SEQ ID NO:4 was produced by further PCR amplification
and cloned into the pCR.RTM.-Blunt cloning vector available from
Invitrogen, using conditions recommended by the manufacturer, and
primers T7 and REV. Plasmid DNA purification and cycle sequencing
were performed as described in Example 11, part A. Translation of
SEQ ID NO:4 indicates that nucleic acid molecule
nei.sub.ca1M.sub.1023 encodes a full-length equine influenza M
protein of about 252 amino acids, referred to herein as
Pei.sub.ca1M252, having amino acid sequence SEQ ID NO:5, assuming
an open reading frame in which the initiation codon spans from
nucleotide 25 through nucleotide 28 of SEQ ID NO:4 and the
termination codon spans from nucleotide 781 through nucleotide 783
of SEQ ID NO:4. The region encoding Pei.sub.ca1M.sub.252,
designated nei.sub.ca1M.sub.756, and having a coding strand
comprising nucleotides 25 to 780 of SEQ ID NO:4, is represented by
SEQ ID NO:6. PCR amplification of a second nucleic acid molecule
encoding a cold-adapted equine influenza M protein in the same
manner resulted in molecules nei.sub.ca2M.sub.1023, identical to
nei.sub.ca1M.sub.1023, and nei.sub.ca2M.sub.756, identical to
nei.sub.ca1M.sub.756.
[0184] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wtM.sub.1023 (SEQ ID NO:1) and
nei.sub.ca1M.sub.1023 (SEQ ID NO:4) by DNA alignment reveals the
following differences: a G to T shift at base 67, a C to T shift at
base 527, and a G to C shift at base 886. Comparison of the amino
acid sequences of proteins Pei.sub.wtM.sub.252 (SEQ ID NO:2) and
Pei.sub.ca1M.sub.252 (SEQ ID NO:5) reveals the following
differences: a V to L shift at amino acid 23 relating to the G to T
shift at base 67 in the DNA sequences; and a T to I shift at amino
acid 187 relating to the C to T shift at base 527 in the DNA
sequences.
EXAMPLE 12
[0185] This example describes the cloning and sequencing of equine
influenza HA (hemagglutinin) protein nucleic acid molecules for
wild type or cold-adapted equine influenza viruses.
[0186] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus HA proteins were produced as follows. A PCR
product containing an equine HA gene was produced by PCR
amplification from equine influenza virus DNA and primers w578 and
w579, designated SEQ ID NO:32 and SEQ ID NO:33, respectively. A
nucleic acid molecule of 1762 nucleotides encoding a wild-type HA
protein, denoted nei.sub.wtHA.sub.1762, with a coding strand having
a nucleic acid sequence designated SEQ ID NO:7 was produced by
further PCR amplification using the above-described PCR product as
a template and cloned into pCR 2.1.RTM.TA cloning vector as
described in Example 11A. Plasmid DNA was purified and sequenced as
in Example 11A, except that primers used in the sequencing kits
were either T7 and REV in one case, or HA-1, designated SEQ ID
NO:34, and HA-2, designated SEQ ID NO:35, in a second case.
[0187] Translation of SEQ ID NO:7 indicates that nucleic acid
molecule nei.sub.wtHA.sub.1762 encodes a full-length equine
influenza HA protein of about 565 amino acids, referred to herein
as Pei.sub.wtHA.sub.565, having amino acid sequence SEQ ID NO:8,
assuming an open reading frame in which the initiation codon spans
from nucleotide 30 through nucleotide 33 of SEQ ID NO:7 and the
termination codon spans from nucleotide 1725 through nucleotide
1727 of SEQ ID NO:7. The region encoding Pei.sub.wtHA.sub.565,
designated nei.sub.wtHA.sub.1695, and having a coding strand
comprising nucleotides 30 to 1724 of SEQ ID NO:7 is represented by
SEQ ID NO:9.
[0188] B. A nucleic acid molecule of 1762 nucleotides encoding a
cold-adapted equine influenza virus HA protein, denoted
nei.sub.ca1HA.sub.1762, with a coding strand having a sequence
designated SEQ ID NO:10 was produced as described in Example 11B.
Plasmid DNA purification and cycle sequencing were performed as
described in Example 12, part A.
[0189] Translation of SEQ ID NO: 10 indicates that nucleic acid
molecule nei.sub.ca1HA.sub.1762 encodes a full-length equine
influenza HA protein of about 565 amino acids, referred to herein
as Pei.sub.ca1HA.sub.565, having amino acid sequence SEQ ID NO:11,
assuming an open reading frame in which the initiation codon spans
from nucleotide 30 through nucleotide 33 of SEQ ID NO:10 and the
termination codon spans from nucleotide 1725 through nucleotide
1727 of SEQ ID NO:10. The region encoding Pei.sub.ca1HA.sub.565,
designated nei.sub.ca1HA.sub.1695, and having a coding strand
comprising nucleotides 30 to 1724 of SEQ ID NO:10, is represented
by SEQ ID NO:12.
[0190] PCR amplification of a second nucleic acid molecule encoding
a cold-adapted equine influenza HA protein in the same manner
resulted in molecules nei.sub.ca2HA.sub.1762, identical to
nei.sub.ca1HA.sub.1762, and nei.sub.ca2HA.sub.1695, identical to
nei.sub.ca1HA.sub.1695.
[0191] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wtHA.sub.1762 (SEQ ID NO:7) and
nei.sub.ca1HA.sub.1762 (SEQ ID NO:10) by DNA alignment reveals the
following differences: a C to T shift at base 55, a G to A shift at
base 499, a G to A shift at base 671, a C to T shift at base 738, a
T to C shift at base 805, a G to A shift at base 1289, and an A to
G shift at base 1368. Comparison of the amino acid sequences of
proteins Pei.sub.wtHA.sub.565 (SEQ ID NO:8) and
Pei.sub.ca1HA.sub.565 (SEQ ID NO:11) reveals the following
differences: a P to L shift at amino acid 18 relating to the C to T
shift at base 55 in the DNA sequences; a G to E shift at amino acid
166 relating to the G to A shift at base 499 in the DNA sequences;
an R to W shift at amino acid 246 relating to the C to T shift at
base 738 in the DNA sequences; an M to T shift at amino acid 268
relating to the T to C shift at base 805 in the DNA sequences; a K
to E shift at amino acid 456 relating to the A to G shift at base
1368 in the DNA sequences. There is no change of the serine (S) at
residue 223 relating to the G to A shift at base 671 in the DNA
sequences, nor is there a change of the arginine (R) at residue 429
relating to the G to A shift at base 1289 in the DNA sequences.
EXAMPLE 13
[0192] This example describes the cloning and sequencing of equine
influenza PB2 protein (RNA-directed RNA polymerase) nucleic acid
molecules corresponding to the N-terminal portion of the protein,
for wild type or cold-adapted equine influenza viruses.
[0193] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus PB2-N proteins were produced as follows. A
PCR product containing an N-terminal portion of the equine PB2 gene
was produced by PCR amplification from equine influenza virus DNA,
and primers w570 and w571, designated SEQ ID NO:36 and SEQ ID
NO:37, respectively. A nucleic acid molecule of 1241 nucleotides
encoding a wild type PB2-N protein, denoted
nei.sub.wtPB2-N.sub.1241, with a coding strand having a nucleic
acid sequence designated SEQ ID NO:13 was produced by further PCR
amplification using the above described PCR product as a template
and cloned as described in Example 11B. Plasmid DNA was purified
and sequenced as in Example 11B, except that only T7 and REV
primers were used in the sequencing kits.
[0194] Translation of SEQ ID NO:13 indicates that nucleic acid
molecule nei.sub.wtPB2-N.sub.1241 encodes an N-terminal portion of
influenza PB2 protein of about 404 amino acids, referred to herein
as P.sub.wtPB2-N.sub.404, having amino acid sequence SEQ ID NO:14,
assuming an open reading frame in which the initiation codon spans
from nucleotide 28 through nucleotide 30 of SEQ ID NO:13, and the
last codon spans from nucleotide 1237 through nucleotide 1239. The
region encoding P.sub.wtPB2-N.sub.404, designated
nei.sub.wtPB2-N.sub.1214, and having a coding strand comprising
nucleotides 28 to 1239 of SEQ ID NO:13 is represented by SEQ ID
NO:15.
[0195] B. A nucleic acid molecule of 1239 nucleotides encoding an
N-terminal portion of influenza PB2 cold-adapted equine influenza
virus PB2-N protein, denoted nei.sub.ca1PB2-N.sub.1241, with a
coding strand having a sequence designated SEQ ID NO:16 was
produced, and sequenced as described in as in Example 12, part
A.
[0196] Translation of SEQ ID NO:16 indicates that nucleic acid
molecule nei.sub.ca1PB2-N.sub.1241 encodes an N-terminal portion of
equine influenza PB-2 protein of about 404 amino acids, referred to
herein as P.sub.ca1PB2-N.sub.404, having amino acid sequence SEQ ID
NO:17, assuming an open reading frame in which the initiation codon
spans from nucleotide 28 through nucleotide 30 of SEQ ID NO:16, and
the last codon spans from nucleotide 1237 through nucleotide 1239.
The region encoding P.sub.ca1PB2-N.sub.404, designated
nei.sub.ca1PB2-N.sub.1214, and having a coding strand comprising
nucleotides 28 to 1239 of SEQ ID NO:16, is represented by SEQ ID
NO:18.
[0197] PCR amplification of a second nucleic acid molecule encoding
a cold-adapted equine influenza PB2-N protein in the same manner
resulted in molecules nei.sub.ca2PB2-N.sub.1241, identical to
nei.sub.ca1PB2-N.sub.1241, and nei.sub.ca2PB2-N.sub.1214, identical
to nei.sub.ca1PB2-N.sub.1214.
[0198] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wtPB2-N.sub.1241 (SEQ ID NO:13) and
nei.sub.ca1PB2-N.sub.1241 (SEQ ID NO:16) by DNA alignment reveals
the following difference: a T to C base shift at base 370.
Comparison of the amino acid sequences of proteins
P.sub.wtPB2-N.sub.404 (SEQ ID NO:14) and P.sub.ca1PB2-N.sub.404
(SEQ ID NO:17) reveals the following difference: a Y to H shift at
amino acid 124 relating to the a T to C shift at base 370 in the
DNA sequence.
EXAMPLE 14
[0199] This example describes the cloning and sequencing of equine
influenza PB2 protein (RNA-directed RNA polymerase) nucleic acid
molecules corresponding to the C-terminal portion of the protein,
for wild type or cold-adapted equine influenza viruses.
[0200] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus PB2-C proteins were produced as follows. A
PCR product containing the C-terminal portion of the equine PB2
gene was produced by PCR amplification using from equine influenza
virus DNA and primers w572 and w573, designated SEQ ID NO:38 and
SEQ ID NO:39, respectively. A nucleic acid molecule of 1233
nucleotides encoding a wild type PB2-C protein, denoted
nei.sub.wtPB2-C.sub.1233, with a coding strand having a nucleic
acid sequence designated SEQ ID NO:19 was produced by further PCR
amplification using the above-described PCR product as a template
and cloned as described in Example 11B. Plasmid DNA was purified
and sequenced as in Example 11A, except that different primers were
used in the sequencing kits. T7 and REV were used in one instance;
efPB2-a1, designated SEQ ID NO:40 and efPB2-s1, designated SEQ ID
NO:41 were used in another instance, and efPB2-a2, designated SEQ
ID NO:42 and efPB2-s2, designated SEQ ID NO:43 were used in another
instance.
[0201] Translation of SEQ ID NO:19 indicates that nucleic acid
molecule nei.sub.wt1PB2-C.sub.1233 encodes a C-terminal portion of
influenza PB2 protein of about 398 amino acids, referred to herein
as P.sub.wtPB2-C.sub.398, having amino acid sequence SEQ ID NO:20,
assuming an open reading frame having a first codon spans from
nucleotide 3 through nucleotide 5 and a termination codon which
spans from nucleotide 1197 through nucleotide 1199 of SEQ ID NO:19.
Because SEQ ID NO:19 is only a partial gene sequence, it does not
contain an initiation codon. The region encoding
P.sub.wtPB2-C.sub.398, designated nei.sub.wtPB2-C.sub.1194, and
having a coding strand comprising nucleotides 3 to 1196 of SEQ ID
NO:19 is represented by SEQ ID NO:21.
[0202] PCR amplification of a second nucleic acid molecule encoding
a wild type equine influenza PB2-N protein in the same manner
resulted in a nucleic acid molecule of 1232 nucleotides denoted
nei.sub.wt2PB2-N.sub.1232, with a coding strand with a sequence
designated SEQ ID NO:22. nei.sub.wt2PB2-N.sub.1232 is identical to
nei.sub.wt1PB2-C.sub.1233, expect that nei.sub.wt2PB2-N.sub.1232
lacks one nucleotide on the 5'-end. Translation of SEQ ID NO:22
indicates that nucleic acid molecule nei.sub.wt1PB2-C.sub.1233 also
encodes P.sub.wtPB2-C.sub.398 (SEQ ID NO:20), assuming an open
reading frame having a first codon which spans from nucleotide 2
through nucleotide 4 and a termination codon spans from nucleotide
1196 through nucleotide 1198 of SEQ ID NO:22. Because SEQ ID NO:22
is only a partial gene sequence, it does not contain an initiation
codon. The nucleic acid molecule having a coding strand comprising
nucleotides 2 to 1195 of SEQ ID NO:22, denoted
nei.sub.wt2PB2-C.sub.1194, is identical to SEQ ID NO:21.
[0203] B. A nucleic acid molecule of 1232 nucleotides encoding a
C-terminal portion of influenza PB2 cold-adapted equine influenza
virus protein, denoted nei.sub.ca1PB2-C.sub.1232, and having a
coding strand having a sequence designated SEQ ID NO:23 was
produced as described in as in Example 14, part A, except that the
pCR.RTM.-Blunt cloning vector was used.
[0204] Translation of SEQ ID NO:23 indicates that nucleic acid
molecule nei.sub.ca1PB2-C.sub.1232 encodes a C-terminal portion of
equine influenza PB-2 protein of about 398 amino acids, referred to
herein as P.sub.ca1PB2-C.sub.398, having amino acid sequence SEQ ID
NO:24, assuming an open reading frame having a first codon which
spans from nucleotide 2 through nucleotide 4 and a termination
codon spans from nucleotide 1196 through nucleotide 1198 of SEQ ID
NO:23. Because SEQ ID NO:23 is only a partial gene sequence, it
does not contain an initiation codon. The region encoding
P.sub.ca1PB2-C.sub.398, designated nei.sub.ca1PB2-C1194, and having
a coding strand comprising nucleotides 2 to 1195 of SEQ ID NO:23,
is represented by SEQ ID NO:25.
[0205] PCR amplification of a second nucleic acid molecule encoding
a cold-adapted equine influenza PB2-C protein in the same manner
resulted in molecules nei.sub.ca2PB2-C.sub.1231, containing one
less nucleotide at the 3'end than nei.sub.ca1PB2-N.sub.1241; and
nei.sub.ca2PB2-N.sub.1214, identical to
nei.sub.ca1PB2-N.sub.1214.
[0206] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wt1PB2-C.sub.1233 (SEQ ID NO:19) and
nei.sub.ca1PB2-C.sub.1232 (SEQ ID NO:23) by DNA alignment reveals
the following differences: an A to C base shift at base 153 of SEQ
ID NO:19, and a G to A base shift at base 929 of SEQ ID NO:19.
Comparison of the amino acid sequences of proteins
P.sub.wtPB2-C.sub.398 (SEQ ID NO:20) and P.sub.ca1PB2-.sub.398 (SEQ
ID NO:24) reveals the following difference: a K to Q shift at amino
acid 51 when relating to the an A to C base shift at base 153 in
the DNA sequences. There is no amino acid shift resulting from the
G to A base shift at base 929.
EXAMPLE 15
[0207] This example describes the cloning and sequencing of equine
influenza PB2 protein (RNA-directed RNA polymerase) nucleic acid
molecules for wild type or cold-adapted equine influenza
viruses.
[0208] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus PB2 proteins were produced as follows. The
wild type or cold-adapted equine influenza genes were cloned in two
fragments, the N-terminal portion was produced as in Example 13 and
the C-terminal portion of the gene was produced as in Example
14.
[0209] The DNA sequence for the wild type equine influenza PB2 gene
was generated by combining the consensus sequences for the wild
type PB2-N protein, denoted nei.sub.wtPB2-N.sub.1241 (SEQ ID NO:
13) with the gene fragments for the wild type PB2-C protein,
denoted nei.sub.wt1PB2-C.sub.1233 (SEQ ID NO:19) and
nei.sub.wt2PB2-C.sub.1232 (SEQ ID NO: 22). The result of combining
the consensus sequences from the N-terminal and C-terminal portions
of the PB2 wild type influenza virus yielded a complete DNA
sequence denoted nei.sub.wtPB2.sub.2341 (SEQ ID NO:44). Translation
of SEQ ID NO:44 indicates that the nucleic acid molecule
nei.sub.wtPB2.sub.2341 encodes a full length equine influenza PB2
protein of about 759 amino acids referred to herein as
Pei.sub.wtPB2.sub.759, having amino acid sequence SEQ ID NO: 45,
assuming an open reading frame in which the initiation codon spans
from nucleotide 28 through nucleotide 30 of SEQ ID NO: 44 and the
termination codon spans from nucleotide 2305 through nucleotide
2307 of SEQ ID NO: 44. The region encoding Pei.sub.wtPB2.sub.759,
designated nei.sub.wtPB2.sub.2277, and having a coding strand
comprising nucleotides 28 to 2304 of SEQ ID NO: 44, is SEQ ID NO:
46.
[0210] B. A DNA sequence of 2341 nucleotides encoding a
cold-adapted equine influenza virus PB2, denoted
nei.sub.ca1PB2.sub.2341, with a sequence denoted SEQ ID NO: 47 was
produced by combining the sequences for the N-terminal and
C-terminal portions of the PB2 cold-adapted equine influenza gene.
The clones for the N-terminal sequences are denoted
nei.sub.ca1PB2-N.sub.1241 and nei.sub.ca2PB2-N.sub.1241 which are
identical and are represented by SEQ ID NO:16. The clones for the
C-terminal sequences are denoted nei.sub.ca1PB2-C.sub.1232 and
nei.sub.ca2PB2-C.sub.1231, represented by SEQ ID NO:23.
[0211] Translation of SEQ ID NO:47 indicates that nucleic acid
molecule nei.sub.ca1PB2.sub.2341 encodes a full-length equine
influenza PB2 protein of about 759 amino acids, referred to herein
as Pei.sub.ca1PB2.sub.759 having amino acid sequence SEQ ID NO:48,
assuming an open reading frame in which the initiation codon spans
from nucleotide 28 through nucleotide 30 of SEQ ID NO: 47 and the
termination codon spans from nucleotide 2305 through nucleotide
2307 of SEQ ID NO:47. The region encoding Pei.sub.ca1PB2.sub.759
designated nei.sub.ca1PB2.sub.2277 and having a coding strand
comprising nucleotides 28 to 2304 of SEQ ID NO:49.
[0212] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wtPB.sub.2341 (SEQ ID NO:44) and
nei.sub.ca1PB2.sub.2341 (SEQ ID NO:47) by DNA alignment reveals the
following differences: a T to C base shift at base 370, an A to C
base shift at base 1261, and a G to A base shift at base 2037.
Comparison of the amino acid sequences of proteins
Pei.sub.wtPB2.sub.759 (SEQ ID NO:45) and Pei.sub.ca1PB2.sub.759
(SEQ ID NO:48) reveals the following differences: a Y to H shift at
amino acid 124 relating to the a T to C shift at base 370 in the
DNA sequence, a K to Q shift at amino acid 421 relating to the A to
C shift at base 1261 in the DNA sequence. The third nucleotide
shift at base 2037 does not result in an amino acid shift at
amino.
EXAMPLE 16
[0213] This example describes the cloning and sequencing of equine
influenza NS (nonstructural) protein nucleic acid molecules for
wild type or cold-adapted equine influenza viruses.
[0214] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus NS proteins were produced as follows. A PCR
product containing an equine NS gene was produced by PCR
amplification from equine influenza virus DNA and primers w586 and
w587, designated SEQ ID NO:59 and SEQ ID NO:60, respectively. A
nucleic acid molecule of 891 nucleotides encoding a wild-type NS
protein, denoted nei.sub.wtNS.sub.891, with a coding strand having
a nucleic acid sequence designated SEQ ID NO:50 was produced by
further PCR amplification using the above-described PCR product as
a template and cloned into pCR 2.1.RTM.TA cloning vector as
described in Example 11A. Plasmid DNA was purified and sequenced as
in Example 11A, except that primers used in the sequencing kits
were only T7 and REV were used in the sequencing kits.
[0215] Translation of SEQ ID NO:50 indicates that nucleic acid
molecule nei.sub.wt1NS.sub.891 encodes a full-length equine
influenza NS protein of about 230 amino acids, referred to herein
as Pei.sub.wt1NS.sub.230, having amino acid sequence SEQ ID NO:51,
assuming an open reading frame in which the initiation codon spans
from nucleotide 27 through nucleotide 29 of SEQ ID NO:50 and the
termination codon spans from nucleotide 717 through nucleotide 719
of SEQ ID NO:50. The region encoding Pei.sub.wt1NS.sub.230,
designated nei.sub.wt1NS.sub.690, and having a coding strand
comprising nucleotides 27 to 716 of SEQ ID NO:50 is represented by
SEQ ID NO:52.
[0216] PCR amplification of a second nucleic acid molecule encoding
a wild type equine influenza NS protein in the same manner resulted
in molecules nei.sub.wt2NS.sub.891, identical to
nei.sub.wt1NS.sub.891 in the coding region; i.e.
nei.sub.wt2NS.sub.690, is identical to nei.sub.wt1NS.sub.690.
nei.sub.wt2NS.sub.891 differs from nei.sub.wt1NS.sub.891 in one
nucleotide at base 827 (G to A) which is 111 bases downstream from
the stop codon. PCR amplification of a third nucleic acid encoding
a wild type equine influenza NS protein in the same manner resulted
in a nucleic acid molecule of 888 nucleotides denoted
nei.sub.wt3NS.sub.888, with a coding strand with a nucleic acid
sequence designated SEQ ID NO: 53. nei.sub.wt3NS.sub.888 is
identical to nei.sub.wt1NS.sub.891, except that
nei.sub.wt3NS.sub.888, lacks two nucleotides on the 5' end and one
nucleotide on the 3' end. Translation of SEQ ID NO:53 indicates
that nucleic acid molecule nei.sub.wt3NS.sub.888 also encodes
Pei.sub.wt1NS.sub.230 (SEQ ID NO:51), assuming an open reading
frame having an initiation codon which spans from nucleotide 25
through nucleotide 27 of SEQ ID NO: 53 and a termination codon
which spans from nucleotide 715 through nucleotide 717 of SEQ ID
NO:53. The nucleic acid molecule having a coding strand comprising
nucleotides 25 to 714 of SEQ ID 53, denoted nei.sub.wt3NS.sub.690,
is identical to SEQ ID NO:52.
[0217] PCR amplification of a fourth nucleic acid of 468
nucleotides encoding a C-terminal portion of the wild type equine
influenza NS protein, denoted nei.sub.wt4NS.sub.468 and having a
coding sequence designated SEQ ID NO:54 was produced. Translation
of SEQ ID NO:54 indicates that nucleic acid molecule
nei.sub.wt4NS.sub.468 encodes a C-terminal portion of equine
influenza NS protein of about 97 amino acids, referred to herein as
Pei.sub.wt4NS.sub.97, having amino acid sequence SEQ ID NO:55,
assuming an open reading frame having a first codon which spans
from nucleotide 3 to 5 of SEQ ID NO: 54, and a termination codon
spans from nucleotide 294 through 296 of SEQ ID NO:54. Because SEQ
ID NO:54 is only a partial gene sequence, it does not contain an
initiation codon. The region encoding Pei.sub.wt4NS.sub.97,
designated nei.sub.wt4NS.sub.293, and having a coding strand
comprising nucleotides 1 to 293 of SEQ ID NO:54, is represented by
SEQ ID NO:56.
[0218] B. A nucleic acid molecule of 888 nucleotides encoding a
cold-adapted equine influenza virus NS protein, denoted
nei.sub.ca1NS.sub.888 with a coding strand having a sequence
designated SEQ ID NO:57 was produced and sequenced as described in
Example 16, part A.
[0219] Translation of SEQ ID NO:57 indicates that nucleic acid
molecule nei.sub.ca1NS.sub.888 encodes a full-length equine
influenza NS protein of about 230 amino acids, referred to herein
as Pei.sub.ca1NS.sub.230, having amino acid sequence SEQ ID NO:58,
assuming an open reading frame in which the initiation codon spans
from nucleotide 27 through nucleotide 29 of SEQ ID NO:57 and the
termination codon spans from nucleotide 717 through nucleotide 719
of SEQ ID NO:57. The region encoding Pei.sub.ca1NS.sub.230,
designated nei.sub.ca1NS.sub.690, and having a coding strand
comprising nucleotides 27 to 716 of SEQ ID NO:57, is represented by
SEQ ID NO:59.
[0220] PCR amplification of a second nucleic acid molecule encoding
a cold-adapted equine influenza NS protein in the same manner
resulted in molecules nei.sub.ca2NS.sub.887, containing one less
nucleotide at the 3' end than nei.sub.ca1NS.sub.888; the coding
region nei.sub.ca2NS.sub.690 is identical to
nei.sub.ca1NS.sub.690.
[0221] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wtNS.sub.891 (SEQ ID NO:50) and
nei.sub.ca1NS.sub.888 (SEQ ID NO:57) by DNA alignment reveals the
following difference: an A to G shift at base 827 which is 111
bases downstream from the stop codon. The 3' fragment encoding
nei.sub.wt4NS.sub.468 (SEQ ID NO:54) has one shift T to C found at
base 633 relative to the full-length consensus sequence. Comparison
of the amino acid sequences of proteins Pei.sub.wtNS.sub.230 (SEQ
ID NO:51) and Pei.sub.ca1NS.sub.230 (SEQ ID NO:58) reveals that
there are no differences between amino acid sequences of the wild
type and cold-adapted proteins.
EXAMPLE 17
[0222] This example describes the cloning and sequencing of equine
influenza PB1 protein (RNA-directed RNA polymerase 1) nucleic acid
molecules corresponding to the N-terminal portion of the protein,
for wild type or cold-adapted equine influenza viruses.
[0223] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus PB1-N proteins were produced as follows. A
PCR product containing an N-terminal portion of the equine PB1 gene
was produced by PCR amplification from equine influenza virus DNA,
and primers T7 and REV. A nucleic acid molecule of 1229 nucleotides
encoding a wild type PB1-N protein, denoted
nei.sub.wt1PB1-N.sub.1229, with a coding strand having a nucleic
acid sequence designated SEQ ID NO:62 was produced by further PCR
amplification using the above described PCR product as a template
and cloned as described in Example 11B. Plasmid DNA was purified
and sequenced as in Example 11B, except that only T7 and REV
primers were used in the sequencing kits.
[0224] Translation of SEQ ID NO:62 indicates that nucleic acid
molecule nei.sub.wt1PB1-N.sub.1229 encodes an N-terminal portion of
influenza PB1 protein of about 398 amino acids, referred to herein
as Pei.sub.wt1PB1-N.sub.398, having amino acid sequence SEQ ID
NO:63, assuming an open reading frame in which the initiation codon
spans from nucleotide 36 through nucleotide 38 of SEQ ID NO:62, and
the last codon spans from nucleotide 1227 through nucleotide 1229
of SEQ ID NO:62. The region encoding Pei.sub.wt1PB1-N.sub.398,
designated nei.sub.wt1PB1-N.sub.1194, and having a coding strand
comprising nucleotides 36 to 1229 of SEQ ID NO:62 is represented by
SEQ ID NO:64.
[0225] PCR amplification of a second nucleic acid molecule encoding
a wild type equine influenza PB1-N protein in the same manner
resulted in a nucleic acid molecule of 673 nucleotides denoted
nei.sub.wt2PB1-N.sub.673, with a coding strand with a sequence
designated SEQ ID NO:65. Translation of SEQ ID NO:65 indicates that
nucleic acid molecule nei.sub.wt2PB1-N.sub.673 encodes
Pei.sub.wt2PB1-N.sub.212 (SEQ ID NO:66), assuming an open reading
frame having an initiation codon which spans from nucleotide 36
through nucleotide 38 of SEQ ID NO:65 and a last codon which spans
from nucleotide 671 through nucleotide 673 of SEQ ID NO:65. Because
SEQ ID NO:65 is only a partial gene sequence, it does not contain a
stop codon. The nucleic acid molecule having a coding strand
comprising nucleotides 36 to 671 of SEQ ID NO:65, denoted
nei.sub.wt2PB1-N.sub.636, is designated SEQ ID NO:67.
[0226] B. A nucleic acid molecule of 1225 nucleotides encoding an
N-terminal portion of influenza PB1 cold-adapted equine influenza
virus PB1-N protein, denoted nei.sub.ca1PB1-N.sub.1225, with a
coding strand having a sequence designated SEQ ID NO:68 was
produced, and sequenced as described in as in Example 17, part
A.
[0227] Translation of SEQ ID NO:68 indicates that nucleic acid
molecule nei.sub.ca1PB1-N.sub.1225 encodes an N-terminal portion of
equine influenza PB-1 protein of about 395 amino acids, referred to
herein as Pei.sub.ca1PB1-N.sub.395, having amino acid sequence SEQ
ID NO:69, assuming an open reading frame in which the initiation
codon spans from nucleotide 34 through nucleotide 36 of SEQ ID
NO:68, and a last codon which spans from nucleotide 1216 through
nucleotide 1218 of SEQ ID NO:68. The region encoding
Pei.sub.ca1PB1-N.sub.395, designated nei.sub.ca1PB1-N.sub.1185, and
having a coding strand comprising nucleotides 34 to 1218 of SEQ ID
NO:68, is represented by SEQ ID NO:70.
[0228] PCR amplification of a second nucleic acid molecule encoding
a cold-adapted equine influenza PB1-N protein in the same manner
resulted in molecules nei.sub.ca2PB1-N.sub.1221, designated SEQ ID
NO:71, containing four less nucleotides at the 5' end than
nei.sub.ca1PB1-N.sub.1225; the coding region
nei.sub.ca2PB1-N.sub.1185, is identical to
nei.sub.ca1PB1-N.sub.1185.
[0229] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wtPB1-N.sub.1229 (SEQ ID NO:62) and
nei.sub.ca1PB1-N.sub.1225 (SEQ ID NO:68) by DNA alignment reveals
no differences in the coding regions. Comparison of the amino acid
sequences of proteins Pei.sub.wtPB1-N.sub.395 (SEQ ID NO:63) and
Pei.sub.ca1PB1-N.sub.395 (SEQ ID NO:69) also reveals no
differences.
EXAMPLE 18
[0230] This example describes the cloning and sequencing of equine
influenza PB 1 protein (RNA-directed RNA polymerase 1) nucleic acid
molecules corresponding to the C-terminal portion of the protein,
for wild type or cold-adapted equine influenza viruses.
[0231] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus PB1-C proteins were produced as follows. A
PCR product containing an C-terminal portion of the equine PB1 gene
was produced by PCR amplification from equine influenza virus DNA,
and primer w569 designated SEQ ID NO:102. A nucleic acid molecule
of 1234 nucleotides encoding a wild type PB1-C protein, denoted
nei.sub.wt1PB1-C.sub.1234, with a coding strand having a nucleic
acid sequence designated SEQ ID NO:85 was produced by further PCR
amplification using the above described PCR product as a template
and cloned as described in Example 11B. Plasmid DNA was purified
and sequenced as in Example 11A, except that different primers were
used in the sequencing kits. T7, REV, w569, efPB1-a1, designated
SEQ ID NO:97, efPB1-a2, designated SEQ ID NO:98, efPB1-s1,
designated SEQ ID NO: 99, efPB1-s2, designated SEQ ID NO: 100, and
efPB1-s3, designated SEQ ID NO:101 were used in one instance, T7,
REV, efPB1-a1, efPB1-a2, efPB1-s1, efPB1-s2, and efPB1-s3 were used
in another instance and T7 and REV were used in another
instance.
[0232] Translation of SEQ ID NO:85 indicates that nucleic acid
molecule nei.sub.wt1PB1-C.sub.1234 encodes an C-terminal portion of
influenza PB1 protein of about 396 amino acids, referred to herein
as Pei.sub.wt1PB1-C.sub.396, having amino acid sequence SEQ ID
NO:86, assuming an open reading frame in which the first codon
spans from nucleotide 1 through nucleotide 3 of SEQ ID NO:85 and a
termination codon which spans from nucleotide 1189 through
nucleotide 1191 of SEQ ID NO:85. Because SEQ ID NO:85 is only a
partial gene sequence, it does not contain an initiation codon. The
region encoding Pei.sub.wt1PB1-C.sub.396, designated
nei.sub.wt1PB1-C.sub.1188, and having a coding strand comprising
nucleotides 1 to 1188 of SEQ ID NO:85 is represented by SEQ ID
NO:87.
[0233] PCR amplification of a second nucleic acid molecule encoding
a wild type equine influenza PB 1-C protein in the same manner
resulted in a nucleic acid molecule of 1240 nucleotides denoted
nei.sub.wt2PB1-C.sub.1240, with a coding strand with a sequence
designated SEQ ID NO:88. Translation of SEQ ID NO:88 indicates that
nucleic acid molecule nei.sub.wt2PB1-N.sub.1240 encodes a molecule
designated Pei.sub.wt2PB1-C.sub.396 (SEQ ID NO: 89) which differs
from Pei.sub.wt1PB1-C.sub.396 (SEQ ID NO:85) in one nucleotide.
Nucleotide 382 of nei.sub.wt1PB1-C.sub.1234, i.e. nucleotide 382 of
nei.sub.wt1PB1-C.sub.1188 was A, while nucleotide 389 of
nei.sub.wt2PB1-C.sub.1240, i.e. nucleotide 382 of
nei.sub.wt2PB1-C.sub.1188 was T. Translation of
nei.sub.wt2PB1-C.sub.1240 results in an amino acid change of T to
S.
[0234] B. A nucleic acid molecule of 1241 nucleotides encoding an
C-terminal portion of influenza PB1 cold-adapted equine influenza
virus PB 1-C protein, denoted nei.sub.ca1PB1-C.sub.1241, with a
coding strand having a sequence designated SEQ ID NO:91 was
produced, and sequenced as described in as in Example 18, part
A.
[0235] Translation of SEQ ID NO:91 indicates that nucleic acid
molecule nei.sub.ca1PB1-C.sub.1241 encodes an C-terminal portion of
equine influenza PB-1 protein of about 396 amino acids, referred to
herein as Pei.sub.ca1PB1-C.sub.396, having amino acid sequence SEQ
ID NO:92, assuming an open reading frame in which the first codon
spans from nucleotide 8 through nucleotide 10 of SEQ ID NO:91 and a
termination codon that spans from nucleotide 1196 through
nucleotide 1198 of SEQ ID NO:91. Because SEQ ID NO:91 is only a
partial gene sequence, it does not contain an initiation codon. The
region encoding Pei.sub.ca1PB1-C.sub.396, designated
nei.sub.ca1PB1-C.sub.1188, and having a coding strand comprising
nucleotides 8 to 1195 of SEQ ID NO:91, is represented by SEQ ID
NO:93.
[0236] PCR amplification of a second nucleic acid molecule encoding
a cold-adapted equine influenza PB1-C protein in the same manner
resulted in a nucleic acid molecule of 1241 nucleotides denoted
nei.sub.ca2PB1-C.sub.1241, with a coding strand with a sequence
designated SEQ ID NO:94. Translation of SEQ ID NO:94 indicates that
nucleic acid molecule nei.sub.ca2PB1-C.sub.1241 encodes a molecule
designated Pei.sub.ca2PB1-C.sub.396 (SEQ ID NO: 95) which differs
from Pei.sub.ca1PB1-C.sub.396(SEQ ID NO:92) in one nucleotide.
Nucleotide 1044 of nei.sub.ca1PB1-C.sub.1241, i.e. nucleotide 1037
of nei.sub.ca1PB1-N.sub.1188 was A, while nucleotide 1044 of
nei.sub.ca2PB1-C.sub.1241, i.e. nucleotide 1037 of
nei.sub.ca2PB1-C.sub.1188 was G. Translation of
nei.sub.ca2PB1-C.sub.1241 results in an amino acid change of R to
K.
[0237] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wt1PB1-C.sub.1234 (SEQ ID NO:85) and
nei.sub.ca1PB1-C.sub.1241 (SEQ ID NO:91) by DNA alignment reveals
the following differences: a C to T shift at base 600 of SEQ ID
NO:85, and a T to A shift at base 603 of SEQ ID NO:85. Comparison
of the amino acid sequences of proteins Pei.sub.wt1PB1-C.sub.396
(SEQ ID NO:86) and Pei.sub.ca1PB1-N.sub.396 (SEQ ID NO:92) reveals
the following difference: a H to Q amino acid shift 203 when
relating to the T to A base shift at base 603 in the DNA sequences.
There is no amino acid shift resulting from the C to T base shift
at base 600.
EXAMPLE 19
[0238] This example describes the cloning and sequencing of equine
influenza PB1 protein (RNA-directed RNA polymerase) nucleic acid
molecules for wild type or cold-adapted equine influenza
viruses.
[0239] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus PB 1 proteins were produced as follows. The
wild type or cold-adapted equine influenza genes were cloned in two
fragments, the N-terminal portion was produced as in Example 17 and
the C-terminal portion of the gene was produced as in Example
18.
[0240] The DNA sequence for the wild type equine influenza PB1 gene
was generated by combining the sequences for the wild type PB1-N
protein, nei.sub.wtPB1-N.sub.1229 (SEQ ID NO:62) and
nei.sub.wt2PB1-N.sub.673 (SEQ ID NO: 65) with the gene fragments
for the wild type PB1-C protein, denoted nei.sub.wt1PB1-C.sub.1234
(SEQ ID NO:85) and nei.sub.wt2PB1-C.sub.1240 (SEQ ID NO: 88). The
result of combining the N-terminal and C-terminal portions of the
PB1 wild type influenza virus yielded a complete DNA sequence of
2341 nucleotides denoted nei.sub.wtPB1.sub.2341 (SEQ ID NO:103).
Translation of SEQ ID NO:103 indicates that the nucleic acid
molecule nei.sub.wtPB2.sub.2341 encodes a full length equine
influenza PB1 protein of about 757 amino acids referred to herein
as Pei.sub.wtPB1.sub.757, having amino acid sequence SEQ ID NO:104,
assuming an open reading frame in which the initiation codon spans
from nucleotide 25 through nucleotide 27 of SEQ ID NO: 103 and the
termination codon spans from nucleotide 2293 through nucleotide
2295 of SEQ ID NO: 103. The region encoding Pei.sub.wtPB1.sub.757
designated nei.sub.wtPB1.sub.2271, and having a coding strand
comprising nucleotides 25 to 2292 of SEQ ID NO: 103, is SEQ ID NO:
105.
[0241] B. A DNA sequence of 2341 nucleotides encoding a
cold-adapted equine influenza virus PB1, denoted
nei.sub.ca1PB1.sub.2341, with a sequence denoted SEQ ID NO: 106 was
produced by combining the sequences for the N-terminal and
C-terminal portions of the PB1 cold-adapted equine influenza gene.
The clones for the N-terminal sequences are denoted
nei.sub.ca1PB1-N.sub.1225 (SEQ ID NO: 68) and
nei.sub.ca2PB1-N.sub.1221 (SEQ ID NO: 71). The clones for the
C-terminal sequences are denoted nei.sub.ca1PB1-C.sub.1241 (SEQ ID
NO:91) and nei.sub.ca2PB1-C.sub.1241, (SEQ ID NO: 94).
[0242] Translation of SEQ ID NO:106 indicates that nucleic acid
molecule nei.sub.ca1PB1.sub.2341 encodes a full-length equine
influenza PB1 protein of about 757 amino acids, referred to herein
as Pei.sub.ca1PB1.sub.757 having amino acid sequence SEQ ID NO:107,
assuming an open reading frame in which the initiation codon spans
from nucleotide 25 through nucleotide 27 SEQ ID NO: 106 and the
termination codon spans from nucleotide 2296 through nucleotide
2298 of SEQ ID NO:106. The region encoding Pei.sub.ca1PB1.sub.757
designated nei.sub.ca1PB1.sub.2271 and having a coding strand
comprising nucleotides 25 to 2295 of SEQ ID NO:108.
[0243] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wtPB1.sub.2341 (SEQ ID NO:103) and
nei.sub.ca1PB1.sub.2341 (SEQ ID NO:106) by DNA alignment reveals
the following differences: a C to T base shift at base 1683, and a
T to A base shift at base 1686. Comparison of the amino acid
sequences of proteins Pei.sub.wtPB1.sub.757 (SEQ ID NO:104) and
Pei.sub.ca1PB1.sub.757 (SEQ ID NO:107) reveals the following
differences: no shift in base C at amino acid 561 relating to the C
to T shift at base 1683, and a H to Q shift at amino acid 562
relating to the a T to A shift at base 1683 in the DNA
sequence.
EXAMPLE 20
[0244] This example describes the cloning and sequencing of equine
influenza PA protein (RNA polymerase A) nucleic acid molecules
corresponding to the C-terminal portion of the protein, for wild
type or cold-adapted equine influenza viruses.
[0245] A. Nucleic acid molecules encoding wild type or cold-adapted
equine influenza virus PA-C proteins were produced as follows. A
PCR product containing the C-terminal portion of the equine PA gene
was produced by PCR amplification using from equine influenza virus
DNA and primers C+PA and C-PA, designated SEQ ID NO:83 and SEQ ID
NO:84 respectively. A nucleic acid molecule of 1228 nucleotides
encoding a wild type PA-C protein, denoted
nei.sub.wt1PA-C.sub.1228, with a coding strand having a nucleic
acid sequence designated SEQ ID NO:76 was produced by further PCR
amplification using the above-described PCR product as a template
and cloned as described in Example 1B. Plasmid DNA was purified and
sequenced as in Example 11A, except that different primers were
used in the sequencing kits. T7 and REV were used in one instance;
PAC-1, designated SEQ ID NO:72, PAC-2, designated SEQ ID NO:73,
PAC-3, designated SEQ ID NO:74, PAC-4, designated SEQ ID NO: 75, T7
and REV were used in another instance; and PAC-1, PAC-2, T7 and REV
were used in another instance.
[0246] Translation of SEQ ID NO:76 indicates that nucleic acid
molecule nei.sub.wt1PA-C.sub.1228 encodes a C-terminal portion of
influenza PA protein of about 388 amino acids, referred to herein
as Pei.sub.wt1PA-C.sub.388, having amino acid sequence SEQ ID
NO:77, assuming an open reading frame having a first codon spans
from nucleotide 3 through nucleotide 5 of SEQ ID NO:76 and a
termination codon which spans from nucleotide 1167 through
nucleotide 1169 of SEQ ID NO:76. Because SEQ ID NO:76 is only a
partial gene sequence, it does not contain an initiation codon. The
region encoding Pei.sub.wt1PA-C.sub.388, designated
nei.sub.wt1PA-C.sub.1164, and having a coding strand comprising
nucleotides 3 to 1166 of SEQ ID NO:76 is represented by SEQ ID
NO:78.
[0247] PCR amplification of a second nucleic acid molecule encoding
a wild type equine influenza PA-C protein in the same manner
resulted in a nucleic acid molecule of 1223 nucleotides denoted
nei.sub.wt2PA-C.sub.1223, with a coding strand with a sequence
designated SEQ ID NO:79. nei.sub.wt2PA-C.sub.1223 is identical to
nei.sub.wt1PA-C.sub.1228, with the exception of a T to C base shift
at base 753 and that nei.sub.wt2PA-C.sub.1223 lacks five
nucleotides on the 3'-end. Translation of SEQ ID NO:79 indicates
that nucleic acid molecule nei.sub.wt2PA-C.sub.1223 also encodes
Pei.sub.wt1PA-C.sub.388 (SEQ ID NO:77), assuming an open reading
frame having a first codon which spans from nucleotide 3 through
nucleotide 5 of SEQ ID NO:79 and a termination codon which spans
from nucleotide 1167 through nucleotide 1169 of SEQ ID NO:79.
Because SEQ ID NO:79 is only a partial gene sequence, it does not
contain an initiation codon. The nucleic acid molecule having a
coding strand comprising nucleotides 3 to 1166 of SEQ ID NO:79,
denoted nei.sub.wt2PA-C.sub.1223, is identical to SEQ ID NO 78.
[0248] B. A nucleic acid molecule of 1233 nucleotides encoding a
C-terminal portion of influenza PA-C cold-adapted equine influenza
virus protein, denoted nei.sub.ca1PA-C.sub.1233, and having a
coding strand having a sequence designated SEQ ID NO:80 was
produced as described in as in Example 20, part A, except that the
pCR.RTM.-Blunt cloning vector was used.
[0249] Translation of SEQ ID NO:80 indicates that nucleic acid
molecule nei.sub.ca1PA-C.sub.1233 encodes a C-terminal portion of
equine influenza PA protein of about 390 amino acids, referred to
herein as Pei.sub.ca1PA-C.sub.390, having amino acid sequence SEQ
ID NO:81, assuming an open reading frame having a first codon which
spans from nucleotide 3 through nucleotide 5 of SEQ ID NO:80 and a
termination codon which spans from nucleotide 1173 through
nucleotide 1175 of SEQ ID NO:80. Because SEQ ID NO:80 is only a
partial gene sequence, it does not contain an initiation codon. The
region encoding Pei.sub.ca1PA-C.sub.390, designated
nei.sub.ca1PA-C.sub.1170, and having a coding strand comprising
nucleotides 3 to 1172 of SEQ ID NO:80, is represented by SEQ ID
NO:82.
[0250] PCR amplification of a second nucleic acid molecule encoding
a cold-adapted equine influenza PA-C protein in the same manner
resulted in molecule nei.sub.ca2PA-C.sub.1233, containing one A to
G base shift at base 953 as compared to nei.sub.ca1PA-C.sub.1233;
this base shift does not result in an amino acid change so
Pei.sub.ca2PA-C.sub.390, is identical to Pei.sub.ca1PA-C.sub.390
(SEQ ID NO: 81.)
[0251] C. Comparison of the nucleic acid sequences of the coding
strands of nei.sub.wt1PA-C.sub.1228 (SEQ ID NO:76) and
nei.sub.ca1PA-C.sub.1233 (SEQ ID NO:80) by DNA alignment reveals
the following difference: an C to T base shift at base 753 of SEQ
ID NO:80. Comparison of the amino acid sequences of proteins
Pei.sub.wt1PA-C.sub.388 (SEQ ID NO:77) and Pei.sub.ca1PA-.sub.390
(SEQ ID NO:81) reveals the following difference: a W to R shift at
amino acid 251 when relating to the C to T base shift at base 753
in the DNA sequences.
[0252] While various embodiments of the present invention have been
described in detail, it is apparent that modifications and
adaptations of those embodiments will occur to those skilled in the
art. It is to be expressly understood, however, that such
modifications and adaptations are within the scope of the present
invention, as set forth in the following claims.
Sequence CWU 1
1
10811023DNAEquine influenza virus
H3N8CDS(25)..(780)misc_feature(663)..(663)At nucleotide 663, r = a
or g At amino acid residue 213, Xaa = Val 1gcaaaagcag gtagatattt
aaag atg agt ctt ctg acc gag gtc gaa acg 51Met Ser Leu Leu Thr Glu
Val Glu Thr1 5tac gtt ctc tct atc gta cca tca ggc ccc ctc aaa gcc
gag atc gcg 99Tyr Val Leu Ser Ile Val Pro Ser Gly Pro Leu Lys Ala
Glu Ile Ala10 15 20 25cag aga ctt gaa gat gtc ttt gca ggg aag aac
acc gat ctt gag gca 147Gln Arg Leu Glu Asp Val Phe Ala Gly Lys Asn
Thr Asp Leu Glu Ala30 35 40ctc atg gaa tgg cta aag aca aga cca atc
ctg tca cct ctg act aaa 195Leu Met Glu Trp Leu Lys Thr Arg Pro Ile
Leu Ser Pro Leu Thr Lys45 50 55ggg att tta gga ttc gta ttc acg ctc
acc gtg ccc agt gag cga gga 243Gly Ile Leu Gly Phe Val Phe Thr Leu
Thr Val Pro Ser Glu Arg Gly60 65 70ctg cag cgt aga cgc ttt gtc caa
aat gcc ctt agt gga aac gga gat 291Leu Gln Arg Arg Arg Phe Val Gln
Asn Ala Leu Ser Gly Asn Gly Asp75 80 85cca aac aac atg gac aga gca
gta aaa ctg tac agg aag ctt aaa aga 339Pro Asn Asn Met Asp Arg Ala
Val Lys Leu Tyr Arg Lys Leu Lys Arg90 95 100 105gaa ata aca ttc cat
ggg gca aaa gag gtg gca ctc agc tat tcc act 387Glu Ile Thr Phe His
Gly Ala Lys Glu Val Ala Leu Ser Tyr Ser Thr110 115 120ggt gca cta
gcc agc tgc atg gga ctc ata tac aac aga atg gga act 435Gly Ala Leu
Ala Ser Cys Met Gly Leu Ile Tyr Asn Arg Met Gly Thr125 130 135gtg
aca acc gaa gtg gca ttt ggc ctg gta tgc gcc aca tgt gaa cag 483Val
Thr Thr Glu Val Ala Phe Gly Leu Val Cys Ala Thr Cys Glu Gln140 145
150atc gct gat tcc cag cat cga tct cac agg cag atg gtg aca aca acc
531Ile Ala Asp Ser Gln His Arg Ser His Arg Gln Met Val Thr Thr
Thr155 160 165aac cca tta atc aga cat gaa aac aga atg gta tta gcc
agt acc acg 579Asn Pro Leu Ile Arg His Glu Asn Arg Met Val Leu Ala
Ser Thr Thr170 175 180 185gct aaa gcc atg gag cag atg gca ggg tcg
agt gag cag gca gca gag 627Ala Lys Ala Met Glu Gln Met Ala Gly Ser
Ser Glu Gln Ala Ala Glu190 195 200gcc atg gag gtt gct agt aag gct
agg cag atg gtr cag gca atg aga 675Ala Met Glu Val Ala Ser Lys Ala
Arg Gln Met Xaa Gln Ala Met Arg205 210 215acc att ggg acc cac cct
agc tcc agt gcc ggt ttg aaa gat gat ctc 723Thr Ile Gly Thr His Pro
Ser Ser Ser Ala Gly Leu Lys Asp Asp Leu220 225 230ctt gaa aat ttg
cag gcc tac cag aaa cgg atg gga gtg caa atg cag 771Leu Glu Asn Leu
Gln Ala Tyr Gln Lys Arg Met Gly Val Gln Met Gln235 240 245cga ttc
aag tgatcctctc gttattgcag caagtatcat tgggatcttg 820Arg Phe
Lys250cacttgatat tgtggattct tgatcgcctt ttcttcaaat tcatttatcg
tcgccttaaa 880tacgggttga aaagagggcc ttctacggaa ggagtacctg
agtctatgag ggaagaatat 940cggcaggaac agcagaatgc tgtggatgtt
gacgatggtc attttgtcaa catagagctg 1000gagtaaaaaa ctaccttgtt tct
10232252PRTEquine influenza virus H3N8misc_feature(213)..(213)The
'Xaa' at location 213 stands for Val. 2Met Ser Leu Leu Thr Glu Val
Glu Thr Tyr Val Leu Ser Ile Val Pro1 5 10 15Ser Gly Pro Leu Lys Ala
Glu Ile Ala Gln Arg Leu Glu Asp Val Phe20 25 30Ala Gly Lys Asn Thr
Asp Leu Glu Ala Leu Met Glu Trp Leu Lys Thr35 40 45Arg Pro Ile Leu
Ser Pro Leu Thr Lys Gly Ile Leu Gly Phe Val Phe50 55 60Thr Leu Thr
Val Pro Ser Glu Arg Gly Leu Gln Arg Arg Arg Phe Val65 70 75 80Gln
Asn Ala Leu Ser Gly Asn Gly Asp Pro Asn Asn Met Asp Arg Ala85 90
95Val Lys Leu Tyr Arg Lys Leu Lys Arg Glu Ile Thr Phe His Gly
Ala100 105 110Lys Glu Val Ala Leu Ser Tyr Ser Thr Gly Ala Leu Ala
Ser Cys Met115 120 125Gly Leu Ile Tyr Asn Arg Met Gly Thr Val Thr
Thr Glu Val Ala Phe130 135 140Gly Leu Val Cys Ala Thr Cys Glu Gln
Ile Ala Asp Ser Gln His Arg145 150 155 160Ser His Arg Gln Met Val
Thr Thr Thr Asn Pro Leu Ile Arg His Glu165 170 175Asn Arg Met Val
Leu Ala Ser Thr Thr Ala Lys Ala Met Glu Gln Met180 185 190Ala Gly
Ser Ser Glu Gln Ala Ala Glu Ala Met Glu Val Ala Ser Lys195 200
205Ala Arg Gln Met Xaa Gln Ala Met Arg Thr Ile Gly Thr His Pro
Ser210 215 220Ser Ser Ala Gly Leu Lys Asp Asp Leu Leu Glu Asn Leu
Gln Ala Tyr225 230 235 240Gln Lys Arg Met Gly Val Gln Met Gln Arg
Phe Lys245 2503756DNAEquine influenza virus H3N8 3atgagtcttc
tgaccgaggt cgaaacgtac gttctctcta tcgtaccatc aggccccctc 60aaagccgaga
tcgcgcagag acttgaagat gtctttgcag ggaagaacac cgatcttgag
120gcactcatgg aatggctaaa gacaagacca atcctgtcac ctctgactaa
agggatttta 180ggattcgtat tcacgctcac cgtgcccagt gagcgaggac
tgcagcgtag acgctttgtc 240caaaatgccc ttagtggaaa cggagatcca
aacaacatgg acagagcagt aaaactgtac 300aggaagctta aaagagaaat
aacattccat ggggcaaaag aggtggcact cagctattcc 360actggtgcac
tagccagctg catgggactc atatacaaca gaatgggaac tgtgacaacc
420gaagtggcat ttggcctggt atgcgccaca tgtgaacaga tcgctgattc
ccagcatcga 480tctcacaggc agatggtgac aacaaccaac ccattaatca
gacatgaaaa cagaatggta 540ttagccagta ccacggctaa agccatggag
cagatggcag ggtcgagtga gcaggcagca 600gaggccatgg aggttgctag
taaggctagg cagatggtrc aggcaatgag aaccattggg 660acccacccta
gctccagtgc cggtttgaaa gatgatctcc ttgaaaattt gcaggcctac
720cagaaacgga tgggagtgca aatgcagcga ttcaag 75641023DNAEquine
influenza virus H3N8CDS(25)..(780) 4gcaaaagcag gtagatattt aaag atg
agt ctt ctg acc gag gtc gaa acg 51Met Ser Leu Leu Thr Glu Val Glu
Thr1 5tac gtt ctc tct atc tta cca tca ggc ccc ctc aaa gcc gag atc
gcg 99Tyr Val Leu Ser Ile Leu Pro Ser Gly Pro Leu Lys Ala Glu Ile
Ala10 15 20 25cag aga ctt gaa gat gtc ttt gca ggg aag aac acc gat
ctt gag gca 147Gln Arg Leu Glu Asp Val Phe Ala Gly Lys Asn Thr Asp
Leu Glu Ala30 35 40ctc atg gaa tgg cta aag aca aga cca atc ctg tca
cct ctg act aaa 195Leu Met Glu Trp Leu Lys Thr Arg Pro Ile Leu Ser
Pro Leu Thr Lys45 50 55ggg att tta gga ttc gta ttc acg ctc acc gtg
ccc agt gag cga gga 243Gly Ile Leu Gly Phe Val Phe Thr Leu Thr Val
Pro Ser Glu Arg Gly60 65 70ctg cag cgt aga cgc ttt gtc caa aat gcc
ctt agt gga aac gga gat 291Leu Gln Arg Arg Arg Phe Val Gln Asn Ala
Leu Ser Gly Asn Gly Asp75 80 85cca aac aac atg gac aga gca gta aaa
ctg tac agg aag ctt aaa aga 339Pro Asn Asn Met Asp Arg Ala Val Lys
Leu Tyr Arg Lys Leu Lys Arg90 95 100 105gaa ata aca ttc cat ggg gca
aaa gag gtg gca ctc agc tat tcc act 387Glu Ile Thr Phe His Gly Ala
Lys Glu Val Ala Leu Ser Tyr Ser Thr110 115 120ggt gca cta gcc agc
tgc atg gga ctc ata tac aac aga atg gga act 435Gly Ala Leu Ala Ser
Cys Met Gly Leu Ile Tyr Asn Arg Met Gly Thr125 130 135gtg aca acc
gaa gtg gca ttt ggc ctg gta tgc gcc aca tgt gaa cag 483Val Thr Thr
Glu Val Ala Phe Gly Leu Val Cys Ala Thr Cys Glu Gln140 145 150atc
gct gat tcc cag cat cga tct cac agg cag atg gtg aca ata acc 531Ile
Ala Asp Ser Gln His Arg Ser His Arg Gln Met Val Thr Ile Thr155 160
165aac cca tta atc aga cat gaa aac aga atg gta tta gcc agt acc acg
579Asn Pro Leu Ile Arg His Glu Asn Arg Met Val Leu Ala Ser Thr
Thr170 175 180 185gct aaa gcc atg gag cag atg gca ggg tcg agt gag
cag gca gca gag 627Ala Lys Ala Met Glu Gln Met Ala Gly Ser Ser Glu
Gln Ala Ala Glu190 195 200gcc atg gag gtt gct agt aag gct agg cag
atg gta cag gca atg aga 675Ala Met Glu Val Ala Ser Lys Ala Arg Gln
Met Val Gln Ala Met Arg205 210 215acc att ggg acc cac cct agc tcc
agt gcc ggt ttg aaa gat gat ctc 723Thr Ile Gly Thr His Pro Ser Ser
Ser Ala Gly Leu Lys Asp Asp Leu220 225 230ctt gaa aat ttg cag gcc
tac cag aaa cgg atg gga gtg caa atg cag 771Leu Glu Asn Leu Gln Ala
Tyr Gln Lys Arg Met Gly Val Gln Met Gln235 240 245cga ttc aag
tgatcctctc gttattgcag caagtatcat tgggatcttg 820Arg Phe
Lys250cacttgatat tgtggattct tgatcgcctt ttcttcaaat tcatttatcg
tcgccttaaa 880tacggcttga aaagagggcc ttctacggaa ggagtacctg
agtctatgag ggaagaatat 940cggcaggaac agcagaatgc tgtggatgtt
gacgatggtc attttgtcaa catagagctg 1000gagtaaaaaa ctaccttgtt tct
10235252PRTEquine influenza virus H3N8 5Met Ser Leu Leu Thr Glu Val
Glu Thr Tyr Val Leu Ser Ile Leu Pro1 5 10 15Ser Gly Pro Leu Lys Ala
Glu Ile Ala Gln Arg Leu Glu Asp Val Phe20 25 30Ala Gly Lys Asn Thr
Asp Leu Glu Ala Leu Met Glu Trp Leu Lys Thr35 40 45Arg Pro Ile Leu
Ser Pro Leu Thr Lys Gly Ile Leu Gly Phe Val Phe50 55 60Thr Leu Thr
Val Pro Ser Glu Arg Gly Leu Gln Arg Arg Arg Phe Val65 70 75 80Gln
Asn Ala Leu Ser Gly Asn Gly Asp Pro Asn Asn Met Asp Arg Ala85 90
95Val Lys Leu Tyr Arg Lys Leu Lys Arg Glu Ile Thr Phe His Gly
Ala100 105 110Lys Glu Val Ala Leu Ser Tyr Ser Thr Gly Ala Leu Ala
Ser Cys Met115 120 125Gly Leu Ile Tyr Asn Arg Met Gly Thr Val Thr
Thr Glu Val Ala Phe130 135 140Gly Leu Val Cys Ala Thr Cys Glu Gln
Ile Ala Asp Ser Gln His Arg145 150 155 160Ser His Arg Gln Met Val
Thr Ile Thr Asn Pro Leu Ile Arg His Glu165 170 175Asn Arg Met Val
Leu Ala Ser Thr Thr Ala Lys Ala Met Glu Gln Met180 185 190Ala Gly
Ser Ser Glu Gln Ala Ala Glu Ala Met Glu Val Ala Ser Lys195 200
205Ala Arg Gln Met Val Gln Ala Met Arg Thr Ile Gly Thr His Pro
Ser210 215 220Ser Ser Ala Gly Leu Lys Asp Asp Leu Leu Glu Asn Leu
Gln Ala Tyr225 230 235 240Gln Lys Arg Met Gly Val Gln Met Gln Arg
Phe Lys245 2506756DNAEquine influenza virus H3N8 6atgagtcttc
tgaccgaggt cgaaacgtac gttctctcta tcttaccatc aggccccctc 60aaagccgaga
tcgcgcagag acttgaagat gtctttgcag ggaagaacac cgatcttgag
120gcactcatgg aatggctaaa gacaagacca atcctgtcac ctctgactaa
agggatttta 180ggattcgtat tcacgctcac cgtgcccagt gagcgaggac
tgcagcgtag acgctttgtc 240caaaatgccc ttagtggaaa cggagatcca
aacaacatgg acagagcagt aaaactgtac 300aggaagctta aaagagaaat
aacattccat ggggcaaaag aggtggcact cagctattcc 360actggtgcac
tagccagctg catgggactc atatacaaca gaatgggaac tgtgacaacc
420gaagtggcat ttggcctggt atgcgccaca tgtgaacaga tcgctgattc
ccagcatcga 480tctcacaggc agatggtgac aataaccaac ccattaatca
gacatgaaaa cagaatggta 540ttagccagta ccacggctaa agccatggag
cagatggcag ggtcgagtga gcaggcagca 600gaggccatgg aggttgctag
taaggctagg cagatggtac aggcaatgag aaccattggg 660acccacccta
gctccagtgc cggtttgaaa gatgatctcc ttgaaaattt gcaggcctac
720cagaaacgga tgggagtgca aatgcagcga ttcaag 75671762DNAEquine
influenza virus H3N8CDS(30)..(1724) 7agcaaaagca ggggatattt
ctgtcaatc atg aag aca acc att att ttg ata 53Met Lys Thr Thr Ile Ile
Leu Ile1 5cca ctg acc cat tgg gtc tac agt caa aac cca acc agt ggc
aac aac 101Pro Leu Thr His Trp Val Tyr Ser Gln Asn Pro Thr Ser Gly
Asn Asn10 15 20aca gcc aca tta tgt ctg gga cac cat gca gta gca aat
gga aca ttg 149Thr Ala Thr Leu Cys Leu Gly His His Ala Val Ala Asn
Gly Thr Leu25 30 35 40gta aaa aca ata act gat gac caa att gag gtg
aca aat gct act gaa 197Val Lys Thr Ile Thr Asp Asp Gln Ile Glu Val
Thr Asn Ala Thr Glu45 50 55tta gtt cag agc att tca ata ggg aaa ata
tgc aac aac tca tat aga 245Leu Val Gln Ser Ile Ser Ile Gly Lys Ile
Cys Asn Asn Ser Tyr Arg60 65 70gtt cta gat gga aga aat tgc aca tta
ata gat gca atg cta gga gac 293Val Leu Asp Gly Arg Asn Cys Thr Leu
Ile Asp Ala Met Leu Gly Asp75 80 85ccc cac tgt gat gtc ttt cag tat
gag aat tgg gac ctc ttc ata gaa 341Pro His Cys Asp Val Phe Gln Tyr
Glu Asn Trp Asp Leu Phe Ile Glu90 95 100aga agc agc gct ttc agc agt
tgc tac cca tat gac atc cct gac tat 389Arg Ser Ser Ala Phe Ser Ser
Cys Tyr Pro Tyr Asp Ile Pro Asp Tyr105 110 115 120gca tcg ctc cgg
tcc att gta gca tcc tca gga aca ttg gaa ttc aca 437Ala Ser Leu Arg
Ser Ile Val Ala Ser Ser Gly Thr Leu Glu Phe Thr125 130 135gca gag
gga ttc aca tgg aca ggt gtc act caa aac gga aga agt gga 485Ala Glu
Gly Phe Thr Trp Thr Gly Val Thr Gln Asn Gly Arg Ser Gly140 145
150tcc tgc aaa agg gga tca gcc gat agt ttc ttt agc cga ctg aat tgg
533Ser Cys Lys Arg Gly Ser Ala Asp Ser Phe Phe Ser Arg Leu Asn
Trp155 160 165cta aca gaa tct gga aac tct tac ccc aca ttg aat gtg
aca atg cct 581Leu Thr Glu Ser Gly Asn Ser Tyr Pro Thr Leu Asn Val
Thr Met Pro170 175 180aac aat aaa aat ttc gac aaa cta tac atc tgg
ggg att cat cac ccg 629Asn Asn Lys Asn Phe Asp Lys Leu Tyr Ile Trp
Gly Ile His His Pro185 190 195 200agc tca aac aaa gag cag aca aaa
ttg tac atc caa gaa tcg gga cga 677Ser Ser Asn Lys Glu Gln Thr Lys
Leu Tyr Ile Gln Glu Ser Gly Arg205 210 215gta aca gtc tca aca aaa
aga agt caa caa aca ata atc cct aac atc 725Val Thr Val Ser Thr Lys
Arg Ser Gln Gln Thr Ile Ile Pro Asn Ile220 225 230gga tct aga ccg
cgg gtc agg ggt caa tca ggc agg ata agc ata tac 773Gly Ser Arg Pro
Arg Val Arg Gly Gln Ser Gly Arg Ile Ser Ile Tyr235 240 245tgg acc
att gta aaa cct gga gat atc cta atg ata aac agt aat ggc 821Trp Thr
Ile Val Lys Pro Gly Asp Ile Leu Met Ile Asn Ser Asn Gly250 255
260aac tta gtt gca ccg cgg gga tat ttt aaa ttg aaa aca ggg aaa agc
869Asn Leu Val Ala Pro Arg Gly Tyr Phe Lys Leu Lys Thr Gly Lys
Ser265 270 275 280tct gta atg aga tca gat gca ccc ata gac att tgt
gtg tct gaa tgt 917Ser Val Met Arg Ser Asp Ala Pro Ile Asp Ile Cys
Val Ser Glu Cys285 290 295att aca cca aat gga agc atc ccc aac gac
aaa cca ttt caa aat gtg 965Ile Thr Pro Asn Gly Ser Ile Pro Asn Asp
Lys Pro Phe Gln Asn Val300 305 310aac aaa gtt aca tat gga aaa tgc
ccc aag tat atc agg caa aac act 1013Asn Lys Val Thr Tyr Gly Lys Cys
Pro Lys Tyr Ile Arg Gln Asn Thr315 320 325tta aag ctg gcc act ggg
atg agg aat gta cca gaa aag caa atc aga 1061Leu Lys Leu Ala Thr Gly
Met Arg Asn Val Pro Glu Lys Gln Ile Arg330 335 340gga atc ttt gga
gca ata gcg gga ttc ata gaa aac ggc tgg gaa gga 1109Gly Ile Phe Gly
Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu Gly345 350 355 360atg
gtt gat ggg tgg tat gga ttc cga tat caa aac tcg gaa gga aca 1157Met
Val Asp Gly Trp Tyr Gly Phe Arg Tyr Gln Asn Ser Glu Gly Thr365 370
375gga caa gct gca gat cta aag agc act caa gca gcc atc gac cag atc
1205Gly Gln Ala Ala Asp Leu Lys Ser Thr Gln Ala Ala Ile Asp Gln
Ile380 385 390aat gga aaa tta aac aga gtg att gaa agg acc aat gag
aaa ttc cat 1253Asn Gly Lys Leu Asn Arg Val Ile Glu Arg Thr Asn Glu
Lys Phe His395 400 405caa ata gag aag gaa ttc tca gaa gta gaa ggg
agg atc cag gac ttg 1301Gln Ile Glu Lys Glu Phe Ser Glu Val Glu Gly
Arg Ile Gln Asp Leu410 415 420gag aag tat gta gaa gac acc aaa ata
gac cta tgg tcc tac aat gca 1349Glu Lys Tyr Val Glu Asp Thr Lys Ile
Asp Leu Trp Ser Tyr Asn Ala425 430 435 440gaa ttg ctg gtg gct cta
aaa aat caa cat aca att gac tta aca gat 1397Glu Leu Leu Val Ala Leu
Lys Asn Gln His Thr Ile Asp Leu Thr Asp445 450 455gca gaa atg aat
aaa tta ttc gag aag act aga cgc cag tta aga gaa 1445Ala Glu Met Asn
Lys Leu Phe Glu Lys Thr Arg Arg Gln Leu Arg Glu460 465 470aac gcg
gaa gac atg gga ggt gga tgt ttc aag ata tac cac aaa tgt 1493Asn Ala
Glu Asp Met Gly Gly Gly Cys Phe Lys Ile Tyr His Lys Cys475 480
485gat aat gca tgc att gga tca ata aga aat ggg aca tat gac cat tac
1541Asp Asn Ala Cys Ile Gly Ser Ile Arg Asn Gly Thr Tyr Asp His
Tyr490 495 500ata tac aga gat gaa gca tta aac aac cgg ttt caa atc
aaa ggt gtt 1589Ile Tyr Arg Asp Glu Ala Leu Asn Asn Arg Phe Gln Ile
Lys Gly Val505 510 515
520gag ttg aaa tca ggc tac aaa gat tgg ata ctg tgg att tca ttc gcc
1637Glu Leu Lys Ser Gly Tyr Lys Asp Trp Ile Leu Trp Ile Ser Phe
Ala525 530 535ata tca tgc ttc tta att tgc gtt gtt cta ttg ggt ttc
att atg tgg 1685Ile Ser Cys Phe Leu Ile Cys Val Val Leu Leu Gly Phe
Ile Met Trp540 545 550gct tgc caa aaa ggc aac atc aga tgc aac att
tgc att tgagtaaact 1734Ala Cys Gln Lys Gly Asn Ile Arg Cys Asn Ile
Cys Ile555 560 565gatagttaaa aacacccttg tttctact 17628565PRTEquine
influenza virus H3N8 8Met Lys Thr Thr Ile Ile Leu Ile Pro Leu Thr
His Trp Val Tyr Ser1 5 10 15Gln Asn Pro Thr Ser Gly Asn Asn Thr Ala
Thr Leu Cys Leu Gly His20 25 30His Ala Val Ala Asn Gly Thr Leu Val
Lys Thr Ile Thr Asp Asp Gln35 40 45Ile Glu Val Thr Asn Ala Thr Glu
Leu Val Gln Ser Ile Ser Ile Gly50 55 60Lys Ile Cys Asn Asn Ser Tyr
Arg Val Leu Asp Gly Arg Asn Cys Thr65 70 75 80Leu Ile Asp Ala Met
Leu Gly Asp Pro His Cys Asp Val Phe Gln Tyr85 90 95Glu Asn Trp Asp
Leu Phe Ile Glu Arg Ser Ser Ala Phe Ser Ser Cys100 105 110Tyr Pro
Tyr Asp Ile Pro Asp Tyr Ala Ser Leu Arg Ser Ile Val Ala115 120
125Ser Ser Gly Thr Leu Glu Phe Thr Ala Glu Gly Phe Thr Trp Thr
Gly130 135 140Val Thr Gln Asn Gly Arg Ser Gly Ser Cys Lys Arg Gly
Ser Ala Asp145 150 155 160Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr
Glu Ser Gly Asn Ser Tyr165 170 175Pro Thr Leu Asn Val Thr Met Pro
Asn Asn Lys Asn Phe Asp Lys Leu180 185 190Tyr Ile Trp Gly Ile His
His Pro Ser Ser Asn Lys Glu Gln Thr Lys195 200 205Leu Tyr Ile Gln
Glu Ser Gly Arg Val Thr Val Ser Thr Lys Arg Ser210 215 220Gln Gln
Thr Ile Ile Pro Asn Ile Gly Ser Arg Pro Arg Val Arg Gly225 230 235
240Gln Ser Gly Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly
Asp245 250 255Ile Leu Met Ile Asn Ser Asn Gly Asn Leu Val Ala Pro
Arg Gly Tyr260 265 270Phe Lys Leu Lys Thr Gly Lys Ser Ser Val Met
Arg Ser Asp Ala Pro275 280 285Ile Asp Ile Cys Val Ser Glu Cys Ile
Thr Pro Asn Gly Ser Ile Pro290 295 300Asn Asp Lys Pro Phe Gln Asn
Val Asn Lys Val Thr Tyr Gly Lys Cys305 310 315 320Pro Lys Tyr Ile
Arg Gln Asn Thr Leu Lys Leu Ala Thr Gly Met Arg325 330 335Asn Val
Pro Glu Lys Gln Ile Arg Gly Ile Phe Gly Ala Ile Ala Gly340 345
350Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly
Phe355 360 365Arg Tyr Gln Asn Ser Glu Gly Thr Gly Gln Ala Ala Asp
Leu Lys Ser370 375 380Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys
Leu Asn Arg Val Ile385 390 395 400Glu Arg Thr Asn Glu Lys Phe His
Gln Ile Glu Lys Glu Phe Ser Glu405 410 415Val Glu Gly Arg Ile Gln
Asp Leu Glu Lys Tyr Val Glu Asp Thr Lys420 425 430Ile Asp Leu Trp
Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Lys Asn435 440 445Gln His
Thr Ile Asp Leu Thr Asp Ala Glu Met Asn Lys Leu Phe Glu450 455
460Lys Thr Arg Arg Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Gly
Gly465 470 475 480Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys
Ile Gly Ser Ile485 490 495Arg Asn Gly Thr Tyr Asp His Tyr Ile Tyr
Arg Asp Glu Ala Leu Asn500 505 510Asn Arg Phe Gln Ile Lys Gly Val
Glu Leu Lys Ser Gly Tyr Lys Asp515 520 525Trp Ile Leu Trp Ile Ser
Phe Ala Ile Ser Cys Phe Leu Ile Cys Val530 535 540Val Leu Leu Gly
Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile Arg545 550 555 560Cys
Asn Ile Cys Ile56591695DNAEquine influenza virus H3N8 9atgaagacaa
ccattatttt gataccactg acccattggg tctacagtca aaacccaacc 60agtggcaaca
acacagccac attatgtctg ggacaccatg cagtagcaaa tggaacattg
120gtaaaaacaa taactgatga ccaaattgag gtgacaaatg ctactgaatt
agttcagagc 180atttcaatag ggaaaatatg caacaactca tatagagttc
tagatggaag aaattgcaca 240ttaatagatg caatgctagg agacccccac
tgtgatgtct ttcagtatga gaattgggac 300ctcttcatag aaagaagcag
cgctttcagc agttgctacc catatgacat ccctgactat 360gcatcgctcc
ggtccattgt agcatcctca ggaacattgg aattcacagc agagggattc
420acatggacag gtgtcactca aaacggaaga agtggatcct gcaaaagggg
atcagccgat 480agtttcttta gccgactgaa ttggctaaca gaatctggaa
actcttaccc cacattgaat 540gtgacaatgc ctaacaataa aaatttcgac
aaactataca tctgggggat tcatcacccg 600agctcaaaca aagagcagac
aaaattgtac atccaagaat cgggacgagt aacagtctca 660acaaaaagaa
gtcaacaaac aataatccct aacatcggat ctagaccgcg ggtcaggggt
720caatcaggca ggataagcat atactggacc attgtaaaac ctggagatat
cctaatgata 780aacagtaatg gcaacttagt tgcaccgcgg ggatatttta
aattgaaaac agggaaaagc 840tctgtaatga gatcagatgc acccatagac
atttgtgtgt ctgaatgtat tacaccaaat 900ggaagcatcc ccaacgacaa
accatttcaa aatgtgaaca aagttacata tggaaaatgc 960cccaagtata
tcaggcaaaa cactttaaag ctggccactg ggatgaggaa tgtaccagaa
1020aagcaaatca gaggaatctt tggagcaata gcgggattca tagaaaacgg
ctgggaagga 1080atggttgatg ggtggtatgg attccgatat caaaactcgg
aaggaacagg acaagctgca 1140gatctaaaga gcactcaagc agccatcgac
cagatcaatg gaaaattaaa cagagtgatt 1200gaaaggacca atgagaaatt
ccatcaaata gagaaggaat tctcagaagt agaagggagg 1260atccaggact
tggagaagta tgtagaagac accaaaatag acctatggtc ctacaatgca
1320gaattgctgg tggctctaaa aaatcaacat acaattgact taacagatgc
agaaatgaat 1380aaattattcg agaagactag acgccagtta agagaaaacg
cggaagacat gggaggtgga 1440tgtttcaaga tataccacaa atgtgataat
gcatgcattg gatcaataag aaatgggaca 1500tatgaccatt acatatacag
agatgaagca ttaaacaacc ggtttcaaat caaaggtgtt 1560gagttgaaat
caggctacaa agattggata ctgtggattt cattcgccat atcatgcttc
1620ttaatttgcg ttgttctatt gggtttcatt atgtgggctt gccaaaaagg
caacatcaga 1680tgcaacattt gcatt 1695101762DNAEquine influenza virus
H3N8CDS(30)..(1724) 10agcaaaagca ggggatattt ctgtcaatc atg aag aca
acc att att ttg ata 53Met Lys Thr Thr Ile Ile Leu Ile1 5cta ctg acc
cat tgg gtc tac agt caa aac cca acc agt ggc aac aac 101Leu Leu Thr
His Trp Val Tyr Ser Gln Asn Pro Thr Ser Gly Asn Asn10 15 20aca gcc
aca tta tgt ctg gga cac cat gca gta gca aat gga aca ttg 149Thr Ala
Thr Leu Cys Leu Gly His His Ala Val Ala Asn Gly Thr Leu25 30 35
40gta aaa aca ata act gat gac caa att gag gtg aca aat gct act gaa
197Val Lys Thr Ile Thr Asp Asp Gln Ile Glu Val Thr Asn Ala Thr
Glu45 50 55tta gtt cag agc att tca ata ggg aaa ata tgc aac aac tca
tat aga 245Leu Val Gln Ser Ile Ser Ile Gly Lys Ile Cys Asn Asn Ser
Tyr Arg60 65 70gtt cta gat gga aga aat tgc aca tta ata gat gca atg
cta gga gac 293Val Leu Asp Gly Arg Asn Cys Thr Leu Ile Asp Ala Met
Leu Gly Asp75 80 85ccc cac tgt gat gtc ttt cag tat gag aat tgg gac
ctc ttc ata gaa 341Pro His Cys Asp Val Phe Gln Tyr Glu Asn Trp Asp
Leu Phe Ile Glu90 95 100aga agc agc gct ttc agc agt tgc tac cca tat
gac atc cct gac tat 389Arg Ser Ser Ala Phe Ser Ser Cys Tyr Pro Tyr
Asp Ile Pro Asp Tyr105 110 115 120gca tcg ctc cgg tcc att gta gca
tcc tca gga aca ttg gaa ttc aca 437Ala Ser Leu Arg Ser Ile Val Ala
Ser Ser Gly Thr Leu Glu Phe Thr125 130 135gca gag gga ttc aca tgg
aca ggt gtc act caa aac gga aga agt gga 485Ala Glu Gly Phe Thr Trp
Thr Gly Val Thr Gln Asn Gly Arg Ser Gly140 145 150tcc tgc aaa agg
gaa tca gcc gat agt ttc ttt agc cga ctg aat tgg 533Ser Cys Lys Arg
Glu Ser Ala Asp Ser Phe Phe Ser Arg Leu Asn Trp155 160 165cta aca
gaa tct gga aac tct tac ccc aca ttg aat gtg aca atg cct 581Leu Thr
Glu Ser Gly Asn Ser Tyr Pro Thr Leu Asn Val Thr Met Pro170 175
180aac aat aaa aat ttc gac aaa cta tac atc tgg ggg att cat cac ccg
629Asn Asn Lys Asn Phe Asp Lys Leu Tyr Ile Trp Gly Ile His His
Pro185 190 195 200agc tca aac aaa gag cag aca aaa ttg tac atc caa
gaa tca gga cga 677Ser Ser Asn Lys Glu Gln Thr Lys Leu Tyr Ile Gln
Glu Ser Gly Arg205 210 215gta aca gtc tca aca aaa aga agt caa caa
aca ata atc cct aac atc 725Val Thr Val Ser Thr Lys Arg Ser Gln Gln
Thr Ile Ile Pro Asn Ile220 225 230gga tct aga ccg tgg gtc agg ggt
caa tca ggc agg ata agc ata tac 773Gly Ser Arg Pro Trp Val Arg Gly
Gln Ser Gly Arg Ile Ser Ile Tyr235 240 245tgg acc att gta aaa cct
gga gat atc cta acg ata aac agt aat ggc 821Trp Thr Ile Val Lys Pro
Gly Asp Ile Leu Thr Ile Asn Ser Asn Gly250 255 260aac tta gtt gca
ccg cgg gga tat ttt aaa ttg aaa aca ggg aaa agc 869Asn Leu Val Ala
Pro Arg Gly Tyr Phe Lys Leu Lys Thr Gly Lys Ser265 270 275 280tct
gta atg aga tca gat gca ccc ata gac att tgt gtg tct gaa tgt 917Ser
Val Met Arg Ser Asp Ala Pro Ile Asp Ile Cys Val Ser Glu Cys285 290
295att aca cca aat gga agc atc ccc aac gac aaa cca ttt caa aat gtg
965Ile Thr Pro Asn Gly Ser Ile Pro Asn Asp Lys Pro Phe Gln Asn
Val300 305 310aac aaa gtt aca tat gga aaa tgc ccc aag tat atc agg
caa aac act 1013Asn Lys Val Thr Tyr Gly Lys Cys Pro Lys Tyr Ile Arg
Gln Asn Thr315 320 325tta aag ctg gcc act ggg atg agg aat gta cca
gaa aag caa atc aga 1061Leu Lys Leu Ala Thr Gly Met Arg Asn Val Pro
Glu Lys Gln Ile Arg330 335 340gga atc ttt gga gca ata gcg gga ttc
ata gaa aac ggc tgg gaa gga 1109Gly Ile Phe Gly Ala Ile Ala Gly Phe
Ile Glu Asn Gly Trp Glu Gly345 350 355 360atg gtt gat ggg tgg tat
gga ttc cga tat caa aac tcg gaa gga aca 1157Met Val Asp Gly Trp Tyr
Gly Phe Arg Tyr Gln Asn Ser Glu Gly Thr365 370 375gga caa gct gca
gat cta aag agc act caa gca gcc atc gac cag atc 1205Gly Gln Ala Ala
Asp Leu Lys Ser Thr Gln Ala Ala Ile Asp Gln Ile380 385 390aat gga
aaa tta aac aga gtg att gaa agg acc aat gag aaa ttc cat 1253Asn Gly
Lys Leu Asn Arg Val Ile Glu Arg Thr Asn Glu Lys Phe His395 400
405caa ata gag aag gaa ttc tca gaa gta gaa ggg aga atc cag gac ttg
1301Gln Ile Glu Lys Glu Phe Ser Glu Val Glu Gly Arg Ile Gln Asp
Leu410 415 420gag aag tat gta gaa gac acc aaa ata gac cta tgg tcc
tac aat gca 1349Glu Lys Tyr Val Glu Asp Thr Lys Ile Asp Leu Trp Ser
Tyr Asn Ala425 430 435 440gaa ttg ctg gtg gct cta gaa aat caa cat
aca att gac tta aca gat 1397Glu Leu Leu Val Ala Leu Glu Asn Gln His
Thr Ile Asp Leu Thr Asp445 450 455gca gaa atg aat aaa tta ttc gag
aag act aga cgc cag tta aga gaa 1445Ala Glu Met Asn Lys Leu Phe Glu
Lys Thr Arg Arg Gln Leu Arg Glu460 465 470aac gcg gaa gac atg gga
ggt gga tgt ttc aag ata tac cac aaa tgt 1493Asn Ala Glu Asp Met Gly
Gly Gly Cys Phe Lys Ile Tyr His Lys Cys475 480 485gat aat gca tgc
att gga tca ata aga aat ggg aca tat gac cat tac 1541Asp Asn Ala Cys
Ile Gly Ser Ile Arg Asn Gly Thr Tyr Asp His Tyr490 495 500ata tac
aga gat gaa gca tta aac aac cgg ttt caa atc aaa ggt gtt 1589Ile Tyr
Arg Asp Glu Ala Leu Asn Asn Arg Phe Gln Ile Lys Gly Val505 510 515
520gag ttg aaa tca ggc tac aaa gat tgg ata ctg tgg att tca ttc gcc
1637Glu Leu Lys Ser Gly Tyr Lys Asp Trp Ile Leu Trp Ile Ser Phe
Ala525 530 535ata tca tgc ttc tta att tgc gtt gtt cta ttg ggt ttc
att atg tgg 1685Ile Ser Cys Phe Leu Ile Cys Val Val Leu Leu Gly Phe
Ile Met Trp540 545 550gct tgc caa aaa ggc aac atc aga tgc aac att
tgc att tgagtaaact 1734Ala Cys Gln Lys Gly Asn Ile Arg Cys Asn Ile
Cys Ile555 560 565gatagttaaa aacacccttg tttctact 176211565PRTEquine
influenza virus H3N8 11Met Lys Thr Thr Ile Ile Leu Ile Leu Leu Thr
His Trp Val Tyr Ser1 5 10 15Gln Asn Pro Thr Ser Gly Asn Asn Thr Ala
Thr Leu Cys Leu Gly His20 25 30His Ala Val Ala Asn Gly Thr Leu Val
Lys Thr Ile Thr Asp Asp Gln35 40 45Ile Glu Val Thr Asn Ala Thr Glu
Leu Val Gln Ser Ile Ser Ile Gly50 55 60Lys Ile Cys Asn Asn Ser Tyr
Arg Val Leu Asp Gly Arg Asn Cys Thr65 70 75 80Leu Ile Asp Ala Met
Leu Gly Asp Pro His Cys Asp Val Phe Gln Tyr85 90 95Glu Asn Trp Asp
Leu Phe Ile Glu Arg Ser Ser Ala Phe Ser Ser Cys100 105 110Tyr Pro
Tyr Asp Ile Pro Asp Tyr Ala Ser Leu Arg Ser Ile Val Ala115 120
125Ser Ser Gly Thr Leu Glu Phe Thr Ala Glu Gly Phe Thr Trp Thr
Gly130 135 140Val Thr Gln Asn Gly Arg Ser Gly Ser Cys Lys Arg Glu
Ser Ala Asp145 150 155 160Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr
Glu Ser Gly Asn Ser Tyr165 170 175Pro Thr Leu Asn Val Thr Met Pro
Asn Asn Lys Asn Phe Asp Lys Leu180 185 190Tyr Ile Trp Gly Ile His
His Pro Ser Ser Asn Lys Glu Gln Thr Lys195 200 205Leu Tyr Ile Gln
Glu Ser Gly Arg Val Thr Val Ser Thr Lys Arg Ser210 215 220Gln Gln
Thr Ile Ile Pro Asn Ile Gly Ser Arg Pro Trp Val Arg Gly225 230 235
240Gln Ser Gly Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly
Asp245 250 255Ile Leu Thr Ile Asn Ser Asn Gly Asn Leu Val Ala Pro
Arg Gly Tyr260 265 270Phe Lys Leu Lys Thr Gly Lys Ser Ser Val Met
Arg Ser Asp Ala Pro275 280 285Ile Asp Ile Cys Val Ser Glu Cys Ile
Thr Pro Asn Gly Ser Ile Pro290 295 300Asn Asp Lys Pro Phe Gln Asn
Val Asn Lys Val Thr Tyr Gly Lys Cys305 310 315 320Pro Lys Tyr Ile
Arg Gln Asn Thr Leu Lys Leu Ala Thr Gly Met Arg325 330 335Asn Val
Pro Glu Lys Gln Ile Arg Gly Ile Phe Gly Ala Ile Ala Gly340 345
350Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly
Phe355 360 365Arg Tyr Gln Asn Ser Glu Gly Thr Gly Gln Ala Ala Asp
Leu Lys Ser370 375 380Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys
Leu Asn Arg Val Ile385 390 395 400Glu Arg Thr Asn Glu Lys Phe His
Gln Ile Glu Lys Glu Phe Ser Glu405 410 415Val Glu Gly Arg Ile Gln
Asp Leu Glu Lys Tyr Val Glu Asp Thr Lys420 425 430Ile Asp Leu Trp
Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu Asn435 440 445Gln His
Thr Ile Asp Leu Thr Asp Ala Glu Met Asn Lys Leu Phe Glu450 455
460Lys Thr Arg Arg Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Gly
Gly465 470 475 480Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys
Ile Gly Ser Ile485 490 495Arg Asn Gly Thr Tyr Asp His Tyr Ile Tyr
Arg Asp Glu Ala Leu Asn500 505 510Asn Arg Phe Gln Ile Lys Gly Val
Glu Leu Lys Ser Gly Tyr Lys Asp515 520 525Trp Ile Leu Trp Ile Ser
Phe Ala Ile Ser Cys Phe Leu Ile Cys Val530 535 540Val Leu Leu Gly
Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile Arg545 550 555 560Cys
Asn Ile Cys Ile565121695DNAEquine influenza virus H3N8 12atgaagacaa
ccattatttt gatactactg acccattggg tctacagtca aaacccaacc 60agtggcaaca
acacagccac attatgtctg ggacaccatg cagtagcaaa tggaacattg
120gtaaaaacaa taactgatga ccaaattgag gtgacaaatg ctactgaatt
agttcagagc 180atttcaatag ggaaaatatg caacaactca tatagagttc
tagatggaag aaattgcaca 240ttaatagatg caatgctagg agacccccac
tgtgatgtct ttcagtatga gaattgggac 300ctcttcatag aaagaagcag
cgctttcagc agttgctacc catatgacat ccctgactat 360gcatcgctcc
ggtccattgt agcatcctca ggaacattgg aattcacagc agagggattc
420acatggacag gtgtcactca aaacggaaga agtggatcct gcaaaaggga
atcagccgat 480agtttcttta gccgactgaa ttggctaaca gaatctggaa
actcttaccc cacattgaat 540gtgacaatgc ctaacaataa aaatttcgac
aaactataca tctgggggat tcatcacccg 600agctcaaaca aagagcagac
aaaattgtac atccaagaat caggacgagt aacagtctca 660acaaaaagaa
gtcaacaaac aataatccct aacatcggat ctagaccgtg ggtcaggggt
720caatcaggca ggataagcat atactggacc attgtaaaac ctggagatat
cctaacgata 780aacagtaatg gcaacttagt tgcaccgcgg ggatatttta
aattgaaaac agggaaaagc 840tctgtaatga gatcagatgc
acccatagac atttgtgtgt ctgaatgtat tacaccaaat 900ggaagcatcc
ccaacgacaa accatttcaa aatgtgaaca aagttacata tggaaaatgc
960cccaagtata tcaggcaaaa cactttaaag ctggccactg ggatgaggaa
tgtaccagaa 1020aagcaaatca gaggaatctt tggagcaata gcgggattca
tagaaaacgg ctgggaagga 1080atggttgatg ggtggtatgg attccgatat
caaaactcgg aaggaacagg acaagctgca 1140gatctaaaga gcactcaagc
agccatcgac cagatcaatg gaaaattaaa cagagtgatt 1200gaaaggacca
atgagaaatt ccatcaaata gagaaggaat tctcagaagt agaagggaga
1260atccaggact tggagaagta tgtagaagac accaaaatag acctatggtc
ctacaatgca 1320gaattgctgg tggctctaga aaatcaacat acaattgact
taacagatgc agaaatgaat 1380aaattattcg agaagactag acgccagtta
agagaaaacg cggaagacat gggaggtgga 1440tgtttcaaga tataccacaa
atgtgataat gcatgcattg gatcaataag aaatgggaca 1500tatgaccatt
acatatacag agatgaagca ttaaacaacc ggtttcaaat caaaggtgtt
1560gagttgaaat caggctacaa agattggata ctgtggattt cattcgccat
atcatgcttc 1620ttaatttgcg ttgttctatt gggtttcatt atgtgggctt
gccaaaaagg caacatcaga 1680tgcaacattt gcatt 1695131241DNAEquine
influenza virus H3N8CDS(28)..(1239) 13agcaaaagca ggtcaaatat attcaat
atg gag aga ata aaa gaa ctg aga gat 54Met Glu Arg Ile Lys Glu Leu
Arg Asp1 5cta atg tca caa tcc cgc acc cgc gag ata cta aca aaa act
act gtg 102Leu Met Ser Gln Ser Arg Thr Arg Glu Ile Leu Thr Lys Thr
Thr Val10 15 20 25gac cac atg gcc ata atc aag aaa tac aca tca gga
aga caa gag aag 150Asp His Met Ala Ile Ile Lys Lys Tyr Thr Ser Gly
Arg Gln Glu Lys30 35 40aac ccc gca ctt agg atg aag tgg atg atg gca
atg aaa tac cca att 198Asn Pro Ala Leu Arg Met Lys Trp Met Met Ala
Met Lys Tyr Pro Ile45 50 55aca gca gat aag agg ata atg gaa atg att
cct gag aga aat gaa cag 246Thr Ala Asp Lys Arg Ile Met Glu Met Ile
Pro Glu Arg Asn Glu Gln60 65 70ggg caa acc ctt tgg agc aaa acg aac
gat gct ggc tca gac cgc gta 294Gly Gln Thr Leu Trp Ser Lys Thr Asn
Asp Ala Gly Ser Asp Arg Val75 80 85atg gta tca cct ctg gca gtg aca
tgg tgg aat agg aat gga cca aca 342Met Val Ser Pro Leu Ala Val Thr
Trp Trp Asn Arg Asn Gly Pro Thr90 95 100 105acg agc aca att cat tat
cca aaa gtc tac aaa act tat ttt gaa aaa 390Thr Ser Thr Ile His Tyr
Pro Lys Val Tyr Lys Thr Tyr Phe Glu Lys110 115 120gtt gaa aga tta
aaa cac gga acc ttt ggc ccc gtt cat ttt agg aat 438Val Glu Arg Leu
Lys His Gly Thr Phe Gly Pro Val His Phe Arg Asn125 130 135caa gtc
aag ata aga cgg aga gtt gat gta aac cct ggt cac gcg gac 486Gln Val
Lys Ile Arg Arg Arg Val Asp Val Asn Pro Gly His Ala Asp140 145
150ctc agt gcc aaa gaa gca caa gat gtg atc atg gaa gtt gtt ttc cca
534Leu Ser Ala Lys Glu Ala Gln Asp Val Ile Met Glu Val Val Phe
Pro155 160 165aat gaa gtg gga gcc aga att cta aca tcg gaa tca caa
cta aca ata 582Asn Glu Val Gly Ala Arg Ile Leu Thr Ser Glu Ser Gln
Leu Thr Ile170 175 180 185acc aaa gag aaa aaa gaa gaa ctt cag gac
tgc aaa att gcc ccc ttg 630Thr Lys Glu Lys Lys Glu Glu Leu Gln Asp
Cys Lys Ile Ala Pro Leu190 195 200atg gta gca tac atg cta gaa aga
gag ttg gtc cga aaa aca aga ttc 678Met Val Ala Tyr Met Leu Glu Arg
Glu Leu Val Arg Lys Thr Arg Phe205 210 215ctc cca gtg gct ggc gga
aca agc agt gta tac att gaa gtg ttg cat 726Leu Pro Val Ala Gly Gly
Thr Ser Ser Val Tyr Ile Glu Val Leu His220 225 230ctg act cag gga
aca tgc tgg gaa caa atg tac acc cca gga gga gaa 774Leu Thr Gln Gly
Thr Cys Trp Glu Gln Met Tyr Thr Pro Gly Gly Glu235 240 245gtt aga
aac gat gac att gat caa agt tta att att gct gcc cgg aac 822Val Arg
Asn Asp Asp Ile Asp Gln Ser Leu Ile Ile Ala Ala Arg Asn250 255 260
265ata gtg aga aga gcg aca gta tca gca gat cca cta gca tcc ctg ctg
870Ile Val Arg Arg Ala Thr Val Ser Ala Asp Pro Leu Ala Ser Leu
Leu270 275 280gaa atg tgc cac agt aca cag att ggt gga ata agg atg
gta gac atc 918Glu Met Cys His Ser Thr Gln Ile Gly Gly Ile Arg Met
Val Asp Ile285 290 295ctt aag cag aat cca aca gag gaa caa gct gtg
gat ata tgc aaa gca 966Leu Lys Gln Asn Pro Thr Glu Glu Gln Ala Val
Asp Ile Cys Lys Ala300 305 310gca atg ggg tta aga att agc tca tca
ttc agc ttt ggt gga ttc acc 1014Ala Met Gly Leu Arg Ile Ser Ser Ser
Phe Ser Phe Gly Gly Phe Thr315 320 325ttt aag aga aca agt gga tca
tca gtc aag aga gaa gaa gaa atg ctt 1062Phe Lys Arg Thr Ser Gly Ser
Ser Val Lys Arg Glu Glu Glu Met Leu330 335 340 345acg ggc aac ctt
caa aca ttg aaa ata aga gtg cat gaa ggc tat gaa 1110Thr Gly Asn Leu
Gln Thr Leu Lys Ile Arg Val His Glu Gly Tyr Glu350 355 360gaa ttc
aca atg gtc gga aga aga gca aca gcc att ctc aga aag gca 1158Glu Phe
Thr Met Val Gly Arg Arg Ala Thr Ala Ile Leu Arg Lys Ala365 370
375acc aga aga ttg att caa ttg ata gta agt ggg aga gat gaa caa tca
1206Thr Arg Arg Leu Ile Gln Leu Ile Val Ser Gly Arg Asp Glu Gln
Ser380 385 390att gct gaa gca ata att gta gcc atg gtg ttt tc
1241Ile Ala Glu Ala Ile Ile Val Ala Met Val Phe395
40014404PRTEquine influenza virus H3N8 14Met Glu Arg Ile Lys Glu
Leu Arg Asp Leu Met Ser Gln Ser Arg Thr1 5 10 15Arg Glu Ile Leu Thr
Lys Thr Thr Val Asp His Met Ala Ile Ile Lys20 25 30Lys Tyr Thr Ser
Gly Arg Gln Glu Lys Asn Pro Ala Leu Arg Met Lys35 40 45Trp Met Met
Ala Met Lys Tyr Pro Ile Thr Ala Asp Lys Arg Ile Met50 55 60Glu Met
Ile Pro Glu Arg Asn Glu Gln Gly Gln Thr Leu Trp Ser Lys65 70 75
80Thr Asn Asp Ala Gly Ser Asp Arg Val Met Val Ser Pro Leu Ala Val85
90 95Thr Trp Trp Asn Arg Asn Gly Pro Thr Thr Ser Thr Ile His Tyr
Pro100 105 110Lys Val Tyr Lys Thr Tyr Phe Glu Lys Val Glu Arg Leu
Lys His Gly115 120 125Thr Phe Gly Pro Val His Phe Arg Asn Gln Val
Lys Ile Arg Arg Arg130 135 140Val Asp Val Asn Pro Gly His Ala Asp
Leu Ser Ala Lys Glu Ala Gln145 150 155 160Asp Val Ile Met Glu Val
Val Phe Pro Asn Glu Val Gly Ala Arg Ile165 170 175Leu Thr Ser Glu
Ser Gln Leu Thr Ile Thr Lys Glu Lys Lys Glu Glu180 185 190Leu Gln
Asp Cys Lys Ile Ala Pro Leu Met Val Ala Tyr Met Leu Glu195 200
205Arg Glu Leu Val Arg Lys Thr Arg Phe Leu Pro Val Ala Gly Gly
Thr210 215 220Ser Ser Val Tyr Ile Glu Val Leu His Leu Thr Gln Gly
Thr Cys Trp225 230 235 240Glu Gln Met Tyr Thr Pro Gly Gly Glu Val
Arg Asn Asp Asp Ile Asp245 250 255Gln Ser Leu Ile Ile Ala Ala Arg
Asn Ile Val Arg Arg Ala Thr Val260 265 270Ser Ala Asp Pro Leu Ala
Ser Leu Leu Glu Met Cys His Ser Thr Gln275 280 285Ile Gly Gly Ile
Arg Met Val Asp Ile Leu Lys Gln Asn Pro Thr Glu290 295 300Glu Gln
Ala Val Asp Ile Cys Lys Ala Ala Met Gly Leu Arg Ile Ser305 310 315
320Ser Ser Phe Ser Phe Gly Gly Phe Thr Phe Lys Arg Thr Ser Gly
Ser325 330 335Ser Val Lys Arg Glu Glu Glu Met Leu Thr Gly Asn Leu
Gln Thr Leu340 345 350Lys Ile Arg Val His Glu Gly Tyr Glu Glu Phe
Thr Met Val Gly Arg355 360 365Arg Ala Thr Ala Ile Leu Arg Lys Ala
Thr Arg Arg Leu Ile Gln Leu370 375 380Ile Val Ser Gly Arg Asp Glu
Gln Ser Ile Ala Glu Ala Ile Ile Val385 390 395 400Ala Met Val
Phe151214DNAEquine influenza virus H3N8 15atggagagaa taaaagaact
gagagatcta atgtcacaat cccgcacccg cgagatacta 60acaaaaacta ctgtggacca
catggccata atcaagaaat acacatcagg aagacaagag 120aagaaccccg
cacttaggat gaagtggatg atggcaatga aatacccaat tacagcagat
180aagaggataa tggaaatgat tcctgagaga aatgaacagg ggcaaaccct
ttggagcaaa 240acgaacgatg ctggctcaga ccgcgtaatg gtatcacctc
tggcagtgac atggtggaat 300aggaatggac caacaacgag cacaattcat
tatccaaaag tctacaaaac ttattttgaa 360aaagttgaaa gattaaaaca
cggaaccttt ggccccgttc attttaggaa tcaagtcaag 420ataagacgga
gagttgatgt aaaccctggt cacgcggacc tcagtgccaa agaagcacaa
480gatgtgatca tggaagttgt tttcccaaat gaagtgggag ccagaattct
aacatcggaa 540tcacaactaa caataaccaa agagaaaaaa gaagaacttc
aggactgcaa aattgccccc 600ttgatggtag catacatgct agaaagagag
ttggtccgaa aaacaagatt cctcccagtg 660gctggcggaa caagcagtgt
atacattgaa gtgttgcatc tgactcaggg aacatgctgg 720gaacaaatgt
acaccccagg aggagaagtt agaaacgatg acattgatca aagtttaatt
780attgctgccc ggaacatagt gagaagagcg acagtatcag cagatccact
agcatccctg 840ctggaaatgt gccacagtac acagattggt ggaataagga
tggtagacat ccttaagcag 900aatccaacag aggaacaagc tgtggatata
tgcaaagcag caatggggtt aagaattagc 960tcatcattca gctttggtgg
attcaccttt aagagaacaa gtggatcatc agtcaagaga 1020gaagaagaaa
tgcttacggg caaccttcaa acattgaaaa taagagtgca tgaaggctat
1080gaagaattca caatggtcgg aagaagagca acagccattc tcagaaaggc
aaccagaaga 1140ttgattcaat tgatagtaag tgggagagat gaacaatcaa
ttgctgaagc aataattgta 1200gccatggtgt tttc 1214161241DNAEquine
influenza virus H3N8CDS(28)..(1239) 16agcaaaagca ggtcaaatat attcaat
atg gag aga ata aaa gaa ctg aga gat 54Met Glu Arg Ile Lys Glu Leu
Arg Asp1 5cta atg tca caa tcc cgc acc cgc gag ata cta aca aaa act
act gtg 102Leu Met Ser Gln Ser Arg Thr Arg Glu Ile Leu Thr Lys Thr
Thr Val10 15 20 25gac cac atg gcc ata atc aag aaa tac aca tca gga
aga caa gag aag 150Asp His Met Ala Ile Ile Lys Lys Tyr Thr Ser Gly
Arg Gln Glu Lys30 35 40aac ccc gca ctt agg atg aag tgg atg atg gca
atg aaa tac cca att 198Asn Pro Ala Leu Arg Met Lys Trp Met Met Ala
Met Lys Tyr Pro Ile45 50 55aca gca gat aag agg ata atg gaa atg att
cct gag aga aat gaa cag 246Thr Ala Asp Lys Arg Ile Met Glu Met Ile
Pro Glu Arg Asn Glu Gln60 65 70ggg caa acc ctt tgg agc aaa acg aac
gat gct ggc tca gac cgc gta 294Gly Gln Thr Leu Trp Ser Lys Thr Asn
Asp Ala Gly Ser Asp Arg Val75 80 85atg gta tca cct ctg gca gtg aca
tgg tgg aat agg aat gga cca aca 342Met Val Ser Pro Leu Ala Val Thr
Trp Trp Asn Arg Asn Gly Pro Thr90 95 100 105acg agc aca att cat tat
cca aaa gtc cac aaa act tat ttt gaa aaa 390Thr Ser Thr Ile His Tyr
Pro Lys Val His Lys Thr Tyr Phe Glu Lys110 115 120gtt gaa aga tta
aaa cac gga acc ttt ggc ccc gtt cat ttt agg aat 438Val Glu Arg Leu
Lys His Gly Thr Phe Gly Pro Val His Phe Arg Asn125 130 135caa gtc
aag ata aga cgg aga gtt gat gta aac cct ggt cac gcg gac 486Gln Val
Lys Ile Arg Arg Arg Val Asp Val Asn Pro Gly His Ala Asp140 145
150ctc agt gcc aaa gaa gca caa gat gtg atc atg gaa gtt gtt ttc cca
534Leu Ser Ala Lys Glu Ala Gln Asp Val Ile Met Glu Val Val Phe
Pro155 160 165aat gaa gtg gga gcc aga att cta aca tcg gaa tca caa
cta aca ata 582Asn Glu Val Gly Ala Arg Ile Leu Thr Ser Glu Ser Gln
Leu Thr Ile170 175 180 185acc aaa gag aaa aaa gaa gaa ctt cag gac
tgc aaa att gcc ccc ttg 630Thr Lys Glu Lys Lys Glu Glu Leu Gln Asp
Cys Lys Ile Ala Pro Leu190 195 200atg gta gca tac atg cta gaa aga
gag ttg gtc cga aaa aca aga ttc 678Met Val Ala Tyr Met Leu Glu Arg
Glu Leu Val Arg Lys Thr Arg Phe205 210 215ctc cca gtg gct ggc gga
aca agc agt gta tac att gaa gtg ttg cat 726Leu Pro Val Ala Gly Gly
Thr Ser Ser Val Tyr Ile Glu Val Leu His220 225 230ctg act cag gga
aca tgc tgg gaa caa atg tac acc cca gga gga gaa 774Leu Thr Gln Gly
Thr Cys Trp Glu Gln Met Tyr Thr Pro Gly Gly Glu235 240 245gtt aga
aac gat gac att gat caa agt tta att att gct gcc cgg aac 822Val Arg
Asn Asp Asp Ile Asp Gln Ser Leu Ile Ile Ala Ala Arg Asn250 255 260
265ata gtg aga aga gcg aca gta tca gca gat cca cta gca tcc ctg ctg
870Ile Val Arg Arg Ala Thr Val Ser Ala Asp Pro Leu Ala Ser Leu
Leu270 275 280gaa atg tgc cac agt aca cag att ggt gga ata agg atg
gta gac atc 918Glu Met Cys His Ser Thr Gln Ile Gly Gly Ile Arg Met
Val Asp Ile285 290 295ctt aag cag aat cca aca gag gaa caa gct gtg
gat ata tgc aaa gca 966Leu Lys Gln Asn Pro Thr Glu Glu Gln Ala Val
Asp Ile Cys Lys Ala300 305 310gca atg ggg tta aga att agc tca tca
ttc agc ttt ggt gga ttc acc 1014Ala Met Gly Leu Arg Ile Ser Ser Ser
Phe Ser Phe Gly Gly Phe Thr315 320 325ttt aag aga aca agt gga tca
tca gtc aag aga gaa gaa gaa atg ctt 1062Phe Lys Arg Thr Ser Gly Ser
Ser Val Lys Arg Glu Glu Glu Met Leu330 335 340 345acg ggc aac ctt
caa aca ttg aaa ata aga gtg cat gaa ggc tat gaa 1110Thr Gly Asn Leu
Gln Thr Leu Lys Ile Arg Val His Glu Gly Tyr Glu350 355 360gaa ttc
aca atg gtc gga aga aga gca aca gcc att ctc aga aag gca 1158Glu Phe
Thr Met Val Gly Arg Arg Ala Thr Ala Ile Leu Arg Lys Ala365 370
375acc aga aga ttg att caa ttg ata gta agt ggg aga gat gaa caa tca
1206Thr Arg Arg Leu Ile Gln Leu Ile Val Ser Gly Arg Asp Glu Gln
Ser380 385 390att gct gaa gca ata att gta gcc atg gtg ttt tc
1241Ile Ala Glu Ala Ile Ile Val Ala Met Val Phe395
40017404PRTEquine influenza virus H3N8 17Met Glu Arg Ile Lys Glu
Leu Arg Asp Leu Met Ser Gln Ser Arg Thr1 5 10 15Arg Glu Ile Leu Thr
Lys Thr Thr Val Asp His Met Ala Ile Ile Lys20 25 30Lys Tyr Thr Ser
Gly Arg Gln Glu Lys Asn Pro Ala Leu Arg Met Lys35 40 45Trp Met Met
Ala Met Lys Tyr Pro Ile Thr Ala Asp Lys Arg Ile Met50 55 60Glu Met
Ile Pro Glu Arg Asn Glu Gln Gly Gln Thr Leu Trp Ser Lys65 70 75
80Thr Asn Asp Ala Gly Ser Asp Arg Val Met Val Ser Pro Leu Ala Val85
90 95Thr Trp Trp Asn Arg Asn Gly Pro Thr Thr Ser Thr Ile His Tyr
Pro100 105 110Lys Val His Lys Thr Tyr Phe Glu Lys Val Glu Arg Leu
Lys His Gly115 120 125Thr Phe Gly Pro Val His Phe Arg Asn Gln Val
Lys Ile Arg Arg Arg130 135 140Val Asp Val Asn Pro Gly His Ala Asp
Leu Ser Ala Lys Glu Ala Gln145 150 155 160Asp Val Ile Met Glu Val
Val Phe Pro Asn Glu Val Gly Ala Arg Ile165 170 175Leu Thr Ser Glu
Ser Gln Leu Thr Ile Thr Lys Glu Lys Lys Glu Glu180 185 190Leu Gln
Asp Cys Lys Ile Ala Pro Leu Met Val Ala Tyr Met Leu Glu195 200
205Arg Glu Leu Val Arg Lys Thr Arg Phe Leu Pro Val Ala Gly Gly
Thr210 215 220Ser Ser Val Tyr Ile Glu Val Leu His Leu Thr Gln Gly
Thr Cys Trp225 230 235 240Glu Gln Met Tyr Thr Pro Gly Gly Glu Val
Arg Asn Asp Asp Ile Asp245 250 255Gln Ser Leu Ile Ile Ala Ala Arg
Asn Ile Val Arg Arg Ala Thr Val260 265 270Ser Ala Asp Pro Leu Ala
Ser Leu Leu Glu Met Cys His Ser Thr Gln275 280 285Ile Gly Gly Ile
Arg Met Val Asp Ile Leu Lys Gln Asn Pro Thr Glu290 295 300Glu Gln
Ala Val Asp Ile Cys Lys Ala Ala Met Gly Leu Arg Ile Ser305 310 315
320Ser Ser Phe Ser Phe Gly Gly Phe Thr Phe Lys Arg Thr Ser Gly
Ser325 330 335Ser Val Lys Arg Glu Glu Glu Met Leu Thr Gly Asn Leu
Gln Thr Leu340 345 350Lys Ile Arg Val His Glu Gly Tyr Glu Glu Phe
Thr Met Val Gly Arg355 360 365Arg Ala Thr Ala Ile Leu Arg Lys Ala
Thr Arg Arg Leu Ile Gln Leu370 375 380Ile Val Ser Gly Arg Asp Glu
Gln Ser Ile Ala Glu Ala Ile Ile Val385 390 395 400Ala Met Val
Phe181214DNAEquine influenza virus H3N8 18atggagagaa taaaagaact
gagagatcta atgtcacaat cccgcacccg cgagatacta 60acaaaaacta ctgtggacca
catggccata atcaagaaat acacatcagg aagacaagag 120aagaaccccg
cacttaggat gaagtggatg atggcaatga aatacccaat tacagcagat
180aagaggataa tggaaatgat tcctgagaga aatgaacagg ggcaaaccct
ttggagcaaa 240acgaacgatg ctggctcaga ccgcgtaatg gtatcacctc
tggcagtgac atggtggaat 300aggaatggac caacaacgag cacaattcat
tatccaaaag tccacaaaac ttattttgaa 360aaagttgaaa gattaaaaca
cggaaccttt ggccccgttc attttaggaa tcaagtcaag 420ataagacgga
gagttgatgt aaaccctggt cacgcggacc tcagtgccaa
agaagcacaa 480gatgtgatca tggaagttgt tttcccaaat gaagtgggag
ccagaattct aacatcggaa 540tcacaactaa caataaccaa agagaaaaaa
gaagaacttc aggactgcaa aattgccccc 600ttgatggtag catacatgct
agaaagagag ttggtccgaa aaacaagatt cctcccagtg 660gctggcggaa
caagcagtgt atacattgaa gtgttgcatc tgactcaggg aacatgctgg
720gaacaaatgt acaccccagg aggagaagtt agaaacgatg acattgatca
aagtttaatt 780attgctgccc ggaacatagt gagaagagcg acagtatcag
cagatccact agcatccctg 840ctggaaatgt gccacagtac acagattggt
ggaataagga tggtagacat ccttaagcag 900aatccaacag aggaacaagc
tgtggatata tgcaaagcag caatggggtt aagaattagc 960tcatcattca
gctttggtgg attcaccttt aagagaacaa gtggatcatc agtcaagaga
1020gaagaagaaa tgcttacggg caaccttcaa acattgaaaa taagagtgca
tgaaggctat 1080gaagaattca caatggtcgg aagaagagca acagccattc
tcagaaaggc aaccagaaga 1140ttgattcaat tgatagtaag tgggagagat
gaacaatcaa ttgctgaagc aataattgta 1200gccatggtgt tttc
1214191233DNAEquine influenza virus H3N8CDS(3)..(1196) 19ta gaa ttc
aca atg gtc gga aga aga gca aca gcc att ctc aga aag 47Glu Phe Thr
Met Val Gly Arg Arg Ala Thr Ala Ile Leu Arg Lys1 5 10 15gca acc aga
aga ttg att caa ttg ata gta agt ggg aga gat gaa caa 95Ala Thr Arg
Arg Leu Ile Gln Leu Ile Val Ser Gly Arg Asp Glu Gln20 25 30tca att
gct gaa gca ata att gta gcc atg gtg ttt tcg caa gaa gat 143Ser Ile
Ala Glu Ala Ile Ile Val Ala Met Val Phe Ser Gln Glu Asp35 40 45tgc
atg ata aaa gca gtt cga ggc gat ttg aac ttc gtt aat aga gca 191Cys
Met Ile Lys Ala Val Arg Gly Asp Leu Asn Phe Val Asn Arg Ala50 55
60aat cag cgc ttg aac ccc atg cat caa ctc ttg agg cat ttc caa aaa
239Asn Gln Arg Leu Asn Pro Met His Gln Leu Leu Arg His Phe Gln
Lys65 70 75gat gca aaa gtg ctt ttc cag aat tgg ggg att gaa ccc atc
gac aat 287Asp Ala Lys Val Leu Phe Gln Asn Trp Gly Ile Glu Pro Ile
Asp Asn80 85 90 95gtg atg gga atg att gga ata ttg cct gac atg acc
cca agc acc gag 335Val Met Gly Met Ile Gly Ile Leu Pro Asp Met Thr
Pro Ser Thr Glu100 105 110atg tca ttg aga gga gtg aga gtc agc aaa
atg gga gtg gat gag tac 383Met Ser Leu Arg Gly Val Arg Val Ser Lys
Met Gly Val Asp Glu Tyr115 120 125tcc agc act gag aga gtg gtg gtg
agc att gac cgt ttt tta aga gtt 431Ser Ser Thr Glu Arg Val Val Val
Ser Ile Asp Arg Phe Leu Arg Val130 135 140cgg gat caa agg gga aac
ata cta ctg tcc cct gaa gag gtc agt gaa 479Arg Asp Gln Arg Gly Asn
Ile Leu Leu Ser Pro Glu Glu Val Ser Glu145 150 155aca caa gga acg
gaa aag ctg aca ata att tat tca tca tca atg atg 527Thr Gln Gly Thr
Glu Lys Leu Thr Ile Ile Tyr Ser Ser Ser Met Met160 165 170 175tgg
gag att aat ggt ccc gaa tca gtg ttg gtc aat act tat caa tgg 575Trp
Glu Ile Asn Gly Pro Glu Ser Val Leu Val Asn Thr Tyr Gln Trp180 185
190atc atc agg aac tgg gaa att gtg aaa att caa tgg tca cag gat ccc
623Ile Ile Arg Asn Trp Glu Ile Val Lys Ile Gln Trp Ser Gln Asp
Pro195 200 205aca atg tta tac aat aag ata gaa ttt gag cca ttc cag
tcc ctg gtc 671Thr Met Leu Tyr Asn Lys Ile Glu Phe Glu Pro Phe Gln
Ser Leu Val210 215 220cct agg gcc acc aga agc caa tac agc ggt ttc
gta aga acc ctg ttt 719Pro Arg Ala Thr Arg Ser Gln Tyr Ser Gly Phe
Val Arg Thr Leu Phe225 230 235cag caa atg cga gat gta ctt gga aca
ttt gat act gct caa ata ata 767Gln Gln Met Arg Asp Val Leu Gly Thr
Phe Asp Thr Ala Gln Ile Ile240 245 250 255aaa ctc ctc cct ttt gcc
gct gct cct ccg gaa cag agt agg atg cag 815Lys Leu Leu Pro Phe Ala
Ala Ala Pro Pro Glu Gln Ser Arg Met Gln260 265 270ttc tct tct ttg
act gtt aat gta aga gga tcg gga atg agg ata ctt 863Phe Ser Ser Leu
Thr Val Asn Val Arg Gly Ser Gly Met Arg Ile Leu275 280 285gta aga
ggc aat tcc cca gtg ttc aac tac aat aaa gcc act aag agg 911Val Arg
Gly Asn Ser Pro Val Phe Asn Tyr Asn Lys Ala Thr Lys Arg290 295
300ctc aca gtc ctc gga aag gat gca ggt gcg ctt act gaa gac cca gat
959Leu Thr Val Leu Gly Lys Asp Ala Gly Ala Leu Thr Glu Asp Pro
Asp305 310 315gaa ggt acg gct gga gta gaa tct gct gtt cta aga ggg
ttt ctc att 1007Glu Gly Thr Ala Gly Val Glu Ser Ala Val Leu Arg Gly
Phe Leu Ile320 325 330 335tta ggt aaa gaa aac aag aga tat ggc cca
gca cta agc atc aat gaa 1055Leu Gly Lys Glu Asn Lys Arg Tyr Gly Pro
Ala Leu Ser Ile Asn Glu340 345 350ctg agc aaa ctt gca aaa ggg gag
aaa gct aat gtg cta att ggg caa 1103Leu Ser Lys Leu Ala Lys Gly Glu
Lys Ala Asn Val Leu Ile Gly Gln355 360 365ggg gac gtg gtg ttg gta
atg aaa cgg aaa cgt gac tct agc ata ctt 1151Gly Asp Val Val Leu Val
Met Lys Arg Lys Arg Asp Ser Ser Ile Leu370 375 380act gac agc cag
aca gcg acc aaa agg att cgg atg gcc atc aat 1196Thr Asp Ser Gln Thr
Ala Thr Lys Arg Ile Arg Met Ala Ile Asn385 390 395tagtgttgaa
ttgtttaaaa acgaccttgt ttctact 123320398PRTEquine influenza virus
H3N8 20Glu Phe Thr Met Val Gly Arg Arg Ala Thr Ala Ile Leu Arg Lys
Ala1 5 10 15Thr Arg Arg Leu Ile Gln Leu Ile Val Ser Gly Arg Asp Glu
Gln Ser20 25 30Ile Ala Glu Ala Ile Ile Val Ala Met Val Phe Ser Gln
Glu Asp Cys35 40 45Met Ile Lys Ala Val Arg Gly Asp Leu Asn Phe Val
Asn Arg Ala Asn50 55 60Gln Arg Leu Asn Pro Met His Gln Leu Leu Arg
His Phe Gln Lys Asp65 70 75 80Ala Lys Val Leu Phe Gln Asn Trp Gly
Ile Glu Pro Ile Asp Asn Val85 90 95Met Gly Met Ile Gly Ile Leu Pro
Asp Met Thr Pro Ser Thr Glu Met100 105 110Ser Leu Arg Gly Val Arg
Val Ser Lys Met Gly Val Asp Glu Tyr Ser115 120 125Ser Thr Glu Arg
Val Val Val Ser Ile Asp Arg Phe Leu Arg Val Arg130 135 140Asp Gln
Arg Gly Asn Ile Leu Leu Ser Pro Glu Glu Val Ser Glu Thr145 150 155
160Gln Gly Thr Glu Lys Leu Thr Ile Ile Tyr Ser Ser Ser Met Met
Trp165 170 175Glu Ile Asn Gly Pro Glu Ser Val Leu Val Asn Thr Tyr
Gln Trp Ile180 185 190Ile Arg Asn Trp Glu Ile Val Lys Ile Gln Trp
Ser Gln Asp Pro Thr195 200 205Met Leu Tyr Asn Lys Ile Glu Phe Glu
Pro Phe Gln Ser Leu Val Pro210 215 220Arg Ala Thr Arg Ser Gln Tyr
Ser Gly Phe Val Arg Thr Leu Phe Gln225 230 235 240Gln Met Arg Asp
Val Leu Gly Thr Phe Asp Thr Ala Gln Ile Ile Lys245 250 255Leu Leu
Pro Phe Ala Ala Ala Pro Pro Glu Gln Ser Arg Met Gln Phe260 265
270Ser Ser Leu Thr Val Asn Val Arg Gly Ser Gly Met Arg Ile Leu
Val275 280 285Arg Gly Asn Ser Pro Val Phe Asn Tyr Asn Lys Ala Thr
Lys Arg Leu290 295 300Thr Val Leu Gly Lys Asp Ala Gly Ala Leu Thr
Glu Asp Pro Asp Glu305 310 315 320Gly Thr Ala Gly Val Glu Ser Ala
Val Leu Arg Gly Phe Leu Ile Leu325 330 335Gly Lys Glu Asn Lys Arg
Tyr Gly Pro Ala Leu Ser Ile Asn Glu Leu340 345 350Ser Lys Leu Ala
Lys Gly Glu Lys Ala Asn Val Leu Ile Gly Gln Gly355 360 365Asp Val
Val Leu Val Met Lys Arg Lys Arg Asp Ser Ser Ile Leu Thr370 375
380Asp Ser Gln Thr Ala Thr Lys Arg Ile Arg Met Ala Ile Asn385 390
395211194DNAEquine influenza virus H3N8 21gaattcacaa tggtcggaag
aagagcaaca gccattctca gaaaggcaac cagaagattg 60attcaattga tagtaagtgg
gagagatgaa caatcaattg ctgaagcaat aattgtagcc 120atggtgtttt
cgcaagaaga ttgcatgata aaagcagttc gaggcgattt gaacttcgtt
180aatagagcaa atcagcgctt gaaccccatg catcaactct tgaggcattt
ccaaaaagat 240gcaaaagtgc ttttccagaa ttgggggatt gaacccatcg
acaatgtgat gggaatgatt 300ggaatattgc ctgacatgac cccaagcacc
gagatgtcat tgagaggagt gagagtcagc 360aaaatgggag tggatgagta
ctccagcact gagagagtgg tggtgagcat tgaccgtttt 420ttaagagttc
gggatcaaag gggaaacata ctactgtccc ctgaagaggt cagtgaaaca
480caaggaacgg aaaagctgac aataatttat tcatcatcaa tgatgtggga
gattaatggt 540cccgaatcag tgttggtcaa tacttatcaa tggatcatca
ggaactggga aattgtgaaa 600attcaatggt cacaggatcc cacaatgtta
tacaataaga tagaatttga gccattccag 660tccctggtcc ctagggccac
cagaagccaa tacagcggtt tcgtaagaac cctgtttcag 720caaatgcgag
atgtacttgg aacatttgat actgctcaaa taataaaact cctccctttt
780gccgctgctc ctccggaaca gagtaggatg cagttctctt ctttgactgt
taatgtaaga 840ggatcgggaa tgaggatact tgtaagaggc aattccccag
tgttcaacta caataaagcc 900actaagaggc tcacagtcct cggaaaggat
gcaggtgcgc ttactgaaga cccagatgaa 960ggtacggctg gagtagaatc
tgctgttcta agagggtttc tcattttagg taaagaaaac 1020aagagatatg
gcccagcact aagcatcaat gaactgagca aacttgcaaa aggggagaaa
1080gctaatgtgc taattgggca aggggacgtg gtgttggtaa tgaaacggaa
acgtgactct 1140agcatactta ctgacagcca gacagcgacc aaaaggattc
ggatggccat caat 1194221232DNAEquine influenza virus H3N8
22agaattcaca atggtcggaa gaagagcaac agccattctc agaaaggcaa ccagaagatt
60gattcaattg atagtaagtg ggagagatga acaatcaatt gctgaagcaa taattgtagc
120catggtgttt tcgcaagaag attgcatgat aaaagcagtt cgaggcgatt
tgaacttcgt 180taatagagca aatcagcgct tgaaccccat gcatcaactc
ttgaggcatt tccaaaaaga 240tgcaaaagtg cttttccaga attgggggat
tgaacccatc gacaatgtga tgggaatgat 300tggaatattg cctgacatga
ccccaagcac cgagatgtca ttgagaggag tgagagtcag 360caaaatggga
gtggatgagt actccagcac tgagagagtg gtggtgagca ttgaccgttt
420tttaagagtt cgggatcaaa ggggaaacat actactgtcc cctgaagagg
tcagtgaaac 480acaaggaacg gaaaagctga caataattta ttcatcatca
atgatgtggg agattaatgg 540tcccgaatca gtgttggtca atacttatca
atggatcatc aggaactggg aaattgtgaa 600aattcaatgg tcacaggatc
ccacaatgtt atacaataag atagaatttg agccattcca 660gtccctggtc
cctagggcca ccagaagcca atacagcggt ttcgtaagaa ccctgtttca
720gcaaatgcga gatgtacttg gaacatttga tactgctcaa ataataaaac
tcctcccttt 780tgccgctgct cctccggaac agagtaggat gcagttctct
tctttgactg ttaatgtaag 840aggatcggga atgaggatac ttgtaagagg
caattcccca gtgttcaact acaataaagc 900cactaagagg ctcacagtcc
tcggaaagga tgcaggtgcg cttactgaag acccagatga 960aggtacggct
ggagtagaat ctgctgttct aagagggttt ctcattttag gtaaagaaaa
1020caagagatat ggcccagcac taagcatcaa tgaactgagc aaacttgcaa
aaggggagaa 1080agctaatgtg ctaattgggc aaggggacgt ggtgttggta
atgaaacgga aacgtgactc 1140tagcatactt actgacagcc agacagcgac
caaaaggatt cggatggcca tcaattagtg 1200ttgaattgtt taaaaacgac
cttgtttcta ct 1232231232DNAEquine influenza virus
H3N8CDS(2)..(1195) 23a gaa ttc aca atg gtc gga aga aga gca aca gcc
att ctc aga aag gca 49Glu Phe Thr Met Val Gly Arg Arg Ala Thr Ala
Ile Leu Arg Lys Ala1 5 10 15acc aga aga ttg att caa ttg ata gta agt
ggg aga gat gaa caa tca 97Thr Arg Arg Leu Ile Gln Leu Ile Val Ser
Gly Arg Asp Glu Gln Ser20 25 30att gct gaa gca ata att gta gcc atg
gtg ttt tcg caa gaa gat tgc 145Ile Ala Glu Ala Ile Ile Val Ala Met
Val Phe Ser Gln Glu Asp Cys35 40 45atg ata caa gca gtt cga ggc gat
ttg aac ttc gtt aat aga gca aat 193Met Ile Gln Ala Val Arg Gly Asp
Leu Asn Phe Val Asn Arg Ala Asn50 55 60cag cgc ttg aac ccc atg cat
caa ctc ttg agg cat ttc caa aaa gat 241Gln Arg Leu Asn Pro Met His
Gln Leu Leu Arg His Phe Gln Lys Asp65 70 75 80gca aaa gtg ctt ttc
cag aat tgg ggg att gaa ccc atc gac aat gtg 289Ala Lys Val Leu Phe
Gln Asn Trp Gly Ile Glu Pro Ile Asp Asn Val85 90 95atg gga atg att
gga ata ttg cct gac atg acc cca agc acc gag atg 337Met Gly Met Ile
Gly Ile Leu Pro Asp Met Thr Pro Ser Thr Glu Met100 105 110tca ttg
aga gga gtg aga gtc agc aaa atg gga gtg gat gag tac tcc 385Ser Leu
Arg Gly Val Arg Val Ser Lys Met Gly Val Asp Glu Tyr Ser115 120
125agc act gag aga gtg gtg gtg agc att gac cgt ttt tta aga gtt cgg
433Ser Thr Glu Arg Val Val Val Ser Ile Asp Arg Phe Leu Arg Val
Arg130 135 140gat caa agg gga aac ata cta ctg tcc cct gaa gag gtc
agt gaa aca 481Asp Gln Arg Gly Asn Ile Leu Leu Ser Pro Glu Glu Val
Ser Glu Thr145 150 155 160caa gga acg gaa aag ctg aca ata att tat
tca tca tca atg atg tgg 529Gln Gly Thr Glu Lys Leu Thr Ile Ile Tyr
Ser Ser Ser Met Met Trp165 170 175gag att aat ggt ccc gaa tca gtg
ttg gtc aat act tat caa tgg atc 577Glu Ile Asn Gly Pro Glu Ser Val
Leu Val Asn Thr Tyr Gln Trp Ile180 185 190atc agg aac tgg gaa att
gtg aaa att caa tgg tca cag gat ccc aca 625Ile Arg Asn Trp Glu Ile
Val Lys Ile Gln Trp Ser Gln Asp Pro Thr195 200 205atg tta tac aat
aag ata gaa ttt gag cca ttc cag tcc ctg gtc cct 673Met Leu Tyr Asn
Lys Ile Glu Phe Glu Pro Phe Gln Ser Leu Val Pro210 215 220agg gcc
acc aga agc caa tac agc ggt ttc gta aga acc ctg ttt cag 721Arg Ala
Thr Arg Ser Gln Tyr Ser Gly Phe Val Arg Thr Leu Phe Gln225 230 235
240caa atg cga gat gta ctt gga aca ttt gat act gct caa ata ata aaa
769Gln Met Arg Asp Val Leu Gly Thr Phe Asp Thr Ala Gln Ile Ile
Lys245 250 255ctc ctc cct ttt gcc gct gct cct ccg gaa cag agt agg
atg cag ttc 817Leu Leu Pro Phe Ala Ala Ala Pro Pro Glu Gln Ser Arg
Met Gln Phe260 265 270tct tct ttg act gtt aat gta aga gga tcg gga
atg agg ata ctt gta 865Ser Ser Leu Thr Val Asn Val Arg Gly Ser Gly
Met Arg Ile Leu Val275 280 285aga ggc aat tcc cca gtg ttc aac tac
aat aaa gcc act aag agg ctc 913Arg Gly Asn Ser Pro Val Phe Asn Tyr
Asn Lys Ala Thr Lys Arg Leu290 295 300aca gtc ctc gga aaa gat gca
ggt gcg ctt act gaa gac cca gat gaa 961Thr Val Leu Gly Lys Asp Ala
Gly Ala Leu Thr Glu Asp Pro Asp Glu305 310 315 320ggt acg gct gga
gta gaa tct gct gtt cta aga ggg ttt ctc att tta 1009Gly Thr Ala Gly
Val Glu Ser Ala Val Leu Arg Gly Phe Leu Ile Leu325 330 335ggt aaa
gaa aac aag aga tat ggc cca gca cta agc atc aat gaa ctg 1057Gly Lys
Glu Asn Lys Arg Tyr Gly Pro Ala Leu Ser Ile Asn Glu Leu340 345
350agc aaa ctt gca aaa ggg gag aaa gct aat gtg cta att ggg caa ggg
1105Ser Lys Leu Ala Lys Gly Glu Lys Ala Asn Val Leu Ile Gly Gln
Gly355 360 365gac gtg gtg ttg gta atg aaa cgg aaa cgt gac tct agc
ata ctt act 1153Asp Val Val Leu Val Met Lys Arg Lys Arg Asp Ser Ser
Ile Leu Thr370 375 380gac agc cag aca gcg acc aaa agg att cgg atg
gcc atc aat 1195Asp Ser Gln Thr Ala Thr Lys Arg Ile Arg Met Ala Ile
Asn385 390 395tagtgttgaa ttgtttaaaa acgaccttgt ttctact
123224398PRTEquine influenza virus H3N8 24Glu Phe Thr Met Val Gly
Arg Arg Ala Thr Ala Ile Leu Arg Lys Ala1 5 10 15Thr Arg Arg Leu Ile
Gln Leu Ile Val Ser Gly Arg Asp Glu Gln Ser20 25 30Ile Ala Glu Ala
Ile Ile Val Ala Met Val Phe Ser Gln Glu Asp Cys35 40 45Met Ile Gln
Ala Val Arg Gly Asp Leu Asn Phe Val Asn Arg Ala Asn50 55 60Gln Arg
Leu Asn Pro Met His Gln Leu Leu Arg His Phe Gln Lys Asp65 70 75
80Ala Lys Val Leu Phe Gln Asn Trp Gly Ile Glu Pro Ile Asp Asn Val85
90 95Met Gly Met Ile Gly Ile Leu Pro Asp Met Thr Pro Ser Thr Glu
Met100 105 110Ser Leu Arg Gly Val Arg Val Ser Lys Met Gly Val Asp
Glu Tyr Ser115 120 125Ser Thr Glu Arg Val Val Val Ser Ile Asp Arg
Phe Leu Arg Val Arg130 135 140Asp Gln Arg Gly Asn Ile Leu Leu Ser
Pro Glu Glu Val Ser Glu Thr145 150 155 160Gln Gly Thr Glu Lys Leu
Thr Ile Ile Tyr Ser Ser Ser Met Met Trp165 170 175Glu Ile Asn Gly
Pro Glu Ser Val Leu Val Asn Thr Tyr Gln Trp Ile180 185 190Ile Arg
Asn Trp Glu Ile Val Lys Ile Gln Trp Ser Gln Asp Pro Thr195 200
205Met Leu Tyr Asn Lys Ile Glu Phe Glu Pro Phe Gln Ser Leu Val
Pro210 215 220Arg Ala Thr Arg Ser Gln Tyr Ser Gly Phe Val Arg Thr
Leu Phe Gln225 230 235 240Gln Met Arg Asp Val Leu Gly Thr Phe Asp
Thr Ala Gln Ile Ile Lys245 250 255Leu Leu Pro Phe Ala Ala Ala Pro
Pro Glu Gln Ser Arg Met Gln Phe260 265 270Ser Ser Leu Thr Val Asn
Val Arg Gly Ser Gly Met Arg Ile Leu Val275 280 285Arg Gly Asn Ser
Pro Val Phe Asn Tyr Asn Lys Ala Thr Lys Arg Leu290 295
300Thr Val Leu Gly Lys Asp Ala Gly Ala Leu Thr Glu Asp Pro Asp
Glu305 310 315 320Gly Thr Ala Gly Val Glu Ser Ala Val Leu Arg Gly
Phe Leu Ile Leu325 330 335Gly Lys Glu Asn Lys Arg Tyr Gly Pro Ala
Leu Ser Ile Asn Glu Leu340 345 350Ser Lys Leu Ala Lys Gly Glu Lys
Ala Asn Val Leu Ile Gly Gln Gly355 360 365Asp Val Val Leu Val Met
Lys Arg Lys Arg Asp Ser Ser Ile Leu Thr370 375 380Asp Ser Gln Thr
Ala Thr Lys Arg Ile Arg Met Ala Ile Asn385 390 395251194DNAEquine
influenza virus H3N8 25gaattcacaa tggtcggaag aagagcaaca gccattctca
gaaaggcaac cagaagattg 60attcaattga tagtaagtgg gagagatgaa caatcaattg
ctgaagcaat aattgtagcc 120atggtgtttt cgcaagaaga ttgcatgata
caagcagttc gaggcgattt gaacttcgtt 180aatagagcaa atcagcgctt
gaaccccatg catcaactct tgaggcattt ccaaaaagat 240gcaaaagtgc
ttttccagaa ttgggggatt gaacccatcg acaatgtgat gggaatgatt
300ggaatattgc ctgacatgac cccaagcacc gagatgtcat tgagaggagt
gagagtcagc 360aaaatgggag tggatgagta ctccagcact gagagagtgg
tggtgagcat tgaccgtttt 420ttaagagttc gggatcaaag gggaaacata
ctactgtccc ctgaagaggt cagtgaaaca 480caaggaacgg aaaagctgac
aataatttat tcatcatcaa tgatgtggga gattaatggt 540cccgaatcag
tgttggtcaa tacttatcaa tggatcatca ggaactggga aattgtgaaa
600attcaatggt cacaggatcc cacaatgtta tacaataaga tagaatttga
gccattccag 660tccctggtcc ctagggccac cagaagccaa tacagcggtt
tcgtaagaac cctgtttcag 720caaatgcgag atgtacttgg aacatttgat
actgctcaaa taataaaact cctccctttt 780gccgctgctc ctccggaaca
gagtaggatg cagttctctt ctttgactgt taatgtaaga 840ggatcgggaa
tgaggatact tgtaagaggc aattccccag tgttcaacta caataaagcc
900actaagaggc tcacagtcct cggaaaagat gcaggtgcgc ttactgaaga
cccagatgaa 960ggtacggctg gagtagaatc tgctgttcta agagggtttc
tcattttagg taaagaaaac 1020aagagatatg gcccagcact aagcatcaat
gaactgagca aacttgcaaa aggggagaaa 1080gctaatgtgc taattgggca
aggggacgtg gtgttggtaa tgaaacggaa acgtgactct 1140agcatactta
ctgacagcca gacagcgacc aaaaggattc ggatggccat caat
11942623DNAArtificialSynthetic Primer 26agcaaaagca ggtagatatt gaa
232724DNAArtificialSynthetic Primer 27agtagaaaca aggtagtttt ttac
242818DNAArtificialSynthetic Primer 28caggaaacag ctatgacc
182920DNAArtificialSynthetic Primer 29taatacgact cactataggg
203018DNAArtificialSynthetic Primer 30tggtgcacta gccagctg
183118DNAArtificialSynthetic Primer 31ttgcctgtac catctgcc
183223DNAArtificialSynthetic Primer 32agcaaaagca ggggatattt ctg
233323DNAArtificialSynthetic Primer 33agtagaaaca agggtgtttt taa
233416DNAArtificialSynthetic Primer 34gacatccctg actatg
163516DNAArtificialSynthetic Primer 35gcatctgtta agtcaa
163625DNAArtificialSynthetic Primer 36agcaaaagca ggtcaaatat attca
253726DNAArtificialSynthetic Primer 37gaaaacacca tggctacaat tattgc
263827DNAArtificialSynthetic Primer 38agaattcaca atggtcggaa gaagagc
273927DNAArtificialSynthetic Primer 39agtagaaaca aggtcgtttt taaacaa
274019DNAArtificialSynthetic Primer 40agccgtacct tcatctggg
194119DNAArtificialSynthetic Primer 41agcactgaga gagtggtgg
194219DNAArtificialSynthetic Primer 42gtaagaggca attccccag
194318DNAArtificialSynthetic Primer 43cagcttttcc gttccttg
18442341DNAEquine influenza virus H3N8CDS(28)..(2304) 44agcaaaagca
ggtcaaatat attcaat atg gag aga ata aaa gaa ctg aga gat 54Met Glu
Arg Ile Lys Glu Leu Arg Asp1 5cta atg tca caa tcc cgc acc cgc gag
ata cta aca aaa act act gtg 102Leu Met Ser Gln Ser Arg Thr Arg Glu
Ile Leu Thr Lys Thr Thr Val10 15 20 25gac cac atg gcc ata atc aag
aaa tac aca tca gga aga caa gag aag 150Asp His Met Ala Ile Ile Lys
Lys Tyr Thr Ser Gly Arg Gln Glu Lys30 35 40aac ccc gca ctt agg atg
aag tgg atg atg gca atg aaa tac cca att 198Asn Pro Ala Leu Arg Met
Lys Trp Met Met Ala Met Lys Tyr Pro Ile45 50 55aca gca gat aag agg
ata atg gaa atg att cct gag aga aat gaa cag 246Thr Ala Asp Lys Arg
Ile Met Glu Met Ile Pro Glu Arg Asn Glu Gln60 65 70ggg caa acc ctt
tgg agc aaa acg aac gat gct ggc tca gac cgc gta 294Gly Gln Thr Leu
Trp Ser Lys Thr Asn Asp Ala Gly Ser Asp Arg Val75 80 85atg gta tca
cct ctg gca gtg aca tgg tgg aat agg aat gga cca aca 342Met Val Ser
Pro Leu Ala Val Thr Trp Trp Asn Arg Asn Gly Pro Thr90 95 100 105acg
agc aca att cat tat cca aaa gtc tac aaa act tat ttt gaa aaa 390Thr
Ser Thr Ile His Tyr Pro Lys Val Tyr Lys Thr Tyr Phe Glu Lys110 115
120gtt gaa aga tta aaa cac gga acc ttt ggc ccc gtt cat ttt agg aat
438Val Glu Arg Leu Lys His Gly Thr Phe Gly Pro Val His Phe Arg
Asn125 130 135caa gtc aag ata aga cgg aga gtt gat gta aac cct ggt
cac gcg gac 486Gln Val Lys Ile Arg Arg Arg Val Asp Val Asn Pro Gly
His Ala Asp140 145 150ctc agt gcc aaa gaa gca caa gat gtg atc atg
gaa gtt gtt ttc cca 534Leu Ser Ala Lys Glu Ala Gln Asp Val Ile Met
Glu Val Val Phe Pro155 160 165aat gaa gtg gga gcc aga att cta aca
tcg gaa tca caa cta aca ata 582Asn Glu Val Gly Ala Arg Ile Leu Thr
Ser Glu Ser Gln Leu Thr Ile170 175 180 185acc aaa gag aaa aaa gaa
gaa ctt cag gac tgc aaa att gcc ccc ttg 630Thr Lys Glu Lys Lys Glu
Glu Leu Gln Asp Cys Lys Ile Ala Pro Leu190 195 200atg gta gca tac
atg cta gaa aga gag ttg gtc cga aaa aca aga ttc 678Met Val Ala Tyr
Met Leu Glu Arg Glu Leu Val Arg Lys Thr Arg Phe205 210 215ctc cca
gtg gct ggc gga aca agc agt gta tac att gaa gtg ttg cat 726Leu Pro
Val Ala Gly Gly Thr Ser Ser Val Tyr Ile Glu Val Leu His220 225
230ctg act cag gga aca tgc tgg gaa caa atg tac acc cca gga gga gaa
774Leu Thr Gln Gly Thr Cys Trp Glu Gln Met Tyr Thr Pro Gly Gly
Glu235 240 245gtt aga aac gat gac att gat caa agt tta att att gct
gcc cgg aac 822Val Arg Asn Asp Asp Ile Asp Gln Ser Leu Ile Ile Ala
Ala Arg Asn250 255 260 265ata gtg aga aga gcg aca gta tca gca gat
cca cta gca tcc ctg ctg 870Ile Val Arg Arg Ala Thr Val Ser Ala Asp
Pro Leu Ala Ser Leu Leu270 275 280gaa atg tgc cac agt aca cag att
ggt gga ata agg atg gta gac atc 918Glu Met Cys His Ser Thr Gln Ile
Gly Gly Ile Arg Met Val Asp Ile285 290 295ctt aag cag aat cca aca
gag gaa caa gct gtg gat ata tgc aaa gca 966Leu Lys Gln Asn Pro Thr
Glu Glu Gln Ala Val Asp Ile Cys Lys Ala300 305 310gca atg ggg tta
aga att agc tca tca ttc agc ttt ggt gga ttc acc 1014Ala Met Gly Leu
Arg Ile Ser Ser Ser Phe Ser Phe Gly Gly Phe Thr315 320 325ttt aag
aga aca agt gga tca tca gtc aag aga gaa gaa gaa atg ctt 1062Phe Lys
Arg Thr Ser Gly Ser Ser Val Lys Arg Glu Glu Glu Met Leu330 335 340
345acg ggc aac ctt caa aca ttg aaa ata aga gtg cat gaa ggc tat gaa
1110Thr Gly Asn Leu Gln Thr Leu Lys Ile Arg Val His Glu Gly Tyr
Glu350 355 360gaa ttc aca atg gtc gga aga aga gca aca gcc att ctc
aga aag gca 1158Glu Phe Thr Met Val Gly Arg Arg Ala Thr Ala Ile Leu
Arg Lys Ala365 370 375acc aga aga ttg att caa ttg ata gta agt ggg
aga gat gaa caa tca 1206Thr Arg Arg Leu Ile Gln Leu Ile Val Ser Gly
Arg Asp Glu Gln Ser380 385 390att gct gaa gca ata att gta gcc atg
gtg ttt tcg caa gaa gat tgc 1254Ile Ala Glu Ala Ile Ile Val Ala Met
Val Phe Ser Gln Glu Asp Cys395 400 405atg ata aaa gca gtt cga ggc
gat ttg aac ttc gtt aat aga gca aat 1302Met Ile Lys Ala Val Arg Gly
Asp Leu Asn Phe Val Asn Arg Ala Asn410 415 420 425cag cgc ttg aac
ccc atg cat caa ctc ttg agg cat ttc caa aaa gat 1350Gln Arg Leu Asn
Pro Met His Gln Leu Leu Arg His Phe Gln Lys Asp430 435 440gca aaa
gtg ctt ttc cag aat tgg ggg att gaa ccc atc gac aat gtg 1398Ala Lys
Val Leu Phe Gln Asn Trp Gly Ile Glu Pro Ile Asp Asn Val445 450
455atg gga atg att gga ata ttg cct gac atg acc cca agc acc gag atg
1446Met Gly Met Ile Gly Ile Leu Pro Asp Met Thr Pro Ser Thr Glu
Met460 465 470tca ttg aga gga gtg aga gtc agc aaa atg gga gtg gat
gag tac tcc 1494Ser Leu Arg Gly Val Arg Val Ser Lys Met Gly Val Asp
Glu Tyr Ser475 480 485agc act gag aga gtg gtg gtg agc att gac cgt
ttt tta aga gtt cgg 1542Ser Thr Glu Arg Val Val Val Ser Ile Asp Arg
Phe Leu Arg Val Arg490 495 500 505gat caa agg gga aac ata cta ctg
tcc cct gaa gag gtc agt gaa aca 1590Asp Gln Arg Gly Asn Ile Leu Leu
Ser Pro Glu Glu Val Ser Glu Thr510 515 520caa gga acg gaa aag ctg
aca ata att tat tca tca tca atg atg tgg 1638Gln Gly Thr Glu Lys Leu
Thr Ile Ile Tyr Ser Ser Ser Met Met Trp525 530 535gag att aat ggt
ccc gaa tca gtg ttg gtc aat act tat caa tgg atc 1686Glu Ile Asn Gly
Pro Glu Ser Val Leu Val Asn Thr Tyr Gln Trp Ile540 545 550atc agg
aac tgg gaa att gtg aaa att caa tgg tca cag gat ccc aca 1734Ile Arg
Asn Trp Glu Ile Val Lys Ile Gln Trp Ser Gln Asp Pro Thr555 560
565atg tta tac aat aag ata gaa ttt gag cca ttc cag tcc ctg gtc cct
1782Met Leu Tyr Asn Lys Ile Glu Phe Glu Pro Phe Gln Ser Leu Val
Pro570 575 580 585agg gcc acc aga agc caa tac agc ggt ttc gta aga
acc ctg ttt cag 1830Arg Ala Thr Arg Ser Gln Tyr Ser Gly Phe Val Arg
Thr Leu Phe Gln590 595 600caa atg cga gat gta ctt gga aca ttt gat
act gct caa ata ata aaa 1878Gln Met Arg Asp Val Leu Gly Thr Phe Asp
Thr Ala Gln Ile Ile Lys605 610 615ctc ctc cct ttt gcc gct gct cct
ccg gaa cag agt agg atg cag ttc 1926Leu Leu Pro Phe Ala Ala Ala Pro
Pro Glu Gln Ser Arg Met Gln Phe620 625 630tct tct ttg act gtt aat
gta aga gga tcg gga atg agg ata ctt gta 1974Ser Ser Leu Thr Val Asn
Val Arg Gly Ser Gly Met Arg Ile Leu Val635 640 645aga ggc aat tcc
cca gtg ttc aac tac aat aaa gcc act aag agg ctc 2022Arg Gly Asn Ser
Pro Val Phe Asn Tyr Asn Lys Ala Thr Lys Arg Leu650 655 660 665aca
gtc ctc gga aag gat gca ggt gcg ctt act gaa gac cca gat gaa 2070Thr
Val Leu Gly Lys Asp Ala Gly Ala Leu Thr Glu Asp Pro Asp Glu670 675
680ggt acg gct gga gta gaa tct gct gtt cta aga ggg ttt ctc att tta
2118Gly Thr Ala Gly Val Glu Ser Ala Val Leu Arg Gly Phe Leu Ile
Leu685 690 695ggt aaa gaa aac aag aga tat ggc cca gca cta agc atc
aat gaa ctg 2166Gly Lys Glu Asn Lys Arg Tyr Gly Pro Ala Leu Ser Ile
Asn Glu Leu700 705 710agc aaa ctt gca aaa ggg gag aaa gct aat gtg
cta att ggg caa ggg 2214Ser Lys Leu Ala Lys Gly Glu Lys Ala Asn Val
Leu Ile Gly Gln Gly715 720 725gac gtg gtg ttg gta atg aaa cgg aaa
cgt gac tct agc ata ctt act 2262Asp Val Val Leu Val Met Lys Arg Lys
Arg Asp Ser Ser Ile Leu Thr730 735 740 745gac agc cag aca gcg acc
aaa agg att cgg atg gcc atc aat 2304Asp Ser Gln Thr Ala Thr Lys Arg
Ile Arg Met Ala Ile Asn750 755tagtgttgaa ttgtttaaaa acgaccttgt
ttctact 234145759PRTEquine influenza virus H3N8 45Met Glu Arg Ile
Lys Glu Leu Arg Asp Leu Met Ser Gln Ser Arg Thr1 5 10 15Arg Glu Ile
Leu Thr Lys Thr Thr Val Asp His Met Ala Ile Ile Lys20 25 30Lys Tyr
Thr Ser Gly Arg Gln Glu Lys Asn Pro Ala Leu Arg Met Lys35 40 45Trp
Met Met Ala Met Lys Tyr Pro Ile Thr Ala Asp Lys Arg Ile Met50 55
60Glu Met Ile Pro Glu Arg Asn Glu Gln Gly Gln Thr Leu Trp Ser Lys65
70 75 80Thr Asn Asp Ala Gly Ser Asp Arg Val Met Val Ser Pro Leu Ala
Val85 90 95Thr Trp Trp Asn Arg Asn Gly Pro Thr Thr Ser Thr Ile His
Tyr Pro100 105 110Lys Val Tyr Lys Thr Tyr Phe Glu Lys Val Glu Arg
Leu Lys His Gly115 120 125Thr Phe Gly Pro Val His Phe Arg Asn Gln
Val Lys Ile Arg Arg Arg130 135 140Val Asp Val Asn Pro Gly His Ala
Asp Leu Ser Ala Lys Glu Ala Gln145 150 155 160Asp Val Ile Met Glu
Val Val Phe Pro Asn Glu Val Gly Ala Arg Ile165 170 175Leu Thr Ser
Glu Ser Gln Leu Thr Ile Thr Lys Glu Lys Lys Glu Glu180 185 190Leu
Gln Asp Cys Lys Ile Ala Pro Leu Met Val Ala Tyr Met Leu Glu195 200
205Arg Glu Leu Val Arg Lys Thr Arg Phe Leu Pro Val Ala Gly Gly
Thr210 215 220Ser Ser Val Tyr Ile Glu Val Leu His Leu Thr Gln Gly
Thr Cys Trp225 230 235 240Glu Gln Met Tyr Thr Pro Gly Gly Glu Val
Arg Asn Asp Asp Ile Asp245 250 255Gln Ser Leu Ile Ile Ala Ala Arg
Asn Ile Val Arg Arg Ala Thr Val260 265 270Ser Ala Asp Pro Leu Ala
Ser Leu Leu Glu Met Cys His Ser Thr Gln275 280 285Ile Gly Gly Ile
Arg Met Val Asp Ile Leu Lys Gln Asn Pro Thr Glu290 295 300Glu Gln
Ala Val Asp Ile Cys Lys Ala Ala Met Gly Leu Arg Ile Ser305 310 315
320Ser Ser Phe Ser Phe Gly Gly Phe Thr Phe Lys Arg Thr Ser Gly
Ser325 330 335Ser Val Lys Arg Glu Glu Glu Met Leu Thr Gly Asn Leu
Gln Thr Leu340 345 350Lys Ile Arg Val His Glu Gly Tyr Glu Glu Phe
Thr Met Val Gly Arg355 360 365Arg Ala Thr Ala Ile Leu Arg Lys Ala
Thr Arg Arg Leu Ile Gln Leu370 375 380Ile Val Ser Gly Arg Asp Glu
Gln Ser Ile Ala Glu Ala Ile Ile Val385 390 395 400Ala Met Val Phe
Ser Gln Glu Asp Cys Met Ile Lys Ala Val Arg Gly405 410 415Asp Leu
Asn Phe Val Asn Arg Ala Asn Gln Arg Leu Asn Pro Met His420 425
430Gln Leu Leu Arg His Phe Gln Lys Asp Ala Lys Val Leu Phe Gln
Asn435 440 445Trp Gly Ile Glu Pro Ile Asp Asn Val Met Gly Met Ile
Gly Ile Leu450 455 460Pro Asp Met Thr Pro Ser Thr Glu Met Ser Leu
Arg Gly Val Arg Val465 470 475 480Ser Lys Met Gly Val Asp Glu Tyr
Ser Ser Thr Glu Arg Val Val Val485 490 495Ser Ile Asp Arg Phe Leu
Arg Val Arg Asp Gln Arg Gly Asn Ile Leu500 505 510Leu Ser Pro Glu
Glu Val Ser Glu Thr Gln Gly Thr Glu Lys Leu Thr515 520 525Ile Ile
Tyr Ser Ser Ser Met Met Trp Glu Ile Asn Gly Pro Glu Ser530 535
540Val Leu Val Asn Thr Tyr Gln Trp Ile Ile Arg Asn Trp Glu Ile
Val545 550 555 560Lys Ile Gln Trp Ser Gln Asp Pro Thr Met Leu Tyr
Asn Lys Ile Glu565 570 575Phe Glu Pro Phe Gln Ser Leu Val Pro Arg
Ala Thr Arg Ser Gln Tyr580 585 590Ser Gly Phe Val Arg Thr Leu Phe
Gln Gln Met Arg Asp Val Leu Gly595 600 605Thr Phe Asp Thr Ala Gln
Ile Ile Lys Leu Leu Pro Phe Ala Ala Ala610 615 620Pro Pro Glu Gln
Ser Arg Met Gln Phe Ser Ser Leu Thr Val Asn Val625 630 635 640Arg
Gly Ser Gly Met Arg Ile Leu Val Arg Gly Asn Ser Pro Val Phe645 650
655Asn Tyr Asn Lys Ala Thr Lys Arg Leu Thr Val Leu Gly Lys Asp
Ala660 665 670Gly Ala Leu Thr Glu Asp Pro Asp Glu Gly Thr Ala Gly
Val Glu Ser675 680 685Ala Val Leu Arg Gly Phe Leu Ile Leu Gly Lys
Glu Asn Lys Arg Tyr690 695 700Gly Pro Ala Leu Ser Ile Asn Glu Leu
Ser Lys Leu Ala Lys Gly Glu705 710 715 720Lys Ala Asn Val Leu Ile
Gly Gln Gly Asp Val Val Leu Val Met Lys725 730 735Arg Lys Arg Asp
Ser Ser Ile Leu Thr Asp Ser Gln Thr Ala Thr Lys740 745 750Arg Ile
Arg Met Ala Ile Asn755462277DNAEquine influenza virus H3N8
46atggagagaa taaaagaact gagagatcta atgtcacaat cccgcacccg
cgagatacta 60acaaaaacta ctgtggacca catggccata atcaagaaat acacatcagg
aagacaagag 120aagaaccccg cacttaggat gaagtggatg atggcaatga
aatacccaat tacagcagat 180aagaggataa tggaaatgat tcctgagaga
aatgaacagg ggcaaaccct ttggagcaaa 240acgaacgatg ctggctcaga
ccgcgtaatg gtatcacctc tggcagtgac atggtggaat 300aggaatggac
caacaacgag cacaattcat tatccaaaag tctacaaaac ttattttgaa
360aaagttgaaa gattaaaaca cggaaccttt ggccccgttc attttaggaa
tcaagtcaag 420ataagacgga gagttgatgt aaaccctggt cacgcggacc
tcagtgccaa agaagcacaa 480gatgtgatca tggaagttgt tttcccaaat
gaagtgggag ccagaattct aacatcggaa 540tcacaactaa caataaccaa
agagaaaaaa gaagaacttc aggactgcaa aattgccccc 600ttgatggtag
catacatgct agaaagagag ttggtccgaa aaacaagatt cctcccagtg
660gctggcggaa caagcagtgt atacattgaa gtgttgcatc tgactcaggg
aacatgctgg 720gaacaaatgt acaccccagg aggagaagtt agaaacgatg
acattgatca aagtttaatt 780attgctgccc ggaacatagt gagaagagcg
acagtatcag cagatccact agcatccctg 840ctggaaatgt gccacagtac
acagattggt ggaataagga tggtagacat ccttaagcag 900aatccaacag
aggaacaagc tgtggatata tgcaaagcag caatggggtt aagaattagc
960tcatcattca gctttggtgg attcaccttt aagagaacaa gtggatcatc
agtcaagaga 1020gaagaagaaa tgcttacggg caaccttcaa acattgaaaa
taagagtgca tgaaggctat 1080gaagaattca caatggtcgg aagaagagca
acagccattc tcagaaaggc aaccagaaga 1140ttgattcaat tgatagtaag
tgggagagat gaacaatcaa ttgctgaagc aataattgta 1200gccatggtgt
tttcgcaaga agattgcatg ataaaagcag ttcgaggcga tttgaacttc
1260gttaatagag caaatcagcg cttgaacccc atgcatcaac tcttgaggca
tttccaaaaa 1320gatgcaaaag tgcttttcca gaattggggg attgaaccca
tcgacaatgt gatgggaatg 1380attggaatat tgcctgacat gaccccaagc
accgagatgt cattgagagg agtgagagtc 1440agcaaaatgg gagtggatga
gtactccagc actgagagag tggtggtgag cattgaccgt 1500tttttaagag
ttcgggatca aaggggaaac atactactgt cccctgaaga ggtcagtgaa
1560acacaaggaa cggaaaagct gacaataatt tattcatcat caatgatgtg
ggagattaat 1620ggtcccgaat cagtgttggt caatacttat caatggatca
tcaggaactg ggaaattgtg 1680aaaattcaat ggtcacagga tcccacaatg
ttatacaata agatagaatt tgagccattc 1740cagtccctgg tccctagggc
caccagaagc caatacagcg gtttcgtaag aaccctgttt 1800cagcaaatgc
gagatgtact tggaacattt gatactgctc aaataataaa actcctccct
1860tttgccgctg ctcctccgga acagagtagg atgcagttct cttctttgac
tgttaatgta 1920agaggatcgg gaatgaggat acttgtaaga ggcaattccc
cagtgttcaa ctacaataaa 1980gccactaaga ggctcacagt cctcggaaag
gatgcaggtg cgcttactga agacccagat 2040gaaggtacgg ctggagtaga
atctgctgtt ctaagagggt ttctcatttt aggtaaagaa 2100aacaagagat
atggcccagc actaagcatc aatgaactga gcaaacttgc aaaaggggag
2160aaagctaatg tgctaattgg gcaaggggac gtggtgttgg taatgaaacg
gaaacgtgac 2220tctagcatac ttactgacag ccagacagcg accaaaagga
ttcggatggc catcaat 2277472341DNAEquine influenza virus
H3N8CDS(28)..(2304) 47agcaaaagca ggtcaaatat attcaat atg gag aga ata
aaa gaa ctg aga gat 54Met Glu Arg Ile Lys Glu Leu Arg Asp1 5cta atg
tca caa tcc cgc acc cgc gag ata cta aca aaa act act gtg 102Leu Met
Ser Gln Ser Arg Thr Arg Glu Ile Leu Thr Lys Thr Thr Val10 15 20
25gac cac atg gcc ata atc aag aaa tac aca tca gga aga caa gag aag
150Asp His Met Ala Ile Ile Lys Lys Tyr Thr Ser Gly Arg Gln Glu
Lys30 35 40aac ccc gca ctt agg atg aag tgg atg atg gca atg aaa tac
cca att 198Asn Pro Ala Leu Arg Met Lys Trp Met Met Ala Met Lys Tyr
Pro Ile45 50 55aca gca gat aag agg ata atg gaa atg att cct gag aga
aat gaa cag 246Thr Ala Asp Lys Arg Ile Met Glu Met Ile Pro Glu Arg
Asn Glu Gln60 65 70ggg caa acc ctt tgg agc aaa acg aac gat gct ggc
tca gac cgc gta 294Gly Gln Thr Leu Trp Ser Lys Thr Asn Asp Ala Gly
Ser Asp Arg Val75 80 85atg gta tca cct ctg gca gtg aca tgg tgg aat
agg aat gga cca aca 342Met Val Ser Pro Leu Ala Val Thr Trp Trp Asn
Arg Asn Gly Pro Thr90 95 100 105acg agc aca att cat tat cca aaa gtc
cac aaa act tat ttt gaa aaa 390Thr Ser Thr Ile His Tyr Pro Lys Val
His Lys Thr Tyr Phe Glu Lys110 115 120gtt gaa aga tta aaa cac gga
acc ttt ggc ccc gtt cat ttt agg aat 438Val Glu Arg Leu Lys His Gly
Thr Phe Gly Pro Val His Phe Arg Asn125 130 135caa gtc aag ata aga
cgg aga gtt gat gta aac cct ggt cac gcg gac 486Gln Val Lys Ile Arg
Arg Arg Val Asp Val Asn Pro Gly His Ala Asp140 145 150ctc agt gcc
aaa gaa gca caa gat gtg atc atg gaa gtt gtt ttc cca 534Leu Ser Ala
Lys Glu Ala Gln Asp Val Ile Met Glu Val Val Phe Pro155 160 165aat
gaa gtg gga gcc aga att cta aca tcg gaa tca caa cta aca ata 582Asn
Glu Val Gly Ala Arg Ile Leu Thr Ser Glu Ser Gln Leu Thr Ile170 175
180 185acc aaa gag aaa aaa gaa gaa ctt cag gac tgc aaa att gcc ccc
ttg 630Thr Lys Glu Lys Lys Glu Glu Leu Gln Asp Cys Lys Ile Ala Pro
Leu190 195 200atg gta gca tac atg cta gaa aga gag ttg gtc cga aaa
aca aga ttc 678Met Val Ala Tyr Met Leu Glu Arg Glu Leu Val Arg Lys
Thr Arg Phe205 210 215ctc cca gtg gct ggc gga aca agc agt gta tac
att gaa gtg ttg cat 726Leu Pro Val Ala Gly Gly Thr Ser Ser Val Tyr
Ile Glu Val Leu His220 225 230ctg act cag gga aca tgc tgg gaa caa
atg tac acc cca gga gga gaa 774Leu Thr Gln Gly Thr Cys Trp Glu Gln
Met Tyr Thr Pro Gly Gly Glu235 240 245gtt aga aac gat gac att gat
caa agt tta att att gct gcc cgg aac 822Val Arg Asn Asp Asp Ile Asp
Gln Ser Leu Ile Ile Ala Ala Arg Asn250 255 260 265ata gtg aga aga
gcg aca gta tca gca gat cca cta gca tcc ctg ctg 870Ile Val Arg Arg
Ala Thr Val Ser Ala Asp Pro Leu Ala Ser Leu Leu270 275 280gaa atg
tgc cac agt aca cag att ggt gga ata agg atg gta gac atc 918Glu Met
Cys His Ser Thr Gln Ile Gly Gly Ile Arg Met Val Asp Ile285 290
295ctt aag cag aat cca aca gag gaa caa gct gtg gat ata tgc aaa gca
966Leu Lys Gln Asn Pro Thr Glu Glu Gln Ala Val Asp Ile Cys Lys
Ala300 305 310gca atg ggg tta aga att agc tca tca ttc agc ttt ggt
gga ttc acc 1014Ala Met Gly Leu Arg Ile Ser Ser Ser Phe Ser Phe Gly
Gly Phe Thr315 320 325ttt aag aga aca agt gga tca tca gtc aag aga
gaa gaa gaa atg ctt 1062Phe Lys Arg Thr Ser Gly Ser Ser Val Lys Arg
Glu Glu Glu Met Leu330 335 340 345acg ggc aac ctt caa aca ttg aaa
ata aga gtg cat gaa ggc tat gaa 1110Thr Gly Asn Leu Gln Thr Leu Lys
Ile Arg Val His Glu Gly Tyr Glu350 355 360gaa ttc aca atg gtc gga
aga aga gca aca gcc att ctc aga aag gca 1158Glu Phe Thr Met Val Gly
Arg Arg Ala Thr Ala Ile Leu Arg Lys Ala365 370 375acc aga aga ttg
att caa ttg ata gta agt ggg aga gat gaa caa tca 1206Thr Arg Arg Leu
Ile Gln Leu Ile Val Ser Gly Arg Asp Glu Gln Ser380 385 390att gct
gaa gca ata att gta gcc atg gtg ttt tcg caa gaa gat tgc 1254Ile Ala
Glu Ala Ile Ile Val Ala Met Val Phe Ser Gln Glu Asp Cys395 400
405atg ata caa gca gtt cga ggc gat ttg aac ttc gtt aat aga gca aat
1302Met Ile Gln Ala Val Arg Gly Asp Leu Asn Phe Val Asn Arg Ala
Asn410 415 420 425cag cgc ttg aac ccc atg cat caa ctc ttg agg cat
ttc caa aaa gat 1350Gln Arg Leu Asn Pro Met His Gln Leu Leu Arg His
Phe Gln Lys Asp430 435 440gca aaa gtg ctt ttc cag aat tgg ggg att
gaa ccc atc gac aat gtg 1398Ala Lys Val Leu Phe Gln Asn Trp Gly Ile
Glu Pro Ile Asp Asn Val445 450 455atg gga atg att gga ata ttg cct
gac atg acc cca agc acc gag atg 1446Met Gly Met Ile Gly Ile Leu Pro
Asp Met Thr Pro Ser Thr Glu Met460 465 470tca ttg aga gga gtg aga
gtc agc aaa atg gga gtg gat gag tac tcc 1494Ser Leu Arg Gly Val Arg
Val Ser Lys Met Gly Val Asp Glu Tyr Ser475 480 485agc act gag aga
gtg gtg gtg agc att gac cgt ttt tta aga gtt cgg 1542Ser Thr Glu Arg
Val Val Val Ser Ile Asp Arg Phe Leu Arg Val Arg490 495 500 505gat
caa agg gga aac ata cta ctg tcc cct gaa gag gtc agt gaa aca 1590Asp
Gln Arg Gly Asn Ile Leu Leu Ser Pro Glu Glu Val Ser Glu Thr510 515
520caa gga acg gaa aag ctg aca ata att tat tca tca tca atg atg tgg
1638Gln Gly Thr Glu Lys Leu Thr Ile Ile Tyr Ser Ser Ser Met Met
Trp525 530 535gag att aat ggt ccc gaa tca gtg ttg gtc aat act tat
caa tgg atc 1686Glu Ile Asn Gly Pro Glu Ser Val Leu Val Asn Thr Tyr
Gln Trp Ile540 545 550atc agg aac tgg gaa att gtg aaa att caa tgg
tca cag gat ccc aca 1734Ile Arg Asn Trp Glu Ile Val Lys Ile Gln Trp
Ser Gln Asp Pro Thr555 560 565atg tta tac aat aag ata gaa ttt gag
cca ttc cag tcc ctg gtc cct 1782Met Leu Tyr Asn Lys Ile Glu Phe Glu
Pro Phe Gln Ser Leu Val Pro570 575 580 585agg gcc acc aga agc caa
tac agc ggt ttc gta aga acc ctg ttt cag 1830Arg Ala Thr Arg Ser Gln
Tyr Ser Gly Phe Val Arg Thr Leu Phe Gln590 595 600caa atg cga gat
gta ctt gga aca ttt gat act gct caa ata ata aaa 1878Gln Met Arg Asp
Val Leu Gly Thr Phe Asp Thr Ala Gln Ile Ile Lys605 610 615ctc ctc
cct ttt gcc gct gct cct ccg gaa cag agt agg atg cag ttc 1926Leu Leu
Pro Phe Ala Ala Ala Pro Pro Glu Gln Ser Arg Met Gln Phe620 625
630tct tct ttg act gtt aat gta aga gga tcg gga atg agg ata ctt gta
1974Ser Ser Leu Thr Val Asn Val Arg Gly Ser Gly Met Arg Ile Leu
Val635 640 645aga ggc aat tcc cca gtg ttc aac tac aat aaa gcc act
aag agg ctc 2022Arg Gly Asn Ser Pro Val Phe Asn Tyr Asn Lys Ala Thr
Lys Arg Leu650 655 660 665aca gtc ctc gga aaa gat gca ggt gcg ctt
act gaa gac cca gat gaa 2070Thr Val Leu Gly Lys Asp Ala Gly Ala Leu
Thr Glu Asp Pro Asp Glu670 675 680ggt acg gct gga gta gaa tct gct
gtt cta aga ggg ttt ctc att tta 2118Gly Thr Ala Gly Val Glu Ser Ala
Val Leu Arg Gly Phe Leu Ile Leu685 690 695ggt aaa gaa aac aag aga
tat ggc cca gca cta agc atc aat gaa ctg 2166Gly Lys Glu Asn Lys Arg
Tyr Gly Pro Ala Leu Ser Ile Asn Glu Leu700 705 710agc aaa ctt gca
aaa ggg gag aaa gct aat gtg cta att ggg caa ggg 2214Ser Lys Leu Ala
Lys Gly Glu Lys Ala Asn Val Leu Ile Gly Gln Gly715 720 725gac gtg
gtg ttg gta atg aaa cgg aaa cgt gac tct agc ata ctt act 2262Asp Val
Val Leu Val Met Lys Arg Lys Arg Asp Ser Ser Ile Leu Thr730 735 740
745gac agc cag aca gcg acc aaa agg att cgg atg gcc atc aat 2304Asp
Ser Gln Thr Ala Thr Lys Arg Ile Arg Met Ala Ile Asn750
755tagtgttgaa ttgtttaaaa acgaccttgt ttctact 234148759PRTEquine
influenza virus H3N8 48Met Glu Arg Ile Lys Glu Leu Arg Asp Leu Met
Ser Gln Ser Arg Thr1 5 10 15Arg Glu Ile Leu Thr Lys Thr Thr Val Asp
His Met Ala Ile Ile Lys20 25 30Lys Tyr Thr Ser Gly Arg Gln Glu Lys
Asn Pro Ala Leu Arg Met Lys35 40 45Trp Met Met Ala Met Lys Tyr Pro
Ile Thr Ala Asp Lys Arg Ile Met50 55 60Glu Met Ile Pro Glu Arg Asn
Glu Gln Gly Gln Thr Leu Trp Ser Lys65 70 75 80Thr Asn Asp Ala Gly
Ser Asp Arg Val Met Val Ser Pro Leu Ala Val85 90 95Thr Trp Trp Asn
Arg Asn Gly Pro Thr Thr Ser Thr Ile His Tyr Pro100 105 110Lys Val
His Lys Thr Tyr Phe Glu Lys Val Glu Arg Leu Lys His Gly115 120
125Thr Phe Gly Pro Val His Phe Arg Asn Gln Val Lys Ile Arg Arg
Arg130 135 140Val Asp Val Asn Pro Gly His Ala Asp Leu Ser Ala Lys
Glu Ala Gln145 150 155 160Asp Val Ile Met Glu Val Val Phe Pro Asn
Glu Val Gly Ala Arg Ile165 170 175Leu Thr Ser Glu Ser Gln Leu Thr
Ile Thr Lys Glu Lys Lys Glu Glu180 185 190Leu Gln Asp Cys Lys Ile
Ala Pro Leu Met Val Ala Tyr Met Leu Glu195 200 205Arg Glu Leu Val
Arg Lys Thr Arg Phe Leu Pro Val Ala Gly Gly Thr210 215 220Ser Ser
Val Tyr Ile Glu Val Leu His Leu Thr Gln Gly Thr Cys Trp225 230 235
240Glu Gln Met Tyr Thr Pro Gly Gly Glu Val Arg Asn Asp Asp Ile
Asp245 250 255Gln Ser Leu Ile Ile Ala Ala Arg Asn Ile Val Arg Arg
Ala Thr Val260 265 270Ser Ala Asp Pro Leu Ala Ser Leu Leu Glu Met
Cys His Ser Thr Gln275 280 285Ile Gly Gly Ile Arg Met Val Asp Ile
Leu Lys Gln Asn Pro Thr Glu290 295 300Glu Gln Ala Val Asp Ile Cys
Lys Ala Ala Met Gly Leu Arg Ile Ser305 310 315 320Ser Ser Phe Ser
Phe Gly Gly Phe Thr Phe Lys Arg Thr Ser Gly Ser325 330 335Ser Val
Lys Arg Glu Glu Glu Met Leu Thr Gly Asn Leu Gln Thr Leu340 345
350Lys Ile Arg Val His Glu Gly Tyr Glu Glu Phe Thr Met Val Gly
Arg355 360 365Arg Ala Thr Ala Ile Leu Arg Lys Ala Thr Arg Arg Leu
Ile Gln Leu370 375 380Ile Val Ser Gly Arg Asp Glu Gln Ser Ile Ala
Glu Ala Ile Ile Val385 390 395 400Ala Met Val Phe Ser Gln Glu Asp
Cys Met Ile Gln Ala Val Arg Gly405 410 415Asp Leu Asn Phe Val Asn
Arg Ala Asn Gln Arg Leu Asn Pro Met His420 425 430Gln Leu Leu Arg
His Phe Gln Lys Asp Ala Lys Val Leu Phe Gln Asn435 440 445Trp Gly
Ile Glu Pro Ile Asp Asn Val Met Gly Met Ile Gly Ile Leu450 455
460Pro Asp Met Thr Pro Ser Thr Glu Met Ser Leu Arg Gly Val Arg
Val465 470 475 480Ser Lys Met Gly Val Asp Glu Tyr Ser Ser Thr Glu
Arg Val Val Val485 490 495Ser Ile Asp Arg Phe Leu Arg Val Arg Asp
Gln Arg Gly Asn Ile Leu500 505 510Leu Ser Pro Glu Glu Val Ser Glu
Thr Gln Gly Thr Glu Lys Leu Thr515 520 525Ile Ile Tyr Ser Ser Ser
Met Met Trp Glu Ile Asn Gly Pro Glu Ser530 535 540Val Leu Val Asn
Thr Tyr Gln Trp Ile Ile Arg Asn Trp Glu Ile Val545 550 555 560Lys
Ile Gln Trp Ser Gln Asp Pro Thr Met Leu Tyr Asn Lys Ile Glu565 570
575Phe Glu Pro Phe Gln Ser Leu Val Pro Arg Ala Thr Arg Ser Gln
Tyr580 585 590Ser Gly Phe Val Arg Thr Leu Phe Gln Gln Met Arg Asp
Val Leu Gly595 600 605Thr Phe Asp Thr Ala Gln Ile Ile Lys Leu Leu
Pro Phe Ala Ala Ala610 615 620Pro Pro Glu Gln Ser Arg Met Gln Phe
Ser Ser Leu Thr Val Asn Val625 630 635 640Arg Gly Ser Gly Met Arg
Ile Leu Val Arg Gly Asn Ser Pro Val Phe645 650 655Asn Tyr Asn Lys
Ala Thr Lys Arg Leu Thr Val Leu Gly Lys Asp Ala660 665 670Gly Ala
Leu Thr Glu Asp Pro Asp Glu Gly Thr Ala Gly Val Glu Ser675 680
685Ala Val Leu Arg Gly Phe Leu Ile Leu Gly Lys Glu Asn Lys Arg
Tyr690 695 700Gly Pro Ala Leu Ser Ile Asn Glu Leu Ser Lys Leu Ala
Lys Gly Glu705 710 715 720Lys Ala Asn Val Leu Ile Gly Gln Gly Asp
Val Val Leu Val Met Lys725 730 735Arg Lys Arg Asp Ser Ser Ile Leu
Thr Asp Ser Gln Thr Ala Thr Lys740 745 750Arg Ile Arg Met Ala Ile
Asn755492277DNAEquine influenza virus H3N8 49atggagagaa taaaagaact
gagagatcta atgtcacaat cccgcacccg cgagatacta 60acaaaaacta ctgtggacca
catggccata atcaagaaat acacatcagg aagacaagag 120aagaaccccg
cacttaggat gaagtggatg atggcaatga aatacccaat tacagcagat
180aagaggataa tggaaatgat tcctgagaga aatgaacagg ggcaaaccct
ttggagcaaa 240acgaacgatg ctggctcaga ccgcgtaatg gtatcacctc
tggcagtgac atggtggaat 300aggaatggac caacaacgag cacaattcat
tatccaaaag tccacaaaac ttattttgaa 360aaagttgaaa gattaaaaca
cggaaccttt ggccccgttc attttaggaa tcaagtcaag 420ataagacgga
gagttgatgt aaaccctggt cacgcggacc tcagtgccaa agaagcacaa
480gatgtgatca tggaagttgt tttcccaaat gaagtgggag ccagaattct
aacatcggaa 540tcacaactaa caataaccaa agagaaaaaa gaagaacttc
aggactgcaa aattgccccc 600ttgatggtag catacatgct agaaagagag
ttggtccgaa aaacaagatt cctcccagtg 660gctggcggaa caagcagtgt
atacattgaa gtgttgcatc tgactcaggg aacatgctgg 720gaacaaatgt
acaccccagg aggagaagtt agaaacgatg acattgatca aagtttaatt
780attgctgccc ggaacatagt gagaagagcg acagtatcag cagatccact
agcatccctg 840ctggaaatgt gccacagtac acagattggt ggaataagga
tggtagacat ccttaagcag 900aatccaacag aggaacaagc tgtggatata
tgcaaagcag caatggggtt aagaattagc 960tcatcattca gctttggtgg
attcaccttt aagagaacaa gtggatcatc agtcaagaga 1020gaagaagaaa
tgcttacggg caaccttcaa acattgaaaa taagagtgca tgaaggctat
1080gaagaattca caatggtcgg aagaagagca acagccattc tcagaaaggc
aaccagaaga 1140ttgattcaat tgatagtaag tgggagagat gaacaatcaa
ttgctgaagc aataattgta 1200gccatggtgt tttcgcaaga
agattgcatg atacaagcag ttcgaggcga tttgaacttc 1260gttaatagag
caaatcagcg cttgaacccc atgcatcaac tcttgaggca tttccaaaaa
1320gatgcaaaag tgcttttcca gaattggggg attgaaccca tcgacaatgt
gatgggaatg 1380attggaatat tgcctgacat gaccccaagc accgagatgt
cattgagagg agtgagagtc 1440agcaaaatgg gagtggatga gtactccagc
actgagagag tggtggtgag cattgaccgt 1500tttttaagag ttcgggatca
aaggggaaac atactactgt cccctgaaga ggtcagtgaa 1560acacaaggaa
cggaaaagct gacaataatt tattcatcat caatgatgtg ggagattaat
1620ggtcccgaat cagtgttggt caatacttat caatggatca tcaggaactg
ggaaattgtg 1680aaaattcaat ggtcacagga tcccacaatg ttatacaata
agatagaatt tgagccattc 1740cagtccctgg tccctagggc caccagaagc
caatacagcg gtttcgtaag aaccctgttt 1800cagcaaatgc gagatgtact
tggaacattt gatactgctc aaataataaa actcctccct 1860tttgccgctg
ctcctccgga acagagtagg atgcagttct cttctttgac tgttaatgta
1920agaggatcgg gaatgaggat acttgtaaga ggcaattccc cagtgttcaa
ctacaataaa 1980gccactaaga ggctcacagt cctcggaaaa gatgcaggtg
cgcttactga agacccagat 2040gaaggtacgg ctggagtaga atctgctgtt
ctaagagggt ttctcatttt aggtaaagaa 2100aacaagagat atggcccagc
actaagcatc aatgaactga gcaaacttgc aaaaggggag 2160aaagctaatg
tgctaattgg gcaaggggac gtggtgttgg taatgaaacg gaaacgtgac
2220tctagcatac ttactgacag ccagacagcg accaaaagga ttcggatggc catcaat
227750891DNAEquine influenza virus H3N8CDS(27)..(716) 50agcaaaagca
gggtgacaaa aacata atg gat tcc aac act gtg tca agc ttt 53Met Asp Ser
Asn Thr Val Ser Ser Phe1 5cag gta gac tgt ttt ctt tgg cat gtc cgc
aaa cga ttt gca gac caa 101Gln Val Asp Cys Phe Leu Trp His Val Arg
Lys Arg Phe Ala Asp Gln10 15 20 25gaa ctg ggt gat gcc cca ttc ctt
gac cgg ctt cgc cga gac cag aag 149Glu Leu Gly Asp Ala Pro Phe Leu
Asp Arg Leu Arg Arg Asp Gln Lys30 35 40tcc cta aaa gga aga ggt agc
act ctt ggt ctg gac atc gaa aca gcc 197Ser Leu Lys Gly Arg Gly Ser
Thr Leu Gly Leu Asp Ile Glu Thr Ala45 50 55act cgt gca gga aag cag
ata gtg gag cag att ctg gaa gag gaa tca 245Thr Arg Ala Gly Lys Gln
Ile Val Glu Gln Ile Leu Glu Glu Glu Ser60 65 70gat gag gca ctt aaa
atg acc att gcc tct gtt cct gct tca cgc tac 293Asp Glu Ala Leu Lys
Met Thr Ile Ala Ser Val Pro Ala Ser Arg Tyr75 80 85tta act gac atg
act ctt gat gag atg tca aga gac tgg ttc atg ctc 341Leu Thr Asp Met
Thr Leu Asp Glu Met Ser Arg Asp Trp Phe Met Leu90 95 100 105atg ccc
aag cag aaa gta aca ggc tcc cta tgt ata aga atg gac cag 389Met Pro
Lys Gln Lys Val Thr Gly Ser Leu Cys Ile Arg Met Asp Gln110 115
120gca atc atg gat aag aac atc ata ctt aaa gca aac ttt agt gtg att
437Ala Ile Met Asp Lys Asn Ile Ile Leu Lys Ala Asn Phe Ser Val
Ile125 130 135ttc gaa agg ctg gag aca cta ata cta ctt aga gcc ttc
acc gaa gaa 485Phe Glu Arg Leu Glu Thr Leu Ile Leu Leu Arg Ala Phe
Thr Glu Glu140 145 150gga gca gtc gtt ggc gaa att tca cca ttg cct
tct ctt cca gga cat 533Gly Ala Val Val Gly Glu Ile Ser Pro Leu Pro
Ser Leu Pro Gly His155 160 165act aat gag gat gtc aaa aat gca att
ggg gtc ctc atc gga gga ctt 581Thr Asn Glu Asp Val Lys Asn Ala Ile
Gly Val Leu Ile Gly Gly Leu170 175 180 185aaa tgg aat gat aat acg
gtt aga atc tct gaa act cta cag aga ttc 629Lys Trp Asn Asp Asn Thr
Val Arg Ile Ser Glu Thr Leu Gln Arg Phe190 195 200gct tgg aga agc
agt cat gag aat ggg aga cct tca ttc cct cca aag 677Ala Trp Arg Ser
Ser His Glu Asn Gly Arg Pro Ser Phe Pro Pro Lys205 210 215cag aaa
cga aaa atg gag aga aca att gag cca gaa gtt tgaagaaata 726Gln Lys
Arg Lys Met Glu Arg Thr Ile Glu Pro Glu Val220 225 230agatggttga
ttgaagaagt gcgacataga ttgaaaaata cagaaaatag ttttgaacaa
786ataacattta tgcaagcctt acaactattg cttgaagtag gacaagagat
aagaactttc 846tcgtttcagc ttatttaatg ataaaaaaca cccttgtttc tacta
89151230PRTEquine influenza virus H3N8 51Met Asp Ser Asn Thr Val
Ser Ser Phe Gln Val Asp Cys Phe Leu Trp1 5 10 15His Val Arg Lys Arg
Phe Ala Asp Gln Glu Leu Gly Asp Ala Pro Phe20 25 30Leu Asp Arg Leu
Arg Arg Asp Gln Lys Ser Leu Lys Gly Arg Gly Ser35 40 45Thr Leu Gly
Leu Asp Ile Glu Thr Ala Thr Arg Ala Gly Lys Gln Ile50 55 60Val Glu
Gln Ile Leu Glu Glu Glu Ser Asp Glu Ala Leu Lys Met Thr65 70 75
80Ile Ala Ser Val Pro Ala Ser Arg Tyr Leu Thr Asp Met Thr Leu Asp85
90 95Glu Met Ser Arg Asp Trp Phe Met Leu Met Pro Lys Gln Lys Val
Thr100 105 110Gly Ser Leu Cys Ile Arg Met Asp Gln Ala Ile Met Asp
Lys Asn Ile115 120 125Ile Leu Lys Ala Asn Phe Ser Val Ile Phe Glu
Arg Leu Glu Thr Leu130 135 140Ile Leu Leu Arg Ala Phe Thr Glu Glu
Gly Ala Val Val Gly Glu Ile145 150 155 160Ser Pro Leu Pro Ser Leu
Pro Gly His Thr Asn Glu Asp Val Lys Asn165 170 175Ala Ile Gly Val
Leu Ile Gly Gly Leu Lys Trp Asn Asp Asn Thr Val180 185 190Arg Ile
Ser Glu Thr Leu Gln Arg Phe Ala Trp Arg Ser Ser His Glu195 200
205Asn Gly Arg Pro Ser Phe Pro Pro Lys Gln Lys Arg Lys Met Glu
Arg210 215 220Thr Ile Glu Pro Glu Val225 23052690DNAEquine
influenza virus H3N8 52atggattcca acactgtgtc aagctttcag gtagactgtt
ttctttggca tgtccgcaaa 60cgatttgcag accaagaact gggtgatgcc ccattccttg
accggcttcg ccgagaccag 120aagtccctaa aaggaagagg tagcactctt
ggtctggaca tcgaaacagc cactcgtgca 180ggaaagcaga tagtggagca
gattctggaa gaggaatcag atgaggcact taaaatgacc 240attgcctctg
ttcctgcttc acgctactta actgacatga ctcttgatga gatgtcaaga
300gactggttca tgctcatgcc caagcagaaa gtaacaggct ccctatgtat
aagaatggac 360caggcaatca tggataagaa catcatactt aaagcaaact
ttagtgtgat tttcgaaagg 420ctggagacac taatactact tagagccttc
accgaagaag gagcagtcgt tggcgaaatt 480tcaccattgc cttctcttcc
aggacatact aatgaggatg tcaaaaatgc aattggggtc 540ctcatcggag
gacttaaatg gaatgataat acggttagaa tctctgaaac tctacagaga
600ttcgcttgga gaagcagtca tgagaatggg agaccttcat tccctccaaa
gcagaaacga 660aaaatggaga gaacaattga gccagaagtt 69053888DNAEquine
influenza virus H3N8 53caaaagcagg gtgacaaaaa catgatggat tccaacactg
tgtcaagctt tcaggtagac 60tgttttcttt ggcatgtccg caaacgattt gcagaccaag
aactgggtga tgccccattc 120cttgaccggc ttcgccgaga ccagaagtcc
ctaaaaggaa gaggtagcac tcttggtctg 180gacatcgaaa cagccactcg
tgcaggaaag cagatagtgg agcagattct ggaagaggaa 240tcagatgagg
cacttaaaat gaccattgcc tctgttcctg cttcacgcta cttaactgac
300atgactcttg atgagatgtc aagagactgg ttcatgctca tgcccaagca
gaaagtaaca 360ggctccctat gtataagaat ggaccaggca atcatggata
agaacatcat acttaaagca 420aactttagtg tgattttcga aaggctggag
acactaatac tacttagagc cttcaccgaa 480gaaggagcag tcgttggcga
aatttcacca ttgccttctc ttccaggaca tactaatgag 540gatgtcaaaa
atgcaattgg ggtcctcatc ggaggactta aatggaatga taatacggtt
600agaatctctg aaactctaca gagattcgct tggagaagca gtcatgagaa
tgggagacct 660tcattccctc caaagcagaa acgaaaaatg gagagaacaa
ttgagccaga agtttgaaga 720aataagatgg ttgattgaag aagtgcgaca
tagattgaaa aatacagaaa atagttttga 780acaaataaca tttatgcaag
ccttacaact attgcttgaa gtagaacaag agataagaac 840tttctcgttt
cagcttattt aatgataaaa aacacccttg tttctact 88854468DNAEquine
influenza virus H3N8CDS(3)..(293) 54ac ttt agt gtg att ttc gaa agg
ctg gag aca cta ata cta ctt aga 47Phe Ser Val Ile Phe Glu Arg Leu
Glu Thr Leu Ile Leu Leu Arg1 5 10 15gcc ttc acc gaa gaa gga gca gtc
gtt ggc gaa att tca cca ttg cct 95Ala Phe Thr Glu Glu Gly Ala Val
Val Gly Glu Ile Ser Pro Leu Pro20 25 30tct ctt cca gga cat act aat
gag gat gtc aaa aat gca att ggg gtc 143Ser Leu Pro Gly His Thr Asn
Glu Asp Val Lys Asn Ala Ile Gly Val35 40 45ctc atc gga gga ctt aaa
tgg aat gat aat acg gtt aga atc tct gaa 191Leu Ile Gly Gly Leu Lys
Trp Asn Asp Asn Thr Val Arg Ile Ser Glu50 55 60act cta cag aga ttc
gct cgg aga agc agt cat gag aat ggg aga cct 239Thr Leu Gln Arg Phe
Ala Arg Arg Ser Ser His Glu Asn Gly Arg Pro65 70 75tca ttc cct cca
aag cag aaa cga aaa atg gag aga aca att gag cca 287Ser Phe Pro Pro
Lys Gln Lys Arg Lys Met Glu Arg Thr Ile Glu Pro80 85 90 95gaa gtt
tgaagaaata agatggttga ttgaagaagt gcgacataga ttgaaaaata 343Glu
Valcagaaaatag ttttgaacaa ataacattta tgcaagcctt acaactattg
cttgaagtag 403aacaagagat aagaactttc tcgtttcagc ttatttaatg
ataaaaaaca cccttgtttc 463tacta 4685597PRTEquine influenza virus
H3N8 55Phe Ser Val Ile Phe Glu Arg Leu Glu Thr Leu Ile Leu Leu Arg
Ala1 5 10 15Phe Thr Glu Glu Gly Ala Val Val Gly Glu Ile Ser Pro Leu
Pro Ser20 25 30Leu Pro Gly His Thr Asn Glu Asp Val Lys Asn Ala Ile
Gly Val Leu35 40 45Ile Gly Gly Leu Lys Trp Asn Asp Asn Thr Val Arg
Ile Ser Glu Thr50 55 60Leu Gln Arg Phe Ala Arg Arg Ser Ser His Glu
Asn Gly Arg Pro Ser65 70 75 80Phe Pro Pro Lys Gln Lys Arg Lys Met
Glu Arg Thr Ile Glu Pro Glu85 90 95Val56293DNAEquine influenza
virus H3N8 56actttagtgt gattttcgaa aggctggaga cactaatact acttagagcc
ttcaccgaag 60aaggagcagt cgttggcgaa atttcaccat tgccttctct tccaggacat
actaatgagg 120atgtcaaaaa tgcaattggg gtcctcatcg gaggacttaa
atggaatgat aatacggtta 180gaatctctga aactctacag agattcgctc
ggagaagcag tcatgagaat gggagacctt 240cattccctcc aaagcagaaa
cgaaaaatgg agagaacaat tgagccagaa gtt 29357888DNAEquine influenza
virus H3N8CDS(27)..(716) 57agcaaaagca gggtgacaaa aacata atg gat tcc
aac act gtg tca agc ttt 53Met Asp Ser Asn Thr Val Ser Ser Phe1 5cag
gta gac tgt ttt ctt tgg cat gtc cgc aaa cga ttt gca gac caa 101Gln
Val Asp Cys Phe Leu Trp His Val Arg Lys Arg Phe Ala Asp Gln10 15 20
25gaa ctg ggt gat gcc cca ttc ctt gac cgg ctt cgc cga gac cag aag
149Glu Leu Gly Asp Ala Pro Phe Leu Asp Arg Leu Arg Arg Asp Gln
Lys30 35 40tcc cta aaa gga aga ggt agc act ctt ggt ctg gac atc gaa
aca gcc 197Ser Leu Lys Gly Arg Gly Ser Thr Leu Gly Leu Asp Ile Glu
Thr Ala45 50 55act cgt gca gga aag cag ata gtg gag cag att ctg gaa
gag gaa tca 245Thr Arg Ala Gly Lys Gln Ile Val Glu Gln Ile Leu Glu
Glu Glu Ser60 65 70gat gag gca ctt aaa atg acc att gcc tct gtt cct
gct tca cgc tac 293Asp Glu Ala Leu Lys Met Thr Ile Ala Ser Val Pro
Ala Ser Arg Tyr75 80 85tta act gac atg act ctt gat gag atg tca aga
gac tgg ttc atg ctc 341Leu Thr Asp Met Thr Leu Asp Glu Met Ser Arg
Asp Trp Phe Met Leu90 95 100 105atg ccc aag cag aaa gta aca ggc tcc
cta tgt ata aga atg gac cag 389Met Pro Lys Gln Lys Val Thr Gly Ser
Leu Cys Ile Arg Met Asp Gln110 115 120gca atc atg gat aag aac atc
ata ctt aaa gca aac ttt agt gtg att 437Ala Ile Met Asp Lys Asn Ile
Ile Leu Lys Ala Asn Phe Ser Val Ile125 130 135ttc gaa agg ctg gag
aca cta ata cta ctt aga gcc ttc acc gaa gaa 485Phe Glu Arg Leu Glu
Thr Leu Ile Leu Leu Arg Ala Phe Thr Glu Glu140 145 150gga gca gtc
gtt ggc gaa att tca cca ttg cct tct ctt cca gga cat 533Gly Ala Val
Val Gly Glu Ile Ser Pro Leu Pro Ser Leu Pro Gly His155 160 165act
aat gag gat gtc aaa aat gca att ggg gtc ctc atc gga gga ctt 581Thr
Asn Glu Asp Val Lys Asn Ala Ile Gly Val Leu Ile Gly Gly Leu170 175
180 185aaa tgg aat gat aat acg gtt aga atc tct gaa act cta cag aga
ttc 629Lys Trp Asn Asp Asn Thr Val Arg Ile Ser Glu Thr Leu Gln Arg
Phe190 195 200gct tgg aga agc agt cat gag aat ggg aga cct tca ttc
cct cca aag 677Ala Trp Arg Ser Ser His Glu Asn Gly Arg Pro Ser Phe
Pro Pro Lys205 210 215cag aaa cga aaa atg gag aga aca att gag cca
gaa gtt tgaagaaata 726Gln Lys Arg Lys Met Glu Arg Thr Ile Glu Pro
Glu Val220 225 230agatggttga ttgaagaagt gcgacataga ttgaaaaata
cagaaaatag ttttgaacaa 786ataacattta tgcaagcctt acaactattg
cttgaagtag aacaagagat aagaactttc 846tcgtttcagc ttatttaatg
ataaaaaaca cccttgtttc ta 88858230PRTEquine influenza virus H3N8
58Met Asp Ser Asn Thr Val Ser Ser Phe Gln Val Asp Cys Phe Leu Trp1
5 10 15His Val Arg Lys Arg Phe Ala Asp Gln Glu Leu Gly Asp Ala Pro
Phe20 25 30Leu Asp Arg Leu Arg Arg Asp Gln Lys Ser Leu Lys Gly Arg
Gly Ser35 40 45Thr Leu Gly Leu Asp Ile Glu Thr Ala Thr Arg Ala Gly
Lys Gln Ile50 55 60Val Glu Gln Ile Leu Glu Glu Glu Ser Asp Glu Ala
Leu Lys Met Thr65 70 75 80Ile Ala Ser Val Pro Ala Ser Arg Tyr Leu
Thr Asp Met Thr Leu Asp85 90 95Glu Met Ser Arg Asp Trp Phe Met Leu
Met Pro Lys Gln Lys Val Thr100 105 110Gly Ser Leu Cys Ile Arg Met
Asp Gln Ala Ile Met Asp Lys Asn Ile115 120 125Ile Leu Lys Ala Asn
Phe Ser Val Ile Phe Glu Arg Leu Glu Thr Leu130 135 140Ile Leu Leu
Arg Ala Phe Thr Glu Glu Gly Ala Val Val Gly Glu Ile145 150 155
160Ser Pro Leu Pro Ser Leu Pro Gly His Thr Asn Glu Asp Val Lys
Asn165 170 175Ala Ile Gly Val Leu Ile Gly Gly Leu Lys Trp Asn Asp
Asn Thr Val180 185 190Arg Ile Ser Glu Thr Leu Gln Arg Phe Ala Trp
Arg Ser Ser His Glu195 200 205Asn Gly Arg Pro Ser Phe Pro Pro Lys
Gln Lys Arg Lys Met Glu Arg210 215 220Thr Ile Glu Pro Glu Val225
23059690DNAEquine influenza virus H3N8 59atggattcca acactgtgtc
aagctttcag gtagactgtt ttctttggca tgtccgcaaa 60cgatttgcag accaagaact
gggtgatgcc ccattccttg accggcttcg ccgagaccag 120aagtccctaa
aaggaagagg tagcactctt ggtctggaca tcgaaacagc cactcgtgca
180ggaaagcaga tagtggagca gattctggaa gaggaatcag atgaggcact
taaaatgacc 240attgcctctg ttcctgcttc acgctactta actgacatga
ctcttgatga gatgtcaaga 300gactggttca tgctcatgcc caagcagaaa
gtaacaggct ccctatgtat aagaatggac 360caggcaatca tggataagaa
catcatactt aaagcaaact ttagtgtgat tttcgaaagg 420ctggagacac
taatactact tagagccttc accgaagaag gagcagtcgt tggcgaaatt
480tcaccattgc cttctcttcc aggacatact aatgaggatg tcaaaaatgc
aattggggtc 540ctcatcggag gacttaaatg gaatgataat acggttagaa
tctctgaaac tctacagaga 600ttcgcttgga gaagcagtca tgagaatggg
agaccttcat tccctccaaa gcagaaacga 660aaaatggaga gaacaattga
gccagaagtt 6906021DNAArtificialSynthetic Primer 60agcaaagcag
gtgacaaaaa c 216119DNAArtificialSynthetic Primer 61agtagaaaca
agggtgttt 19621229DNAEquine influenza virus H3N8CDS(36)..(1229)
62gaattcggct tagcaaaagc aggcaaacta tttga atg gat gtc aat ccg act
53Met Asp Val Asn Pro Thr1 5cta ctc ttc tta aag gtg cca gcg caa aat
gct ata agc aca aca ttc 101Leu Leu Phe Leu Lys Val Pro Ala Gln Asn
Ala Ile Ser Thr Thr Phe10 15 20cct tat act gga gat cct ccc tac agt
cat gga aca ggg aca gga tac 149Pro Tyr Thr Gly Asp Pro Pro Tyr Ser
His Gly Thr Gly Thr Gly Tyr25 30 35acc atg gat act gtc aac aga aca
cat caa tac tca gaa aag ggg aaa 197Thr Met Asp Thr Val Asn Arg Thr
His Gln Tyr Ser Glu Lys Gly Lys40 45 50tgg aca aca aac act gag att
gga gca cca caa ctt aat cca atc gat 245Trp Thr Thr Asn Thr Glu Ile
Gly Ala Pro Gln Leu Asn Pro Ile Asp55 60 65 70gga ccg ctt cct gaa
gac aat gaa cca agt ggg tac gcc caa aca gat 293Gly Pro Leu Pro Glu
Asp Asn Glu Pro Ser Gly Tyr Ala Gln Thr Asp75 80 85tgt gta ttg gaa
gca atg gct ttc ctt gaa gaa tcc cat ccc gga atc 341Cys Val Leu Glu
Ala Met Ala Phe Leu Glu Glu Ser His Pro Gly Ile90 95 100ttt gaa aat
tcg tgt ctt gaa aca atg gag gtg gtt cag cag aca aga 389Phe Glu Asn
Ser Cys Leu Glu Thr Met Glu Val Val Gln Gln Thr Arg105 110 115gtg
gac aaa cta aca caa ggc cga caa act tac gat tgg acc ttg aat 437Val
Asp Lys Leu Thr Gln Gly Arg Gln Thr Tyr Asp Trp Thr Leu Asn120 125
130agg aat caa cct gcc gca aca gca ctt gct aat aca att gaa gtg ttc
485Arg Asn Gln Pro Ala Ala Thr Ala Leu Ala Asn Thr Ile Glu Val
Phe135 140 145 150aga tca aat gat ctg act tcc agt gag tca ggg aga
tta atg gac ttc 533Arg Ser Asn Asp Leu Thr Ser Ser Glu Ser Gly Arg
Leu Met Asp Phe155 160 165ctc aaa gat gtc atg gag tcc atg aac aag
gaa gaa atg gaa ata aca 581Leu Lys Asp Val Met Glu Ser Met Asn Lys
Glu
Glu Met Glu Ile Thr170 175 180aca cac ttc caa cgg aag aga aga gta
aga gac aac atg aca aag aga 629Thr His Phe Gln Arg Lys Arg Arg Val
Arg Asp Asn Met Thr Lys Arg185 190 195atg gtg aca cag aga acc ata
ggg aag aaa aaa caa cga tta aac aga 677Met Val Thr Gln Arg Thr Ile
Gly Lys Lys Lys Gln Arg Leu Asn Arg200 205 210aag agc tat ctg atc
agg gca tta acc tta aac aca atg acc aag gac 725Lys Ser Tyr Leu Ile
Arg Ala Leu Thr Leu Asn Thr Met Thr Lys Asp215 220 225 230gct gag
aga ggg aaa ttg aaa cga cga gca att gca acc cca gga atg 773Ala Glu
Arg Gly Lys Leu Lys Arg Arg Ala Ile Ala Thr Pro Gly Met235 240
245cag ata aga ggg ttt gta tat ttt gtt gaa aca tta gcc cga aga ata
821Gln Ile Arg Gly Phe Val Tyr Phe Val Glu Thr Leu Ala Arg Arg
Ile250 255 260tgt gaa aag ctt gaa caa tca gga ttg cca gtt ggc ggt
aat gag aaa 869Cys Glu Lys Leu Glu Gln Ser Gly Leu Pro Val Gly Gly
Asn Glu Lys265 270 275aag gcc aaa ctg gct aat gtc gtc aga aaa atg
atg act aat tcc caa 917Lys Ala Lys Leu Ala Asn Val Val Arg Lys Met
Met Thr Asn Ser Gln280 285 290gac act gaa ctc tcc ttc acc atc act
ggg gac aat acc aaa tgg aat 965Asp Thr Glu Leu Ser Phe Thr Ile Thr
Gly Asp Asn Thr Lys Trp Asn295 300 305 310gaa aat cag aac cca cgc
atg ttc ctg gca atg atc aca tac ata act 1013Glu Asn Gln Asn Pro Arg
Met Phe Leu Ala Met Ile Thr Tyr Ile Thr315 320 325aga aac cag cca
gaa tgg ttc aga aat gtt cta agc att gca ccg att 1061Arg Asn Gln Pro
Glu Trp Phe Arg Asn Val Leu Ser Ile Ala Pro Ile330 335 340atg ttc
tca aat aaa atg gca aga ctg ggg aaa gga tat atg ttt gaa 1109Met Phe
Ser Asn Lys Met Ala Arg Leu Gly Lys Gly Tyr Met Phe Glu345 350
355agc aaa agt atg aaa ttg aga act caa ata cca gca gaa atg ctc gca
1157Ser Lys Ser Met Lys Leu Arg Thr Gln Ile Pro Ala Glu Met Leu
Ala360 365 370agc att gat ctg aaa tat ttc aat gat tca aca aaa aag
aaa att gag 1205Ser Ile Asp Leu Lys Tyr Phe Asn Asp Ser Thr Lys Lys
Lys Ile Glu375 380 385 390aag ata cga cca caa gcc gaa ttc 1229Lys
Ile Arg Pro Gln Ala Glu Phe39563398PRTEquine influenza virus H3N8
63Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val Pro Ala Gln Asn1
5 10 15Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp Pro Pro Tyr Ser
His20 25 30Gly Thr Gly Thr Gly Tyr Thr Met Asp Thr Val Asn Arg Thr
His Gln35 40 45Tyr Ser Glu Lys Gly Lys Trp Thr Thr Asn Thr Glu Ile
Gly Ala Pro50 55 60Gln Leu Asn Pro Ile Asp Gly Pro Leu Pro Glu Asp
Asn Glu Pro Ser65 70 75 80Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu
Ala Met Ala Phe Leu Glu85 90 95Glu Ser His Pro Gly Ile Phe Glu Asn
Ser Cys Leu Glu Thr Met Glu100 105 110Val Val Gln Gln Thr Arg Val
Asp Lys Leu Thr Gln Gly Arg Gln Thr115 120 125Tyr Asp Trp Thr Leu
Asn Arg Asn Gln Pro Ala Ala Thr Ala Leu Ala130 135 140Asn Thr Ile
Glu Val Phe Arg Ser Asn Asp Leu Thr Ser Ser Glu Ser145 150 155
160Gly Arg Leu Met Asp Phe Leu Lys Asp Val Met Glu Ser Met Asn
Lys165 170 175Glu Glu Met Glu Ile Thr Thr His Phe Gln Arg Lys Arg
Arg Val Arg180 185 190Asp Asn Met Thr Lys Arg Met Val Thr Gln Arg
Thr Ile Gly Lys Lys195 200 205Lys Gln Arg Leu Asn Arg Lys Ser Tyr
Leu Ile Arg Ala Leu Thr Leu210 215 220Asn Thr Met Thr Lys Asp Ala
Glu Arg Gly Lys Leu Lys Arg Arg Ala225 230 235 240Ile Ala Thr Pro
Gly Met Gln Ile Arg Gly Phe Val Tyr Phe Val Glu245 250 255Thr Leu
Ala Arg Arg Ile Cys Glu Lys Leu Glu Gln Ser Gly Leu Pro260 265
270Val Gly Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val Val Arg
Lys275 280 285Met Met Thr Asn Ser Gln Asp Thr Glu Leu Ser Phe Thr
Ile Thr Gly290 295 300Asp Asn Thr Lys Trp Asn Glu Asn Gln Asn Pro
Arg Met Phe Leu Ala305 310 315 320Met Ile Thr Tyr Ile Thr Arg Asn
Gln Pro Glu Trp Phe Arg Asn Val325 330 335Leu Ser Ile Ala Pro Ile
Met Phe Ser Asn Lys Met Ala Arg Leu Gly340 345 350Lys Gly Tyr Met
Phe Glu Ser Lys Ser Met Lys Leu Arg Thr Gln Ile355 360 365Pro Ala
Glu Met Leu Ala Ser Ile Asp Leu Lys Tyr Phe Asn Asp Ser370 375
380Thr Lys Lys Lys Ile Glu Lys Ile Arg Pro Gln Ala Glu Phe385 390
395641194DNAEquine influenza virus H3N8 64atggatgtca atccgactct
actcttctta aaggtgccag cgcaaaatgc tataagcaca 60acattccctt atactggaga
tcctccctac agtcatggaa cagggacagg atacaccatg 120gatactgtca
acagaacaca tcaatactca gaaaagggga aatggacaac aaacactgag
180attggagcac cacaacttaa tccaatcgat ggaccgcttc ctgaagacaa
tgaaccaagt 240gggtacgccc aaacagattg tgtattggaa gcaatggctt
tccttgaaga atcccatccc 300ggaatctttg aaaattcgtg tcttgaaaca
atggaggtgg ttcagcagac aagagtggac 360aaactaacac aaggccgaca
aacttacgat tggaccttga ataggaatca acctgccgca 420acagcacttg
ctaatacaat tgaagtgttc agatcaaatg atctgacttc cagtgagtca
480gggagattaa tggacttcct caaagatgtc atggagtcca tgaacaagga
agaaatggaa 540ataacaacac acttccaacg gaagagaaga gtaagagaca
acatgacaaa gagaatggtg 600acacagagaa ccatagggaa gaaaaaacaa
cgattaaaca gaaagagcta tctgatcagg 660gcattaacct taaacacaat
gaccaaggac gctgagagag ggaaattgaa acgacgagca 720attgcaaccc
caggaatgca gataagaggg tttgtatatt ttgttgaaac attagcccga
780agaatatgtg aaaagcttga acaatcagga ttgccagttg gcggtaatga
gaaaaaggcc 840aaactggcta atgtcgtcag aaaaatgatg actaattccc
aagacactga actctccttc 900accatcactg gggacaatac caaatggaat
gaaaatcaga acccacgcat gttcctggca 960atgatcacat acataactag
aaaccagcca gaatggttca gaaatgttct aagcattgca 1020ccgattatgt
tctcaaataa aatggcaaga ctggggaaag gatatatgtt tgaaagcaaa
1080agtatgaaat tgagaactca aataccagca gaaatgctcg caagcattga
tctgaaatat 1140ttcaatgatt caacaaaaaa gaaaattgag aagatacgac
cacaagccga attc 119465673DNAEquine influenza virus
H3N8CDS(36)..(671) 65gaattcggct tagcaaaagc aggcaaacta tttga atg gat
gtc aat ccg act 53Met Asp Val Asn Pro Thr1 5cta ctc ttc tta aag gtg
cca gcg caa aat gct ata agc aca aca ttc 101Leu Leu Phe Leu Lys Val
Pro Ala Gln Asn Ala Ile Ser Thr Thr Phe10 15 20cct tat act gga gat
cct ccc tac agt cat gga aca ggg aca gga tac 149Pro Tyr Thr Gly Asp
Pro Pro Tyr Ser His Gly Thr Gly Thr Gly Tyr25 30 35acc atg gat act
gtc aac aga aca cat caa tac tca gaa aag ggg aaa 197Thr Met Asp Thr
Val Asn Arg Thr His Gln Tyr Ser Glu Lys Gly Lys40 45 50tgg aca aca
aac act gag att gga gca cca caa ctt aat cca atc gat 245Trp Thr Thr
Asn Thr Glu Ile Gly Ala Pro Gln Leu Asn Pro Ile Asp55 60 65 70gga
ccg ctt cct gaa gac aat gaa cca agt ggg tac gcc caa aca gat 293Gly
Pro Leu Pro Glu Asp Asn Glu Pro Ser Gly Tyr Ala Gln Thr Asp75 80
85tgt gta ttg gaa gca atg gct ttc ctt gaa gaa tcc cat ccc gga atc
341Cys Val Leu Glu Ala Met Ala Phe Leu Glu Glu Ser His Pro Gly
Ile90 95 100ttt gaa aat tcg tgt ctt gaa aca atg gag gtg gtt cag cag
aca aga 389Phe Glu Asn Ser Cys Leu Glu Thr Met Glu Val Val Gln Gln
Thr Arg105 110 115gtg gac aaa cta aca caa ggc cga caa act tac gat
tgg acc ttg aat 437Val Asp Lys Leu Thr Gln Gly Arg Gln Thr Tyr Asp
Trp Thr Leu Asn120 125 130agg aat caa cct gcc gca aca gca ctt gct
aat aca att gaa gtg ttc 485Arg Asn Gln Pro Ala Ala Thr Ala Leu Ala
Asn Thr Ile Glu Val Phe135 140 145 150aga tca aat gat ctg act tcc
agt gag tca ggg aga tta atg gac ttc 533Arg Ser Asn Asp Leu Thr Ser
Ser Glu Ser Gly Arg Leu Met Asp Phe155 160 165ctc aaa gat gtc atg
gag tcc atg aac aag gaa gaa atg gaa ata aca 581Leu Lys Asp Val Met
Glu Ser Met Asn Lys Glu Glu Met Glu Ile Thr170 175 180aca cac ttc
caa cgg aag aga aga gta aga gac aac atg aca aag aga 629Thr His Phe
Gln Arg Lys Arg Arg Val Arg Asp Asn Met Thr Lys Arg185 190 195atg
gtg aca cag aga acc ata ggg aag aaa aaa caa cga tta aa 673Met Val
Thr Gln Arg Thr Ile Gly Lys Lys Lys Gln Arg Leu200 205
21066212PRTEquine influenza virus H3N8 66Met Asp Val Asn Pro Thr
Leu Leu Phe Leu Lys Val Pro Ala Gln Asn1 5 10 15Ala Ile Ser Thr Thr
Phe Pro Tyr Thr Gly Asp Pro Pro Tyr Ser His20 25 30Gly Thr Gly Thr
Gly Tyr Thr Met Asp Thr Val Asn Arg Thr His Gln35 40 45Tyr Ser Glu
Lys Gly Lys Trp Thr Thr Asn Thr Glu Ile Gly Ala Pro50 55 60Gln Leu
Asn Pro Ile Asp Gly Pro Leu Pro Glu Asp Asn Glu Pro Ser65 70 75
80Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu Ala Met Ala Phe Leu Glu85
90 95Glu Ser His Pro Gly Ile Phe Glu Asn Ser Cys Leu Glu Thr Met
Glu100 105 110Val Val Gln Gln Thr Arg Val Asp Lys Leu Thr Gln Gly
Arg Gln Thr115 120 125Tyr Asp Trp Thr Leu Asn Arg Asn Gln Pro Ala
Ala Thr Ala Leu Ala130 135 140Asn Thr Ile Glu Val Phe Arg Ser Asn
Asp Leu Thr Ser Ser Glu Ser145 150 155 160Gly Arg Leu Met Asp Phe
Leu Lys Asp Val Met Glu Ser Met Asn Lys165 170 175Glu Glu Met Glu
Ile Thr Thr His Phe Gln Arg Lys Arg Arg Val Arg180 185 190Asp Asn
Met Thr Lys Arg Met Val Thr Gln Arg Thr Ile Gly Lys Lys195 200
205Lys Gln Arg Leu21067636DNAEquine influenza virus H3N8
67atggatgtca atccgactct actcttctta aaggtgccag cgcaaaatgc tataagcaca
60acattccctt atactggaga tcctccctac agtcatggaa cagggacagg atacaccatg
120gatactgtca acagaacaca tcaatactca gaaaagggga aatggacaac
aaacactgag 180attggagcac cacaacttaa tccaatcgat ggaccgcttc
ctgaagacaa tgaaccaagt 240gggtacgccc aaacagattg tgtattggaa
gcaatggctt tccttgaaga atcccatccc 300ggaatctttg aaaattcgtg
tcttgaaaca atggaggtgg ttcagcagac aagagtggac 360aaactaacac
aaggccgaca aacttacgat tggaccttga ataggaatca acctgccgca
420acagcacttg ctaatacaat tgaagtgttc agatcaaatg atctgacttc
cagtgagtca 480gggagattaa tggacttcct caaagatgtc atggagtcca
tgaacaagga agaaatggaa 540ataacaacac acttccaacg gaagagaaga
gtaagagaca acatgacaaa gagaatggtg 600acacagagaa ccatagggaa
gaaaaaacaa cgatta 636681225DNAEquine influenza virus
H3N8CDS(34)..(1218) 68gaattcagga gcaaaagcag gcaaactatt tga atg gat
gtc aat ccg act cta 54Met Asp Val Asn Pro Thr Leu1 5ctc ttc tta aag
gtg cca gcg caa aat gct ata agc aca aca ttc cct 102Leu Phe Leu Lys
Val Pro Ala Gln Asn Ala Ile Ser Thr Thr Phe Pro10 15 20tat act gga
gat cct ccc tac agt cat gga aca ggg aca gga tac acc 150Tyr Thr Gly
Asp Pro Pro Tyr Ser His Gly Thr Gly Thr Gly Tyr Thr25 30 35atg gat
act gtc aac aga aca cat caa tac tca gaa aag ggg aaa tgg 198Met Asp
Thr Val Asn Arg Thr His Gln Tyr Ser Glu Lys Gly Lys Trp40 45 50
55aca aca aac act gag att gga gca cca caa ctt aat cca atc gat gga
246Thr Thr Asn Thr Glu Ile Gly Ala Pro Gln Leu Asn Pro Ile Asp
Gly60 65 70ccg ctt cct gaa gac aat gaa cca agt ggg tac gcc caa aca
gat tgt 294Pro Leu Pro Glu Asp Asn Glu Pro Ser Gly Tyr Ala Gln Thr
Asp Cys75 80 85gta ttg gaa gca atg gct ttc ctt gaa gaa tcc cat ccc
gga atc ttt 342Val Leu Glu Ala Met Ala Phe Leu Glu Glu Ser His Pro
Gly Ile Phe90 95 100gaa aat tcg tgt ctt gaa aca atg gag gtg gtt cag
cag aca aga gtg 390Glu Asn Ser Cys Leu Glu Thr Met Glu Val Val Gln
Gln Thr Arg Val105 110 115gac aaa cta aca caa ggc cga caa act tac
gat tgg acc ttg aat agg 438Asp Lys Leu Thr Gln Gly Arg Gln Thr Tyr
Asp Trp Thr Leu Asn Arg120 125 130 135aat caa cct gcc gca aca gca
ctt gct aat aca att gaa gtg ttc aga 486Asn Gln Pro Ala Ala Thr Ala
Leu Ala Asn Thr Ile Glu Val Phe Arg140 145 150tca aat gat ctg act
tcc agt gag tca ggg aga tta atg gac ttc ctc 534Ser Asn Asp Leu Thr
Ser Ser Glu Ser Gly Arg Leu Met Asp Phe Leu155 160 165aaa gat gtc
atg gag tcc atg aac aag gaa gaa atg gaa ata aca aca 582Lys Asp Val
Met Glu Ser Met Asn Lys Glu Glu Met Glu Ile Thr Thr170 175 180cac
ttc caa cgg aag aga aga gta aga gac aac atg aca aag aga atg 630His
Phe Gln Arg Lys Arg Arg Val Arg Asp Asn Met Thr Lys Arg Met185 190
195gtg aca cag aga acc ata ggg aag aaa aaa caa cga tta aac aga aag
678Val Thr Gln Arg Thr Ile Gly Lys Lys Lys Gln Arg Leu Asn Arg
Lys200 205 210 215agc tat ctg atc agg gca tta acc tta aac aca atg
acc aag gac gct 726Ser Tyr Leu Ile Arg Ala Leu Thr Leu Asn Thr Met
Thr Lys Asp Ala220 225 230gag aga ggg aaa ttg aaa cga cga gca att
gca acc cca gga atg cag 774Glu Arg Gly Lys Leu Lys Arg Arg Ala Ile
Ala Thr Pro Gly Met Gln235 240 245ata aga ggg ttt gta tat ttt gtt
gaa aca tta gcc cga aga ata tgt 822Ile Arg Gly Phe Val Tyr Phe Val
Glu Thr Leu Ala Arg Arg Ile Cys250 255 260gaa aag ctt gaa caa tca
gga ttg cca gtt ggc ggt aat gag aaa aag 870Glu Lys Leu Glu Gln Ser
Gly Leu Pro Val Gly Gly Asn Glu Lys Lys265 270 275gcc aaa ctg gct
aat gtc gtc aga aaa atg atg act aat tcc caa gac 918Ala Lys Leu Ala
Asn Val Val Arg Lys Met Met Thr Asn Ser Gln Asp280 285 290 295act
gaa ctc tcc ttc acc atc act ggg gac aat acc aaa tgg aat gaa 966Thr
Glu Leu Ser Phe Thr Ile Thr Gly Asp Asn Thr Lys Trp Asn Glu300 305
310aat cag aac cca cgc atg ttc ctg gca atg atc aca tac ata act aga
1014Asn Gln Asn Pro Arg Met Phe Leu Ala Met Ile Thr Tyr Ile Thr
Arg315 320 325aac cag cca gaa tgg ttc aga aat gtt cta agc att gca
ccg att atg 1062Asn Gln Pro Glu Trp Phe Arg Asn Val Leu Ser Ile Ala
Pro Ile Met330 335 340ttc tca aat aaa atg gca aga ctg ggg aaa gga
tat atg ttt gaa agc 1110Phe Ser Asn Lys Met Ala Arg Leu Gly Lys Gly
Tyr Met Phe Glu Ser345 350 355aaa agt atg aaa ttg aga act caa ata
cca gca gaa atg ctc gca agc 1158Lys Ser Met Lys Leu Arg Thr Gln Ile
Pro Ala Glu Met Leu Ala Ser360 365 370 375att gat ctg aaa tat ttc
aat gat tca aca aaa aag aaa att gag aag 1206Ile Asp Leu Lys Tyr Phe
Asn Asp Ser Thr Lys Lys Lys Ile Glu Lys380 385 390ata cga cca ccc
tgaattc 1225Ile Arg Pro Pro39569395PRTEquine influenza virus H3N8
69Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val Pro Ala Gln Asn1
5 10 15Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp Pro Pro Tyr Ser
His20 25 30Gly Thr Gly Thr Gly Tyr Thr Met Asp Thr Val Asn Arg Thr
His Gln35 40 45Tyr Ser Glu Lys Gly Lys Trp Thr Thr Asn Thr Glu Ile
Gly Ala Pro50 55 60Gln Leu Asn Pro Ile Asp Gly Pro Leu Pro Glu Asp
Asn Glu Pro Ser65 70 75 80Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu
Ala Met Ala Phe Leu Glu85 90 95Glu Ser His Pro Gly Ile Phe Glu Asn
Ser Cys Leu Glu Thr Met Glu100 105 110Val Val Gln Gln Thr Arg Val
Asp Lys Leu Thr Gln Gly Arg Gln Thr115 120 125Tyr Asp Trp Thr Leu
Asn Arg Asn Gln Pro Ala Ala Thr Ala Leu Ala130 135 140Asn Thr Ile
Glu Val Phe Arg Ser Asn Asp Leu Thr Ser Ser Glu Ser145 150 155
160Gly Arg Leu Met Asp Phe Leu Lys Asp Val Met Glu Ser Met Asn
Lys165 170 175Glu Glu Met Glu Ile Thr Thr His Phe Gln Arg Lys Arg
Arg Val Arg180 185 190Asp Asn Met Thr Lys Arg Met Val Thr Gln Arg
Thr Ile Gly Lys Lys195 200 205Lys Gln Arg Leu Asn Arg Lys Ser Tyr
Leu Ile Arg Ala Leu Thr Leu210 215 220Asn Thr Met Thr Lys Asp Ala
Glu Arg Gly Lys Leu Lys Arg Arg Ala225 230 235 240Ile Ala Thr Pro
Gly Met Gln Ile Arg Gly Phe Val Tyr Phe Val Glu245 250 255Thr Leu
Ala Arg Arg Ile Cys Glu Lys Leu Glu Gln Ser Gly Leu Pro260 265
270Val Gly Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val Val Arg
Lys275
280 285Met Met Thr Asn Ser Gln Asp Thr Glu Leu Ser Phe Thr Ile Thr
Gly290 295 300Asp Asn Thr Lys Trp Asn Glu Asn Gln Asn Pro Arg Met
Phe Leu Ala305 310 315 320Met Ile Thr Tyr Ile Thr Arg Asn Gln Pro
Glu Trp Phe Arg Asn Val325 330 335Leu Ser Ile Ala Pro Ile Met Phe
Ser Asn Lys Met Ala Arg Leu Gly340 345 350Lys Gly Tyr Met Phe Glu
Ser Lys Ser Met Lys Leu Arg Thr Gln Ile355 360 365Pro Ala Glu Met
Leu Ala Ser Ile Asp Leu Lys Tyr Phe Asn Asp Ser370 375 380Thr Lys
Lys Lys Ile Glu Lys Ile Arg Pro Pro385 390 395701185DNAEquine
influenza virus H3N8 70atggatgtca atccgactct actcttctta aaggtgccag
cgcaaaatgc tataagcaca 60acattccctt atactggaga tcctccctac agtcatggaa
cagggacagg atacaccatg 120gatactgtca acagaacaca tcaatactca
gaaaagggga aatggacaac aaacactgag 180attggagcac cacaacttaa
tccaatcgat ggaccgcttc ctgaagacaa tgaaccaagt 240gggtacgccc
aaacagattg tgtattggaa gcaatggctt tccttgaaga atcccatccc
300ggaatctttg aaaattcgtg tcttgaaaca atggaggtgg ttcagcagac
aagagtggac 360aaactaacac aaggccgaca aacttacgat tggaccttga
ataggaatca acctgccgca 420acagcacttg ctaatacaat tgaagtgttc
agatcaaatg atctgacttc cagtgagtca 480gggagattaa tggacttcct
caaagatgtc atggagtcca tgaacaagga agaaatggaa 540ataacaacac
acttccaacg gaagagaaga gtaagagaca acatgacaaa gagaatggtg
600acacagagaa ccatagggaa gaaaaaacaa cgattaaaca gaaagagcta
tctgatcagg 660gcattaacct taaacacaat gaccaaggac gctgagagag
ggaaattgaa acgacgagca 720attgcaaccc caggaatgca gataagaggg
tttgtatatt ttgttgaaac attagcccga 780agaatatgtg aaaagcttga
acaatcagga ttgccagttg gcggtaatga gaaaaaggcc 840aaactggcta
atgtcgtcag aaaaatgatg actaattccc aagacactga actctccttc
900accatcactg gggacaatac caaatggaat gaaaatcaga acccacgcat
gttcctggca 960atgatcacat acataactag aaaccagcca gaatggttca
gaaatgttct aagcattgca 1020ccgattatgt tctcaaataa aatggcaaga
ctggggaaag gatatatgtt tgaaagcaaa 1080agtatgaaat tgagaactca
aataccagca gaaatgctcg caagcattga tctgaaatat 1140ttcaatgatt
caacaaaaaa gaaaattgag aagatacgac caccc 1185711221DNAEquine
influenza virus H3N8 71gaattcagga aagcaggcaa actatttgaa tggatgtcaa
tccgactcta ctcttcttaa 60aggtgccagc gcaaaatgct ataagcacaa cattccctta
tactggagat cctccctaca 120gtcatggaac agggacagga tacaccatgg
atactgtcaa cagaacacat caatactcag 180aaaaggggaa atggacaaca
aacactgaga ttggagcacc acaacttaat ccaatcgatg 240gaccgcttcc
tgaagacaat gaaccaagtg ggtacgccca aacagattgt gtattggaag
300caatggcttt ccttgaagaa tcccatcccg gaatctttga aaattcgtgt
cttgaaacaa 360tggaggtggt tcagcagaca agagtggaca aactaacaca
aggccgacaa acttacgatt 420ggaccttgaa taggaatcaa cctgccgcaa
cagcacttgc taatacaatt gaagtgttca 480gatcaaatga tctgacttcc
agtgagtcag ggagattaat ggacttcctc aaagatgtca 540tggagtccat
gaacaaggaa gaaatggaaa taacaacaca cttccaacgg aagagaagag
600taagagacaa catgacaaag agaatggtga cacagagaac catagggaag
aaaaaacaac 660gattaaacag aaagagctat ctgatcaggg cattaacctt
aaacacaatg accaaggacg 720ctgagagagg gaaattgaaa cgacgagcaa
ttgcaacccc aggaatgcag ataagagggt 780ttgtatattt tgttgaaaca
ttagcccgaa gaatatgtga aaagcttgaa caatcaggat 840tgccagttgg
cggtaatgag aaaaaggcca aactggctaa tgtcgtcaga aaaatgatga
900ctaattccca agacactgaa ctctccttca ccatcactgg ggacaatacc
aaatggaatg 960aaaatcagaa cccacgcatg ttcctggcaa tgatcacata
cataactaga aaccagccag 1020aatggttcag aaatgttcta agcattgcac
cgattatgtt ctcaaataaa atggcaagac 1080tggggaaagg atatatgttt
gaaagcaaaa gtatgaaatt gagaactcaa ataccagcag 1140aaatgctcgc
aagcattgat ctgaaatatt tcaatgattc aacaaaaaag aaaattgaga
1200agatacgacc accctgaatt c 12217218DNAArtificialSynthetic Primer
72gcaaatgcag gaccaaag 187318DNAArtificialSynthetic Primer
73gactgaggac tcagcttc 187419DNAArtificialSynthetic Primer
74caatatcctc cccaatttc 197519DNAArtificialSynthetic Primer
75ggaaggtttg caggacctt 19761228DNAEquine influenza virus
H3N8CDS(3)..(1166) 76gg ggc ggg tac cca aac tat ctc caa gct tgg aag
caa gta tta gca 47Gly Gly Tyr Pro Asn Tyr Leu Gln Ala Trp Lys Gln
Val Leu Ala1 5 10 15gaa cta caa gac ctt gag aac gaa gaa aag acc cct
aag acc aag aat 95Glu Leu Gln Asp Leu Glu Asn Glu Glu Lys Thr Pro
Lys Thr Lys Asn20 25 30atg aaa aaa aca agc caa ttg aaa tgg gca ctc
ggt gaa aat atg gca 143Met Lys Lys Thr Ser Gln Leu Lys Trp Ala Leu
Gly Glu Asn Met Ala35 40 45cca gag aaa gtg gat ttt gag gat tgt aaa
gac atc aat gat ttg aaa 191Pro Glu Lys Val Asp Phe Glu Asp Cys Lys
Asp Ile Asn Asp Leu Lys50 55 60cag tat gac agt gat gag cca gaa aca
agg tct ctt gca agt tgg att 239Gln Tyr Asp Ser Asp Glu Pro Glu Thr
Arg Ser Leu Ala Ser Trp Ile65 70 75caa agt gag ttc aac aaa gct tgt
gag ctg aca gat tca agc tgg ata 287Gln Ser Glu Phe Asn Lys Ala Cys
Glu Leu Thr Asp Ser Ser Trp Ile80 85 90 95gag ctc gat gaa att ggg
gag gat att gcc cca ata gaa tac att gcg 335Glu Leu Asp Glu Ile Gly
Glu Asp Ile Ala Pro Ile Glu Tyr Ile Ala100 105 110agc atg agg aga
aat tat ttt act gct gag gtt tcc cat tgt aga gca 383Ser Met Arg Arg
Asn Tyr Phe Thr Ala Glu Val Ser His Cys Arg Ala115 120 125aca gaa
tat ata atg aag gga gtg tac atc aac act gct cta ctc aat 431Thr Glu
Tyr Ile Met Lys Gly Val Tyr Ile Asn Thr Ala Leu Leu Asn130 135
140gca tcc tgt gct gcg atg gat gaa ttc caa tta att ccg atg ata agc
479Ala Ser Cys Ala Ala Met Asp Glu Phe Gln Leu Ile Pro Met Ile
Ser145 150 155aaa tgc agg acc aaa gaa ggg aga agg aag aca aat tta
tat gga ttc 527Lys Cys Arg Thr Lys Glu Gly Arg Arg Lys Thr Asn Leu
Tyr Gly Phe160 165 170 175ata ata aag gga agg tcc cat tta agg aat
gat acc gac gtg gta aac 575Ile Ile Lys Gly Arg Ser His Leu Arg Asn
Asp Thr Asp Val Val Asn180 185 190ttt gta agt atg gaa ttt tct ctc
act gat cca aga ttt gag cca cat 623Phe Val Ser Met Glu Phe Ser Leu
Thr Asp Pro Arg Phe Glu Pro His195 200 205aaa tgg gaa aaa tac tgc
gtt cta gaa att gga gac atg ctc cta agg 671Lys Trp Glu Lys Tyr Cys
Val Leu Glu Ile Gly Asp Met Leu Leu Arg210 215 220act gct gta ggt
caa gtg tca aga ccc atg ttt ttg tat gta agg aca 719Thr Ala Val Gly
Gln Val Ser Arg Pro Met Phe Leu Tyr Val Arg Thr225 230 235aat gga
acc tct aaa att aaa atg aaa cgg gga atg gaa atg aga cgc 767Asn Gly
Thr Ser Lys Ile Lys Met Lys Arg Gly Met Glu Met Arg Arg240 245 250
255tgc ctc ctt cag tct ctg caa cag att gaa agc atg atc gaa gct gag
815Cys Leu Leu Gln Ser Leu Gln Gln Ile Glu Ser Met Ile Glu Ala
Glu260 265 270tcc tca gtc aaa gaa aag gac atg acc aaa gaa ttc ttt
gag aac aaa 863Ser Ser Val Lys Glu Lys Asp Met Thr Lys Glu Phe Phe
Glu Asn Lys275 280 285tca gag aca tgg cct ata gga gag tcc ccc aaa
gga gtg gaa gag ggc 911Ser Glu Thr Trp Pro Ile Gly Glu Ser Pro Lys
Gly Val Glu Glu Gly290 295 300tca atc ggg aag gtt tgc agg acc tta
tta gca aaa tct gtg ttt aac 959Ser Ile Gly Lys Val Cys Arg Thr Leu
Leu Ala Lys Ser Val Phe Asn305 310 315agt ttg tat gca tct cca caa
ctg gaa ggg ttt tca gct gaa tct agg 1007Ser Leu Tyr Ala Ser Pro Gln
Leu Glu Gly Phe Ser Ala Glu Ser Arg320 325 330 335aaa tta ctt ctc
att gtt cag gcc ctt agg gat aac ctg gaa cct gga 1055Lys Leu Leu Leu
Ile Val Gln Ala Leu Arg Asp Asn Leu Glu Pro Gly340 345 350acc ttt
gat att ggg ggg tta tat gaa tca att gag gag tgc ctg att 1103Thr Phe
Asp Ile Gly Gly Leu Tyr Glu Ser Ile Glu Glu Cys Leu Ile355 360
365aat gat ccc tgg gtt ttg ctc aat gca tct tgg ttc aac tcc ttc ctt
1151Asn Asp Pro Trp Val Leu Leu Asn Ala Ser Trp Phe Asn Ser Phe
Leu370 375 380aca cat gca ctg aag tagttgtagc aatgctacta tttgctatcc
atactgtcca 1206Thr His Ala Leu Lys385aaaaagtact cgagccccca ag
122877388PRTEquine influenza virus H3N8 77Gly Gly Tyr Pro Asn Tyr
Leu Gln Ala Trp Lys Gln Val Leu Ala Glu1 5 10 15Leu Gln Asp Leu Glu
Asn Glu Glu Lys Thr Pro Lys Thr Lys Asn Met20 25 30Lys Lys Thr Ser
Gln Leu Lys Trp Ala Leu Gly Glu Asn Met Ala Pro35 40 45Glu Lys Val
Asp Phe Glu Asp Cys Lys Asp Ile Asn Asp Leu Lys Gln50 55 60Tyr Asp
Ser Asp Glu Pro Glu Thr Arg Ser Leu Ala Ser Trp Ile Gln65 70 75
80Ser Glu Phe Asn Lys Ala Cys Glu Leu Thr Asp Ser Ser Trp Ile Glu85
90 95Leu Asp Glu Ile Gly Glu Asp Ile Ala Pro Ile Glu Tyr Ile Ala
Ser100 105 110Met Arg Arg Asn Tyr Phe Thr Ala Glu Val Ser His Cys
Arg Ala Thr115 120 125Glu Tyr Ile Met Lys Gly Val Tyr Ile Asn Thr
Ala Leu Leu Asn Ala130 135 140Ser Cys Ala Ala Met Asp Glu Phe Gln
Leu Ile Pro Met Ile Ser Lys145 150 155 160Cys Arg Thr Lys Glu Gly
Arg Arg Lys Thr Asn Leu Tyr Gly Phe Ile165 170 175Ile Lys Gly Arg
Ser His Leu Arg Asn Asp Thr Asp Val Val Asn Phe180 185 190Val Ser
Met Glu Phe Ser Leu Thr Asp Pro Arg Phe Glu Pro His Lys195 200
205Trp Glu Lys Tyr Cys Val Leu Glu Ile Gly Asp Met Leu Leu Arg
Thr210 215 220Ala Val Gly Gln Val Ser Arg Pro Met Phe Leu Tyr Val
Arg Thr Asn225 230 235 240Gly Thr Ser Lys Ile Lys Met Lys Arg Gly
Met Glu Met Arg Arg Cys245 250 255Leu Leu Gln Ser Leu Gln Gln Ile
Glu Ser Met Ile Glu Ala Glu Ser260 265 270Ser Val Lys Glu Lys Asp
Met Thr Lys Glu Phe Phe Glu Asn Lys Ser275 280 285Glu Thr Trp Pro
Ile Gly Glu Ser Pro Lys Gly Val Glu Glu Gly Ser290 295 300Ile Gly
Lys Val Cys Arg Thr Leu Leu Ala Lys Ser Val Phe Asn Ser305 310 315
320Leu Tyr Ala Ser Pro Gln Leu Glu Gly Phe Ser Ala Glu Ser Arg
Lys325 330 335Leu Leu Leu Ile Val Gln Ala Leu Arg Asp Asn Leu Glu
Pro Gly Thr340 345 350Phe Asp Ile Gly Gly Leu Tyr Glu Ser Ile Glu
Glu Cys Leu Ile Asn355 360 365Asp Pro Trp Val Leu Leu Asn Ala Ser
Trp Phe Asn Ser Phe Leu Thr370 375 380His Ala Leu
Lys385781164DNAEquine influenza virus H3N8 78ggcgggtacc caaactatct
ccaagcttgg aagcaagtat tagcagaact acaagacctt 60gagaacgaag aaaagacccc
taagaccaag aatatgaaaa aaacaagcca attgaaatgg 120gcactcggtg
aaaatatggc accagagaaa gtggattttg aggattgtaa agacatcaat
180gatttgaaac agtatgacag tgatgagcca gaaacaaggt ctcttgcaag
ttggattcaa 240agtgagttca acaaagcttg tgagctgaca gattcaagct
ggatagagct cgatgaaatt 300ggggaggata ttgccccaat agaatacatt
gcgagcatga ggagaaatta ttttactgct 360gaggtttccc attgtagagc
aacagaatat ataatgaagg gagtgtacat caacactgct 420ctactcaatg
catcctgtgc tgcgatggat gaattccaat taattccgat gataagcaaa
480tgcaggacca aagaagggag aaggaagaca aatttatatg gattcataat
aaagggaagg 540tcccatttaa ggaatgatac cgacgtggta aactttgtaa
gtatggaatt ttctctcact 600gatccaagat ttgagccaca taaatgggaa
aaatactgcg ttctagaaat tggagacatg 660ctcctaagga ctgctgtagg
tcaagtgtca agacccatgt ttttgtatgt aaggacaaat 720ggaacctcta
aaattaaaat gaaacgggga atggaaatga gacgctgcct ccttcagtct
780ctgcaacaga ttgaaagcat gatcgaagct gagtcctcag tcaaagaaaa
ggacatgacc 840aaagaattct ttgagaacaa atcagagaca tggcctatag
gagagtcccc caaaggagtg 900gaagagggct caatcgggaa ggtttgcagg
accttattag caaaatctgt gtttaacagt 960ttgtatgcat ctccacaact
ggaagggttt tcagctgaat ctaggaaatt acttctcatt 1020gttcaggccc
ttagggataa cctggaacct ggaacctttg atattggggg gttatatgaa
1080tcaattgagg agtgcctgat taatgatccc tgggttttgc tcaatgcatc
ttggttcaac 1140tccttcctta cacatgcact gaag 1164791223DNAEquine
influenza virus H3N8 79ggggcgggta cccaaactat ctccaagctt ggaagcaagt
attagcagaa ctacaagacc 60ttgagaacga agaaaagacc cctaagacca agaatatgaa
aaaaacaagc caattgaaat 120gggcactcgg tgaaaatatg gcaccagaga
aagtggattt tgaggattgt aaagacatca 180atgatttgaa acagtatgac
agtgatgagc cagaaacaag gtctcttgca agttggattc 240aaagtgagtt
caacaaagct tgtgagctga cagattcaag ctggatagag ctcgatgaaa
300ttggggagga tattgcccca atagaataca ttgcgagcat gaggagaaat
tattttactg 360ctgaggtttc ccattgtaga gcaacagaat atataatgaa
gggagtgtac atcaacactg 420ctctactcaa tgcatcctgt gctgcgatgg
atgaattcca attaattccg atgataagca 480aatgcaggac caaagaaggg
agaaggaaga caaatttata tggattcata ataaagggaa 540ggtcccattt
aaggaatgat accgacgtgg taaactttgt aagtatggaa ttttctctca
600ctgatccaag atttgagcca cataaatggg aaaaatactg cgttctagaa
attggagaca 660tgctcctaag gactgctgta ggtcaagtgt caagacccat
gtttttgtat gtaaggacaa 720atggaacctc taaaattaaa atgaaatggg
gaatggaaat gagacgctgc ctccttcagt 780ctctgcaaca gattgaaagc
atgatcgaag ctgagtcctc agtcaaagaa aaggacatga 840ccaaagaatt
ctttgagaac aaatcagaga catggcctat aggagagtcc cccaaaggag
900tggaagaggg ctcaatcggg aaggtttgca ggaccttatt agcaaaatct
gtgtttaaca 960gtttgtatgc atctccacaa ctggaagggt tttcagctga
atctaggaaa ttacttctca 1020ttgttcaggc ccttagggat aacctggaac
ctggaacctt tgatattggg gggttatatg 1080aatcaattga ggagtgcctg
attaatgatc cctgggtttt gctcaatgca tcttggttca 1140actccttcct
tacacatgca ctgaagtagt tgtagcaatg ctactatttg ctatccatac
1200tgtccaaaaa agtactcgag ccc 1223801233DNAEquine influenza virus
H3N8CDS(3)..(1172) 80at gaa aag ggt ata aac cca aac tat ctc caa gct
tgg aag caa gta 47Glu Lys Gly Ile Asn Pro Asn Tyr Leu Gln Ala Trp
Lys Gln Val1 5 10 15tta gca gaa cta caa gac ctt gag aac gaa gaa aag
acc cct aag acc 95Leu Ala Glu Leu Gln Asp Leu Glu Asn Glu Glu Lys
Thr Pro Lys Thr20 25 30aag aat atg aaa aaa aca agc caa ttg aaa tgg
gca ctc ggt gaa aat 143Lys Asn Met Lys Lys Thr Ser Gln Leu Lys Trp
Ala Leu Gly Glu Asn35 40 45atg gca cca gag aaa gtg gat ttt gag gat
tgt aaa gac atc aat gat 191Met Ala Pro Glu Lys Val Asp Phe Glu Asp
Cys Lys Asp Ile Asn Asp50 55 60ttg aaa cag tat gac agt gat gag cca
gaa aca agg tct ctt gca agt 239Leu Lys Gln Tyr Asp Ser Asp Glu Pro
Glu Thr Arg Ser Leu Ala Ser65 70 75tgg att caa agt gag ttc aac aaa
gct tgt gag ctg aca gat tca agc 287Trp Ile Gln Ser Glu Phe Asn Lys
Ala Cys Glu Leu Thr Asp Ser Ser80 85 90 95tgg ata gag ctc gat gaa
att ggg gag gat att gcc cca ata gaa tac 335Trp Ile Glu Leu Asp Glu
Ile Gly Glu Asp Ile Ala Pro Ile Glu Tyr100 105 110att gcg agc atg
agg aga aat tat ttt act gct gag gtt tcc cat tgt 383Ile Ala Ser Met
Arg Arg Asn Tyr Phe Thr Ala Glu Val Ser His Cys115 120 125aga gca
aca gaa tat ata atg aag gga gtg tac atc aac act gct cta 431Arg Ala
Thr Glu Tyr Ile Met Lys Gly Val Tyr Ile Asn Thr Ala Leu130 135
140ctc aat gca tcc tgt gct gcg atg gat gaa ttc caa tta att ccg atg
479Leu Asn Ala Ser Cys Ala Ala Met Asp Glu Phe Gln Leu Ile Pro
Met145 150 155ata agc aaa tgc agg acc aaa gaa ggg aga agg aag aca
aat tta tat 527Ile Ser Lys Cys Arg Thr Lys Glu Gly Arg Arg Lys Thr
Asn Leu Tyr160 165 170 175gga ttc ata ata aag gga agg tcc cat tta
agg aat gat acc gac gtg 575Gly Phe Ile Ile Lys Gly Arg Ser His Leu
Arg Asn Asp Thr Asp Val180 185 190gta aac ttt gta agt atg gaa ttt
tct ctc act gat cca aga ttt gag 623Val Asn Phe Val Ser Met Glu Phe
Ser Leu Thr Asp Pro Arg Phe Glu195 200 205cca cat aaa tgg gaa aaa
tac tgc gtt cta gaa att gga gac atg ctc 671Pro His Lys Trp Glu Lys
Tyr Cys Val Leu Glu Ile Gly Asp Met Leu210 215 220cta agg act gct
gta ggt caa gtg tca aga ccc atg ttt ttg tat gta 719Leu Arg Thr Ala
Val Gly Gln Val Ser Arg Pro Met Phe Leu Tyr Val225 230 235agg aca
aat gga acc tct aaa att aaa atg aaa tgg gga atg gaa atg 767Arg Thr
Asn Gly Thr Ser Lys Ile Lys Met Lys Trp Gly Met Glu Met240 245 250
255aga cgc tgc ctc ctt cag tct ctg caa cag att gaa agc atg atc gaa
815Arg Arg Cys Leu Leu Gln Ser Leu Gln Gln Ile Glu Ser Met Ile
Glu260 265 270gct gag tcc tca gtc aaa gaa aag gac atg acc aaa gaa
ttc ttt gag 863Ala Glu Ser Ser Val Lys Glu Lys Asp Met Thr Lys Glu
Phe Phe Glu275 280 285aac aaa tca gag aca tgg cct ata gga gag tcc
ccc aaa gga gtg gaa 911Asn Lys Ser Glu Thr Trp Pro Ile Gly Glu Ser
Pro Lys Gly Val Glu290 295 300gag ggc tca atc ggg aag gtt tgc agg
acc tta tta gca aaa tct gtg 959Glu Gly Ser Ile Gly Lys Val Cys Arg
Thr Leu Leu
Ala Lys Ser Val305 310 315ttt aac agt ttg tat gca tct cca caa ctg
gaa ggg ttt tca gct gaa 1007Phe Asn Ser Leu Tyr Ala Ser Pro Gln Leu
Glu Gly Phe Ser Ala Glu320 325 330 335tct agg aaa tta ctt ctc att
gtt cag gcc ctt agg gat aac ctg gaa 1055Ser Arg Lys Leu Leu Leu Ile
Val Gln Ala Leu Arg Asp Asn Leu Glu340 345 350cct gga acc ttt gat
att ggg ggg tta tat gaa tca att gag gag tgc 1103Pro Gly Thr Phe Asp
Ile Gly Gly Leu Tyr Glu Ser Ile Glu Glu Cys355 360 365ctg att aat
gat ccc tgg gtt ttg ctc aat gca tct tgg ttc aac tcc 1151Leu Ile Asn
Asp Pro Trp Val Leu Leu Asn Ala Ser Trp Phe Asn Ser370 375 380ttc
ctt aca cat gca ctg aag tagttgtagc aatgctacta tttgctatcc 1202Phe
Leu Thr His Ala Leu Lys385 390atactgtcca aaaaagtacc ttgtttctac t
123381390PRTEquine influenza virus H3N8 81Glu Lys Gly Ile Asn Pro
Asn Tyr Leu Gln Ala Trp Lys Gln Val Leu1 5 10 15Ala Glu Leu Gln Asp
Leu Glu Asn Glu Glu Lys Thr Pro Lys Thr Lys20 25 30Asn Met Lys Lys
Thr Ser Gln Leu Lys Trp Ala Leu Gly Glu Asn Met35 40 45Ala Pro Glu
Lys Val Asp Phe Glu Asp Cys Lys Asp Ile Asn Asp Leu50 55 60Lys Gln
Tyr Asp Ser Asp Glu Pro Glu Thr Arg Ser Leu Ala Ser Trp65 70 75
80Ile Gln Ser Glu Phe Asn Lys Ala Cys Glu Leu Thr Asp Ser Ser Trp85
90 95Ile Glu Leu Asp Glu Ile Gly Glu Asp Ile Ala Pro Ile Glu Tyr
Ile100 105 110Ala Ser Met Arg Arg Asn Tyr Phe Thr Ala Glu Val Ser
His Cys Arg115 120 125Ala Thr Glu Tyr Ile Met Lys Gly Val Tyr Ile
Asn Thr Ala Leu Leu130 135 140Asn Ala Ser Cys Ala Ala Met Asp Glu
Phe Gln Leu Ile Pro Met Ile145 150 155 160Ser Lys Cys Arg Thr Lys
Glu Gly Arg Arg Lys Thr Asn Leu Tyr Gly165 170 175Phe Ile Ile Lys
Gly Arg Ser His Leu Arg Asn Asp Thr Asp Val Val180 185 190Asn Phe
Val Ser Met Glu Phe Ser Leu Thr Asp Pro Arg Phe Glu Pro195 200
205His Lys Trp Glu Lys Tyr Cys Val Leu Glu Ile Gly Asp Met Leu
Leu210 215 220Arg Thr Ala Val Gly Gln Val Ser Arg Pro Met Phe Leu
Tyr Val Arg225 230 235 240Thr Asn Gly Thr Ser Lys Ile Lys Met Lys
Trp Gly Met Glu Met Arg245 250 255Arg Cys Leu Leu Gln Ser Leu Gln
Gln Ile Glu Ser Met Ile Glu Ala260 265 270Glu Ser Ser Val Lys Glu
Lys Asp Met Thr Lys Glu Phe Phe Glu Asn275 280 285Lys Ser Glu Thr
Trp Pro Ile Gly Glu Ser Pro Lys Gly Val Glu Glu290 295 300Gly Ser
Ile Gly Lys Val Cys Arg Thr Leu Leu Ala Lys Ser Val Phe305 310 315
320Asn Ser Leu Tyr Ala Ser Pro Gln Leu Glu Gly Phe Ser Ala Glu
Ser325 330 335Arg Lys Leu Leu Leu Ile Val Gln Ala Leu Arg Asp Asn
Leu Glu Pro340 345 350Gly Thr Phe Asp Ile Gly Gly Leu Tyr Glu Ser
Ile Glu Glu Cys Leu355 360 365Ile Asn Asp Pro Trp Val Leu Leu Asn
Ala Ser Trp Phe Asn Ser Phe370 375 380Leu Thr His Ala Leu Lys385
390821170DNAEquine influenza virus H3N8 82gaaaagggta taaacccaaa
ctatctccaa gcttggaagc aagtattagc agaactacaa 60gaccttgaga acgaagaaaa
gacccctaag accaagaata tgaaaaaaac aagccaattg 120aaatgggcac
tcggtgaaaa tatggcacca gagaaagtgg attttgagga ttgtaaagac
180atcaatgatt tgaaacagta tgacagtgat gagccagaaa caaggtctct
tgcaagttgg 240attcaaagtg agttcaacaa agcttgtgag ctgacagatt
caagctggat agagctcgat 300gaaattgggg aggatattgc cccaatagaa
tacattgcga gcatgaggag aaattatttt 360actgctgagg tttcccattg
tagagcaaca gaatatataa tgaagggagt gtacatcaac 420actgctctac
tcaatgcatc ctgtgctgcg atggatgaat tccaattaat tccgatgata
480agcaaatgca ggaccaaaga agggagaagg aagacaaatt tatatggatt
cataataaag 540ggaaggtccc atttaaggaa tgataccgac gtggtaaact
ttgtaagtat ggaattttct 600ctcactgatc caagatttga gccacataaa
tgggaaaaat actgcgttct agaaattgga 660gacatgctcc taaggactgc
tgtaggtcaa gtgtcaagac ccatgttttt gtatgtaagg 720acaaatggaa
cctctaaaat taaaatgaaa tggggaatgg aaatgagacg ctgcctcctt
780cagtctctgc aacagattga aagcatgatc gaagctgagt cctcagtcaa
agaaaaggac 840atgaccaaag aattctttga gaacaaatca gagacatggc
ctataggaga gtcccccaaa 900ggagtggaag agggctcaat cgggaaggtt
tgcaggacct tattagcaaa atctgtgttt 960aacagtttgt atgcatctcc
acaactggaa gggttttcag ctgaatctag gaaattactt 1020ctcattgttc
aggcccttag ggataacctg gaacctggaa cctttgatat tggggggtta
1080tatgaatcaa ttgaggagtg cctgattaat gatccctggg ttttgctcaa
tgcatcttgg 1140ttcaactcct tccttacaca tgcactgaag
11708325DNAArtificialSynthetic Primer 83ggggcgggta cccaaactat ctcca
258427DNAArtificialSynthetic Primer 84gggggctcga gtactttttt ggacagt
27851234DNAEquine influenza virus H3N8CDS(1)..(1188) 85atg aaa ttg
aga act caa ata cca gca gaa atg ctc gca agc att gat 48Met Lys Leu
Arg Thr Gln Ile Pro Ala Glu Met Leu Ala Ser Ile Asp1 5 10 15ctg aaa
tat ttc aat gat tca aca aaa aag aaa att gag aag ata cga 96Leu Lys
Tyr Phe Asn Asp Ser Thr Lys Lys Lys Ile Glu Lys Ile Arg20 25 30cca
ctt ctg gtc gat ggg act gct tca ctg agt cct ggc atg atg atg 144Pro
Leu Leu Val Asp Gly Thr Ala Ser Leu Ser Pro Gly Met Met Met35 40
45gga atg ttc aac atg ttg agc act gta cta ggt gta tcc ata tta aac
192Gly Met Phe Asn Met Leu Ser Thr Val Leu Gly Val Ser Ile Leu
Asn50 55 60ctg ggc cag agg aaa tac aca aag acc aca tac tgg tgg gat
ggt ctg 240Leu Gly Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp Trp Asp
Gly Leu65 70 75 80caa tca tcc gat gat ttt gct ttg ata gtg aat gcg
cct aat cat gaa 288Gln Ser Ser Asp Asp Phe Ala Leu Ile Val Asn Ala
Pro Asn His Glu85 90 95gga ata cag gct gga gta gac aga ttc tat aga
act tgc aaa ctg gtc 336Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr Arg
Thr Cys Lys Leu Val100 105 110ggg atc aac atg agc aaa aag aag tcc
tac ata aat aga acc ggc aca 384Gly Ile Asn Met Ser Lys Lys Lys Ser
Tyr Ile Asn Arg Thr Gly Thr115 120 125ttc gaa ttc aca agc ttt ttc
tac cgg tat ggt ttt gtc gcc aat ttc 432Phe Glu Phe Thr Ser Phe Phe
Tyr Arg Tyr Gly Phe Val Ala Asn Phe130 135 140agc atg gag cta ccc
agt ttt ggg gtt tcc ggg ata aat gaa tct gca 480Ser Met Glu Leu Pro
Ser Phe Gly Val Ser Gly Ile Asn Glu Ser Ala145 150 155 160gac atg
agc att gga atg aca gtt atc aaa aac aac atg ata aat aat 528Asp Met
Ser Ile Gly Met Thr Val Ile Lys Asn Asn Met Ile Asn Asn165 170
175gat ctc ggt ccc gcc acg gca caa atg gca ctc caa ctc ttc att aag
576Asp Leu Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu Phe Ile
Lys180 185 190gat tat cgg tac aca tac cgg tgc cat aga ggc gat acc
cag ata caa 624Asp Tyr Arg Tyr Thr Tyr Arg Cys His Arg Gly Asp Thr
Gln Ile Gln195 200 205acc aga aga tcc ttt gag ttg aag aaa ctg tgg
gaa cag act cga tca 672Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp
Glu Gln Thr Arg Ser210 215 220aag act ggt cta ctg gta tca gat ggg
ggt cca aac cta tac aac atc 720Lys Thr Gly Leu Leu Val Ser Asp Gly
Gly Pro Asn Leu Tyr Asn Ile225 230 235 240aga aac cta cac atc ccg
gaa gtc tgt ttg aaa tgg gag ctg atg gat 768Arg Asn Leu His Ile Pro
Glu Val Cys Leu Lys Trp Glu Leu Met Asp245 250 255gaa gat tat aaa
ggg agg cta tgt aat cca ttg aat cct ttc gtt agc 816Glu Asp Tyr Lys
Gly Arg Leu Cys Asn Pro Leu Asn Pro Phe Val Ser260 265 270cac aaa
gaa att gaa tca gtg aac agt gca gta gta atg cct gcg cat 864His Lys
Glu Ile Glu Ser Val Asn Ser Ala Val Val Met Pro Ala His275 280
285ggc cct gcc aaa agc atg gag tat gat gct gtt gca aca aca cac tct
912Gly Pro Ala Lys Ser Met Glu Tyr Asp Ala Val Ala Thr Thr His
Ser290 295 300tgg atc ccc aag agg aac cgg tcc ata ttg aac aca agt
caa agg gga 960Trp Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser
Gln Arg Gly305 310 315 320ata ctc gaa gat gag cag atg tat cag aaa
tgc tgc aac ctg ttt gaa 1008Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys
Cys Cys Asn Leu Phe Glu325 330 335aaa ttc ttc ccc agc agc tca tac
aga aga cca gtc gga att tct agt 1056Lys Phe Phe Pro Ser Ser Ser Tyr
Arg Arg Pro Val Gly Ile Ser Ser340 345 350atg gtt gag gcc atg gtg
tcc agg gcc cgc att gat gca cga att gac 1104Met Val Glu Ala Met Val
Ser Arg Ala Arg Ile Asp Ala Arg Ile Asp355 360 365ttc gaa tct gga
cgg ata aag aag gat gag ttc gct gag atc atg aag 1152Phe Glu Ser Gly
Arg Ile Lys Lys Asp Glu Phe Ala Glu Ile Met Lys370 375 380atc tgt
tcc acc att gaa gag ctc aga cgg caa aaa tagtgaattt 1198Ile Cys Ser
Thr Ile Glu Glu Leu Arg Arg Gln Lys385 390 395agcttgatct tcgtgaaaaa
atgccttgtt tctact 123486396PRTEquine influenza virus H3N8 86Met Lys
Leu Arg Thr Gln Ile Pro Ala Glu Met Leu Ala Ser Ile Asp1 5 10 15Leu
Lys Tyr Phe Asn Asp Ser Thr Lys Lys Lys Ile Glu Lys Ile Arg20 25
30Pro Leu Leu Val Asp Gly Thr Ala Ser Leu Ser Pro Gly Met Met Met35
40 45Gly Met Phe Asn Met Leu Ser Thr Val Leu Gly Val Ser Ile Leu
Asn50 55 60Leu Gly Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp Trp Asp
Gly Leu65 70 75 80Gln Ser Ser Asp Asp Phe Ala Leu Ile Val Asn Ala
Pro Asn His Glu85 90 95Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr Arg
Thr Cys Lys Leu Val100 105 110Gly Ile Asn Met Ser Lys Lys Lys Ser
Tyr Ile Asn Arg Thr Gly Thr115 120 125Phe Glu Phe Thr Ser Phe Phe
Tyr Arg Tyr Gly Phe Val Ala Asn Phe130 135 140Ser Met Glu Leu Pro
Ser Phe Gly Val Ser Gly Ile Asn Glu Ser Ala145 150 155 160Asp Met
Ser Ile Gly Met Thr Val Ile Lys Asn Asn Met Ile Asn Asn165 170
175Asp Leu Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu Phe Ile
Lys180 185 190Asp Tyr Arg Tyr Thr Tyr Arg Cys His Arg Gly Asp Thr
Gln Ile Gln195 200 205Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp
Glu Gln Thr Arg Ser210 215 220Lys Thr Gly Leu Leu Val Ser Asp Gly
Gly Pro Asn Leu Tyr Asn Ile225 230 235 240Arg Asn Leu His Ile Pro
Glu Val Cys Leu Lys Trp Glu Leu Met Asp245 250 255Glu Asp Tyr Lys
Gly Arg Leu Cys Asn Pro Leu Asn Pro Phe Val Ser260 265 270His Lys
Glu Ile Glu Ser Val Asn Ser Ala Val Val Met Pro Ala His275 280
285Gly Pro Ala Lys Ser Met Glu Tyr Asp Ala Val Ala Thr Thr His
Ser290 295 300Trp Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser
Gln Arg Gly305 310 315 320Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys
Cys Cys Asn Leu Phe Glu325 330 335Lys Phe Phe Pro Ser Ser Ser Tyr
Arg Arg Pro Val Gly Ile Ser Ser340 345 350Met Val Glu Ala Met Val
Ser Arg Ala Arg Ile Asp Ala Arg Ile Asp355 360 365Phe Glu Ser Gly
Arg Ile Lys Lys Asp Glu Phe Ala Glu Ile Met Lys370 375 380Ile Cys
Ser Thr Ile Glu Glu Leu Arg Arg Gln Lys385 390 395871188DNAEquine
influenza virus H3N8 87atgaaattga gaactcaaat accagcagaa atgctcgcaa
gcattgatct gaaatatttc 60aatgattcaa caaaaaagaa aattgagaag atacgaccac
ttctggtcga tgggactgct 120tcactgagtc ctggcatgat gatgggaatg
ttcaacatgt tgagcactgt actaggtgta 180tccatattaa acctgggcca
gaggaaatac acaaagacca catactggtg ggatggtctg 240caatcatccg
atgattttgc tttgatagtg aatgcgccta atcatgaagg aatacaggct
300ggagtagaca gattctatag aacttgcaaa ctggtcggga tcaacatgag
caaaaagaag 360tcctacataa atagaaccgg cacattcgaa ttcacaagct
ttttctaccg gtatggtttt 420gtcgccaatt tcagcatgga gctacccagt
tttggggttt ccgggataaa tgaatctgca 480gacatgagca ttggaatgac
agttatcaaa aacaacatga taaataatga tctcggtccc 540gccacggcac
aaatggcact ccaactcttc attaaggatt atcggtacac ataccggtgc
600catagaggcg atacccagat acaaaccaga agatcctttg agttgaagaa
actgtgggaa 660cagactcgat caaagactgg tctactggta tcagatgggg
gtccaaacct atacaacatc 720agaaacctac acatcccgga agtctgtttg
aaatgggagc tgatggatga agattataaa 780gggaggctat gtaatccatt
gaatcctttc gttagccaca aagaaattga atcagtgaac 840agtgcagtag
taatgcctgc gcatggccct gccaaaagca tggagtatga tgctgttgca
900acaacacact cttggatccc caagaggaac cggtccatat tgaacacaag
tcaaagggga 960atactcgaag atgagcagat gtatcagaaa tgctgcaacc
tgtttgaaaa attcttcccc 1020agcagctcat acagaagacc agtcggaatt
tctagtatgg ttgaggccat ggtgtccagg 1080gcccgcattg atgcacgaat
tgacttcgaa tctggacgga taaagaagga tgagttcgct 1140gagatcatga
agatctgttc caccattgaa gagctcagac ggcaaaaa 1188881240DNAEquine
influenza virus H3N8CDS(8)..(1195) 88caaaagt atg aaa ttg aga act
caa ata cca gca gaa atg ctc gca agc 49Met Lys Leu Arg Thr Gln Ile
Pro Ala Glu Met Leu Ala Ser1 5 10att gat ctg aaa tat ttc aat gat
tca aca aaa aag aaa att gag aag 97Ile Asp Leu Lys Tyr Phe Asn Asp
Ser Thr Lys Lys Lys Ile Glu Lys15 20 25 30ata cga cca ctt ctg gtc
gat ggg act gct tca ctg agt cct ggc atg 145Ile Arg Pro Leu Leu Val
Asp Gly Thr Ala Ser Leu Ser Pro Gly Met35 40 45atg atg gga atg ttc
aac atg ttg agc act gta cta ggt gta tcc ata 193Met Met Gly Met Phe
Asn Met Leu Ser Thr Val Leu Gly Val Ser Ile50 55 60tta aac ctg ggc
cag agg aaa tac aca aag acc aca tac tgg tgg gat 241Leu Asn Leu Gly
Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp Trp Asp65 70 75ggt ctg caa
tca tcc gat gat ttt gct ttg ata gtg aat gcg cct aat 289Gly Leu Gln
Ser Ser Asp Asp Phe Ala Leu Ile Val Asn Ala Pro Asn80 85 90cat gaa
gga ata cag gct gga gta gac aga ttc tat aga act tgc aaa 337His Glu
Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr Arg Thr Cys Lys95 100 105
110ctg gtc ggg atc aac atg agc aaa aag aag tcc tac ata aat aga acc
385Leu Val Gly Ile Asn Met Ser Lys Lys Lys Ser Tyr Ile Asn Arg
Thr115 120 125ggc tca ttc gaa ttc aca agc ttt ttc tac cgg tat ggt
ttt gtc gcc 433Gly Ser Phe Glu Phe Thr Ser Phe Phe Tyr Arg Tyr Gly
Phe Val Ala130 135 140aat ttc agc atg gag cta ccc agt ttt ggg gtt
tcc ggg ata aat gaa 481Asn Phe Ser Met Glu Leu Pro Ser Phe Gly Val
Ser Gly Ile Asn Glu145 150 155tct gca gac atg agc att gga atg aca
gtt atc aaa aac aac atg ata 529Ser Ala Asp Met Ser Ile Gly Met Thr
Val Ile Lys Asn Asn Met Ile160 165 170aat aat gat ctc ggt ccc gcc
acg gca caa atg gca ctc caa ctc ttc 577Asn Asn Asp Leu Gly Pro Ala
Thr Ala Gln Met Ala Leu Gln Leu Phe175 180 185 190att aag gat tat
cgg tac aca tac cgg tgc cat aga ggc gat acc cag 625Ile Lys Asp Tyr
Arg Tyr Thr Tyr Arg Cys His Arg Gly Asp Thr Gln195 200 205ata caa
acc aga aga tcc ttt gag ttg aag aaa ctg tgg gaa cag act 673Ile Gln
Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp Glu Gln Thr210 215
220cga tca aag act ggt cta ctg gta tca gat ggg ggt cca aac cta tac
721Arg Ser Lys Thr Gly Leu Leu Val Ser Asp Gly Gly Pro Asn Leu
Tyr225 230 235aac atc aga aac cta cac atc ccg gaa gtc tgt ttg aaa
tgg gag ctg 769Asn Ile Arg Asn Leu His Ile Pro Glu Val Cys Leu Lys
Trp Glu Leu240 245 250atg gat gaa gat tat aaa ggg agg cta tgt aat
cca ttg aat cct ttc 817Met Asp Glu Asp Tyr Lys Gly Arg Leu Cys Asn
Pro Leu Asn Pro Phe255 260 265 270gtt agc cac aaa gaa att gaa tca
gtg aac agt gca gta gta atg cct 865Val Ser His Lys Glu Ile Glu Ser
Val Asn Ser Ala Val Val Met Pro275 280 285gcg cat ggc cct gcc aaa
agc atg gag tat gat gct gtt gca aca aca 913Ala His Gly Pro Ala Lys
Ser Met Glu Tyr Asp Ala Val Ala Thr Thr290 295 300cac tct tgg atc
ccc aag agg aac cgg tcc ata ttg aac aca agt caa 961His Ser Trp Ile
Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser Gln305 310 315agg gga
ata ctc gaa gat gag cag atg tat cag aaa tgc tgc aac ctg 1009Arg Gly
Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys Cys Cys Asn Leu320 325
330ttt gaa aaa ttc ttc ccc agc agc tca tac aga
aga cca gtc gga att 1057Phe Glu Lys Phe Phe Pro Ser Ser Ser Tyr Arg
Arg Pro Val Gly Ile335 340 345 350tct agt atg gtt gag gcc atg gtg
tcc agg gcc cgc att gat gca cga 1105Ser Ser Met Val Glu Ala Met Val
Ser Arg Ala Arg Ile Asp Ala Arg355 360 365att gac ttc gaa tct gga
cgg ata aag aag gat gag ttc gct gag atc 1153Ile Asp Phe Glu Ser Gly
Arg Ile Lys Lys Asp Glu Phe Ala Glu Ile370 375 380atg aag atc tgt
tcc acc att gaa gag ctc aga cgg caa aaa 1195Met Lys Ile Cys Ser Thr
Ile Glu Glu Leu Arg Arg Gln Lys385 390 395tagtgaattt agcttgatct
tcgtgaaaaa atgccttgtt ctact 124089396PRTEquine influenza virus H3N8
89Met Lys Leu Arg Thr Gln Ile Pro Ala Glu Met Leu Ala Ser Ile Asp1
5 10 15Leu Lys Tyr Phe Asn Asp Ser Thr Lys Lys Lys Ile Glu Lys Ile
Arg20 25 30Pro Leu Leu Val Asp Gly Thr Ala Ser Leu Ser Pro Gly Met
Met Met35 40 45Gly Met Phe Asn Met Leu Ser Thr Val Leu Gly Val Ser
Ile Leu Asn50 55 60Leu Gly Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp
Trp Asp Gly Leu65 70 75 80Gln Ser Ser Asp Asp Phe Ala Leu Ile Val
Asn Ala Pro Asn His Glu85 90 95Gly Ile Gln Ala Gly Val Asp Arg Phe
Tyr Arg Thr Cys Lys Leu Val100 105 110Gly Ile Asn Met Ser Lys Lys
Lys Ser Tyr Ile Asn Arg Thr Gly Ser115 120 125Phe Glu Phe Thr Ser
Phe Phe Tyr Arg Tyr Gly Phe Val Ala Asn Phe130 135 140Ser Met Glu
Leu Pro Ser Phe Gly Val Ser Gly Ile Asn Glu Ser Ala145 150 155
160Asp Met Ser Ile Gly Met Thr Val Ile Lys Asn Asn Met Ile Asn
Asn165 170 175Asp Leu Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu
Phe Ile Lys180 185 190Asp Tyr Arg Tyr Thr Tyr Arg Cys His Arg Gly
Asp Thr Gln Ile Gln195 200 205Thr Arg Arg Ser Phe Glu Leu Lys Lys
Leu Trp Glu Gln Thr Arg Ser210 215 220Lys Thr Gly Leu Leu Val Ser
Asp Gly Gly Pro Asn Leu Tyr Asn Ile225 230 235 240Arg Asn Leu His
Ile Pro Glu Val Cys Leu Lys Trp Glu Leu Met Asp245 250 255Glu Asp
Tyr Lys Gly Arg Leu Cys Asn Pro Leu Asn Pro Phe Val Ser260 265
270His Lys Glu Ile Glu Ser Val Asn Ser Ala Val Val Met Pro Ala
His275 280 285Gly Pro Ala Lys Ser Met Glu Tyr Asp Ala Val Ala Thr
Thr His Ser290 295 300Trp Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn
Thr Ser Gln Arg Gly305 310 315 320Ile Leu Glu Asp Glu Gln Met Tyr
Gln Lys Cys Cys Asn Leu Phe Glu325 330 335Lys Phe Phe Pro Ser Ser
Ser Tyr Arg Arg Pro Val Gly Ile Ser Ser340 345 350Met Val Glu Ala
Met Val Ser Arg Ala Arg Ile Asp Ala Arg Ile Asp355 360 365Phe Glu
Ser Gly Arg Ile Lys Lys Asp Glu Phe Ala Glu Ile Met Lys370 375
380Ile Cys Ser Thr Ile Glu Glu Leu Arg Arg Gln Lys385 390
395901188DNAEquine influenza virus H3N8 90atgaaattga gaactcaaat
accagcagaa atgctcgcaa gcattgatct gaaatatttc 60aatgattcaa caaaaaagaa
aattgagaag atacgaccac ttctggtcga tgggactgct 120tcactgagtc
ctggcatgat gatgggaatg ttcaacatgt tgagcactgt actaggtgta
180tccatattaa acctgggcca gaggaaatac acaaagacca catactggtg
ggatggtctg 240caatcatccg atgattttgc tttgatagtg aatgcgccta
atcatgaagg aatacaggct 300ggagtagaca gattctatag aacttgcaaa
ctggtcggga tcaacatgag caaaaagaag 360tcctacataa atagaaccgg
ctcattcgaa ttcacaagct ttttctaccg gtatggtttt 420gtcgccaatt
tcagcatgga gctacccagt tttggggttt ccgggataaa tgaatctgca
480gacatgagca ttggaatgac agttatcaaa aacaacatga taaataatga
tctcggtccc 540gccacggcac aaatggcact ccaactcttc attaaggatt
atcggtacac ataccggtgc 600catagaggcg atacccagat acaaaccaga
agatcctttg agttgaagaa actgtgggaa 660cagactcgat caaagactgg
tctactggta tcagatgggg gtccaaacct atacaacatc 720agaaacctac
acatcccgga agtctgtttg aaatgggagc tgatggatga agattataaa
780gggaggctat gtaatccatt gaatcctttc gttagccaca aagaaattga
atcagtgaac 840agtgcagtag taatgcctgc gcatggccct gccaaaagca
tggagtatga tgctgttgca 900acaacacact cttggatccc caagaggaac
cggtccatat tgaacacaag tcaaagggga 960atactcgaag atgagcagat
gtatcagaaa tgctgcaacc tgtttgaaaa attcttcccc 1020agcagctcat
acagaagacc agtcggaatt tctagtatgg ttgaggccat ggtgtccagg
1080gcccgcattg atgcacgaat tgacttcgaa tctggacgga taaagaagga
tgagttcgct 1140gagatcatga agatctgttc caccattgaa gagctcagac ggcaaaaa
1188911241DNAEquine influenza virus H3N8CDS(8)..(1195) 91caaaagt
atg aaa ttg aga act caa ata cca gca gaa atg ctc gca agc 49Met Lys
Leu Arg Thr Gln Ile Pro Ala Glu Met Leu Ala Ser1 5 10att gat ctg
aaa tat ttc aat gat tca aca aaa aag aaa att gag aag 97Ile Asp Leu
Lys Tyr Phe Asn Asp Ser Thr Lys Lys Lys Ile Glu Lys15 20 25 30ata
cga cca ctt ctg gtc gat ggg act gct tca ctg agt cct ggc atg 145Ile
Arg Pro Leu Leu Val Asp Gly Thr Ala Ser Leu Ser Pro Gly Met35 40
45atg atg gga atg ttc aac atg ttg agc act gta cta ggt gta tcc ata
193Met Met Gly Met Phe Asn Met Leu Ser Thr Val Leu Gly Val Ser
Ile50 55 60tta aac ctg ggc cag agg aaa tac aca aag acc aca tac tgg
tgg gat 241Leu Asn Leu Gly Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp
Trp Asp65 70 75ggt ctg caa tca tcc gat gat ttt gct ttg ata gtg aat
gcg cct aat 289Gly Leu Gln Ser Ser Asp Asp Phe Ala Leu Ile Val Asn
Ala Pro Asn80 85 90cat gaa gga ata cag gct gga gta gac aga ttc tat
aga act tgc aaa 337His Glu Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr
Arg Thr Cys Lys95 100 105 110ctg gtc ggg atc aac atg agc aaa aag
aag tcc tac ata aat aga acc 385Leu Val Gly Ile Asn Met Ser Lys Lys
Lys Ser Tyr Ile Asn Arg Thr115 120 125ggc aca ttc gaa ttc aca agc
ttt ttc tac cgg tat ggt ttt gtc gcc 433Gly Thr Phe Glu Phe Thr Ser
Phe Phe Tyr Arg Tyr Gly Phe Val Ala130 135 140aat ttc agc atg gag
cta ccc agt ttt ggg gtt tcc ggg ata aat gaa 481Asn Phe Ser Met Glu
Leu Pro Ser Phe Gly Val Ser Gly Ile Asn Glu145 150 155tct gca gac
atg agc att gga atg aca gtt atc aaa aac aac atg ata 529Ser Ala Asp
Met Ser Ile Gly Met Thr Val Ile Lys Asn Asn Met Ile160 165 170aat
aat gat ctc ggt ccc gcc acg gca caa atg gca ctc caa ctc ttc 577Asn
Asn Asp Leu Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu Phe175 180
185 190att aag gat tat cgg tac aca tac cgg tgt caa aga ggc gat acc
cag 625Ile Lys Asp Tyr Arg Tyr Thr Tyr Arg Cys Gln Arg Gly Asp Thr
Gln195 200 205ata caa acc aga aga tcc ttt gag ttg aag aaa ctg tgg
gaa cag act 673Ile Gln Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp
Glu Gln Thr210 215 220cga tca aag act ggt cta ctg gta tca gat ggg
ggt cca aac cta tac 721Arg Ser Lys Thr Gly Leu Leu Val Ser Asp Gly
Gly Pro Asn Leu Tyr225 230 235aac atc aga aac cta cac atc ccg gaa
gtc tgt ttg aaa tgg gag ctg 769Asn Ile Arg Asn Leu His Ile Pro Glu
Val Cys Leu Lys Trp Glu Leu240 245 250atg gat gaa gat tat aaa ggg
agg cta tgt aat cca ttg aat cct ttc 817Met Asp Glu Asp Tyr Lys Gly
Arg Leu Cys Asn Pro Leu Asn Pro Phe255 260 265 270gtt agc cac aaa
gaa att gaa tca gtg aac agt gca gta gta atg cct 865Val Ser His Lys
Glu Ile Glu Ser Val Asn Ser Ala Val Val Met Pro275 280 285gcg cat
ggc cct gcc aaa agc atg gag tat gat gct gtt gca aca aca 913Ala His
Gly Pro Ala Lys Ser Met Glu Tyr Asp Ala Val Ala Thr Thr290 295
300cac tct tgg atc ccc aag agg aac cgg tcc ata ttg aac aca agt caa
961His Ser Trp Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser
Gln305 310 315agg gga ata ctc gaa gat gag cag atg tat cag aaa tgc
tgc aac ctg 1009Arg Gly Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys Cys
Cys Asn Leu320 325 330ttt gaa aaa ttc ttc ccc agc agc tca tac aga
aaa cca gtc gga att 1057Phe Glu Lys Phe Phe Pro Ser Ser Ser Tyr Arg
Lys Pro Val Gly Ile335 340 345 350tct agt atg gtt gag gcc atg gtg
tcc agg gcc cgc att gat gca cga 1105Ser Ser Met Val Glu Ala Met Val
Ser Arg Ala Arg Ile Asp Ala Arg355 360 365att gac ttc gaa tct gga
cgg ata aag aag gat gag ttc gct gag atc 1153Ile Asp Phe Glu Ser Gly
Arg Ile Lys Lys Asp Glu Phe Ala Glu Ile370 375 380atg aag atc tgt
tcc acc att gaa gag ctc aga cgg caa aaa 1195Met Lys Ile Cys Ser Thr
Ile Glu Glu Leu Arg Arg Gln Lys385 390 395tagtgaattt agcttgatct
tcgtgaaaaa atgccttgtt tctact 124192396PRTEquine influenza virus
H3N8 92Met Lys Leu Arg Thr Gln Ile Pro Ala Glu Met Leu Ala Ser Ile
Asp1 5 10 15Leu Lys Tyr Phe Asn Asp Ser Thr Lys Lys Lys Ile Glu Lys
Ile Arg20 25 30Pro Leu Leu Val Asp Gly Thr Ala Ser Leu Ser Pro Gly
Met Met Met35 40 45Gly Met Phe Asn Met Leu Ser Thr Val Leu Gly Val
Ser Ile Leu Asn50 55 60Leu Gly Gln Arg Lys Tyr Thr Lys Thr Thr Tyr
Trp Trp Asp Gly Leu65 70 75 80Gln Ser Ser Asp Asp Phe Ala Leu Ile
Val Asn Ala Pro Asn His Glu85 90 95Gly Ile Gln Ala Gly Val Asp Arg
Phe Tyr Arg Thr Cys Lys Leu Val100 105 110Gly Ile Asn Met Ser Lys
Lys Lys Ser Tyr Ile Asn Arg Thr Gly Thr115 120 125Phe Glu Phe Thr
Ser Phe Phe Tyr Arg Tyr Gly Phe Val Ala Asn Phe130 135 140Ser Met
Glu Leu Pro Ser Phe Gly Val Ser Gly Ile Asn Glu Ser Ala145 150 155
160Asp Met Ser Ile Gly Met Thr Val Ile Lys Asn Asn Met Ile Asn
Asn165 170 175Asp Leu Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu
Phe Ile Lys180 185 190Asp Tyr Arg Tyr Thr Tyr Arg Cys Gln Arg Gly
Asp Thr Gln Ile Gln195 200 205Thr Arg Arg Ser Phe Glu Leu Lys Lys
Leu Trp Glu Gln Thr Arg Ser210 215 220Lys Thr Gly Leu Leu Val Ser
Asp Gly Gly Pro Asn Leu Tyr Asn Ile225 230 235 240Arg Asn Leu His
Ile Pro Glu Val Cys Leu Lys Trp Glu Leu Met Asp245 250 255Glu Asp
Tyr Lys Gly Arg Leu Cys Asn Pro Leu Asn Pro Phe Val Ser260 265
270His Lys Glu Ile Glu Ser Val Asn Ser Ala Val Val Met Pro Ala
His275 280 285Gly Pro Ala Lys Ser Met Glu Tyr Asp Ala Val Ala Thr
Thr His Ser290 295 300Trp Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn
Thr Ser Gln Arg Gly305 310 315 320Ile Leu Glu Asp Glu Gln Met Tyr
Gln Lys Cys Cys Asn Leu Phe Glu325 330 335Lys Phe Phe Pro Ser Ser
Ser Tyr Arg Lys Pro Val Gly Ile Ser Ser340 345 350Met Val Glu Ala
Met Val Ser Arg Ala Arg Ile Asp Ala Arg Ile Asp355 360 365Phe Glu
Ser Gly Arg Ile Lys Lys Asp Glu Phe Ala Glu Ile Met Lys370 375
380Ile Cys Ser Thr Ile Glu Glu Leu Arg Arg Gln Lys385 390
395931188DNAEquine influenza virus H3N8 93atgaaattga gaactcaaat
accagcagaa atgctcgcaa gcattgatct gaaatatttc 60aatgattcaa caaaaaagaa
aattgagaag atacgaccac ttctggtcga tgggactgct 120tcactgagtc
ctggcatgat gatgggaatg ttcaacatgt tgagcactgt actaggtgta
180tccatattaa acctgggcca gaggaaatac acaaagacca catactggtg
ggatggtctg 240caatcatccg atgattttgc tttgatagtg aatgcgccta
atcatgaagg aatacaggct 300ggagtagaca gattctatag aacttgcaaa
ctggtcggga tcaacatgag caaaaagaag 360tcctacataa atagaaccgg
cacattcgaa ttcacaagct ttttctaccg gtatggtttt 420gtcgccaatt
tcagcatgga gctacccagt tttggggttt ccgggataaa tgaatctgca
480gacatgagca ttggaatgac agttatcaaa aacaacatga taaataatga
tctcggtccc 540gccacggcac aaatggcact ccaactcttc attaaggatt
atcggtacac ataccggtgt 600caaagaggcg atacccagat acaaaccaga
agatcctttg agttgaagaa actgtgggaa 660cagactcgat caaagactgg
tctactggta tcagatgggg gtccaaacct atacaacatc 720agaaacctac
acatcccgga agtctgtttg aaatgggagc tgatggatga agattataaa
780gggaggctat gtaatccatt gaatcctttc gttagccaca aagaaattga
atcagtgaac 840agtgcagtag taatgcctgc gcatggccct gccaaaagca
tggagtatga tgctgttgca 900acaacacact cttggatccc caagaggaac
cggtccatat tgaacacaag tcaaagggga 960atactcgaag atgagcagat
gtatcagaaa tgctgcaacc tgtttgaaaa attcttcccc 1020agcagctcat
acagaaaacc agtcggaatt tctagtatgg ttgaggccat ggtgtccagg
1080gcccgcattg atgcacgaat tgacttcgaa tctggacgga taaagaagga
tgagttcgct 1140gagatcatga agatctgttc caccattgaa gagctcagac ggcaaaaa
1188941241DNAEquine influenza virus H3N8CDS(8)..(1195) 94caaaagt
atg aaa ttg aga act caa ata cca gca gaa atg ctc gca agc 49Met Lys
Leu Arg Thr Gln Ile Pro Ala Glu Met Leu Ala Ser1 5 10att gat ctg
aaa tat ttc aat gat tca aca aaa aag aaa att gag aag 97Ile Asp Leu
Lys Tyr Phe Asn Asp Ser Thr Lys Lys Lys Ile Glu Lys15 20 25 30ata
cga cca ctt ctg gtc gat ggg act gct tca ctg agt cct ggc atg 145Ile
Arg Pro Leu Leu Val Asp Gly Thr Ala Ser Leu Ser Pro Gly Met35 40
45atg atg gga atg ttc aac atg ttg agc act gta cta ggt gta tcc ata
193Met Met Gly Met Phe Asn Met Leu Ser Thr Val Leu Gly Val Ser
Ile50 55 60tta aac ctg ggc cag agg aaa tac aca aag acc aca tac tgg
tgg gat 241Leu Asn Leu Gly Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp
Trp Asp65 70 75ggt ctg caa tca tcc gat gat ttt gct ttg ata gtg aat
gcg cct aat 289Gly Leu Gln Ser Ser Asp Asp Phe Ala Leu Ile Val Asn
Ala Pro Asn80 85 90cat gaa gga ata cag gct gga gta gac aga ttc tat
aga act tgc aaa 337His Glu Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr
Arg Thr Cys Lys95 100 105 110ctg gtc ggg atc aac atg agc aaa aag
aag tcc tac ata aat aga acc 385Leu Val Gly Ile Asn Met Ser Lys Lys
Lys Ser Tyr Ile Asn Arg Thr115 120 125ggc aca ttc gaa ttc aca agc
ttt ttc tac cgg tat ggt ttt gtc gcc 433Gly Thr Phe Glu Phe Thr Ser
Phe Phe Tyr Arg Tyr Gly Phe Val Ala130 135 140aat ttc agc atg gag
cta ccc agt ttt ggg gtt tcc ggg ata aat gaa 481Asn Phe Ser Met Glu
Leu Pro Ser Phe Gly Val Ser Gly Ile Asn Glu145 150 155tct gca gac
atg agc att gga atg aca gtt atc aaa aac aac atg ata 529Ser Ala Asp
Met Ser Ile Gly Met Thr Val Ile Lys Asn Asn Met Ile160 165 170aat
aat gat ctc ggt ccc gcc acg gca caa atg gca ctc caa ctc ttc 577Asn
Asn Asp Leu Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu Phe175 180
185 190att aag gat tat cgg tac aca tac cgg tgt caa aga ggc gat acc
cag 625Ile Lys Asp Tyr Arg Tyr Thr Tyr Arg Cys Gln Arg Gly Asp Thr
Gln195 200 205ata caa acc aga aga tcc ttt gag ttg aag aaa ctg tgg
gaa cag act 673Ile Gln Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp
Glu Gln Thr210 215 220cga tca aag act ggt cta ctg gta tca gat ggg
ggt cca aac cta tac 721Arg Ser Lys Thr Gly Leu Leu Val Ser Asp Gly
Gly Pro Asn Leu Tyr225 230 235aac atc aga aac cta cac atc ccg gaa
gtc tgt ttg aaa tgg gag ctg 769Asn Ile Arg Asn Leu His Ile Pro Glu
Val Cys Leu Lys Trp Glu Leu240 245 250atg gat gaa gat tat aaa ggg
agg cta tgt aat cca ttg aat cct ttc 817Met Asp Glu Asp Tyr Lys Gly
Arg Leu Cys Asn Pro Leu Asn Pro Phe255 260 265 270gtt agc cac aaa
gaa att gaa tca gtg aac agt gca gta gta atg cct 865Val Ser His Lys
Glu Ile Glu Ser Val Asn Ser Ala Val Val Met Pro275 280 285gcg cat
ggc cct gcc aaa agc atg gag tat gat gct gtt gca aca aca 913Ala His
Gly Pro Ala Lys Ser Met Glu Tyr Asp Ala Val Ala Thr Thr290 295
300cac tct tgg atc ccc aag agg aac cgg tcc ata ttg aac aca agt caa
961His Ser Trp Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser
Gln305 310 315agg gga ata ctc gaa gat gag cag atg tat cag aaa tgc
tgc aac ctg 1009Arg Gly Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys Cys
Cys Asn Leu320 325 330ttt gaa aaa ttc ttc ccc agc agc tca tac aga
aga cca gtc gga att 1057Phe Glu Lys Phe Phe Pro Ser Ser Ser Tyr Arg
Arg Pro Val Gly Ile335 340 345 350tct agt atg gtt gag gcc atg gtg
tcc agg gcc cgc att gat gca cga 1105Ser Ser Met Val Glu Ala Met Val
Ser Arg Ala Arg Ile Asp Ala Arg355 360 365att gac ttc gaa tct gga
cgg ata aag aag gat gag ttc gct gag atc
1153Ile Asp Phe Glu Ser Gly Arg Ile Lys Lys Asp Glu Phe Ala Glu
Ile370 375 380atg aag atc tgt tcc acc att gaa gag ctc aga cgg caa
aaa 1195Met Lys Ile Cys Ser Thr Ile Glu Glu Leu Arg Arg Gln Lys385
390 395tagtgaattt agcttgatct tcgtgaaaaa atgccttgtt tctact
124195396PRTEquine influenza virus H3N8 95Met Lys Leu Arg Thr Gln
Ile Pro Ala Glu Met Leu Ala Ser Ile Asp1 5 10 15Leu Lys Tyr Phe Asn
Asp Ser Thr Lys Lys Lys Ile Glu Lys Ile Arg20 25 30Pro Leu Leu Val
Asp Gly Thr Ala Ser Leu Ser Pro Gly Met Met Met35 40 45Gly Met Phe
Asn Met Leu Ser Thr Val Leu Gly Val Ser Ile Leu Asn50 55 60Leu Gly
Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp Trp Asp Gly Leu65 70 75
80Gln Ser Ser Asp Asp Phe Ala Leu Ile Val Asn Ala Pro Asn His Glu85
90 95Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr Arg Thr Cys Lys Leu
Val100 105 110Gly Ile Asn Met Ser Lys Lys Lys Ser Tyr Ile Asn Arg
Thr Gly Thr115 120 125Phe Glu Phe Thr Ser Phe Phe Tyr Arg Tyr Gly
Phe Val Ala Asn Phe130 135 140Ser Met Glu Leu Pro Ser Phe Gly Val
Ser Gly Ile Asn Glu Ser Ala145 150 155 160Asp Met Ser Ile Gly Met
Thr Val Ile Lys Asn Asn Met Ile Asn Asn165 170 175Asp Leu Gly Pro
Ala Thr Ala Gln Met Ala Leu Gln Leu Phe Ile Lys180 185 190Asp Tyr
Arg Tyr Thr Tyr Arg Cys Gln Arg Gly Asp Thr Gln Ile Gln195 200
205Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp Glu Gln Thr Arg
Ser210 215 220Lys Thr Gly Leu Leu Val Ser Asp Gly Gly Pro Asn Leu
Tyr Asn Ile225 230 235 240Arg Asn Leu His Ile Pro Glu Val Cys Leu
Lys Trp Glu Leu Met Asp245 250 255Glu Asp Tyr Lys Gly Arg Leu Cys
Asn Pro Leu Asn Pro Phe Val Ser260 265 270His Lys Glu Ile Glu Ser
Val Asn Ser Ala Val Val Met Pro Ala His275 280 285Gly Pro Ala Lys
Ser Met Glu Tyr Asp Ala Val Ala Thr Thr His Ser290 295 300Trp Ile
Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser Gln Arg Gly305 310 315
320Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys Cys Cys Asn Leu Phe
Glu325 330 335Lys Phe Phe Pro Ser Ser Ser Tyr Arg Arg Pro Val Gly
Ile Ser Ser340 345 350Met Val Glu Ala Met Val Ser Arg Ala Arg Ile
Asp Ala Arg Ile Asp355 360 365Phe Glu Ser Gly Arg Ile Lys Lys Asp
Glu Phe Ala Glu Ile Met Lys370 375 380Ile Cys Ser Thr Ile Glu Glu
Leu Arg Arg Gln Lys385 390 395961188DNAEquine influenza virus H3N8
96atgaaattga gaactcaaat accagcagaa atgctcgcaa gcattgatct gaaatatttc
60aatgattcaa caaaaaagaa aattgagaag atacgaccac ttctggtcga tgggactgct
120tcactgagtc ctggcatgat gatgggaatg ttcaacatgt tgagcactgt
actaggtgta 180tccatattaa acctgggcca gaggaaatac acaaagacca
catactggtg ggatggtctg 240caatcatccg atgattttgc tttgatagtg
aatgcgccta atcatgaagg aatacaggct 300ggagtagaca gattctatag
aacttgcaaa ctggtcggga tcaacatgag caaaaagaag 360tcctacataa
atagaaccgg cacattcgaa ttcacaagct ttttctaccg gtatggtttt
420gtcgccaatt tcagcatgga gctacccagt tttggggttt ccgggataaa
tgaatctgca 480gacatgagca ttggaatgac agttatcaaa aacaacatga
taaataatga tctcggtccc 540gccacggcac aaatggcact ccaactcttc
attaaggatt atcggtacac ataccggtgt 600caaagaggcg atacccagat
acaaaccaga agatcctttg agttgaagaa actgtgggaa 660cagactcgat
caaagactgg tctactggta tcagatgggg gtccaaacct atacaacatc
720agaaacctac acatcccgga agtctgtttg aaatgggagc tgatggatga
agattataaa 780gggaggctat gtaatccatt gaatcctttc gttagccaca
aagaaattga atcagtgaac 840agtgcagtag taatgcctgc gcatggccct
gccaaaagca tggagtatga tgctgttgca 900acaacacact cttggatccc
caagaggaac cggtccatat tgaacacaag tcaaagggga 960atactcgaag
atgagcagat gtatcagaaa tgctgcaacc tgtttgaaaa attcttcccc
1020agcagctcat acagaagacc agtcggaatt tctagtatgg ttgaggccat
ggtgtccagg 1080gcccgcattg atgcacgaat tgacttcgaa tctggacgga
taaagaagga tgagttcgct 1140gagatcatga agatctgttc caccattgaa
gagctcagac ggcaaaaa 11889720DNAArtificialSynthetic Primer
97taaatagaac cggcacattc 209817DNAArtificialSynthetic Primer
98caaagaaatt gaatcag 179918DNAArtificialSynthetic Primer
99caagcattac tactgcac 1810019DNAArtificialSynthetic Primer
100agtctgttcc cacagtttc 1910120DNAArtificialSynthetic Primer
101gaattcgaat gtgccggttc 2010220DNAArtificialSynthetic Primer
102aaaacaagga ttttttcacg 201032341DNAEquine influenza virus
H3N8CDS(25)..(2295)misc_feature(1489)..(1489)At nucleotide 1489, w
= a or t/u At amino acid residue 489, Xaa = Thr or Ser
103agcaaaagca ggcaaactat ttga atg gat gtc aat ccg act cta ctc ttc
51Met Asp Val Asn Pro Thr Leu Leu Phe1 5tta aag gtg cca gcg caa aat
gct ata agc aca aca ttc cct tat act 99Leu Lys Val Pro Ala Gln Asn
Ala Ile Ser Thr Thr Phe Pro Tyr Thr10 15 20 25gga gat cct ccc tac
agt cat gga aca ggg aca gga tac acc atg gat 147Gly Asp Pro Pro Tyr
Ser His Gly Thr Gly Thr Gly Tyr Thr Met Asp30 35 40act gtc aac aga
aca cat caa tac tca gaa aag ggg aaa tgg aca aca 195Thr Val Asn Arg
Thr His Gln Tyr Ser Glu Lys Gly Lys Trp Thr Thr45 50 55aac act gag
att gga gca cca caa ctt aat cca atc gat gga ccg ctt 243Asn Thr Glu
Ile Gly Ala Pro Gln Leu Asn Pro Ile Asp Gly Pro Leu60 65 70cct gaa
gac aat gaa cca agt ggg tac gcc caa aca gat tgt gta ttg 291Pro Glu
Asp Asn Glu Pro Ser Gly Tyr Ala Gln Thr Asp Cys Val Leu75 80 85gaa
gca atg gct ttc ctt gaa gaa tcc cat ccc gga atc ttt gaa aat 339Glu
Ala Met Ala Phe Leu Glu Glu Ser His Pro Gly Ile Phe Glu Asn90 95
100 105tcg tgt ctt gaa aca atg gag gtg gtt cag cag aca aga gtg gac
aaa 387Ser Cys Leu Glu Thr Met Glu Val Val Gln Gln Thr Arg Val Asp
Lys110 115 120cta aca caa ggc cga caa act tac gat tgg acc ttg aat
agg aat caa 435Leu Thr Gln Gly Arg Gln Thr Tyr Asp Trp Thr Leu Asn
Arg Asn Gln125 130 135cct gcc gca aca gca ctt gct aat aca att gaa
gtg ttc aga tca aat 483Pro Ala Ala Thr Ala Leu Ala Asn Thr Ile Glu
Val Phe Arg Ser Asn140 145 150gat ctg act tcc agt gag tca ggg aga
tta atg gac ttc ctc aaa gat 531Asp Leu Thr Ser Ser Glu Ser Gly Arg
Leu Met Asp Phe Leu Lys Asp155 160 165gtc atg gag tcc atg aac aag
gaa gaa atg gaa ata aca aca cac ttc 579Val Met Glu Ser Met Asn Lys
Glu Glu Met Glu Ile Thr Thr His Phe170 175 180 185caa cgg aag aga
aga gta aga gac aac atg aca aag aga atg gtg aca 627Gln Arg Lys Arg
Arg Val Arg Asp Asn Met Thr Lys Arg Met Val Thr190 195 200cag aga
acc ata ggg aag aaa aaa caa cga tta aac aga aag agc tat 675Gln Arg
Thr Ile Gly Lys Lys Lys Gln Arg Leu Asn Arg Lys Ser Tyr205 210
215ctg atc agg gca tta acc tta aac aca atg acc aag gac gct gag aga
723Leu Ile Arg Ala Leu Thr Leu Asn Thr Met Thr Lys Asp Ala Glu
Arg220 225 230ggg aaa ttg aaa cga cga gca att gca acc cca gga atg
cag ata aga 771Gly Lys Leu Lys Arg Arg Ala Ile Ala Thr Pro Gly Met
Gln Ile Arg235 240 245ggg ttt gta tat ttt gtt gaa aca tta gcc cga
aga ata tgt gaa aag 819Gly Phe Val Tyr Phe Val Glu Thr Leu Ala Arg
Arg Ile Cys Glu Lys250 255 260 265ctt gaa caa tca gga ttg cca gtt
ggc ggt aat gag aaa aag gcc aaa 867Leu Glu Gln Ser Gly Leu Pro Val
Gly Gly Asn Glu Lys Lys Ala Lys270 275 280ctg gct aat gtc gtc aga
aaa atg atg act aat tcc caa gac act gaa 915Leu Ala Asn Val Val Arg
Lys Met Met Thr Asn Ser Gln Asp Thr Glu285 290 295ctc tcc ttc acc
atc act ggg gac aat acc aaa tgg aat gaa aat cag 963Leu Ser Phe Thr
Ile Thr Gly Asp Asn Thr Lys Trp Asn Glu Asn Gln300 305 310aac cca
cgc atg ttc ctg gca atg atc aca tac ata act aga aac cag 1011Asn Pro
Arg Met Phe Leu Ala Met Ile Thr Tyr Ile Thr Arg Asn Gln315 320
325cca gaa tgg ttc aga aat gtt cta agc att gca ccg att atg ttc tca
1059Pro Glu Trp Phe Arg Asn Val Leu Ser Ile Ala Pro Ile Met Phe
Ser330 335 340 345aat aaa atg gca aga ctg ggg aaa gga tat atg ttt
gaa agc aaa agt 1107Asn Lys Met Ala Arg Leu Gly Lys Gly Tyr Met Phe
Glu Ser Lys Ser350 355 360atg aaa ttg aga act caa ata cca gca gaa
atg ctc gca agc att gat 1155Met Lys Leu Arg Thr Gln Ile Pro Ala Glu
Met Leu Ala Ser Ile Asp365 370 375ctg aaa tat ttc aat gat tca aca
aaa aag aaa att gag aag ata cga 1203Leu Lys Tyr Phe Asn Asp Ser Thr
Lys Lys Lys Ile Glu Lys Ile Arg380 385 390cca ctt ctg gtc gat ggg
act gct tca ctg agt cct ggc atg atg atg 1251Pro Leu Leu Val Asp Gly
Thr Ala Ser Leu Ser Pro Gly Met Met Met395 400 405gga atg ttc aac
atg ttg agc act gta cta ggt gta tcc ata tta aac 1299Gly Met Phe Asn
Met Leu Ser Thr Val Leu Gly Val Ser Ile Leu Asn410 415 420 425ctg
ggc cag agg aaa tac aca aag acc aca tac tgg tgg gat ggt ctg 1347Leu
Gly Gln Arg Lys Tyr Thr Lys Thr Thr Tyr Trp Trp Asp Gly Leu430 435
440caa tca tcc gat gat ttt gct ttg ata gtg aat gcg cct aat cat gaa
1395Gln Ser Ser Asp Asp Phe Ala Leu Ile Val Asn Ala Pro Asn His
Glu445 450 455gga ata cag gct gga gta gac aga ttc tat aga act tgc
aaa ctg gtc 1443Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr Arg Thr Cys
Lys Leu Val460 465 470ggg atc aac atg agc aaa aag aag tcc tac ata
aat aga acc ggc wca 1491Gly Ile Asn Met Ser Lys Lys Lys Ser Tyr Ile
Asn Arg Thr Gly Xaa475 480 485ttc gaa ttc aca agc ttt ttc tac cgg
tat ggt ttt gtc gcc aat ttc 1539Phe Glu Phe Thr Ser Phe Phe Tyr Arg
Tyr Gly Phe Val Ala Asn Phe490 495 500 505agc atg gag cta ccc agt
ttt ggg gtt tcc ggg ata aat gaa tct gca 1587Ser Met Glu Leu Pro Ser
Phe Gly Val Ser Gly Ile Asn Glu Ser Ala510 515 520gac atg agc att
gga atg aca gtt atc aaa aac aac atg ata aat aat 1635Asp Met Ser Ile
Gly Met Thr Val Ile Lys Asn Asn Met Ile Asn Asn525 530 535gat ctc
ggt ccc gcc acg gca caa atg gca ctc caa ctc ttc att aag 1683Asp Leu
Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu Phe Ile Lys540 545
550gat tat cgg tac aca tac cgg tgc cat aga ggc gat acc cag ata caa
1731Asp Tyr Arg Tyr Thr Tyr Arg Cys His Arg Gly Asp Thr Gln Ile
Gln555 560 565acc aga aga tcc ttt gag ttg aag aaa ctg tgg gaa cag
act cga tca 1779Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp Glu Gln
Thr Arg Ser570 575 580 585aag act ggt cta ctg gta tca gat ggg ggt
cca aac cta tac aac atc 1827Lys Thr Gly Leu Leu Val Ser Asp Gly Gly
Pro Asn Leu Tyr Asn Ile590 595 600aga aac cta cac atc ccg gaa gtc
tgt ttg aaa tgg gag ctg atg gat 1875Arg Asn Leu His Ile Pro Glu Val
Cys Leu Lys Trp Glu Leu Met Asp605 610 615gaa gat tat aaa ggg agg
cta tgt aat cca ttg aat cct ttc gtt agc 1923Glu Asp Tyr Lys Gly Arg
Leu Cys Asn Pro Leu Asn Pro Phe Val Ser620 625 630cac aaa gaa att
gaa tca gtg aac agt gca gta gta atg cct gcg cat 1971His Lys Glu Ile
Glu Ser Val Asn Ser Ala Val Val Met Pro Ala His635 640 645ggc cct
gcc aaa agc atg gag tat gat gct gtt gca aca aca cac tct 2019Gly Pro
Ala Lys Ser Met Glu Tyr Asp Ala Val Ala Thr Thr His Ser650 655 660
665tgg atc ccc aag agg aac cgg tcc ata ttg aac aca agt caa agg gga
2067Trp Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser Gln Arg
Gly670 675 680ata ctc gaa gat gag cag atg tat cag aaa tgc tgc aac
ctg ttt gaa 2115Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys Cys Cys Asn
Leu Phe Glu685 690 695aaa ttc ttc ccc agc agc tca tac aga aga cca
gtc gga att tct agt 2163Lys Phe Phe Pro Ser Ser Ser Tyr Arg Arg Pro
Val Gly Ile Ser Ser700 705 710atg gtt gag gcc atg gtg tcc agg gcc
cgc att gat gca cga att gac 2211Met Val Glu Ala Met Val Ser Arg Ala
Arg Ile Asp Ala Arg Ile Asp715 720 725ttc gaa tct gga cgg ata aag
aag gat gag ttc gct gag atc atg aag 2259Phe Glu Ser Gly Arg Ile Lys
Lys Asp Glu Phe Ala Glu Ile Met Lys730 735 740 745atc tgt tcc acc
att gaa gag ctc aga cgg caa aaa tagtgaattt 2305Ile Cys Ser Thr Ile
Glu Glu Leu Arg Arg Gln Lys750 755agcttgatct tcgtgaaaaa atgccttgtt
tctact 2341104757PRTEquine influenza virus
H3N8misc_feature(489)..(489)The 'Xaa' at location 489 stands for
Thr, or Ser. 104Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val Pro
Ala Gln Asn1 5 10 15Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp Pro
Pro Tyr Ser His20 25 30Gly Thr Gly Thr Gly Tyr Thr Met Asp Thr Val
Asn Arg Thr His Gln35 40 45Tyr Ser Glu Lys Gly Lys Trp Thr Thr Asn
Thr Glu Ile Gly Ala Pro50 55 60Gln Leu Asn Pro Ile Asp Gly Pro Leu
Pro Glu Asp Asn Glu Pro Ser65 70 75 80Gly Tyr Ala Gln Thr Asp Cys
Val Leu Glu Ala Met Ala Phe Leu Glu85 90 95Glu Ser His Pro Gly Ile
Phe Glu Asn Ser Cys Leu Glu Thr Met Glu100 105 110Val Val Gln Gln
Thr Arg Val Asp Lys Leu Thr Gln Gly Arg Gln Thr115 120 125Tyr Asp
Trp Thr Leu Asn Arg Asn Gln Pro Ala Ala Thr Ala Leu Ala130 135
140Asn Thr Ile Glu Val Phe Arg Ser Asn Asp Leu Thr Ser Ser Glu
Ser145 150 155 160Gly Arg Leu Met Asp Phe Leu Lys Asp Val Met Glu
Ser Met Asn Lys165 170 175Glu Glu Met Glu Ile Thr Thr His Phe Gln
Arg Lys Arg Arg Val Arg180 185 190Asp Asn Met Thr Lys Arg Met Val
Thr Gln Arg Thr Ile Gly Lys Lys195 200 205Lys Gln Arg Leu Asn Arg
Lys Ser Tyr Leu Ile Arg Ala Leu Thr Leu210 215 220Asn Thr Met Thr
Lys Asp Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala225 230 235 240Ile
Ala Thr Pro Gly Met Gln Ile Arg Gly Phe Val Tyr Phe Val Glu245 250
255Thr Leu Ala Arg Arg Ile Cys Glu Lys Leu Glu Gln Ser Gly Leu
Pro260 265 270Val Gly Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val
Val Arg Lys275 280 285Met Met Thr Asn Ser Gln Asp Thr Glu Leu Ser
Phe Thr Ile Thr Gly290 295 300Asp Asn Thr Lys Trp Asn Glu Asn Gln
Asn Pro Arg Met Phe Leu Ala305 310 315 320Met Ile Thr Tyr Ile Thr
Arg Asn Gln Pro Glu Trp Phe Arg Asn Val325 330 335Leu Ser Ile Ala
Pro Ile Met Phe Ser Asn Lys Met Ala Arg Leu Gly340 345 350Lys Gly
Tyr Met Phe Glu Ser Lys Ser Met Lys Leu Arg Thr Gln Ile355 360
365Pro Ala Glu Met Leu Ala Ser Ile Asp Leu Lys Tyr Phe Asn Asp
Ser370 375 380Thr Lys Lys Lys Ile Glu Lys Ile Arg Pro Leu Leu Val
Asp Gly Thr385 390 395 400Ala Ser Leu Ser Pro Gly Met Met Met Gly
Met Phe Asn Met Leu Ser405 410 415Thr Val Leu Gly Val Ser Ile Leu
Asn Leu Gly Gln Arg Lys Tyr Thr420 425 430Lys Thr Thr Tyr Trp Trp
Asp Gly Leu Gln Ser Ser Asp Asp Phe Ala435 440 445Leu Ile Val Asn
Ala Pro Asn His Glu Gly Ile Gln Ala Gly Val Asp450 455 460Arg Phe
Tyr Arg Thr Cys Lys Leu Val Gly Ile Asn Met Ser Lys Lys465 470 475
480Lys Ser Tyr Ile Asn Arg Thr Gly Xaa Phe Glu Phe Thr Ser Phe
Phe485 490 495Tyr Arg Tyr Gly Phe Val Ala Asn Phe Ser Met Glu Leu
Pro Ser Phe500 505 510Gly Val Ser Gly Ile Asn Glu Ser Ala Asp Met
Ser Ile Gly Met Thr515 520 525Val Ile Lys Asn Asn Met Ile Asn Asn
Asp Leu Gly Pro Ala Thr Ala530 535 540Gln Met Ala Leu Gln Leu Phe
Ile Lys Asp Tyr Arg Tyr Thr Tyr Arg545 550 555 560Cys His Arg Gly
Asp Thr Gln Ile Gln Thr Arg Arg
Ser Phe Glu Leu565 570 575Lys Lys Leu Trp Glu Gln Thr Arg Ser Lys
Thr Gly Leu Leu Val Ser580 585 590Asp Gly Gly Pro Asn Leu Tyr Asn
Ile Arg Asn Leu His Ile Pro Glu595 600 605Val Cys Leu Lys Trp Glu
Leu Met Asp Glu Asp Tyr Lys Gly Arg Leu610 615 620Cys Asn Pro Leu
Asn Pro Phe Val Ser His Lys Glu Ile Glu Ser Val625 630 635 640Asn
Ser Ala Val Val Met Pro Ala His Gly Pro Ala Lys Ser Met Glu645 650
655Tyr Asp Ala Val Ala Thr Thr His Ser Trp Ile Pro Lys Arg Asn
Arg660 665 670Ser Ile Leu Asn Thr Ser Gln Arg Gly Ile Leu Glu Asp
Glu Gln Met675 680 685Tyr Gln Lys Cys Cys Asn Leu Phe Glu Lys Phe
Phe Pro Ser Ser Ser690 695 700Tyr Arg Arg Pro Val Gly Ile Ser Ser
Met Val Glu Ala Met Val Ser705 710 715 720Arg Ala Arg Ile Asp Ala
Arg Ile Asp Phe Glu Ser Gly Arg Ile Lys725 730 735Lys Asp Glu Phe
Ala Glu Ile Met Lys Ile Cys Ser Thr Ile Glu Glu740 745 750Leu Arg
Arg Gln Lys7551052271DNAEquine influenza virus H3N8 105atggatgtca
atccgactct actcttctta aaggtgccag cgcaaaatgc tataagcaca 60acattccctt
atactggaga tcctccctac agtcatggaa cagggacagg atacaccatg
120gatactgtca acagaacaca tcaatactca gaaaagggga aatggacaac
aaacactgag 180attggagcac cacaacttaa tccaatcgat ggaccgcttc
ctgaagacaa tgaaccaagt 240gggtacgccc aaacagattg tgtattggaa
gcaatggctt tccttgaaga atcccatccc 300ggaatctttg aaaattcgtg
tcttgaaaca atggaggtgg ttcagcagac aagagtggac 360aaactaacac
aaggccgaca aacttacgat tggaccttga ataggaatca acctgccgca
420acagcacttg ctaatacaat tgaagtgttc agatcaaatg atctgacttc
cagtgagtca 480gggagattaa tggacttcct caaagatgtc atggagtcca
tgaacaagga agaaatggaa 540ataacaacac acttccaacg gaagagaaga
gtaagagaca acatgacaaa gagaatggtg 600acacagagaa ccatagggaa
gaaaaaacaa cgattaaaca gaaagagcta tctgatcagg 660gcattaacct
taaacacaat gaccaaggac gctgagagag ggaaattgaa acgacgagca
720attgcaaccc caggaatgca gataagaggg tttgtatatt ttgttgaaac
attagcccga 780agaatatgtg aaaagcttga acaatcagga ttgccagttg
gcggtaatga gaaaaaggcc 840aaactggcta atgtcgtcag aaaaatgatg
actaattccc aagacactga actctccttc 900accatcactg gggacaatac
caaatggaat gaaaatcaga acccacgcat gttcctggca 960atgatcacat
acataactag aaaccagcca gaatggttca gaaatgttct aagcattgca
1020ccgattatgt tctcaaataa aatggcaaga ctggggaaag gatatatgtt
tgaaagcaaa 1080agtatgaaat tgagaactca aataccagca gaaatgctcg
caagcattga tctgaaatat 1140ttcaatgatt caacaaaaaa gaaaattgag
aagatacgac cacttctggt cgatgggact 1200gcttcactga gtcctggcat
gatgatggga atgttcaaca tgttgagcac tgtactaggt 1260gtatccatat
taaacctggg ccagaggaaa tacacaaaga ccacatactg gtgggatggt
1320ctgcaatcat ccgatgattt tgctttgata gtgaatgcgc ctaatcatga
aggaatacag 1380gctggagtag acagattcta tagaacttgc aaactggtcg
ggatcaacat gagcaaaaag 1440aagtcctaca taaatagaac cggcwcattc
gaattcacaa gctttttcta ccggtatggt 1500tttgtcgcca atttcagcat
ggagctaccc agttttgggg tttccgggat aaatgaatct 1560gcagacatga
gcattggaat gacagttatc aaaaacaaca tgataaataa tgatctcggt
1620cccgccacgg cacaaatggc actccaactc ttcattaagg attatcggta
cacataccgg 1680tgccatagag gcgataccca gatacaaacc agaagatcct
ttgagttgaa gaaactgtgg 1740gaacagactc gatcaaagac tggtctactg
gtatcagatg ggggtccaaa cctatacaac 1800atcagaaacc tacacatccc
ggaagtctgt ttgaaatggg agctgatgga tgaagattat 1860aaagggaggc
tatgtaatcc attgaatcct ttcgttagcc acaaagaaat tgaatcagtg
1920aacagtgcag tagtaatgcc tgcgcatggc cctgccaaaa gcatggagta
tgatgctgtt 1980gcaacaacac actcttggat ccccaagagg aaccggtcca
tattgaacac aagtcaaagg 2040ggaatactcg aagatgagca gatgtatcag
aaatgctgca acctgtttga aaaattcttc 2100cccagcagct catacagaag
accagtcgga atttctagta tggttgaggc catggtgtcc 2160agggcccgca
ttgatgcacg aattgacttc gaatctggac ggataaagaa ggatgagttc
2220gctgagatca tgaagatctg ttccaccatt gaagagctca gacggcaaaa a
22711062341DNAEquine influenza virus
H3N8CDS(25)..(2295)misc_feature(2144)..(2144)At nucleotide 2144, r
= a or g At amino acid residue 707, Xaa = Arg or Lys 106agcaaaagca
ggcaaactat ttga atg gat gtc aat ccg act cta ctc ttc 51Met Asp Val
Asn Pro Thr Leu Leu Phe1 5tta aag gtg cca gcg caa aat gct ata agc
aca aca ttc cct tat act 99Leu Lys Val Pro Ala Gln Asn Ala Ile Ser
Thr Thr Phe Pro Tyr Thr10 15 20 25gga gat cct ccc tac agt cat gga
aca ggg aca gga tac acc atg gat 147Gly Asp Pro Pro Tyr Ser His Gly
Thr Gly Thr Gly Tyr Thr Met Asp30 35 40act gtc aac aga aca cat caa
tac tca gaa aag ggg aaa tgg aca aca 195Thr Val Asn Arg Thr His Gln
Tyr Ser Glu Lys Gly Lys Trp Thr Thr45 50 55aac act gag att gga gca
cca caa ctt aat cca atc gat gga ccg ctt 243Asn Thr Glu Ile Gly Ala
Pro Gln Leu Asn Pro Ile Asp Gly Pro Leu60 65 70cct gaa gac aat gaa
cca agt ggg tac gcc caa aca gat tgt gta ttg 291Pro Glu Asp Asn Glu
Pro Ser Gly Tyr Ala Gln Thr Asp Cys Val Leu75 80 85gaa gca atg gct
ttc ctt gaa gaa tcc cat ccc gga atc ttt gaa aat 339Glu Ala Met Ala
Phe Leu Glu Glu Ser His Pro Gly Ile Phe Glu Asn90 95 100 105tcg tgt
ctt gaa aca atg gag gtg gtt cag cag aca aga gtg gac aaa 387Ser Cys
Leu Glu Thr Met Glu Val Val Gln Gln Thr Arg Val Asp Lys110 115
120cta aca caa ggc cga caa act tac gat tgg acc ttg aat agg aat caa
435Leu Thr Gln Gly Arg Gln Thr Tyr Asp Trp Thr Leu Asn Arg Asn
Gln125 130 135cct gcc gca aca gca ctt gct aat aca att gaa gtg ttc
aga tca aat 483Pro Ala Ala Thr Ala Leu Ala Asn Thr Ile Glu Val Phe
Arg Ser Asn140 145 150gat ctg act tcc agt gag tca ggg aga tta atg
gac ttc ctc aaa gat 531Asp Leu Thr Ser Ser Glu Ser Gly Arg Leu Met
Asp Phe Leu Lys Asp155 160 165gtc atg gag tcc atg aac aag gaa gaa
atg gaa ata aca aca cac ttc 579Val Met Glu Ser Met Asn Lys Glu Glu
Met Glu Ile Thr Thr His Phe170 175 180 185caa cgg aag aga aga gta
aga gac aac atg aca aag aga atg gtg aca 627Gln Arg Lys Arg Arg Val
Arg Asp Asn Met Thr Lys Arg Met Val Thr190 195 200cag aga acc ata
ggg aag aaa aaa caa cga tta aac aga aag agc tat 675Gln Arg Thr Ile
Gly Lys Lys Lys Gln Arg Leu Asn Arg Lys Ser Tyr205 210 215ctg atc
agg gca tta acc tta aac aca atg acc aag gac gct gag aga 723Leu Ile
Arg Ala Leu Thr Leu Asn Thr Met Thr Lys Asp Ala Glu Arg220 225
230ggg aaa ttg aaa cga cga gca att gca acc cca gga atg cag ata aga
771Gly Lys Leu Lys Arg Arg Ala Ile Ala Thr Pro Gly Met Gln Ile
Arg235 240 245ggg ttt gta tat ttt gtt gaa aca tta gcc cga aga ata
tgt gaa aag 819Gly Phe Val Tyr Phe Val Glu Thr Leu Ala Arg Arg Ile
Cys Glu Lys250 255 260 265ctt gaa caa tca gga ttg cca gtt ggc ggt
aat gag aaa aag gcc aaa 867Leu Glu Gln Ser Gly Leu Pro Val Gly Gly
Asn Glu Lys Lys Ala Lys270 275 280ctg gct aat gtc gtc aga aaa atg
atg act aat tcc caa gac act gaa 915Leu Ala Asn Val Val Arg Lys Met
Met Thr Asn Ser Gln Asp Thr Glu285 290 295ctc tcc ttc acc atc act
ggg gac aat acc aaa tgg aat gaa aat cag 963Leu Ser Phe Thr Ile Thr
Gly Asp Asn Thr Lys Trp Asn Glu Asn Gln300 305 310aac cca cgc atg
ttc ctg gca atg atc aca tac ata act aga aac cag 1011Asn Pro Arg Met
Phe Leu Ala Met Ile Thr Tyr Ile Thr Arg Asn Gln315 320 325cca gaa
tgg ttc aga aat gtt cta agc att gca ccg att atg ttc tca 1059Pro Glu
Trp Phe Arg Asn Val Leu Ser Ile Ala Pro Ile Met Phe Ser330 335 340
345aat aaa atg gca aga ctg ggg aaa gga tat atg ttt gaa agc aaa agt
1107Asn Lys Met Ala Arg Leu Gly Lys Gly Tyr Met Phe Glu Ser Lys
Ser350 355 360atg aaa ttg aga act caa ata cca gca gaa atg ctc gca
agc att gat 1155Met Lys Leu Arg Thr Gln Ile Pro Ala Glu Met Leu Ala
Ser Ile Asp365 370 375ctg aaa tat ttc aat gat tca aca aaa aag aaa
att gag aag ata cga 1203Leu Lys Tyr Phe Asn Asp Ser Thr Lys Lys Lys
Ile Glu Lys Ile Arg380 385 390cca ctt ctg gtc gat ggg act gct tca
ctg agt cct ggc atg atg atg 1251Pro Leu Leu Val Asp Gly Thr Ala Ser
Leu Ser Pro Gly Met Met Met395 400 405gga atg ttc aac atg ttg agc
act gta cta ggt gta tcc ata tta aac 1299Gly Met Phe Asn Met Leu Ser
Thr Val Leu Gly Val Ser Ile Leu Asn410 415 420 425ctg ggc cag agg
aaa tac aca aag acc aca tac tgg tgg gat ggt ctg 1347Leu Gly Gln Arg
Lys Tyr Thr Lys Thr Thr Tyr Trp Trp Asp Gly Leu430 435 440caa tca
tcc gat gat ttt gct ttg ata gtg aat gcg cct aat cat gaa 1395Gln Ser
Ser Asp Asp Phe Ala Leu Ile Val Asn Ala Pro Asn His Glu445 450
455gga ata cag gct gga gta gac aga ttc tat aga act tgc aaa ctg gtc
1443Gly Ile Gln Ala Gly Val Asp Arg Phe Tyr Arg Thr Cys Lys Leu
Val460 465 470ggg atc aac atg agc aaa aag aag tcc tac ata aat aga
acc ggc aca 1491Gly Ile Asn Met Ser Lys Lys Lys Ser Tyr Ile Asn Arg
Thr Gly Thr475 480 485ttc gaa ttc aca agc ttt ttc tac cgg tat ggt
ttt gtc gcc aat ttc 1539Phe Glu Phe Thr Ser Phe Phe Tyr Arg Tyr Gly
Phe Val Ala Asn Phe490 495 500 505agc atg gag cta ccc agt ttt ggg
gtt tcc ggg ata aat gaa tct gca 1587Ser Met Glu Leu Pro Ser Phe Gly
Val Ser Gly Ile Asn Glu Ser Ala510 515 520gac atg agc att gga atg
aca gtt atc aaa aac aac atg ata aat aat 1635Asp Met Ser Ile Gly Met
Thr Val Ile Lys Asn Asn Met Ile Asn Asn525 530 535gat ctc ggt ccc
gcc acg gca caa atg gca ctc caa ctc ttc att aag 1683Asp Leu Gly Pro
Ala Thr Ala Gln Met Ala Leu Gln Leu Phe Ile Lys540 545 550gat tat
cgg tac aca tac cgg tgt caa aga ggc gat acc cag ata caa 1731Asp Tyr
Arg Tyr Thr Tyr Arg Cys Gln Arg Gly Asp Thr Gln Ile Gln555 560
565acc aga aga tcc ttt gag ttg aag aaa ctg tgg gaa cag act cga tca
1779Thr Arg Arg Ser Phe Glu Leu Lys Lys Leu Trp Glu Gln Thr Arg
Ser570 575 580 585aag act ggt cta ctg gta tca gat ggg ggt cca aac
cta tac aac atc 1827Lys Thr Gly Leu Leu Val Ser Asp Gly Gly Pro Asn
Leu Tyr Asn Ile590 595 600aga aac cta cac atc ccg gaa gtc tgt ttg
aaa tgg gag ctg atg gat 1875Arg Asn Leu His Ile Pro Glu Val Cys Leu
Lys Trp Glu Leu Met Asp605 610 615gaa gat tat aaa ggg agg cta tgt
aat cca ttg aat cct ttc gtt agc 1923Glu Asp Tyr Lys Gly Arg Leu Cys
Asn Pro Leu Asn Pro Phe Val Ser620 625 630cac aaa gaa att gaa tca
gtg aac agt gca gta gta atg cct gcg cat 1971His Lys Glu Ile Glu Ser
Val Asn Ser Ala Val Val Met Pro Ala His635 640 645ggc cct gcc aaa
agc atg gag tat gat gct gtt gca aca aca cac tct 2019Gly Pro Ala Lys
Ser Met Glu Tyr Asp Ala Val Ala Thr Thr His Ser650 655 660 665tgg
atc ccc aag agg aac cgg tcc ata ttg aac aca agt caa agg gga 2067Trp
Ile Pro Lys Arg Asn Arg Ser Ile Leu Asn Thr Ser Gln Arg Gly670 675
680ata ctc gaa gat gag cag atg tat cag aaa tgc tgc aac ctg ttt gaa
2115Ile Leu Glu Asp Glu Gln Met Tyr Gln Lys Cys Cys Asn Leu Phe
Glu685 690 695aaa ttc ttc ccc agc agc tca tac aga ara cca gtc gga
att tct agt 2163Lys Phe Phe Pro Ser Ser Ser Tyr Arg Xaa Pro Val Gly
Ile Ser Ser700 705 710atg gtt gag gcc atg gtg tcc agg gcc cgc att
gat gca cga att gac 2211Met Val Glu Ala Met Val Ser Arg Ala Arg Ile
Asp Ala Arg Ile Asp715 720 725ttc gaa tct gga cgg ata aag aag gat
gag ttc gct gag atc atg aag 2259Phe Glu Ser Gly Arg Ile Lys Lys Asp
Glu Phe Ala Glu Ile Met Lys730 735 740 745atc tgt tcc acc att gaa
gag ctc aga cgg caa aaa tagtgaattt 2305Ile Cys Ser Thr Ile Glu Glu
Leu Arg Arg Gln Lys750 755agcttgatct tcgtgaaaaa atgccttgtt tctact
2341107757PRTEquine influenza virus H3N8misc_feature(707)..(707)The
'Xaa' at location 707 stands for Arg, or Lys. 107Met Asp Val Asn
Pro Thr Leu Leu Phe Leu Lys Val Pro Ala Gln Asn1 5 10 15Ala Ile Ser
Thr Thr Phe Pro Tyr Thr Gly Asp Pro Pro Tyr Ser His20 25 30Gly Thr
Gly Thr Gly Tyr Thr Met Asp Thr Val Asn Arg Thr His Gln35 40 45Tyr
Ser Glu Lys Gly Lys Trp Thr Thr Asn Thr Glu Ile Gly Ala Pro50 55
60Gln Leu Asn Pro Ile Asp Gly Pro Leu Pro Glu Asp Asn Glu Pro Ser65
70 75 80Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu Ala Met Ala Phe Leu
Glu85 90 95Glu Ser His Pro Gly Ile Phe Glu Asn Ser Cys Leu Glu Thr
Met Glu100 105 110Val Val Gln Gln Thr Arg Val Asp Lys Leu Thr Gln
Gly Arg Gln Thr115 120 125Tyr Asp Trp Thr Leu Asn Arg Asn Gln Pro
Ala Ala Thr Ala Leu Ala130 135 140Asn Thr Ile Glu Val Phe Arg Ser
Asn Asp Leu Thr Ser Ser Glu Ser145 150 155 160Gly Arg Leu Met Asp
Phe Leu Lys Asp Val Met Glu Ser Met Asn Lys165 170 175Glu Glu Met
Glu Ile Thr Thr His Phe Gln Arg Lys Arg Arg Val Arg180 185 190Asp
Asn Met Thr Lys Arg Met Val Thr Gln Arg Thr Ile Gly Lys Lys195 200
205Lys Gln Arg Leu Asn Arg Lys Ser Tyr Leu Ile Arg Ala Leu Thr
Leu210 215 220Asn Thr Met Thr Lys Asp Ala Glu Arg Gly Lys Leu Lys
Arg Arg Ala225 230 235 240Ile Ala Thr Pro Gly Met Gln Ile Arg Gly
Phe Val Tyr Phe Val Glu245 250 255Thr Leu Ala Arg Arg Ile Cys Glu
Lys Leu Glu Gln Ser Gly Leu Pro260 265 270Val Gly Gly Asn Glu Lys
Lys Ala Lys Leu Ala Asn Val Val Arg Lys275 280 285Met Met Thr Asn
Ser Gln Asp Thr Glu Leu Ser Phe Thr Ile Thr Gly290 295 300Asp Asn
Thr Lys Trp Asn Glu Asn Gln Asn Pro Arg Met Phe Leu Ala305 310 315
320Met Ile Thr Tyr Ile Thr Arg Asn Gln Pro Glu Trp Phe Arg Asn
Val325 330 335Leu Ser Ile Ala Pro Ile Met Phe Ser Asn Lys Met Ala
Arg Leu Gly340 345 350Lys Gly Tyr Met Phe Glu Ser Lys Ser Met Lys
Leu Arg Thr Gln Ile355 360 365Pro Ala Glu Met Leu Ala Ser Ile Asp
Leu Lys Tyr Phe Asn Asp Ser370 375 380Thr Lys Lys Lys Ile Glu Lys
Ile Arg Pro Leu Leu Val Asp Gly Thr385 390 395 400Ala Ser Leu Ser
Pro Gly Met Met Met Gly Met Phe Asn Met Leu Ser405 410 415Thr Val
Leu Gly Val Ser Ile Leu Asn Leu Gly Gln Arg Lys Tyr Thr420 425
430Lys Thr Thr Tyr Trp Trp Asp Gly Leu Gln Ser Ser Asp Asp Phe
Ala435 440 445Leu Ile Val Asn Ala Pro Asn His Glu Gly Ile Gln Ala
Gly Val Asp450 455 460Arg Phe Tyr Arg Thr Cys Lys Leu Val Gly Ile
Asn Met Ser Lys Lys465 470 475 480Lys Ser Tyr Ile Asn Arg Thr Gly
Thr Phe Glu Phe Thr Ser Phe Phe485 490 495Tyr Arg Tyr Gly Phe Val
Ala Asn Phe Ser Met Glu Leu Pro Ser Phe500 505 510Gly Val Ser Gly
Ile Asn Glu Ser Ala Asp Met Ser Ile Gly Met Thr515 520 525Val Ile
Lys Asn Asn Met Ile Asn Asn Asp Leu Gly Pro Ala Thr Ala530 535
540Gln Met Ala Leu Gln Leu Phe Ile Lys Asp Tyr Arg Tyr Thr Tyr
Arg545 550 555 560Cys Gln Arg Gly Asp Thr Gln Ile Gln Thr Arg Arg
Ser Phe Glu Leu565 570 575Lys Lys Leu Trp Glu Gln Thr Arg Ser Lys
Thr Gly Leu Leu Val Ser580 585 590Asp Gly Gly Pro Asn Leu Tyr Asn
Ile Arg Asn Leu His Ile Pro Glu595 600 605Val Cys Leu Lys Trp Glu
Leu Met Asp Glu Asp Tyr Lys Gly Arg Leu610 615 620Cys Asn Pro Leu
Asn Pro Phe Val Ser His Lys Glu Ile Glu Ser Val625 630 635 640Asn
Ser Ala Val Val Met Pro Ala His Gly Pro Ala Lys Ser Met Glu645 650
655Tyr Asp Ala Val Ala Thr Thr His Ser Trp Ile Pro Lys Arg Asn
Arg660 665 670Ser Ile Leu Asn Thr Ser Gln Arg Gly Ile Leu Glu Asp
Glu Gln Met675 680 685Tyr Gln Lys Cys Cys Asn Leu Phe Glu Lys Phe
Phe Pro Ser Ser Ser690 695 700Tyr Arg Xaa Pro Val Gly Ile Ser Ser
Met Val Glu Ala Met Val Ser705 710 715 720Arg Ala Arg Ile Asp Ala
Arg Ile Asp Phe Glu Ser Gly Arg Ile Lys725 730 735Lys Asp Glu Phe
Ala Glu Ile Met Lys Ile Cys Ser Thr Ile Glu Glu740
745 750Leu Arg Arg Gln Lys7551082271DNAEquine influenza virus H3N8
108atggatgtca atccgactct actcttctta aaggtgccag cgcaaaatgc
tataagcaca 60acattccctt atactggaga tcctccctac agtcatggaa cagggacagg
atacaccatg 120gatactgtca acagaacaca tcaatactca gaaaagggga
aatggacaac aaacactgag 180attggagcac cacaacttaa tccaatcgat
ggaccgcttc ctgaagacaa tgaaccaagt 240gggtacgccc aaacagattg
tgtattggaa gcaatggctt tccttgaaga atcccatccc 300ggaatctttg
aaaattcgtg tcttgaaaca atggaggtgg ttcagcagac aagagtggac
360aaactaacac aaggccgaca aacttacgat tggaccttga ataggaatca
acctgccgca 420acagcacttg ctaatacaat tgaagtgttc agatcaaatg
atctgacttc cagtgagtca 480gggagattaa tggacttcct caaagatgtc
atggagtcca tgaacaagga agaaatggaa 540ataacaacac acttccaacg
gaagagaaga gtaagagaca acatgacaaa gagaatggtg 600acacagagaa
ccatagggaa gaaaaaacaa cgattaaaca gaaagagcta tctgatcagg
660gcattaacct taaacacaat gaccaaggac gctgagagag ggaaattgaa
acgacgagca 720attgcaaccc caggaatgca gataagaggg tttgtatatt
ttgttgaaac attagcccga 780agaatatgtg aaaagcttga acaatcagga
ttgccagttg gcggtaatga gaaaaaggcc 840aaactggcta atgtcgtcag
aaaaatgatg actaattccc aagacactga actctccttc 900accatcactg
gggacaatac caaatggaat gaaaatcaga acccacgcat gttcctggca
960atgatcacat acataactag aaaccagcca gaatggttca gaaatgttct
aagcattgca 1020ccgattatgt tctcaaataa aatggcaaga ctggggaaag
gatatatgtt tgaaagcaaa 1080agtatgaaat tgagaactca aataccagca
gaaatgctcg caagcattga tctgaaatat 1140ttcaatgatt caacaaaaaa
gaaaattgag aagatacgac cacttctggt cgatgggact 1200gcttcactga
gtcctggcat gatgatggga atgttcaaca tgttgagcac tgtactaggt
1260gtatccatat taaacctggg ccagaggaaa tacacaaaga ccacatactg
gtgggatggt 1320ctgcaatcat ccgatgattt tgctttgata gtgaatgcgc
ctaatcatga aggaatacag 1380gctggagtag acagattcta tagaacttgc
aaactggtcg ggatcaacat gagcaaaaag 1440aagtcctaca taaatagaac
cggcacattc gaattcacaa gctttttcta ccggtatggt 1500tttgtcgcca
atttcagcat ggagctaccc agttttgggg tttccgggat aaatgaatct
1560gcagacatga gcattggaat gacagttatc aaaaacaaca tgataaataa
tgatctcggt 1620cccgccacgg cacaaatggc actccaactc ttcattaagg
attatcggta cacataccgg 1680tgtcaaagag gcgataccca gatacaaacc
agaagatcct ttgagttgaa gaaactgtgg 1740gaacagactc gatcaaagac
tggtctactg gtatcagatg ggggtccaaa cctatacaac 1800atcagaaacc
tacacatccc ggaagtctgt ttgaaatggg agctgatgga tgaagattat
1860aaagggaggc tatgtaatcc attgaatcct ttcgttagcc acaaagaaat
tgaatcagtg 1920aacagtgcag tagtaatgcc tgcgcatggc cctgccaaaa
gcatggagta tgatgctgtt 1980gcaacaacac actcttggat ccccaagagg
aaccggtcca tattgaacac aagtcaaagg 2040ggaatactcg aagatgagca
gatgtatcag aaatgctgca acctgtttga aaaattcttc 2100cccagcagct
catacagaar accagtcgga atttctagta tggttgaggc catggtgtcc
2160agggcccgca ttgatgcacg aattgacttc gaatctggac ggataaagaa
ggatgagttc 2220gctgagatca tgaagatctg ttccaccatt gaagagctca
gacggcaaaa a 2271
* * * * *